nvcr-20220331

0001645113-22-000043.txt : 20220428 0001645113-22-000043.hdr.sgml : 20220428 20220428070306 ACCESSION NUMBER: 0001645113-22-000043 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220428 DATE AS OF CHANGE: 20220428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NovoCure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 22862134 BUSINESS ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF FORMER COMPANY: FORMER CONFORMED NAME: Novocure Ltd DATE OF NAME CHANGE: 20150615 10-Q 1 nvcr-20220331.htm 10-Q nvcr-20220331

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________________________________

FORM 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-37565

NovoCure Limited

(Exact Name of Registrant as Specified in Its Charter)


Jersey						98-1057807
(State or Other Jurisdiction of						(I.R.S. Employer
Incorporation or Organization)						Identification No.)

No. 4 The Forum

Grenville Street

St. Helier, Jersey JE2 4UF

(Address of principal executive offices, including zip code)

+44 (0) 15 3475 6700

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name, Former Address and Former Fiscal Year, If Changed Since Last Report)

_______________________________________________________

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary Shares, no par value	NVCR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒.

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.


Class						Outstanding as of April 22, 2022
Ordinary shares, no par value						104,586,094 Shares

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

In addition to historical facts or statements of current condition, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements contained in this report are based on our current plans, expectations, hopes, beliefs, intentions or strategies concerning future developments and their impact on us. Forward-looking statements contained in this report constitute our expectations or forecasts of future events as of the date this report was filed with the Securities and Exchange Commission (the “SEC”) and are not statements of historical fact. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Such statements may include words such as “anticipate,” “will,” “estimate,” “expect,” “project,” “intend,” “should,” “plan,” “believe,” “hope” and other words and terms of similar meaning in connection with any discussion of, among other things, future operating or financial performance, strategic initiatives and business strategies, regulatory or competitive environments, our intellectual property and research and development related to our Tumor Treating Fields devices marketed under various brand names, including Optune and Optune Lua, and software and systems to support and optimize the delivery of Tumor Treating Fields (collectively, our “Products”). In particular, these forward-looking statements include, among others, statements about:

•our research and development, clinical study and commercialization activities and projected expenditures;

•the further commercialization of our Products for current and future indications;

•our business strategies and the expansion of our sales and marketing efforts in the United States and in other countries;

•the market acceptance of our Products for current and future indications by patients, physicians, third-party payers and others in the healthcare and scientific community;

•our plans to pursue the use of our Products for the treatment of solid tumor cancers other than glioblastoma multiforme (“GBM”) and malignant pleural mesothelioma (“MPM”);

•our estimates regarding revenues, expenses, capital requirements and needs for additional financing;

•our ability to obtain regulatory approvals for the use of our Products in indications other than GBM and MPM;

•our ability to acquire from third-party suppliers the supplies needed to manufacture our Products;

•our ability to manufacture adequate supply of our Products;

•our ability to secure and maintain adequate coverage from third-party payers to reimburse us for our Products for current and future indications;

•our ability to receive payment from third-party payers for use of our Products for current and future indications;

•our ability to maintain and develop our intellectual property position;

•our ability to manage the risks associated with business disruptions caused by natural disasters, extreme weather events, pandemics such as the COVID-19 pandemic, including the emergence of variant strains, or international conflict and other disruptions outside of our control;

•our cash needs; and

•our prospects, financial condition and results of operations.

These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors which may cause such differences to occur include those risks and uncertainties set forth under Part I, Item 1A., “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed on February 24, 2022, as well as other risks and uncertainties set forth from time to time in the reports we file with the SEC. In our prior filings, references to NovoTTF-100L now refer

to Optune Lua. We do not intend to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

TRADEMARKS

This Quarterly Report on Form 10-Q includes trademarks of NovoCure Limited and other persons. All trademarks or trade names referred to herein are the property of their respective owners.

Table of Contents

NovoCure Limited

Quarterly Report on Form 10-Q

TABLE OF CONTENTS


		Page
Cautionary Note Regarding Forward Looking Statements		i
Trademarks		ii

PART I—FINANCIAL INFORMATION

Item 1.	Financial Statements	2
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	22
Item 4.	Controls and Procedures	22

PART II—OTHER INFORMATION

Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	23
Item 6.	Exhibits	24

	Signatures	25

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements


NOVOCURE LIMITED AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except share data)
	March 31, 2022		December 31, 2021
	Unaudited		Audited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	190,739	$	208,802
Short-term investments	741,562		728,898
Restricted cash	889		807
Trade receivables, net	100,965		93,567
Receivables and prepaid expenses	17,343		17,025
Inventories	29,084		24,427
Total current assets	1,080,582		1,073,526
LONG-TERM ASSETS:
Property and equipment, net	25,072		22,693
Field equipment, net	12,792		12,923
Right-of-use assets	19,937		18,267
Other long-term assets	11,827		12,086
Total long-term assets	69,628		65,969
TOTAL ASSETS	$	1,150,210	$	1,139,495

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents


NOVOCURE LIMITED AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except share data)
	March 31, 2022		December 31, 2021
	Unaudited		Audited
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables	$	69,186	$	72,600
Other payables, lease liabilities and accrued expenses	58,613		70,002
Total current liabilities	127,799		142,602
LONG-TERM LIABILITIES:
Long-term debt, net	563,026		562,216
Deferred revenue	5,511		6,477
Long-term leases	14,813		12,997
Employee benefit liabilities	3,024		4,543
Other long-term liabilities	156		166
Total long-term liabilities	586,530		586,399
TOTAL LIABILITIES	714,329		729,001
COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY:
Share capital -
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 104,559,088 shares and 103,971,263 shares at March 31, 2022 (unaudited) and December 31, 2021, respectively	—		—
Additional paid-in capital	1,127,782		1,099,589
Accumulated other comprehensive income (loss)	(1,328)		(3,169)
Retained earnings (accumulated deficit)	(690,573)		(685,926)
TOTAL SHAREHOLDERS' EQUITY	435,881		410,494
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	1,150,210	$	1,139,495

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents


NOVOCURE LIMITED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share and per share data)
	Three months ended March 31,			Year ended December 31,
		2022		2021		2021
	Unaudited			Audited
Net revenues		$	137,547	$	134,695	$	535,031
Cost of revenues		27,727		26,385		114,877
Gross profit		109,820		108,310		420,154

Operating costs and expenses:
Research, development and clinical studies		42,234		45,916		201,303
Sales and marketing		37,884		31,357		137,057
General and administrative		30,508		31,125		126,127
Total operating costs and expenses		110,626		108,398		464,487

Operating income (loss)		(806)		(88)		(44,333)
Financial expenses (income), net		1,709		2,646		7,742

Income (loss) before income tax		(2,515)		(2,734)		(52,075)
Income tax		2,132		1,394		6,276
Net income (loss)		$	(4,647)	$	(4,128)	$	(58,351)

Basic net income (loss) per ordinary share		$	(0.04)	$	(0.04)	$	(0.56)
Weighted average number of ordinary shares used in computing basic net income (loss) per share		104,186,120		102,633,545		103,433,274

Diluted net income (loss) per ordinary share		$	(0.04)	$	(0.04)	$	(0.56)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share		104,186,120		102,633,545		103,433,274

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents


CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
U.S. dollars in thousands
	Three months ended March 31,			Year ended December 31,
		2022		2021		2021
	Unaudited			Audited
Net income (loss)		$	(4,647)	$	(4,128)	$	(58,351)
Other comprehensive income (loss), net of tax:
Change in foreign currency translation adjustments		330		(268)		302
Pension benefit plan		1,511		2,152		361
Total comprehensive income (loss)		$	(2,806)	$	(2,244)	$	(57,688)


NOVOCURE LIMITED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
U.S. dollars in thousands (except share data)
	Ordinary shares	Additional paid-in capital		Accumulated other comprehensive loss		Retained earnings (accumulated deficit)		Total shareholders' equity

Balance as of December 31, 2021 (audited)	103,971,263	$	1,099,589	$	(3,169)	$	(685,926)	$	410,494

Share-based compensation to employees	—	25,045		—		—		25,045
Exercise of options and vested RSUs	587,825	3,148		—		—		3,148
Other comprehensive income (loss), net of tax benefit of $0	—	—		1,841		—		1,841
Net income (loss)	—	—		—		(4,647)		(4,647)
Balance as of March 31, 2022 (Unaudited)	104,559,088	$	1,127,782	$	(1,328)	$	(690,573)	$	435,881




	Ordinary shares	Additional paid-in capital		Accumulated other comprehensive loss		Retained earnings (accumulated deficit)		Total shareholders' equity

Balance as of December 31, 2020 (audited)	102,334,276	$	1,111,435	$	(3,832)	$	(631,077)	$	476,526

Share-based compensation to employees	—	18,863		—		—		18,863
Exercise of options and vested RSUs	853,184	7,961		—		—		7,961
Cumulative effect adjustment resulting from ASU 2020-06 early adoption	—	(132,474)		—		3,502		(128,972)
Other comprehensive income (loss), net of tax benefit of $0	—	—		1,884		—		1,884
Net income (loss)	—	—		—		(4,128)		(4,128)
Balance as of March 31, 2021 (Unaudited)	103,187,460	$	1,005,785	$	(1,948)	$	(631,703)	$	372,134

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents


NOVOCURE LIMITED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
	Three months ended March 31,			Year ended December 31,
		2022		2021		2021
	Unaudited			Audited
Cash flows from operating activities:
Net income (loss)		$	(4,647)	$	(4,128)	$	(58,351)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization		2,610		2,370		10,251
Accrued Interest		(221)		—		(94)
Asset write-downs and impairment of field equipment		135		176		649
Share-based compensation		25,045		18,863		94,900
Foreign currency remeasurement loss (gain)		249		2,157		3,231
Decrease (increase) in accounts receivables		(7,461)		4,624		5,270
Amortization of discount (premium)		684		603		3,101
Decrease (increase) in inventories		(4,804)		(1,296)		2,483
Decrease (increase) in other long-term assets		1,863		1,432		4,519
Increase (decrease) in accounts payables and accrued expenses		(14,809)		(2,626)		27,777
Increase (decrease) in other long-term liabilities		(2,331)		(4,394)		(10,980)
Net cash provided by (used in) operating activities		$	(3,687)	$	17,780	$	82,756

Cash flows from investing activities:
Purchase of property, equipment and field equipment		$	(5,093)	$	(3,981)	$	(24,170)
Proceeds from maturity of short-term investments		279,000		608,000		958,000
Purchase of short-term investments		(291,317)		(549,848)		(1,078,664)
Net cash provided by (used in) investing activities		$	(17,410)	$	54,171	$	(144,834)

Cash flows from financing activities:
Proceeds from issuance of shares, net		$	—	$	—	$	4,546

Repayment of long-term debt		(7)		(6)		(26)
Exercise of options		3,148		7,961		21,182
Net cash provided by (used in) financing activities		$	3,141	$	7,955	$	25,702

Effect of exchange rate changes on cash, cash equivalents and restricted cash		$	(25)	$	(102)	$	(188)

Increase (decrease) in cash, cash equivalents and restricted cash		(17,981)		79,804		(36,564)
Cash, cash equivalents and restricted cash at the beginning of the period		209,609		246,173		246,173

Cash, cash equivalents and restricted cash at the end of the period		$	191,628	$	325,977	$	209,609





Supplemental cash flow activities:
Cash paid during the period for:
Income taxes paid (refunded), net		$	1,173	$	(2,405)	$	3,110
Interest paid		$	1	$	1	$	101
Non-cash activities:
Right-of-use assets obtained in exchange for lease liabilities		$	3,580	$	284	$	5,387

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

NOVOCURE LIMITED AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share data)

NOTE 1: ORGANIZATION AND BASIS OF PRESENTATION

Organization. NovoCure Limited (including its consolidated subsidiaries, the "Company") was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields ("TTFields") devices, including Optune and Optune Lua (collectively, our "Products"), for the treatment of solid tumor cancers. The Company currently markets Optune in the United States ("U.S."), Germany, Japan and certain other countries. The Company currently markets Optune Lua in the U.S. and European Union. The Company also has a License and Collaboration Agreement (the "Zai Agreement") with Zai Lab (Shanghai) Co., Ltd. ("Zai") to market Optune in China, Hong Kong, Macau and Taiwan ("Greater China"). See Note 12 to the Consolidated Financial Statements in the 2021 10-K.

During the year ended December 31, 2019, the Company implemented changes to its corporate entity operating structure, including transferring certain intellectual property to its Swiss subsidiary, primarily to align corporate entities with the Company’s evolving operations and business model. As of January 1, 2022, the effective place of daily management and control of the Company moved to Switzerland and the Company has become a Swiss tax resident.

Financial statement preparation. The accompanying unaudited consolidated financial statements include the accounts of the Company and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation for the periods presented. The preparation of these consolidated financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the "2021 10-K") filed with the Securities and Exchange Commission on February 24, 2022.

The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2021 10-K are applied consistently in these unaudited interim consolidated financial statements, except as noted below:

Short-term investments

The Company accounts for investments in debt securities in accordance with ASC 320, "Investments—Debt and Equity Securities."

Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date. The Company classifies part of its debt securities as available-for-sale and the rest of the balance as held-to-maturity since the Company has the intent and ability to hold the securities to maturity.

Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders’ equity. Realized gains and losses on sale of investments are included in financial income, net and are derived using the specific identification method for determining the cost of securities sold.

The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.

Each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company’s ability and intent to hold the investment until a forecasted recovery occurs. Allowance for credit losses on available-for-sale debt securities are recognized in the Company’s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in stockholders’ equity.

Table of Contents

Held-to-maturity debt securities are stated at amortized cost of which is adjusted for amortization of premiums and accretion of discounts to maturity and any credit losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate.

NOTE 2: CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS

Cash equivalents include items almost as liquid as cash, with maturity periods of three months or less when purchased. As of March 31, 2022 and December 31, 2021, the Company’s cash and cash equivalents were composed of:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
Cash	$	8,376	$	3,139
Money market funds	92,071		64,668
Corporate debt securities	2,580		—
Certificate of deposits, notes and term deposits	87,712		140,995
Total cash and cash equivalents	$	190,739	$	208,802

Short-term investments include items with maturity dates between three months and one year when purchased. As of March 31, 2022 and December 31, 2021, the Company’s short-term investments were:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
U.S. Treasury bills	$	24,857	$	199,981
Other government and governmental agency notes	34,786		—
Corporate debt securities	196,274		104,823
Certificate of deposits, notes and term deposits	485,645		424,094
Total short-term investments	$	741,562	$	728,898

The Company invests in marketable U.S. Treasury Bills (“T-bills”), other government and governmental agency notes, term deposits, notes, certificate of deposits, money market funds and corporate debt securities that are classified as "held-to-maturity" or "available for sale" securities. These investments are presented as cash and cash equivalents or short-term investments, according their maturity periods.

The estimated fair value of the Company’s short-term investments as of March 31, 2022 and December 31, 2021 was $741,562 and $728,906, respectively. As of March 31, 2022 and December 31, 2021, amounts of $24,857 and $199,988, respectively were categorized as Level 1 and the remaining balance as level 2 in accordance with ASC 820, “Fair Value Measurements and Disclosures”.

NOTE 3: INVENTORIES

Inventories are stated at the lower of cost or net realizable value. The weighted average methodology is applied to determine cost. As of March 31, 2022 and December 31, 2021, the Company’s inventories were composed of:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
Raw materials	$	1,831	$	1,485
Work in progress	14,010		8,274
Finished products	13,243		14,668
Total	$	29,084	$	24,427

NOTE 4: COMMITMENTS AND CONTINGENT LIABILITIES

Table of Contents

Operating Leases. The facilities of the Company are leased under various operating lease agreements for periods, including options for extensions, ending no later than 2044. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2025.

Pledged deposits and bank guarantees. As of March 31, 2022 and December 31, 2021, the Company pledged bank deposits of $2,344 and $2,350, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained bank guarantees for the fulfillment of the Company’s lease and other contractual commitments of $2,692 and $2,698, respectively.

Senior secured revolving credit facility. On November 6, 2020, the Company entered into a three-year $150,000 senior secured revolving credit facility with a syndicate of relationship banks. For additional information, see Note 12(c) to the Consolidated Financial Statements in the 2021 10-K. As of March 31, 2022, the Company had no outstanding balance borrowed under the facility.

NOTE 5: CONVERTIBLE NOTE

On November 5, 2020, the Company issued $575,000 aggregate principal amount of 0% Convertible Senior Notes due 2025 (the “Notes”).

The Notes mature on November 1, 2025, unless earlier repurchased, redeemed or converted as set forth in the Notes. As of March 31, 2022, the conditions allowing holders of the Notes to convert were not met. The Notes are therefore not convertible as of March 31, 2022 and are classified as long-term liability.

For additional information, see Note 10(a) to the Consolidated Financial Statements in the 2021 10-K.

The net carrying amount of the liability of the Notes as of March 31, 2022 and December 31, 2021 are as follows:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
Liability component, net:
Principal amount	$	575,000	$	575,000
Unamortized issuance costs	(11,974)		(12,784)
Net carrying amount of liability component (1)	$	563,026	$	562,216

(1) An effective interest rate determines the fair value of the Notes, therefore they are categorized as Level 3 in accordance with ASC 820, "Fair Value Measurements and Disclosures." The estimated fair value of the net carrying amount of liability component of the Notes as of March 31, 2022 and December 31, 2021 were $454,285 and $467,469, respectively.

Finance expense related to the Notes was as follows:


	Three months ended March 31,			Year ended December 31, 2021
		2022				2021
	Unaudited			Audited
Amortization of debt issuance costs		810		709			3,339
Total finance expense recognized		$	810	$	709		$	3,339

NOTE 6: SHARE OPTION PLANS AND ESPP

In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). Under the 2015 Plan, the Company can issue various types of equity compensation awards such as share options, restricted shares, performance shares, restricted share units (“RSUs”), performance-based share units (“PSUs”), long-term cash awards and other share-based awards.

Options granted under the 2015 Plan generally have a two-year or four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are canceled or forfeited before expiration become

Table of Contents

available for future grants. RSUs granted under the 2015 Plan generally vest over a three year period. PSUs granted under the 2015 Plan generally vest between a three- and six-year period as performance targets are attained. RSUs and PSUs granted under the 2015 Plan that are canceled before expiration become available for future grants. As of March 31, 2022, 17,070,368 ordinary shares were available for grant under the 2015 Plan.

A summary of the status of the Company’s option plans as of March 31, 2022 and changes during the period then ended is presented below:


	Three months ended March 31, 2022
	Unaudited
	Number of options	Weighted average exercise price
Outstanding at beginning of year	8,549,322	$	33.09
Granted	575,246	80.59
Exercised	(175,650)	18.14
Forfeited and canceled	(13,467)	77.31
Outstanding as of March 31, 2022	8,935,451	$	36.38

Exercisable options	5,787,733	$	24.15

For the three months ended March 31, 2022, options to purchase 175,650 ordinary shares were exercised, resulting in the issuance of 175,650 ordinary shares.

A summary of the status of the Company’s RSUs and PSUs as of March 31, 2022 and changes during the period then ended is presented below.


	Three months ended March 31, 2022
	Unaudited
	Number of RSU/PSUs	Weighted average grant date fair value
Unvested at beginning of year	4,459,107	$	65.56
Granted	964,555	80.59
Vested	(412,175)	84.05
Forfeited and cancelled	(15,928)	99.97
Unvested as of March 31, 2022 (1)	4,995,559	66.83

(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones which are not probable, as of March 31, 2022, in accordance with ASC 718 as follows:

Table of Contents


March 31, 2022
Number of PSUs	Fair value at grant date per PSU		Total fair value at grant date
2,703,852	$	48.16	$	130,218
108,113	69.37		7,500
124,701	80.59		10,050
17,712	84.68		1,500
10,532	94.94		1,000
189,626	$	114.26	21,667
3,154,536			$	171,935

These PSUs will be expensed over the performance period when the vesting conditions become probable in accordance with ASC 718.

In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP are construed in a manner consistent with the requirements of such section. As of March 31, 2022, 4,954,997 ordinary shares were available to be purchased by eligible employees under the ESPP.

The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. We assessed fair value using the following underlying assumptions:


	Three months ended March 31,				Year ended December 31, 2021
	2022		2021
	Unaudited				Audited
Stock Option Plans
Expected term (years)	5.33-5.83		5.86-6.00		5.50-6
Expected volatility	60%-62%		60%-60%		60%-63%
Risk-free interest rate	1.58%-1.61%		0.85%-0.88%		0.78%-1.27%



Dividend yield	0.00	%	0.00	%	0.00	%
ESPP
Expected term (years)	0.50		0.50		0.50
Expected volatility	51	%	54	%	54%-81%
Risk-free interest rate	0.19	%	0.09	%	0.05%-0.09%


Dividend yield	0.00	%	0.00	%	0.00	%

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three months ended March 31, 2022 and 2021 and the year ended December 31, 2021 was:


	Three months ended March 31,			Year ended December 31, 2021
		2022				2021
	Unaudited			Audited
Cost of revenues		$	952	$	733		$	3,471
Research, development and clinical studies		6,801		5,124			27,597
Sales and marketing		6,655		4,471			22,673
General and administrative		10,637		8,535			41,159
Total share-based compensation expense		$	25,045	$	18,863		$	94,900

Table of Contents

NOTE 7: Basic and diluted net income (loss) per ordinary share

Basic net income (loss) per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted net income per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus potential dilutive shares (deriving from options, RSUs, PSUs, convertible notes and the ESPP) considered outstanding during the period, in accordance with ASC 260-10, as determined under the if-converted method.

The following table sets forth the computation of the Company’s basic and diluted net income (loss) per ordinary share:


	Three months ended March 31,			Year ended December 31, 2021
		2022				2021
	Unaudited			Audited
Net income (loss) attributable to ordinary shares as reported used in computing basic and diluted net income (loss) per share		$	(4,647)	$	(4,128)		$	(58,351)

Weighted average number of ordinary shares used in computing basic net income (loss) per share		104,186,120		102,633,545			103,433,274
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share:
Options		—		—			—
Restricted share units		—		—			—
ESPP		—		—			—
Weighted average number of ordinary shares used in computing diluted net income (loss) per share		104,186,120		102,633,545			103,433,274

Weighted anti-dilutive shares outstanding which were not included in the diluted calculation		7,874,118		9,734,269			8,524,922

Basic net income (loss) per ordinary share		$	(0.04)	$	(0.04)		$	(0.56)

Diluted net income (loss) per ordinary share		$	(0.04)	$	(0.04)		$	(0.56)

Table of Contents

NOTE 8: SUPPLEMENTAL INFORMATION

The Company operates in a single reportable segment.

The following table presents long-lived assets by location:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
United States	$	24,336	$	23,263
Israel	5,933		5,297
Switzerland	4,625		4,085
Japan	955		799
Germany	812		1,020
Others	1,203		1,152
Total	$	37,864	$	35,616

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:


	Three months ended March 31,			Year ended December 31, 2021
		2022				2021
	Unaudited			Audited
United States		$	97,416	$	85,908		$	353,110
EMEA:
Germany		19,238		26,364			93,939
Other EMEA		7,775		8,619			30,577
Japan		8,750		8,278			34,640
Greater China (1)		4,368		5,526			22,765
Total net revenues		$	137,547	$	134,695		$	535,031

(1) For additional information, see Note 12 to the Consolidated Financial Statements in the 2021 10-K.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to provide information to assist you in better understanding and evaluating our financial condition and results of operations. We encourage you to read this MD&A in conjunction with our unaudited consolidated financial statements and the notes thereto for the period ended March 31, 2022 included in Part I, Item 1 of this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. Please refer to the information under the heading “Cautionary Note Regarding Forward-Looking Statements” elsewhere in this report. References to the words “we,” “our,” “us,” and the “Company” in this report refer to NovoCure Limited, including its consolidated subsidiaries.

Critical Accounting Policies and Estimates

In accordance with U.S. generally accepted accounting principles (“GAAP”), in preparing our financial statements, we must make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of net revenues and expenses during the reporting period. We develop and periodically change these estimates and assumptions based on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates.

The critical accounting policies requiring estimates, assumptions and judgments that we believe have the most significant impact on our consolidated financial statements can be found in our 2021 10-K. For additional information, see Note 1 to our unaudited consolidated financial statements in Part I, Item 1 of this Quarterly Report. There were no other material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates described in our 2021 10-K.

Overview

We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields tuned to specific frequencies that disrupt cancer cell division. Our key priorities are to drive commercial adoption of Optune and Optune Lua, our commercial TTFields devices, and to advance clinical and product development programs intended to extend overall survival in some of the most aggressive forms of cancer.

Optune is approved by the U.S. Food and Drug Administration ("FDA") under the Premarket Approval ("PMA") pathway for the treatment of adult patients with newly diagnosed glioblastoma ("GBM") together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. We also have a CE certificate to market Optune for the treatment of GBM in the European Union ("EU"), as well as approval or local registration in the United Kingdom ("UK"), Japan and certain other countries. Optune Lua is approved by the FDA under the Humanitarian Device Exemption ("HDE") pathway to treatment malignant pleural mesothelioma ("MPM") together with standard chemotherapies. We have also received CE certification in the EU and approval or local registration to market Optune Lua in certain other countries. We market Optune and Optune Lua in multiple countries around the globe with the majority of our revenues coming from the use of Optune in the U.S., Germany and Japan. We are actively evaluating opportunities to expand our international footprint.

We believe the physical mechanism of action behind TTFields therapy may be broadly applicable to solid tumor cancers. Currently, we are conducting phase 3 pivotal studies evaluating the use of TTFields in non-small cell lung cancer ("NSCLC"), ovarian cancer, brain metastases from non-small cell lung cancer ("brain metastases") and pancreatic cancer. In 2021, we completed patient enrollment in our phase 3 pivotal NSCLC and ovarian cancer studies with data anticipated in 2022 and 2023, respectively. Additionally, we have multiple ongoing phase 2 pilot studies evaluating the use of TTFields. These studies are in gastric cancer, for which patient enrollment is complete, and stage 3 NSCLC, as well as testing the potential incremental survival benefit of TTFields delivered using high-intensity arrays versus standard arrays. We are also currently conducting a global phase 4 post-marketing study testing the potential survival benefit of initiating Optune concurrent with radiation therapy versus following radiation therapy in patients with newly diagnosed GBM. We anticipate expanding our clinical pipeline over time to study the safety and efficacy of TTFields for additional solid tumor indications and combinations with other cancer treatment modalities.

Table of Contents

In March 2022, we announced that an independent data monitoring committee ("DMC") conducted a pre-specified interim analysis for the phase 3 pivotal INNOVATE-3 study for the treatment of platinum-resistant ovarian cancer. As part of the interim analysis, the DMC reviewed the safety data for all enrolled patients and completed an analysis of overall survival on the first 540 patients randomized in the study. The interim analysis did not indicate a need to increase the patient sample size and the DMC recommended that the study should continue to final analysis as planned. The INNOVATE-3 study accrued 540 patients as of October 2021 and data will be reviewed in 2023, following an 18 month follow-up period.

The table below presents the current status of the ongoing clinical studies in our oncology pipeline and anticipated timing of final data.

Our therapy is delivered through a medical device and we continue to advance our Products with the intention to extend survival and maintain quality of life for patients. We have several product development programs underway that are designed to optimize TTFields delivery to the target tumor and enhance patient ease of use. Our intellectual property portfolio contains hundreds of issued patents and numerous patent applications pending worldwide. We believe we possess global commercialization rights to our Products in oncology and are well-positioned to extend those rights into the future as we continue to find innovative ways to improve our Products.

In 2018, we granted Zai Lab (Shanghai) Co., Ltd. ("Zai") a license to commercialize Optune in China, Hong Kong, Macau and Taiwan ("Greater China") under a License and Collaboration Agreement (the "Zai Agreement"). The Zai Agreement also establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. For additional information, see Note 12 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the "2021 10-K").

We view our operations and manage our business in one operating segment. For the three months ended March 31, 2022, our net revenues were $137.5 million. Our net loss for the three months ended March 31, 2022 was $4.6 million. As of March 31, 2022, we had an accumulated deficit of $690.6 million. Our net loss resulted primarily from net revenue growth which was more than offset by increasing investments in sales and marketing initiatives that support our growing commercial business, geographic expansion and pre-commercial activities associated with potential future indication launches.

Impact of COVID-19

In March 2020, the World Health Organization (“WHO”) declared COVID-19 a global pandemic. Since the pandemic began, we have been following the guidance of the WHO, the U.S. Centers for Disease Control and Prevention, and local health authorities in all of our active markets and we have adjusted the way we conduct business to adapt to

Table of Contents

the evolving situation. The COVID-19 pandemic did not have a material impact on our financial results through the first quarter of 2022. The pandemic has had and is having an impact on our day-to-day operations, which varies by region based on factors such as geographical spread, stage of containment and recurrence of the pandemic in each region. We believe the prolonged disruption caused by COVID-19 is resulting in increased volatility across global health care systems, such as fluctuations in patient volumes and changes in patterns of care in certain regions, which is currently impacting and might continue to impact our business and clinical studies in the future. For example, outside the U.S., localized lockdowns are causing disruptions in the ability to monitor clinical studies. In the first quarter of 2022 we were impacted by staff disruptions and turnover internally and at treatment sites, clinical study sites and third-party providers, either directly as a result of illness or indirectly as a result of vaccine mandates and other changes in terms of employment. TTFields is an emerging modality in cancer care and requires significant educational effort to drive awareness and acceptance of our therapy. We have relied heavily on virtual engagement to manage these educational efforts since the onset of the pandemic, which poses challenges to our ability to effectively communicate and engage with our customers and partners around the world.

Given the aggressive nature of the cancers that we treat, we believe that the fundamental value proposition of the TTFields platform remains unchanged. We continue to evaluate and plan for the potential effects of COVID-19 on our business moving forward. The extent to which the COVID-19 pandemic may impact our business and clinical studies in the future will depend on further developments, which are highly uncertain and cannot be predicted with confidence. The COVID-19 pandemic may also have the effect of heightening many of the other risks described in our risk factors disclosed in our 2021 10-K.

Commentary on Results of Operations

Net revenues. Our revenues are primarily derived from patients using our Products in our active markets. We charge for treatment with our Products on a monthly basis. Our potential net revenues per patient are determined by our ability to secure payment, the monthly fee we collect and the number of months that the patient remains on therapy.

We also receive revenues pursuant to the Zai Agreement. For additional information regarding the Zai Agreement, see Note 12 to the Consolidated Financial Statements in our 2021 10-K.

Cost of revenues. We contract with third parties to manufacture our Products. Our cost of revenues is primarily comprised of the following:

•disposable arrays;

•depreciation expense for the field equipment, including the electric field generator used by patients; and

•personnel and overhead costs such as facilities, freight and depreciation of property, plant and equipment associated with managing our inventory, warehousing and order fulfillment functions.

Operating expenses. Our operating expenses consist of research, development and clinical studies, sales and marketing and general and administrative expenses. Personnel costs are a significant component for each category of operating expenses and consist of wages, benefits and bonuses. Personnel costs also include share-based compensation.

Financial expenses, net. Financial expenses, net primarily consists of credit facility interest expense and related debt issuance costs, interest income from cash balances and short-term investments and gains (losses) from foreign currency transactions. Our reporting currency is the U.S. dollar. We have historically held substantially all of our cash balances in U.S. dollar denominated accounts to minimize the risk of translational currency exposure.

Results of Operations

The following discussion provides an analysis of our results of operations and reasons for material changes therein for the three months ended March 31, 2022 as compared to the three months ended March 31, 2021. The tables contained in this section report U.S. dollars in thousands (except share, patient, and prescription data).

Table of Contents

The following table sets forth our consolidated statements of operations data:


	Three months ended March 31,
		2022		2021
	Unaudited
Net revenues		$	137,547	$	134,695
Cost of revenues		27,727		26,385
Gross profit		109,820		108,310

Operating costs and expenses:
Research, development and clinical studies		42,234		45,916
Sales and marketing		37,884		31,357
General and administrative		30,508		31,125
Total operating costs and expenses		110,626		108,398

Operating income (loss)		(806)		(88)
Financial expenses (income), net		1,709		2,646

Income (loss) before income taxes		(2,515)		(2,734)
Income taxes		2,132		1,394
Net income (loss)		$	(4,647)	$	(4,128)

Basic net income (loss) per ordinary share		$	(0.04)	$	(0.04)
Weighted average number of ordinary shares used in computing basic net income (loss) per share		104,186,120		102,633,545
Diluted net income (loss) per ordinary share		$	(0.04)	$	(0.04)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share		104,186,120		102,633,545

The following table details the share-based compensation expense included in costs and expenses:


	Three months ended March 31,
		2022		2021
	Unaudited
Cost of revenues		$	952	$	733
Research, development and clinical studies		6,801		5,124
Sales and marketing		6,655		4,471
General and administrative		10,637		8,535
Total share-based compensation expense		$	25,045	$	18,863

Key performance indicators

We believe certain commercial operating statistics are useful to investors in evaluating our commercial business as they help our management team and investors evaluate and compare the adoption of our Products from period to period. The number of active patients on therapy is our principal revenue driver. An "active patient" is a patient who

Table of Contents

is receiving treatment under a commercial prescription order as of the measurement date, including patients who may be on a temporary break from treatment and who plan to resume treatment in less than 60 days. Prescriptions are a leading indicator of demand. A "prescription received" is a commercial order for Optune or Optune Lua that is received from a physician certified to treat patients with our Products for a patient not previously on Optune or Optune Lua. Orders to renew or extend treatment are not included in this total.

The following table includes certain commercial operating statistics for and as of the end of the periods presented.


	March 31,
Operating statistics	2022	2021
Active patients at period end
North America (1)	2,257	2,183
EMEA:
Germany	529	594
Other EMEA	436	406
Japan	327	271
Total	3,549	3,454


	Three months ended March 31,
		2022	2021
Prescriptions received in period
North America (1)		935	917
EMEA:
Germany		220	248
Other EMEA		127	134
Japan		102	103
Total		1,384	1,402

(1) North America includes data for the United States and Canada for the first quarter of 2022 and the United States only for all other periods.

There were 10 active MPM patients on therapy as of March 31, 2022 and 9 MPM prescriptions were received in the three months ended March 31, 2022.

Three months ended March 31, 2022 compared to three months ended March 31, 2021


	Three months ended March 31,
		2022		2021		% Change
Net revenues		$	137,547	$	134,695	2	%

Net revenues. Net revenues increased 2% to $137.5 million for the three-month period ended March 31, 2022 from $134.7 million for the same period in 2021. The increase resulted primarily from an increase of 95 active patients in our currently active markets, representing 3% growth. Additionally, for the quarter ended March 31, 2022, net revenue per active patient per month was positively impacted by increased collections for previously denied and appealed claims in the U.S., offset by a negative impact in Germany following contract negotiations with several large German payers. We continue to actively appeal and pursue previously denied claims, but the cadence and size of these collections are impossible to predict.


	Three months ended March 31,
		2022		2021		% Change
Cost of revenues		$	27,727	$	26,385	5	%

Cost of revenues. Our cost of revenues increased by 5% to $27.7 million for the three months ended March 31, 2022 from $26.4 million for the same period in 2021. For the three month period, the increase in cost of revenues

Table of Contents

was primarily due to the cost of shipping transducer arrays to a higher volume of commercial patients and increasing shipments of equipment to Zai Lab. We continue to focus on opportunities to increase efficiencies and scale within our supply chain. This includes evaluating new materials, manufacturers, and processes that could lead to lower costs.

Gross margin was 80% for the three months ended March 31, 2022 and 80% for the three months ended March 31, 2021. Excluding sales to Zai, cost of revenues per active patient per month was $2,413 for the three months ended March 31, 2022, virtually unchanged from $2,415 for the same period in 2021, with increasing supply chain efficiencies offsetting the impact of broader economic challenges. Cost of revenues per active patient is calculated by dividing the cost of revenues for the quarter less equipment sales to Zai for the quarter by the average of the active patients at the end of the prior quarter and the ending active patients in the current quarter. This quarterly figure is then divided by three to estimate the monthly cost of revenues per active patient. Sales to Zai are deducted because they are sold at cost and in anticipation of future royalties from Zai, and Zai patient counts are not included in our active patient population. Product sales to Zai totaled $1.9 million for the three months ended March 31, 2022 compared to $1.5 million for the three months ended March 31, 2021.

Operating Expenses.


	Three months ended March 31,
		2022		2021		% Change
Research, development and clinical studies		$	42,234	$	45,916	(8)	%
Sales and marketing		37,884		31,357		21	%
General and administrative		30,508		31,125		(2)	%
Total operating expenses		$	110,626	$	108,398	2	%

Research, development and clinical study expenses. Research, development and clinical study expenses decreased 8% to $42.2 million for the three-month period ended March 31, 2022 from $45.9 million in the same period in 2021, primarily driven by a reduction in direct clinical study costs. Direct clinical study costs historically represent approximately 30% of total research and development expenses and can fluctuate quarter-to-quarter, dependent on the amount of clinical research organization services delivered and clinical materials procured within a given quarter.

Sales and marketing expenses. Sales and marketing expenses increased 21% to $37.9 million for the three-month periods ended March 31, 2022 from $31.4 million for the same period in 2021. For the three month period, the change was primarily due to an increase in market research and strategic planning activities intended to enhance our commercial capabilities in anticipation of potential future approvals in new indications, including NSCLC and ovarian cancer. Additionally, we are investing in market access capabilities in order to evaluate opportunities, identify optimal access pathways, and successfully gain reimbursement in new geographies.

General and administrative expenses. General and administrative expenses decreased 2% to $30.5 million for the three months ended March 31, 2022 from $31.1 million for the same period in 2021. For the three month periods, the change was primarily due to a decrease in personnel costs.


	Three months ended March 31,
		2022		2021		% Change
Financial expenses (income), net		$	1,709	$	2,646	(35)	%

Financial expenses, net. Financial expenses decreased 35% to $1.7 for the three months ended March 31, 2022 from $2.6 for the same period in 2021. For the three month periods, the decrease was primarily due to increased interest income and foreign exchange rate fluctuations.

Table of Contents


	Three months ended March 31,
		2022		2021		% Change
Income taxes		$	2,132	$	1,394	53	%

Income taxes. Income taxes increased by $0.7 million, or 53% to $2.1 million for the three months ended March 31, 2022 compared to a tax expense of $1.4 million for the same period in 2021. For the three months ended March 31, 2022 the increase reflects a change in the mix of applicable statutory tax rates in active jurisdictions.

Non-GAAP financial measures

We also measure our performance using a non-GAAP measurement of earnings before interest, taxes, depreciation, amortization and shared-based compensation (“Adjusted EBITDA”). We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors evaluate and compare the results of our operations from period to period by removing the impact of earnings attributable to our capital structure, tax rate and material non-cash items, specifically share-based compensation.

We calculate Adjusted EBITDA as operating income before financial expenses and income taxes, net of depreciation, amortization and share-based compensation. The following table reconciles net income (loss), which is the most directly comparable GAAP operating performance measure, to Adjusted EBITDA.


	Three months ended March 31,
		2022		2021		% Change
Net income (loss)		$	(4,647)	$	(4,128)	13	%
Add: Income tax		2,132		1,394		53	%
Add: Financial expenses (income), net		1,709		2,646		(35)	%
Add: Depreciation and amortization		2,610		2,370		10	%
EBITDA		$	1,804	$	2,282	(21)	%
Add: Share-based compensation		25,045		18,863		33	%
Adjusted EBITDA		$	26,849	$	21,145	27	%

Adjusted EBITDA for the three months ended March 31, 2022 was $26.8 million. Net income was roughly flat compared to the same period in 2021, which reflects an increase in net revenue generated in the period, offset by investments in research and development, sales and marketing, and other operational activities intended to maximize future growth opportunities. Adjusted EBITDA increased by 27% from $21.1 million for the same period in 2021, which was primarily driven by a change in the mix of cash and non-cash based expenses in the form of share-based compensation.

Liquidity and Capital Resources

We have incurred significant losses and cumulative negative cash flows from operations since our founding in 2000. As of March 31, 2022, we had an accumulated deficit of $690.6 million. To date, we have primarily financed our operations through the issuance and sale of equity and the proceeds from long-term loans.

At March 31, 2022, we had $932.3 million in cash, cash equivalents and short-term investments, a decrease of $5.4 million compared to $937.7 million at December 31, 2021. We believe our cash, cash equivalents and short-term investments as of March 31, 2022 are sufficient for our operations for at least the next 12 months based on our existing business plan and our ability to control the timing of significant expense commitments. We expect that our research, development and clinical study expenses, sales and marketing expenses and general and administrative expenses will continue to increase over the next several years and may outpace our gross profit. As a result, we may need to raise additional capital to fund our operations.

Table of Contents

The following summary of our cash flows for the periods indicated has been derived from our unaudited consolidated financial statements, which are included elsewhere in this Quarterly Report:


	Three months ended March 31,
	2022		2021		Change		% Change
Net cash provided by (used in) operating activities	$	(3,687)	$	17,780	$	(21,467)	(121)	%
Net cash provided by (used in) investing activities	(17,410)		54,171		(71,581)		(132)	%
Net cash provided by financing activities	3,141		7,955		(4,814)		(61)	%
Effect of exchange rate changes on cash and cash equivalents	(25)		(102)		77		(75)	%
Net increase (decrease) in cash, cash equivalents and restricted cash	$	(17,981)	$	79,804	$	(97,785)	(123)	%

Operating activities. Net cash used in or provided by operating activities represents our net income (loss) for the periods presented, share-based compensation and depreciation and amortization. Operating cash flows are also impacted by changes in working capital.

Net cash provided by operating activities decreased by $21.5 million from $17.8 million net cash provided by operating activities for the three months ended March 31, 2021 to $3.7 million net cash used in operating activities for the three months ended March 31, 2022. This decrease was a result of net income being roughly flat compared to the same period in 2021, with a $27.8 million increase in working capital, including a $12.2 million decrease in accounts payables and accrued expenses, $12.1 million increase in accounts receivables and $3.5 million increase in inventories, partially offset by a $6.2 million change in the mix from cash to non-cash based expenses.

Investing activities. Our investing activities consist primarily of investments in and redemptions of our short-term investments as well as investments in property and equipment.

Net cash used in investing activities was $17.4 million for the three months ended March 31, 2022, compared to $54.2 million provided by investing activities for the three months ended March 31, 2021. The net cash used in investing activities for the three months ended March 31, 2022 was primarily attributable to $12.3 million of net purchase of short-term investments, and the purchase of $5.1 million of property and equipment. The net cash provided by investing activities for the three months ended March 31, 2021 was primarily attributable to $58.2 million of net proceeds from maturity of short-term investments, partially offset by the purchase of $4.0 million of property and equipment.

Financing activities. To date, our primary financing activities have been the sale of equity and the proceeds from long-term loans. Net cash provided by financing activities was $3.1 million for the three months ended March 31, 2022, as compared to $8.0 million provided by financing activities for the three months ended March 31, 2021. The net cash provided by financing activities for the three months ended March 31, 2022 and March 31, 2021 included proceeds from the exercise of options under the Company's stock option plan.

Convertible Notes

On November 5, 2020, we issued $575.0 million aggregate principal amount of 0% Convertible Senior Notes due 2025 (the “Notes”). The Notes are senior unsecured obligations. The Notes do not bear regular interest, and the principal amount of the Notes will not accrete. The Notes are convertible at an initial conversion rate of 5.9439 ordinary shares per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $168.24 per ordinary share. The Notes are convertible at the option of the holders upon the satisfaction of certain other conditions and during certain periods, and if the Company exercises its right to redeem the Notes as permitted or required by the indenture. On or after August 1, 2025 until the close of the business on the business day immediately preceding the maturity date, holders may convert all or any portion of their Notes at the conversion rate at any time irrespective of the foregoing conditions.

In January 2021, we irrevocably elected to settle all conversions of Notes by a combination of cash and our ordinary shares and that the cash portion per $1,000 principal amount of Notes for all conversion settlements shall be $1,000. Accordingly, from and after the date of the election, upon conversion of any Notes, holders of Notes will

Table of Contents

receive, with respect to each $1,000 principal amount of Notes converted, cash in an amount up to $1,000 and the balance of the conversion value, if any, in our ordinary shares

For more information, see Note 10a. to the Consolidated Financial Statements in the 2021 10-K.

Term loan credit facility

On November 6, 2020, we entered into a new three-year $150.0 million senior secured revolving credit facility with a syndicate of relationship banks (the "2020 Credit Facility"). We may, subject to certain conditions and limitations, increase the revolving credit commitments outstanding under the 2020 Credit Facility or incur new incremental term loans in an aggregate principal amount not to exceed an additional $100.0 million.

The commitments under the 2020 Credit Facility are guaranteed by certain of our subsidiaries and secured by a first lien on our and certain of our subsidiaries’ assets. Outstanding loans bear interest per annum at a sliding scale based on the our secured leverage ratio from 2.75% to 3.25% above the applicable interbank borrowing reference rate for the currency in which the loan is denominated. Additionally, the 2020 Credit Facility contains a fee for the unused revolving credit commitments at a sliding scale based on our secured leverage ratio from 0.35% to 0.45%. The 2020 Credit Facility contains financial covenants requiring maintenance of a minimum fixed charge coverage ratio and specifying a maximum senior secured net leverage ratio, as well as customary events of default which include a change of control. As of March 31, 2022, we were in compliance with such covenants.

As of March 31, 2022, we had no outstanding balance borrowed under the 2020 Credit Facility.

Contractual Obligations and Commitments

There have been no material changes from the information disclosed in our 2021 10-K.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements as defined under U.S. Securities and Exchange Commission (“SEC”) rules.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes from the information disclosed in our 2021 10-K.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2022, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2022, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting during the quarter ended March 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we are involved in various legal proceedings, claims, investigations and litigation that arise in the ordinary course of our business. Litigation is inherently uncertain. Accordingly, we cannot predict with certainty the outcome of these matters. After considering a number of factors, including (but not limited to) the views of legal counsel, the nature of contingencies to which the Company is subject and prior experience, management believes that the ultimate disposition of these legal actions will not materially affect its consolidated financial position or results of operations.

Item 1A. Risk Factors

There have been no material changes to our risk factors disclosed in Part I, Item 1A “Risk Factors” in the 2021 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits

EXHIBIT INDEX

Exhibit
Number

Incorporated by Reference

Filed
Herewith

Exhibit Description

Form

Date

Number

10.1

Employment Agreement, dated as of April 1, 2022, by and between NovoCure USA LLC and Todd Longsworth#

8-K

April 7, 2022

10.1

31.1

Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended

31.2

Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended

32.1*

Certification of Principal Executive Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350

32.2*

Certification of Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350

101.INS

Inline XBRL Instance Document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Extension Presentation Linkbase Document

104

Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101)

____________________________________________

* The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of NovoCure Limited under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.

# Compensation plans and arrangements for executive officers and others.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


						NovoCure Limited

Date: April 28, 2022						/s/ Ashley Cordova
						Ashley Cordova Chief Financial Officer (principal financial and accounting officer and duly authorized officer)

EX-31.1 2 nvcr-20220331exx311.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATIONS

I, Asaf Danziger, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of NovoCure Limited;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5.The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.


Date: April 28, 2022

/s/ Asaf Danziger
Asaf Danziger
Chief Executive Officer and Director

EX-31.2 3 nvcr-20220331xexx312.htm EX-31.2 Document

Exhibit 31.2

CERTIFICATIONS

I, Ashley Cordova, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of NovoCure Limited;

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.


Date: April 28, 2022

/s/ Ashley Cordova
Ashley Cordova
Chief Financial Officer
(Principal Accounting and Financial Officer)

EX-32.1 4 nvcr-20220331xexx321.htm EX-32.1 Document

Exhibit 32.1

NOVOCURE LIMITED

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of NovoCure Limited (the "Company") on Form 10-Q for the quarter ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Asaf Danziger, Chief Executive Officer (Principal Executive Officer) of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


/s/ Asaf Danziger
Asaf Danziger
Chief Executive Officer
(Principal Executive Officer)

Date: April 28, 2022

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff on request.

This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of NovoCure Limited under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

EX-32.2 5 nvcr-20220331xexx322.htm EX-32.2 Document

Exhibit 32.2

NOVOCURE LIMITED

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of NovoCure Limited (the "Company") on Form 10-Q for the quarter ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Ashley Cordova, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


/s/ Ashley Cordova
Ashley Cordova
Chief Financial Officer
(Principal Financial and Accounting Officer)

Date: April 28, 2022

EX-101.SCH 6 nvcr-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Summary of Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Summary of Amortized Cost And Recorded Basis of T-bills in Short Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 2111104 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 2113105 - Disclosure - CONVERTIBLE NOTE link:presentationLink link:calculationLink link:definitionLink 2314303 - Disclosure - CONVERTIBLE NOTE (Tables) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - CONVERTIBLE NOTE - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - CONVERTIBLE NOTE - Liability and Equity Components of the Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - CONVERTIBLE NOTE - Finance Expense Related to the Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2118106 - Disclosure - SHARE OPTION PLANS AND ESPP link:presentationLink link:calculationLink link:definitionLink 2319304 - Disclosure - SHARE OPTION PLANS AND ESPP (Tables) link:presentationLink link:calculationLink link:definitionLink 2420409 - Disclosure - SHARE OPTION PLANS AND ESPP - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2421410 - Disclosure - SHARE OPTION PLANS AND ESPP - Schedule of Stock Option Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - SHARE OPTION PLANS AND ESPP - Schedule of RSUs and PSUs (Details) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - SHARE OPTION PLANS AND ESPP - Schedule of Fair Value Assumptions Used Only for Equity Based Awards Estimated Using Black-Scholes Option Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - SHARE OPTION PLANS AND ESPP - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) link:presentationLink link:calculationLink link:definitionLink 2125107 - Disclosure - Basic and diluted net income (loss) per ordinary share link:presentationLink link:calculationLink link:definitionLink 2326305 - Disclosure - Basic and diluted net income (loss) per ordinary share (Tables) link:presentationLink link:calculationLink link:definitionLink 2427414 - Disclosure - Basic and diluted net income (loss) per ordinary share (Details) link:presentationLink link:calculationLink link:definitionLink 2128108 - Disclosure - SUPPLEMENTAL INFORMATION link:presentationLink link:calculationLink link:definitionLink 2329306 - Disclosure - SUPPLEMENTAL INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2430415 - Disclosure - SUPPLEMENTAL INFORMATION - Schedule of Long-Lived Assets by Location (Details) link:presentationLink link:calculationLink link:definitionLink 2431416 - Disclosure - SUPPLEMENTAL INFORMATION - Schedule of Revenues by Geographic Region (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nvcr-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 nvcr-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 nvcr-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Risk-free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Number of PSUs (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Not Expected to Vest, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Not Expected to Vest, Nonvested, Number Long-term leases Operating Lease, Liability, Noncurrent Aggregate principal amount Debt Instrument, Face Amount Convertible Debt Convertible Debt [Member] LONG-TERM ASSETS: Assets, Noncurrent [Abstract] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net income (loss) Net income (loss) Net income (loss) attributable to ordinary shares as reported used in computing basic and diluted net income (loss) per share Net Income (Loss) Attributable to Parent Expected volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Right-of-use assets Operating Lease, Right-of-Use Asset Income Statement Location Income Statement Location [Axis] Granted [Axis] Granted [Axis] Granted Statistical Measurement [Domain] Statistical Measurement [Domain] Pledged bank deposits Deposits Assets Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Stock awards granted, expiration period (years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Restricted share units Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Shares issued under plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Filer Category Entity Filer Category Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Forfeited and cancelled (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value U.S. Treasury bills US Treasury Securities [Member] Income Statement [Abstract] Number of options, forfeited and canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Entity Registrant Name Entity Registrant Name Inventory Disclosure [Abstract] Other long-term assets Other Assets, Noncurrent Entity Address, Country Entity Address, Country Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Exercise of options Proceeds from Stock Options Exercised Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Ordinary shares available for grants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Weighted average exercise price, forfeited and canceled (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Income tax Income Tax Expense (Benefit) Share-based compensation to employees APIC, Share-based Payment Arrangement, Increase for Cost Recognition Trade receivables, net Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Equity Components Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Certificate of deposits, notes and term deposits Certificates of Deposit [Member] Award Six Award Six [Member] Award Six Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Sale of Stock Sale of Stock [Domain] Forfeited and cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Inventories Total Inventory, Net Organization, Consolidation and Presentation of Financial Statements [Abstract] Statement of Financial Position [Abstract] Weighted anti-dilutive shares outstanding which were not included in the diluted calculation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Research, development and clinical studies Research and Development Expense [Member] Sale of Stock Sale of Stock [Axis] Summary of Amortized Cost and Recorded Basis of T-bills in Short-Term Investments Debt Securities, Held-to-maturity [Table Text Block] Summary of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Other payables, lease liabilities and accrued expenses Other Accounts Payable Lease Liabilities And Accrued Expenses Current Other accounts payable lease liabilities and accrued expenses current. Granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component Equity Component [Domain] Sales and marketing Selling and Marketing Expense Change in foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Equity Award Award Type [Domain] Summary of the Convertible Notes Convertible Debt [Table Text Block] Local Phone Number Local Phone Number Credit Facility [Domain] Credit Facility [Domain] ASSETS Assets [Abstract] Accrued Interest Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Amortization of discount (premium) Amortization of Debt Discount (Premium) Number of options, exercisable options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Statement [Line Items] Statement [Line Items] Increase (decrease) in other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Weighted average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] the “Notes” 0% Convertible Senior Notes Due 2025 [Member] 0% Convertible Senior Notes Due 2025 (the “Notes”) Number of options, beginning outstanding (in shares) Number of options, ending outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Retained earnings (accumulated deficit) Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Award One Award One [Member] Award One Debt Disclosure [Abstract] Greater China CHINA LONG-TERM LIABILITIES: Liabilities, Noncurrent [Abstract] COMMITMENTS AND CONTINGENT LIABILITIES Commitments and Contingencies Disclosure [Text Block] Income (loss) before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Cash, Cash Equivalents, and Short-term Investments [Text Block] Deferred revenue Contract with Customer, Liability, Noncurrent Others Others Countries [Member] Others countries. Schedule of Long-Lived Assets by Location Long-lived Assets by Geographic Areas [Table Text Block] Decrease (increase) in accounts receivables Increase (Decrease) in Accounts Receivable Estimated fair value of short-term investments Debt Securities, Held-to-maturity, Fair Value Right-of-use assets obtained in exchange for lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Schedule of Basic and Diluted Net Income (Loss) Per Ordinary Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Number of options, granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Germany GERMANY Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Title of 12(b) Security Title of 12(b) Security Proceeds from issuance of shares, net Proceeds from Issuance of Common Stock Other comprehensive income (loss), tax benefit Other Comprehensive Income (Loss), Tax TOTAL ASSETS Assets Plan Name Plan Name [Domain] Basic net income (loss) per ordinary share (in usd per share) Earnings Per Share, Basic Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical Geographical [Domain] Pension benefit plan Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Document Type Document Type Research, development and clinical studies Research and Development Expense Unvested at beginning of year (in shares) Unvested at ending of year (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Total finance expense recognized Interest Expense, Debt Total long-term liabilities Liabilities, Noncurrent Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Switzerland SWITZERLAND Number of RSU/PSUs Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Revolving Credit Facility Revolving Credit Facility [Member] Cash Cash [Member] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Sales and marketing Sales And Marketing [Member] Sales and Marketing. Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Cumulative effect adjustment resulting from ASU 2020-06 early adoption Cumulative Effect, Period of Adoption, Adjustment [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Restricted Cash and Cash Equivalents Items [Line Items] Cash and Cash Equivalents [Line Items] Geographical Geographical [Axis] Diluted net income (loss) per ordinary share (in usd per share) Earnings Per Share, Diluted Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) Weighted Average Number of Shares Outstanding, Basic Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Income taxes paid (refunded), net Income Taxes Paid, Net Geographic Areas, Long-Lived Assets [Abstract] Principal amount Long-term Debt, Gross Accounting standards update [extensible enumeration] Accounting Standards Update [Extensible Enumeration] Award Two Award Two [Member] Award Two Plan Name Plan Name [Axis] Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net carrying amount of liability component Long-term Debt Cost of revenues Cost of Revenue Short-term investments Investment, Policy [Policy Text Block] Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Short-term investments Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Entity Small Business Entity Small Business Stock awards granted, vesting period (years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity Corporate debt securities Corporate Debt Securities [Member] Weighted average exercise price, exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Additional paid-in capital Additional Paid in Capital Supplemental cash flow activities: Supplemental Cash Flow Elements [Abstract] Award Four Award Four [Member] Award Four LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Decrease (increase) in inventories Increase (Decrease) in Inventories Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Basic and diluted net income (loss) per ordinary share Earnings Per Share [Text Block] Operating costs and expenses: Operating Expenses [Abstract] Entity Interactive Data Current Entity Interactive Data Current Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Minimum Minimum [Member] Document Period End Date Document Period End Date ORGANIZATION AND BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Entity Central Index Key Entity Central Index Key Gross profit Gross Profit Amount outstanding Long-term Line of Credit Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Number of options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Unamortized issuance costs Debt Issuance Costs, Net Financial expenses (income), net Interest and Debt Expense Award Five Award Five [Member] Award Five Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Award Three Award Three [Member] Award Three Income Statement Location Income Statement Location [Domain] Contractual term Debt Instrument, Term Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Non-cash activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Receivables and prepaid expenses Receivables And Prepaid Expenses Receivables and prepaid expenses. Property and equipment, net Property, Plant and Equipment, Net Total operating costs and expenses Operating Expenses SHARE OPTION PLANS AND ESPP Shareholders' Equity and Share-based Payments [Text Block] Other long-term liabilities Other Liabilities, Noncurrent CURRENT LIABILITIES: Liabilities, Current [Abstract] Field equipment, net Field Equipment Net Noncurrent Field equipment, net, noncurrent. General and administrative General and Administrative Expense Debt Instrument [Line Items] Debt Instrument [Line Items] CONVERTIBLE NOTE Debt Disclosure [Text Block] Repayment of long-term debt Repayments of Long-term Debt EX-101.PRE 10 nvcr-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 nvcr-20220331_g1.jpg begin 644 nvcr-20220331_g1.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2022	Apr. 22, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-37565
Entity Registrant Name	NovoCure Limited
Entity Incorporation, State or Country Code	Y9
Entity Tax Identification Number	98-1057807
Entity Address, Address Line One	No. 4 The Forum
Entity Address, Address Line Two	Grenville Street
Entity Address, City or Town	St. Helier
Entity Address, Country	JE
Entity Address, Postal Zip Code	JE2 4UF
City Area Code	44 (0) 15
Local Phone Number	3475 6700
Title of 12(b) Security	Ordinary Shares, no par value
Trading Symbol	NVCR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		104,586,094
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001645113
Current Fiscal Year End Date	--12-31

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 190,739	$ 208,802
Short-term investments	741,562	728,898
Restricted cash	889	807
Trade receivables, net	100,965	93,567
Receivables and prepaid expenses	17,343	17,025
Inventories	29,084	24,427
Total current assets	1,080,582	1,073,526
LONG-TERM ASSETS:
Property and equipment, net	25,072	22,693
Field equipment, net	12,792	12,923
Right-of-use assets	19,937	18,267
Other long-term assets	11,827	12,086
Total long-term assets	69,628	65,969
TOTAL ASSETS	1,150,210	1,139,495
CURRENT LIABILITIES:
Trade payables	69,186	72,600
Other payables, lease liabilities and accrued expenses	58,613	70,002
Total current liabilities	127,799	142,602
LONG-TERM LIABILITIES:
Long-term debt, net	563,026	562,216
Deferred revenue	5,511	6,477
Long-term leases	14,813	12,997
Employee benefit liabilities	3,024	4,543
Other long-term liabilities	156	166
Total long-term liabilities	586,530	586,399
TOTAL LIABILITIES	714,329	729,001
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 104,559,088 shares and 103,971,263 shares at March 31, 2022 (unaudited) and December 31, 2021, respectively	0	0
Additional paid-in capital	1,127,782	1,099,589
Accumulated other comprehensive income (loss)	(1,328)	(3,169)
Retained earnings (accumulated deficit)	(690,573)	(685,926)
TOTAL SHAREHOLDERS' EQUITY	435,881	410,494
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 1,150,210	$ 1,139,495

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, shares issued (in shares)	104,559,088	103,971,263
Common stock, shares outstanding (in shares)	104,559,088	103,971,263

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Income Statement [Abstract]
Net revenues	$ 137,547	$ 134,695	$ 535,031
Cost of revenues	27,727	26,385	114,877
Gross profit	109,820	108,310	420,154
Operating costs and expenses:
Research, development and clinical studies	42,234	45,916	201,303
Sales and marketing	37,884	31,357	137,057
General and administrative	30,508	31,125	126,127
Total operating costs and expenses	110,626	108,398	464,487
Operating income (loss)	(806)	(88)	(44,333)
Financial expenses (income), net	1,709	2,646	7,742
Income (loss) before income tax	(2,515)	(2,734)	(52,075)
Income tax	2,132	1,394	6,276
Net income (loss)	$ (4,647)	$ (4,128)	$ (58,351)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.04)	$ (0.04)	$ (0.56)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	104,186,120	102,633,545	103,433,274
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.04)	$ (0.04)	$ (0.56)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	104,186,120	102,633,545	103,433,274

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (4,647)	$ (4,128)	$ (58,351)
Other comprehensive income (loss), net of tax:
Change in foreign currency translation adjustments	330	(268)	302
Pension benefit plan	1,511	2,152	361
Total comprehensive income (loss)	$ (2,806)	$ (2,244)	$ (57,688)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Cumulative effect adjustment resulting from ASU 2020-06 early adoption	Ordinary shares	Additional paid-in capital	Additional paid-in capital Cumulative effect adjustment resulting from ASU 2020-06 early adoption	Accumulated other comprehensive loss	Retained earnings (accumulated deficit)	Retained earnings (accumulated deficit) Cumulative effect adjustment resulting from ASU 2020-06 early adoption
Beginning balance (in shares) at Dec. 31, 2020			102,334,276
Beginning balance at Dec. 31, 2020	$ 476,526	$ (128,972)		$ 1,111,435	$ (132,474)	$ (3,832)	$ (631,077)	$ 3,502
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation to employees	18,863			18,863
Exercise of options and vested RSUs (in shares)			853,184
Exercise of options and vested RSUs	7,961			7,961
Other comprehensive income (loss), net of tax benefit of $0	1,884					1,884
Net income (loss)	(4,128)						(4,128)
Ending balance (in shares) at Mar. 31, 2021			103,187,460
Ending balance at Mar. 31, 2021	372,134			1,005,785		(1,948)	(631,703)
Beginning balance (in shares) at Dec. 31, 2020			102,334,276
Beginning balance at Dec. 31, 2020	476,526	$ (128,972)		1,111,435	$ (132,474)	(3,832)	(631,077)	$ 3,502
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(58,351)
Ending balance (in shares) at Dec. 31, 2021			103,971,263
Ending balance at Dec. 31, 2021	410,494			1,099,589		(3,169)	(685,926)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation to employees	25,045			25,045
Exercise of options and vested RSUs (in shares)			587,825
Exercise of options and vested RSUs	3,148			3,148
Other comprehensive income (loss), net of tax benefit of $0	1,841					1,841
Net income (loss)	(4,647)						(4,647)
Ending balance (in shares) at Mar. 31, 2022			104,559,088
Ending balance at Mar. 31, 2022	$ 435,881			$ 1,127,782		$ (1,328)	$ (690,573)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Statement of Stockholders' Equity [Abstract]
Other comprehensive income (loss), tax benefit	$ 0	$ 0

- Definition

Amount of tax expense (benefit) allocated to other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

XML 19 R8.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net income (loss)	$ (4,647)	$ (4,128)	$ (58,351)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	2,610	2,370	10,251
Accrued Interest	(221)	0	(94)
Asset write-downs and impairment of field equipment	135	176	649
Share-based compensation	25,045	18,863	94,900
Foreign currency remeasurement loss (gain)	249	2,157	3,231
Decrease (increase) in accounts receivables	(7,461)	4,624	5,270
Amortization of discount (premium)	684	603	3,101
Decrease (increase) in inventories	(4,804)	(1,296)	2,483
Decrease (increase) in other long-term assets	1,863	1,432	4,519
Increase (decrease) in accounts payables and accrued expenses	(14,809)	(2,626)	27,777
Increase (decrease) in other long-term liabilities	(2,331)	(4,394)	(10,980)
Net cash provided by (used in) operating activities	(3,687)	17,780	82,756
Cash flows from investing activities:
Purchase of property, equipment and field equipment	(5,093)	(3,981)	(24,170)
Proceeds from maturity of short-term investments	279,000	608,000	958,000
Purchase of short-term investments	(291,317)	(549,848)	(1,078,664)
Net cash provided by (used in) investing activities	(17,410)	54,171	(144,834)
Cash flows from financing activities:
Proceeds from issuance of shares, net	0	0	4,546
Repayment of long-term debt	(7)	(6)	(26)
Exercise of options	3,148	7,961	21,182
Net cash provided by (used in) financing activities	3,141	7,955	25,702
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(25)	(102)	(188)
Increase (decrease) in cash, cash equivalents and restricted cash	(17,981)	79,804	(36,564)
Cash, cash equivalents and restricted cash at the beginning of the period	209,609	246,173	246,173
Cash, cash equivalents and restricted cash at the end of the period	191,628	325,977	209,609
Cash paid during the period for:
Income taxes paid (refunded), net	1,173	(2,405)	3,110
Interest paid	1	1	101
Non-cash activities:
Right-of-use assets obtained in exchange for lease liabilities	$ 3,580	$ 284	$ 5,387

XML 20 R9.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND BASIS OF PRESENTATION	3 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION Organization. NovoCure Limited (including its consolidated subsidiaries, the "Company") was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields ("TTFields") devices, including Optune and Optune Lua (collectively, our "Products"), for the treatment of solid tumor cancers. The Company currently markets Optune in the United States ("U.S."), Germany, Japan and certain other countries. The Company currently markets Optune Lua in the U.S. and European Union. The Company also has a License and Collaboration Agreement (the "Zai Agreement") with Zai Lab (Shanghai) Co., Ltd. ("Zai") to market Optune in China, Hong Kong, Macau and Taiwan ("Greater China"). See Note 12 to the Consolidated Financial Statements in the 2021 10-K. During the year ended December 31, 2019, the Company implemented changes to its corporate entity operating structure, including transferring certain intellectual property to its Swiss subsidiary, primarily to align corporate entities with the Company’s evolving operations and business model. As of January 1, 2022, the effective place of daily management and control of the Company moved to Switzerland and the Company has become a Swiss tax resident. Financial statement preparation. The accompanying unaudited consolidated financial statements include the accounts of the Company and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation for the periods presented. The preparation of these consolidated financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the "2021 10-K") filed with the Securities and Exchange Commission on February 24, 2022. The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2021 10-K are applied consistently in these unaudited interim consolidated financial statements, except as noted below: Short-term investments The Company accounts for investments in debt securities in accordance with ASC 320, "Investments—Debt and Equity Securities." Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date. The Company classifies part of its debt securities as available-for-sale and the rest of the balance as held-to-maturity since the Company has the intent and ability to hold the securities to maturity. Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders’ equity. Realized gains and losses on sale of investments are included in financial income, net and are derived using the specific identification method for determining the cost of securities sold. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net. Each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company’s ability and intent to hold the investment until a forecasted recovery occurs. Allowance for credit losses on available-for-sale debt securities are recognized in the Company’s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in stockholders’ equity. Held-to-maturity debt securities are stated at amortized cost of which is adjusted for amortization of premiums and accretion of discounts to maturity and any credit losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate.

XML 21 R10.htm IDEA: XBRL DOCUMENT

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS

3 Months Ended

Mar. 31, 2022

Cash, Cash Equivalents, and Short-term Investments [Abstract]

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS


	March 31, 2022		December 31, 2021
	Unaudited		Audited
Cash	$	8,376	$	3,139
Money market funds	92,071		64,668
Corporate debt securities	2,580		—
Certificate of deposits, notes and term deposits	87,712		140,995
Total cash and cash equivalents	$	190,739	$	208,802

Short-term investments include items with maturity dates between three months and one year when purchased. As of March 31, 2022 and December 31, 2021, the Company’s short-term investments were:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
U.S. Treasury bills	$	24,857	$	199,981
Other government and governmental agency notes	34,786		—
Corporate debt securities	196,274		104,823
Certificate of deposits, notes and term deposits	485,645		424,094
Total short-term investments	$	741,562	$	728,898

XML 22 R11.htm IDEA: XBRL DOCUMENT

INVENTORIES

3 Months Ended

Mar. 31, 2022

Inventory Disclosure [Abstract]

INVENTORIES

INVENTORIESInventories are stated at the lower of cost or net realizable value. The weighted average methodology is applied to determine cost. As of March 31, 2022 and December 31, 2021, the Company’s inventories were composed of:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
Raw materials	$	1,831	$	1,485
Work in progress	14,010		8,274
Finished products	13,243		14,668
Total	$	29,084	$	24,427

XML 23 R12.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENT LIABILITIES	3 Months Ended
COMMITMENTS AND CONTINGENT LIABILITIES	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	COMMITMENTS AND CONTINGENT LIABILITIES Operating Leases. The facilities of the Company are leased under various operating lease agreements for periods, including options for extensions, ending no later than 2044. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2025. Pledged deposits and bank guarantees. As of March 31, 2022 and December 31, 2021, the Company pledged bank deposits of $2,344 and $2,350, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained bank guarantees for the fulfillment of the Company’s lease and other contractual commitments of $2,692 and $2,698, respectively. Senior secured revolving credit facility. On November 6, 2020, the Company entered into a three-year $150,000 senior secured revolving credit facility with a syndicate of relationship banks. For additional information, see Note 12(c) to the Consolidated Financial Statements in the 2021 10-K. As of March 31, 2022, the Company had no outstanding balance borrowed under the facility.

XML 24 R13.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTE

3 Months Ended

Mar. 31, 2022

Debt Disclosure [Abstract]

CONVERTIBLE NOTE

On November 5, 2020, the Company issued $575,000 aggregate principal amount of 0% Convertible Senior Notes due 2025 (the “Notes”).

For additional information, see Note 10(a) to the Consolidated Financial Statements in the 2021 10-K.

The net carrying amount of the liability of the Notes as of March 31, 2022 and December 31, 2021 are as follows:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
Liability component, net:
Principal amount	$	575,000	$	575,000
Unamortized issuance costs	(11,974)		(12,784)
Net carrying amount of liability component (1)	$	563,026	$	562,216

Finance expense related to the Notes was as follows:


	Three months ended March 31,			Year ended December 31, 2021
		2022				2021
	Unaudited			Audited
Amortization of debt issuance costs		810		709			3,339
Total finance expense recognized		$	810	$	709		$	3,339

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

SHARE OPTION PLANS AND ESPP

3 Months Ended

Mar. 31, 2022

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]

SHARE OPTION PLANS AND ESPP

A summary of the status of the Company’s option plans as of March 31, 2022 and changes during the period then ended is presented below:


	Three months ended March 31, 2022
	Unaudited
	Number of options	Weighted average exercise price
Outstanding at beginning of year	8,549,322	$	33.09
Granted	575,246	80.59
Exercised	(175,650)	18.14
Forfeited and canceled	(13,467)	77.31
Outstanding as of March 31, 2022	8,935,451	$	36.38

Exercisable options	5,787,733	$	24.15

For the three months ended March 31, 2022, options to purchase 175,650 ordinary shares were exercised, resulting in the issuance of 175,650 ordinary shares.

A summary of the status of the Company’s RSUs and PSUs as of March 31, 2022 and changes during the period then ended is presented below.


	Three months ended March 31, 2022
	Unaudited
	Number of RSU/PSUs	Weighted average grant date fair value
Unvested at beginning of year	4,459,107	$	65.56
Granted	964,555	80.59
Vested	(412,175)	84.05
Forfeited and cancelled	(15,928)	99.97
Unvested as of March 31, 2022 (1)	4,995,559	66.83


March 31, 2022
Number of PSUs	Fair value at grant date per PSU		Total fair value at grant date
2,703,852	$	48.16	$	130,218
108,113	69.37		7,500
124,701	80.59		10,050
17,712	84.68		1,500
10,532	94.94		1,000
189,626	$	114.26	21,667
3,154,536			$	171,935

These PSUs will be expensed over the performance period when the vesting conditions become probable in accordance with ASC 718.


	Three months ended March 31,				Year ended December 31, 2021
	2022		2021
	Unaudited				Audited
Stock Option Plans
Expected term (years)	5.33-5.83		5.86-6.00		5.50-6
Expected volatility	60%-62%		60%-60%		60%-63%
Risk-free interest rate	1.58%-1.61%		0.85%-0.88%		0.78%-1.27%



Dividend yield	0.00	%	0.00	%	0.00	%
ESPP
Expected term (years)	0.50		0.50		0.50
Expected volatility	51	%	54	%	54%-81%
Risk-free interest rate	0.19	%	0.09	%	0.05%-0.09%


Dividend yield	0.00	%	0.00	%	0.00	%


	Three months ended March 31,			Year ended December 31, 2021
		2022				2021
	Unaudited			Audited
Cost of revenues		$	952	$	733		$	3,471
Research, development and clinical studies		6,801		5,124			27,597
Sales and marketing		6,655		4,471			22,673
General and administrative		10,637		8,535			41,159
Total share-based compensation expense		$	25,045	$	18,863		$	94,900

XML 26 R15.htm IDEA: XBRL DOCUMENT

Basic and diluted net income (loss) per ordinary share

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Basic and diluted net income (loss) per ordinary share

The following table sets forth the computation of the Company’s basic and diluted net income (loss) per ordinary share:


	Three months ended March 31,			Year ended December 31, 2021
		2022				2021
	Unaudited			Audited
Net income (loss) attributable to ordinary shares as reported used in computing basic and diluted net income (loss) per share		$	(4,647)	$	(4,128)		$	(58,351)

Weighted average number of ordinary shares used in computing basic net income (loss) per share		104,186,120		102,633,545			103,433,274
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share:
Options		—		—			—
Restricted share units		—		—			—
ESPP		—		—			—
Weighted average number of ordinary shares used in computing diluted net income (loss) per share		104,186,120		102,633,545			103,433,274

Weighted anti-dilutive shares outstanding which were not included in the diluted calculation		7,874,118		9,734,269			8,524,922

Basic net income (loss) per ordinary share		$	(0.04)	$	(0.04)		$	(0.56)

Diluted net income (loss) per ordinary share		$	(0.04)	$	(0.04)		$	(0.56)

XML 27 R16.htm IDEA: XBRL DOCUMENT

SUPPLEMENTAL INFORMATION

3 Months Ended

Mar. 31, 2022

Geographic Areas, Long-Lived Assets [Abstract]

SUPPLEMENTAL INFORMATION

The Company operates in a single reportable segment.

The following table presents long-lived assets by location:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
United States	$	24,336	$	23,263
Israel	5,933		5,297
Switzerland	4,625		4,085
Japan	955		799
Germany	812		1,020
Others	1,203		1,152
Total	$	37,864	$	35,616

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:


	Three months ended March 31,			Year ended December 31, 2021
		2022				2021
	Unaudited			Audited
United States		$	97,416	$	85,908		$	353,110
EMEA:
Germany		19,238		26,364			93,939
Other EMEA		7,775		8,619			30,577
Japan		8,750		8,278			34,640
Greater China (1)		4,368		5,526			22,765
Total net revenues		$	137,547	$	134,695		$	535,031

(1) For additional information, see Note 12 to the Consolidated Financial Statements in the 2021 10-K.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND BASIS OF PRESENTATION (Policies)	3 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION (Policies)	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Short-term investments	Short-term investments The Company accounts for investments in debt securities in accordance with ASC 320, "Investments—Debt and Equity Securities." Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date. The Company classifies part of its debt securities as available-for-sale and the rest of the balance as held-to-maturity since the Company has the intent and ability to hold the securities to maturity. Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders’ equity. Realized gains and losses on sale of investments are included in financial income, net and are derived using the specific identification method for determining the cost of securities sold. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net. Each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company’s ability and intent to hold the investment until a forecasted recovery occurs. Allowance for credit losses on available-for-sale debt securities are recognized in the Company’s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in stockholders’ equity. Held-to-maturity debt securities are stated at amortized cost of which is adjusted for amortization of premiums and accretion of discounts to maturity and any credit losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate.

XML 29 R18.htm IDEA: XBRL DOCUMENT

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2022

Cash, Cash Equivalents, and Short-term Investments [Abstract]

Summary of Cash and Cash Equivalents

As of March 31, 2022 and December 31, 2021, the Company’s cash and cash equivalents were composed of:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
Cash	$	8,376	$	3,139
Money market funds	92,071		64,668
Corporate debt securities	2,580		—
Certificate of deposits, notes and term deposits	87,712		140,995
Total cash and cash equivalents	$	190,739	$	208,802

Summary of Amortized Cost and Recorded Basis of T-bills in Short-Term Investments

As of March 31, 2022 and December 31, 2021, the Company’s short-term investments were:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
U.S. Treasury bills	$	24,857	$	199,981
Other government and governmental agency notes	34,786		—
Corporate debt securities	196,274		104,823
Certificate of deposits, notes and term deposits	485,645		424,094
Total short-term investments	$	741,562	$	728,898

XML 30 R19.htm IDEA: XBRL DOCUMENT

INVENTORIES (Tables)

3 Months Ended

Mar. 31, 2022

Inventory Disclosure [Abstract]

Schedule of Inventories

As of March 31, 2022 and December 31, 2021, the Company’s inventories were composed of:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
Raw materials	$	1,831	$	1,485
Work in progress	14,010		8,274
Finished products	13,243		14,668
Total	$	29,084	$	24,427

XML 31 R20.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTE (Tables)

3 Months Ended

Mar. 31, 2022

Debt Disclosure [Abstract]

Summary of the Convertible Notes

The net carrying amount of the liability of the Notes as of March 31, 2022 and December 31, 2021 are as follows:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
Liability component, net:
Principal amount	$	575,000	$	575,000
Unamortized issuance costs	(11,974)		(12,784)
Net carrying amount of liability component (1)	$	563,026	$	562,216

Finance expense related to the Notes was as follows:


	Three months ended March 31,			Year ended December 31, 2021
		2022				2021
	Unaudited			Audited
Amortization of debt issuance costs		810		709			3,339
Total finance expense recognized		$	810	$	709		$	3,339

XML 32 R21.htm IDEA: XBRL DOCUMENT

SHARE OPTION PLANS AND ESPP (Tables)

3 Months Ended

Mar. 31, 2022

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]

Schedule of Stock Option Plans

A summary of the status of the Company’s option plans as of March 31, 2022 and changes during the period then ended is presented below:


	Three months ended March 31, 2022
	Unaudited
	Number of options	Weighted average exercise price
Outstanding at beginning of year	8,549,322	$	33.09
Granted	575,246	80.59
Exercised	(175,650)	18.14
Forfeited and canceled	(13,467)	77.31
Outstanding as of March 31, 2022	8,935,451	$	36.38

Exercisable options	5,787,733	$	24.15

Schedule of RSUs and PSUs

A summary of the status of the Company’s RSUs and PSUs as of March 31, 2022 and changes during the period then ended is presented below.


	Three months ended March 31, 2022
	Unaudited
	Number of RSU/PSUs	Weighted average grant date fair value
Unvested at beginning of year	4,459,107	$	65.56
Granted	964,555	80.59
Vested	(412,175)	84.05
Forfeited and cancelled	(15,928)	99.97
Unvested as of March 31, 2022 (1)	4,995,559	66.83


March 31, 2022
Number of PSUs	Fair value at grant date per PSU		Total fair value at grant date
2,703,852	$	48.16	$	130,218
108,113	69.37		7,500
124,701	80.59		10,050
17,712	84.68		1,500
10,532	94.94		1,000
189,626	$	114.26	21,667
3,154,536			$	171,935

Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model


	Three months ended March 31,				Year ended December 31, 2021
	2022		2021
	Unaudited				Audited
Stock Option Plans
Expected term (years)	5.33-5.83		5.86-6.00		5.50-6
Expected volatility	60%-62%		60%-60%		60%-63%
Risk-free interest rate	1.58%-1.61%		0.85%-0.88%		0.78%-1.27%



Dividend yield	0.00	%	0.00	%	0.00	%
ESPP
Expected term (years)	0.50		0.50		0.50
Expected volatility	51	%	54	%	54%-81%
Risk-free interest rate	0.19	%	0.09	%	0.05%-0.09%


Dividend yield	0.00	%	0.00	%	0.00	%

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards


	Three months ended March 31,			Year ended December 31, 2021
		2022				2021
	Unaudited			Audited
Cost of revenues		$	952	$	733		$	3,471
Research, development and clinical studies		6,801		5,124			27,597
Sales and marketing		6,655		4,471			22,673
General and administrative		10,637		8,535			41,159
Total share-based compensation expense		$	25,045	$	18,863		$	94,900

XML 33 R22.htm IDEA: XBRL DOCUMENT

Basic and diluted net income (loss) per ordinary share (Tables)

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Income (Loss) Per Ordinary Share

The following table sets forth the computation of the Company’s basic and diluted net income (loss) per ordinary share:


	Three months ended March 31,			Year ended December 31, 2021
		2022				2021
	Unaudited			Audited
Net income (loss) attributable to ordinary shares as reported used in computing basic and diluted net income (loss) per share		$	(4,647)	$	(4,128)		$	(58,351)

Weighted average number of ordinary shares used in computing basic net income (loss) per share		104,186,120		102,633,545			103,433,274
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share:
Options		—		—			—
Restricted share units		—		—			—
ESPP		—		—			—
Weighted average number of ordinary shares used in computing diluted net income (loss) per share		104,186,120		102,633,545			103,433,274

Weighted anti-dilutive shares outstanding which were not included in the diluted calculation		7,874,118		9,734,269			8,524,922

Basic net income (loss) per ordinary share		$	(0.04)	$	(0.04)		$	(0.56)

Diluted net income (loss) per ordinary share		$	(0.04)	$	(0.04)		$	(0.56)

XML 34 R23.htm IDEA: XBRL DOCUMENT

SUPPLEMENTAL INFORMATION (Tables)

3 Months Ended

Mar. 31, 2022

Geographic Areas, Long-Lived Assets [Abstract]

Schedule of Long-Lived Assets by Location

The following table presents long-lived assets by location:


	March 31, 2022		December 31, 2021
	Unaudited		Audited
United States	$	24,336	$	23,263
Israel	5,933		5,297
Switzerland	4,625		4,085
Japan	955		799
Germany	812		1,020
Others	1,203		1,152
Total	$	37,864	$	35,616

Schedule of Revenues by Geographic Region

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:


	Three months ended March 31,			Year ended December 31, 2021
		2022				2021
	Unaudited			Audited
United States		$	97,416	$	85,908		$	353,110
EMEA:
Germany		19,238		26,364			93,939
Other EMEA		7,775		8,619			30,577
Japan		8,750		8,278			34,640
Greater China (1)		4,368		5,526			22,765
Total net revenues		$	137,547	$	134,695		$	535,031

(1) For additional information, see Note 12 to the Consolidated Financial Statements in the 2021 10-K.

XML 35 R24.htm IDEA: XBRL DOCUMENT

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Restricted Cash and Cash Equivalents Items [Line Items]
Cash and cash equivalents	$ 190,739	$ 208,802
Cash
Restricted Cash and Cash Equivalents Items [Line Items]
Cash and cash equivalents	8,376	3,139
Money market funds
Restricted Cash and Cash Equivalents Items [Line Items]
Cash and cash equivalents	92,071	64,668
Corporate debt securities
Restricted Cash and Cash Equivalents Items [Line Items]
Cash and cash equivalents	2,580	0
Certificate of deposits, notes and term deposits
Restricted Cash and Cash Equivalents Items [Line Items]
Cash and cash equivalents	$ 87,712	$ 140,995

XML 36 R25.htm IDEA: XBRL DOCUMENT

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Summary of Amortized Cost And Recorded Basis of T-bills in Short Term Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Restricted Cash and Cash Equivalents Items [Line Items]
Short-term investments	$ 741,562	$ 728,898
U.S. Treasury bills
Restricted Cash and Cash Equivalents Items [Line Items]
Short-term investments	24,857	199,981
Other government and governmental agency notes
Restricted Cash and Cash Equivalents Items [Line Items]
Short-term investments	34,786	0
Corporate debt securities
Restricted Cash and Cash Equivalents Items [Line Items]
Short-term investments	196,274	104,823
Certificate of deposits, notes and term deposits
Restricted Cash and Cash Equivalents Items [Line Items]
Short-term investments	$ 485,645	$ 424,094

XML 37 R26.htm IDEA: XBRL DOCUMENT

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Restricted Cash and Cash Equivalents Items [Line Items]
Estimated fair value of short-term investments	$ 741,562	$ 728,906
Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Estimated fair value of short-term investments	$ 24,857	$ 199,988

XML 38 R27.htm IDEA: XBRL DOCUMENT

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 1,831	$ 1,485
Work in progress	14,010	8,274
Finished products	13,243	14,668
Total	$ 29,084	$ 24,427

XML 39 R28.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENT LIABILITIES (Details) - USD ($)	Nov. 06, 2020	Mar. 31, 2022	Dec. 31, 2021
Line of Credit Facility [Line Items]
Pledged bank deposits		$ 2,344,000	$ 2,350,000
Operating lease and other contractual commitments		2,692,000	$ 2,698,000
Revolving Credit Facility
Line of Credit Facility [Line Items]
Contractual term	3 years
Maximum borrowing capacity	$ 150,000,000
Revolving Credit Facility \| Line of Credit
Line of Credit Facility [Line Items]
Amount outstanding		$ 0

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

XML 40 R29.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTE - Additional Information (Details) - Convertible Debt - the “Notes” $ in Thousands	Nov. 05, 2020 USD ($)
Debt Instrument [Line Items]
Aggregate principal amount	$ 575,000
Stated interest rate	0.00%

XML 41 R30.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTE - Liability and Equity Components of the Convertible Notes (Details) - Convertible Debt - the “Notes” - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal amount	$ 575,000	$ 575,000
Unamortized issuance costs	(11,974)	(12,784)
Net carrying amount of liability component	563,026	562,216
Estimated fair value	$ 454,285	$ 467,469

- Definition

Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References + Details

XML 42 R31.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTE - Finance Expense Related to the Convertible Notes (Details) - the “Notes” - Convertible Debt - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
Amortization of debt issuance costs	$ 810	$ 709	$ 3,339
Total finance expense recognized	$ 810	$ 709	$ 3,339

XML 43 R32.htm IDEA: XBRL DOCUMENT

SHARE OPTION PLANS AND ESPP - Additional Information (Details)	3 Months Ended
	Mar. 31, 2022 shares
Share Capital [Line Items]
Options exercised (in shares)	175,650
ESPP
Share Capital [Line Items]
Ordinary shares available for grants (in shares)	4,954,997
Shares issued under plan (in shares)	175,650
2015 Plan
Share Capital [Line Items]
Ordinary shares available for grants (in shares)	17,070,368
2015 Plan \| Options
Share Capital [Line Items]
Stock awards granted, expiration period (years)	10 years
2015 Plan \| Options \| Minimum
Share Capital [Line Items]
Stock awards granted, vesting period (years)	2 years
2015 Plan \| Options \| Maximum
Share Capital [Line Items]
Stock awards granted, vesting period (years)	4 years
2015 Plan \| Restricted share units
Share Capital [Line Items]
Stock awards granted, vesting period (years)	3 years
2015 Plan \| PSUs \| Minimum
Share Capital [Line Items]
Stock awards granted, vesting period (years)	3 years
2015 Plan \| PSUs \| Maximum
Share Capital [Line Items]
Stock awards granted, vesting period (years)	6 years

XML 44 R33.htm IDEA: XBRL DOCUMENT

SHARE OPTION PLANS AND ESPP - Schedule of Stock Option Plan (Details)	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Number of options
Number of options, beginning outstanding (in shares) \| shares	8,549,322
Number of options, granted (in shares) \| shares	575,246
Number of options, exercised (in shares) \| shares	(175,650)
Number of options, forfeited and canceled (in shares) \| shares	(13,467)
Number of options, ending outstanding (in shares) \| shares	8,935,451
Number of options, exercisable options (in shares) \| shares	5,787,733
Weighted average exercise price
Weighted average exercise price, beginning outstanding (in usd per share) \| $ / shares	$ 33.09
Weighted average exercise price, granted (in usd per share) \| $ / shares	80.59
Weighted average exercise price, exercised (in usd per share) \| $ / shares	18.14
Weighted average exercise price, forfeited and canceled (in usd per share) \| $ / shares	77.31
Weighted average exercise price, ending outstanding (in usd per share) \| $ / shares	36.38
Weighted average exercise price, exercisable options (in usd per share) \| $ / shares	$ 24.15

XML 45 R34.htm IDEA: XBRL DOCUMENT

SHARE OPTION PLANS AND ESPP - Schedule of RSUs and PSUs (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($) $ / shares shares
RSUs/PSUs
Number of RSU/PSUs
Unvested at beginning of year (in shares)	4,459,107
Granted (in shares)	964,555
Vested (in shares)	(412,175)
Forfeited and cancelled (in shares)	(15,928)
Unvested at ending of year (in shares)	4,995,559
Weighted average grant date fair value
Unvested at beginning of year (in usd per share) \| $ / shares	$ 65.56
Granted (in usd per share) \| $ / shares	80.59
Vested (in usd per share) \| $ / shares	84.05
Forfeited and cancelled (in usd per share) \| $ / shares	99.97
Unvested at ending of year (in usd per share) \| $ / shares	$ 66.83
PSUs
Weighted average grant date fair value
Number of PSUs (in shares)	3,154,536
Total fair value at grant date \| $	$ 171,935
PSUs \| Award One
Weighted average grant date fair value
Number of PSUs (in shares)	2,703,852
Fair value at grant date per PSU (in usd per share) \| $ / shares	$ 48.16
Total fair value at grant date \| $	$ 130,218
PSUs \| Award Two
Weighted average grant date fair value
Number of PSUs (in shares)	108,113
Fair value at grant date per PSU (in usd per share) \| $ / shares	$ 69.37
Total fair value at grant date \| $	$ 7,500
PSUs \| Award Three
Weighted average grant date fair value
Number of PSUs (in shares)	124,701
Fair value at grant date per PSU (in usd per share) \| $ / shares	$ 80.59
Total fair value at grant date \| $	$ 10,050
PSUs \| Award Four
Weighted average grant date fair value
Number of PSUs (in shares)	17,712
Fair value at grant date per PSU (in usd per share) \| $ / shares	$ 84.68
Total fair value at grant date \| $	$ 1,500
PSUs \| Award Five
Weighted average grant date fair value
Number of PSUs (in shares)	10,532
Fair value at grant date per PSU (in usd per share) \| $ / shares	$ 94.94
Total fair value at grant date \| $	$ 1,000
PSUs \| Award Six
Weighted average grant date fair value
Number of PSUs (in shares)	189,626
Fair value at grant date per PSU (in usd per share) \| $ / shares	$ 114.26
Total fair value at grant date \| $	$ 21,667

XML 46 R35.htm IDEA: XBRL DOCUMENT

SHARE OPTION PLANS AND ESPP - Schedule of Fair Value Assumptions Used Only for Equity Based Awards Estimated Using Black-Scholes Option Pricing Model (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 months	6 months	6 months
Expected volatility, minimum	51.00%	54.00%	54.00%
Expected volatility, maximum			81.00%
Risk-free interest rate, minimum	0.19%	0.09%	0.05%
Risk-free interest rate, maximum			0.09%
Dividend yield	0.00%	0.00%	0.00%
Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	60.00%	60.00%	60.00%
Expected volatility, maximum	62.00%	60.00%	63.00%
Risk-free interest rate, minimum	1.58%	0.85%	0.78%
Risk-free interest rate, maximum	1.61%	0.88%	1.27%
Dividend yield	0.00%	0.00%	0.00%
Stock Option Plans \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years 3 months 29 days	5 years 10 months 9 days	5 years 6 months
Stock Option Plans \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years 9 months 29 days	6 years	6 years

XML 47 R36.htm IDEA: XBRL DOCUMENT

SHARE OPTION PLANS AND ESPP - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 25,045	$ 18,863	$ 94,900
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	952	733	3,471
Research, development and clinical studies
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	6,801	5,124	27,597
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	6,655	4,471	22,673
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 10,637	$ 8,535	$ 41,159

XML 48 R37.htm IDEA: XBRL DOCUMENT

Basic and diluted net income (loss) per ordinary share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net income (loss) attributable to ordinary shares as reported used in computing basic and diluted net income (loss) per share	$ (4,647)	$ (4,128)	$ (58,351)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	104,186,120	102,633,545	103,433,274
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share:
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	104,186,120	102,633,545	103,433,274
Weighted anti-dilutive shares outstanding which were not included in the diluted calculation (in shares)	7,874,118	9,734,269	8,524,922
Basic net income (loss) per ordinary share (in usd per share)	$ (0.04)	$ (0.04)	$ (0.56)
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.04)	$ (0.04)	$ (0.56)
Options
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share:
Share-based payment arrangements (in shares)	0	0	0
Restricted share units
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share:
Share-based payment arrangements (in shares)	0	0	0
ESPP
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share:
Share-based payment arrangements (in shares)	0	0	0

XML 49 R38.htm IDEA: XBRL DOCUMENT

SUPPLEMENTAL INFORMATION - Schedule of Long-Lived Assets by Location (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	$ 37,864	$ 35,616
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	24,336	23,263
Israel
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	5,933	5,297
Switzerland
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	4,625	4,085
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	955	799
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	812	1,020
Others
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-term assets	$ 1,203	$ 1,152

XML 50 R39.htm IDEA: XBRL DOCUMENT

SUPPLEMENTAL INFORMATION - Schedule of Revenues by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 137,547	$ 134,695	$ 535,031
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	97,416	85,908	353,110
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	19,238	26,364	93,939
Other EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	7,775	8,619	30,577
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	8,750	8,278	34,640
Greater China
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 4,368	$ 5,526	$ 22,765

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

XML 51 R9999.htm IDEA: XBRL DOCUMENT

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2020-06 [Member]

- Definition

Indicates amendment to accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S65
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 53: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 54: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 55: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 56: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 57: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 58: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 59: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 60: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 61: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)

Reference 62: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(1)

Reference 63: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(2)

Reference 64: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(3)(iii)(01)

Reference 65: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(3)(iii)(03)

+ Details

XML 52 nvcr-20220331_htm.xml IDEA: XBRL DOCUMENT 0001645113 2022-01-01 2022-03-31 0001645113 2022-04-22 0001645113 2022-03-31 0001645113 2021-12-31 0001645113 2021-01-01 2021-03-31 0001645113 2021-01-01 2021-12-31 0001645113 us-gaap:CommonStockMember 2021-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001645113 us-gaap:RetainedEarningsMember 2021-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001645113 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001645113 2021-07-01 2021-09-30 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001645113 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001645113 us-gaap:CommonStockMember 2022-03-31 0001645113 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001645113 us-gaap:RetainedEarningsMember 2022-03-31 0001645113 us-gaap:CommonStockMember 2020-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001645113 us-gaap:RetainedEarningsMember 2020-12-31 0001645113 2020-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001645113 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001645113 2021-01-01 2021-06-30 0001645113 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001645113 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2020-12-31 0001645113 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-12-31 0001645113 2020-07-01 2020-09-30 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001645113 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001645113 us-gaap:CommonStockMember 2021-03-31 0001645113 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001645113 us-gaap:RetainedEarningsMember 2021-03-31 0001645113 2021-03-31 0001645113 us-gaap:CashMember 2022-03-31 0001645113 us-gaap:CashMember 2021-12-31 0001645113 us-gaap:MoneyMarketFundsMember 2022-03-31 0001645113 us-gaap:MoneyMarketFundsMember 2021-12-31 0001645113 us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001645113 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001645113 us-gaap:CertificatesOfDepositMember 2022-03-31 0001645113 us-gaap:CertificatesOfDepositMember 2021-12-31 0001645113 us-gaap:USTreasurySecuritiesMember 2022-03-31 0001645113 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001645113 nvcr:GovernmentAgenciesDebtSecuritieMember 2022-03-31 0001645113 nvcr:GovernmentAgenciesDebtSecuritieMember 2021-12-31 0001645113 us-gaap:FairValueInputsLevel1Member 2022-03-31 0001645113 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001645113 us-gaap:RevolvingCreditFacilityMember 2020-11-06 2020-11-06 0001645113 us-gaap:RevolvingCreditFacilityMember 2020-11-06 0001645113 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-03-31 0001645113 nvcr:A0ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2020-11-05 0001645113 nvcr:A0ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2022-03-31 0001645113 nvcr:A0ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2021-12-31 0001645113 nvcr:A0ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0001645113 nvcr:A0ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2021-01-01 2021-03-31 0001645113 nvcr:A0ConvertibleSeniorNotesDue2025Member us-gaap:ConvertibleDebtMember 2021-01-01 2021-12-31 0001645113 srt:MinimumMember us-gaap:EmployeeStockOptionMember nvcr:TwoThousandFifteenPlanMember 2022-01-01 2022-03-31 0001645113 srt:MaximumMember us-gaap:EmployeeStockOptionMember nvcr:TwoThousandFifteenPlanMember 2022-01-01 2022-03-31 0001645113 us-gaap:EmployeeStockOptionMember nvcr:TwoThousandFifteenPlanMember 2022-01-01 2022-03-31 0001645113 us-gaap:RestrictedStockUnitsRSUMember nvcr:TwoThousandFifteenPlanMember 2022-01-01 2022-03-31 0001645113 srt:MinimumMember nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:TwoThousandFifteenPlanMember 2022-01-01 2022-03-31 0001645113 srt:MaximumMember nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:TwoThousandFifteenPlanMember 2022-01-01 2022-03-31 0001645113 nvcr:TwoThousandFifteenPlanMember 2022-03-31 0001645113 us-gaap:EmployeeStockMember 2022-01-01 2022-03-31 0001645113 nvcr:RestrictedStockUnitsRSUsAndPerformanceBasedShareUnitsPSUsMember 2021-12-31 0001645113 nvcr:RestrictedStockUnitsRSUsAndPerformanceBasedShareUnitsPSUsMember 2022-01-01 2022-03-31 0001645113 nvcr:RestrictedStockUnitsRSUsAndPerformanceBasedShareUnitsPSUsMember 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:AwardOneMember 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:AwardOneMember 2022-01-01 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:AwardTwoMember 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:AwardTwoMember 2022-01-01 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:AwardThreeMember 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:AwardThreeMember 2022-01-01 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:AwardFourMember 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:AwardFourMember 2022-01-01 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:AwardFiveMember 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:AwardFiveMember 2022-01-01 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:AwardSixMember 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember nvcr:AwardSixMember 2022-01-01 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember 2022-03-31 0001645113 nvcr:PerformanceBasedShareUnitsPSUsMember 2022-01-01 2022-03-31 0001645113 us-gaap:EmployeeStockMember 2022-03-31 0001645113 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001645113 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001645113 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001645113 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001645113 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001645113 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001645113 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001645113 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001645113 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001645113 us-gaap:EmployeeStockMember 2021-01-01 2021-03-31 0001645113 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001645113 nvcr:CostOfRevenueMember 2022-01-01 2022-03-31 0001645113 nvcr:CostOfRevenueMember 2021-01-01 2021-03-31 0001645113 nvcr:CostOfRevenueMember 2021-01-01 2021-12-31 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001645113 nvcr:SalesAndMarketingMember 2022-01-01 2022-03-31 0001645113 nvcr:SalesAndMarketingMember 2021-01-01 2021-03-31 0001645113 nvcr:SalesAndMarketingMember 2021-01-01 2021-12-31 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001645113 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001645113 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001645113 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001645113 us-gaap:EmployeeStockMember 2022-01-01 2022-03-31 0001645113 us-gaap:EmployeeStockMember 2021-01-01 2021-03-31 0001645113 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001645113 country:US 2022-03-31 0001645113 country:US 2021-12-31 0001645113 country:IL 2022-03-31 0001645113 country:IL 2021-12-31 0001645113 country:CH 2022-03-31 0001645113 country:CH 2021-12-31 0001645113 country:JP 2022-03-31 0001645113 country:JP 2021-12-31 0001645113 country:DE 2022-03-31 0001645113 country:DE 2021-12-31 0001645113 nvcr:OthersCountriesMember 2022-03-31 0001645113 nvcr:OthersCountriesMember 2021-12-31 0001645113 country:US 2022-01-01 2022-03-31 0001645113 country:US 2021-01-01 2021-03-31 0001645113 country:US 2021-01-01 2021-12-31 0001645113 country:DE 2022-01-01 2022-03-31 0001645113 country:DE 2021-01-01 2021-03-31 0001645113 country:DE 2021-01-01 2021-12-31 0001645113 nvcr:EMEAExculdingGermanyMember 2022-01-01 2022-03-31 0001645113 nvcr:EMEAExculdingGermanyMember 2021-01-01 2021-03-31 0001645113 nvcr:EMEAExculdingGermanyMember 2021-01-01 2021-12-31 0001645113 country:JP 2022-01-01 2022-03-31 0001645113 country:JP 2021-01-01 2021-03-31 0001645113 country:JP 2021-01-01 2021-12-31 0001645113 country:CN 2022-01-01 2022-03-31 0001645113 country:CN 2021-01-01 2021-03-31 0001645113 country:CN 2021-01-01 2021-12-31 shares iso4217:USD iso4217:USD shares pure false 2022 Q1 0001645113 --12-31

http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member

P3Y

10-Q true 2022-03-31 false 001-37565 NovoCure Limited Y9 98-1057807 No. 4 The Forum Grenville Street St. Helier JE JE2 4UF 44 (0) 15 3475 6700 Ordinary Shares, no par value NVCR NASDAQ Yes Yes Large Accelerated Filer false false false 104586094

190739000

208802000

741562000

728898000

889000

807000

100965000

93567000

17343000 17025000

29084000

24427000

1080582000

1073526000

25072000

22693000

12792000 12923000

19937000

18267000

11827000

12086000

69628000

65969000

1150210000

1139495000

69186000

72600000

58613000 70002000

127799000

142602000

563026000

562216000

5511000

6477000

14813000

12997000

3024000 4543000

156000

166000

586530000

586399000

714329000

729001000

104559088

103971263

1127782000

1099589000

-1328000

-3169000

-690573000

-685926000

435881000

410494000

1150210000

1139495000

137547000

134695000

535031000

27727000

26385000

114877000

109820000

108310000

420154000

42234000

45916000

201303000

37884000

31357000

137057000

30508000

31125000

126127000

110626000

108398000

464487000

-806000

-88000

-44333000

1709000

2646000

7742000

-2515000

-2734000

-52075000

2132000

1394000

6276000

-4647000

-4128000

-58351000

-0.04

-0.56

104186120

102633545

103433274

-0.04

-0.56

104186120

102633545

103433274

-4647000

-4128000

-58351000

330000

-268000

302000

-1511000

-2152000

-361000

-2806000

-2244000

-57688000

103971263

1099589000

-3169000

-685926000

410494000

25045000

587825 3148000 3148000

1841000

-4647000

104559088

1127782000

-1328000

-690573000

435881000

102334276

1111435000

-3832000

-631077000

476526000

18863000

853184 7961000 7961000

-132474000

3502000

-128972000

1884000

-4128000

103187460

1005785000

-1948000

-631703000

372134000

-4647000

-4128000

-58351000

2610000

2370000

10251000

-221000

-94000

135000

176000

649000

25045000

18863000

94900000

-249000

-2157000

-3231000

7461000

-4624000

-5270000

684000

603000

3101000

4804000

1296000

-2483000

-1863000

-1432000

-4519000

-14809000

-2626000

27777000

-2331000

-4394000

-10980000

-3687000

17780000

82756000

5093000

3981000

24170000

279000000

608000000

958000000

291317000

549848000

1078664000

-17410000

54171000

-144834000

4546000

7000

6000

26000

3148000

7961000

21182000

3141000

7955000

25702000

-25000

-102000

-188000

-17981000

79804000

-36564000

209609000

246173000

191628000

325977000

209609000

1173000

-2405000

3110000

1000

101000

3580000

284000

5387000

ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-top:6pt;text-align:justify">Organization. NovoCure Limited (including its consolidated subsidiaries, the "Company") was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields ("TTFields") devices, including Optune and Optune Lua (collectively, our "Products"), for the treatment of solid tumor cancers. The Company currently markets Optune in the United States ("U.S."), Germany, Japan and certain other countries. The Company currently markets Optune Lua in the U.S. and European Union. The Company also has a License and Collaboration Agreement (the "Zai Agreement") with Zai Lab (Shanghai) Co., Ltd. ("Zai") to market Optune in China, Hong Kong, Macau and Taiwan ("Greater China"). See Note 12 to the Consolidated Financial Statements in the 2021 10-K.</div><div style="margin-top:6pt;text-align:justify">During the year ended December 31, 2019, the Company implemented changes to its corporate entity operating structure, including transferring certain intellectual property to its Swiss subsidiary, primarily to align corporate entities with the Company’s evolving operations and business model. As of January 1, 2022, the effective place of daily management and control of the Company moved to Switzerland and the Company has become a Swiss tax resident.</div><div style="margin-top:12pt;text-align:justify">Financial statement preparation. The accompanying unaudited consolidated financial statements include the accounts of the Company and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation for the periods presented. The preparation of these consolidated financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the "2021 10-K") filed with the Securities and Exchange Commission on February 24, 2022.</div><div style="margin-top:12pt;text-align:justify">The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2021 10-K are applied consistently in these unaudited interim consolidated financial statements, except as noted below:</div><div style="margin-top:12pt;text-align:justify">Short-term investments</div><div style="margin-top:12pt;text-align:justify">The Company accounts for investments in debt securities in accordance with ASC 320, "Investments—Debt and Equity Securities." </div><div style="margin-top:12pt;text-align:justify">Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date. The Company classifies part of its debt securities as available-for-sale and the rest of the balance as held-to-maturity since the Company has the intent and ability to hold the securities to maturity.</div><div style="margin-top:12pt;text-align:justify">Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders’ equity. Realized gains and losses on sale of investments are included in financial income, net and are derived using the specific identification method for determining the cost of securities sold.</div><div style="margin-top:12pt;text-align:justify">The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.</div><div style="margin-top:12pt;text-align:justify">Each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company’s ability and intent to hold the investment until a forecasted recovery occurs. Allowance for credit losses on available-for-sale debt securities are recognized in the Company’s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in stockholders’ equity.</div>Held-to-maturity debt securities are stated at amortized cost of which is adjusted for amortization of premiums and accretion of discounts to maturity and any credit losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate.

<div style="margin-top:12pt;text-align:justify">Short-term investments</div><div style="margin-top:12pt;text-align:justify">The Company accounts for investments in debt securities in accordance with ASC 320, "Investments—Debt and Equity Securities." </div><div style="margin-top:12pt;text-align:justify">Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date. The Company classifies part of its debt securities as available-for-sale and the rest of the balance as held-to-maturity since the Company has the intent and ability to hold the securities to maturity.</div><div style="margin-top:12pt;text-align:justify">Available-for-sale debt securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income (loss) in shareholders’ equity. Realized gains and losses on sale of investments are included in financial income, net and are derived using the specific identification method for determining the cost of securities sold.</div><div style="margin-top:12pt;text-align:justify">The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization together with interest on securities is included in financial income, net.</div><div style="margin-top:12pt;text-align:justify">Each reporting period, the Company evaluates whether declines in fair value below amortized cost are due to expected credit losses, as well as the Company’s ability and intent to hold the investment until a forecasted recovery occurs. Allowance for credit losses on available-for-sale debt securities are recognized in the Company’s consolidated statements of income, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in stockholders’ equity.</div>Held-to-maturity debt securities are stated at amortized cost of which is adjusted for amortization of premiums and accretion of discounts to maturity and any credit losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate.

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS<div style="margin-top:6pt;text-align:justify">Cash equivalents include items almost as liquid as cash, with maturity periods of three months or less when purchased. As of March 31, 2022 and December 31, 2021, the Company’s cash and cash equivalents were composed of:</div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2022</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2021</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cash</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,376 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,139 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Money market funds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92,071 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64,668 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Corporate debt securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,580 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Certificate of deposits, notes and term deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87,712 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">140,995 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total cash and cash equivalents</td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">190,739 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">208,802 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify">Short-term investments include items with maturity dates between three months and one year when purchased. As of March 31, 2022 and December 31, 2021, the Company’s short-term investments were:</div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2022</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">U.S. Treasury bills</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">24,857 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">199,981 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other government and governmental agency notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,786 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Corporate debt securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">196,274 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104,823 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Certificate of deposits, notes and term deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">485,645 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">424,094 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total short-term investments</td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">741,562 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">728,898 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify">The Company invests in marketable U.S. Treasury Bills (“T-bills”), other government and governmental agency notes, term deposits, notes, certificate of deposits, money market funds and corporate debt securities that are classified as "held-to-maturity" or "available for sale" securities. These investments are presented as cash and cash equivalents or short-term investments, according their maturity periods. </div><div style="margin-top:12pt;text-align:justify">The estimated fair value of the Company’s short-term investments as of March 31, 2022 and December 31, 2021 was $741,562 and $728,906, respectively. As of March 31, 2022 and December 31, 2021, amounts of $24,857 and $199,988, respectively were categorized as Level 1 and the remaining balance as level 2 in accordance with ASC 820, “Fair Value Measurements and Disclosures”.</div>

As of March 31, 2022 and December 31, 2021, the Company’s cash and cash equivalents were composed of:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2022</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2021</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cash</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,376 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,139 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Money market funds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92,071 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64,668 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Corporate debt securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,580 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Certificate of deposits, notes and term deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87,712 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">140,995 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total cash and cash equivalents</td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">190,739 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">208,802 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>

8376000

3139000

92071000

64668000

2580000

87712000

140995000

190739000

208802000

As of March 31, 2022 and December 31, 2021, the Company’s short-term investments were:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2022</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">U.S. Treasury bills</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">24,857 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">199,981 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other government and governmental agency notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,786 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Corporate debt securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">196,274 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104,823 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Certificate of deposits, notes and term deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">485,645 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">424,094 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total short-term investments</td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">741,562 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">728,898 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>

24857000

199981000

34786000

196274000

104823000

485645000

424094000

741562000

728898000

741562000

728906000

24857000

199988000

INVENTORIESInventories are stated at the lower of cost or net realizable value. The weighted average methodology is applied to determine cost. As of March 31, 2022 and December 31, 2021, the Company’s inventories were composed of:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2022</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Raw materials</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,831 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,485 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Work in progress</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,010 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,274 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Finished products</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,243 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,668 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">29,084 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24,427 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>

As of March 31, 2022 and December 31, 2021, the Company’s inventories were composed of:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2022</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Raw materials</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,831 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,485 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Work in progress</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,010 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,274 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Finished products</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,243 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,668 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">29,084 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24,427 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>

1831000

1485000

14010000

8274000

13243000

14668000

29084000

24427000

COMMITMENTS AND CONTINGENT LIABILITIES<div style="margin-top:6pt;text-align:justify">Operating Leases. The facilities of the Company are leased under various operating lease agreements for periods, including options for extensions, ending no later than 2044. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2025.</div><div style="margin-top:12pt;text-align:justify">Pledged deposits and bank guarantees. As of March 31, 2022 and December 31, 2021, the Company pledged bank deposits of $2,344 and $2,350, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained bank guarantees for the fulfillment of the Company’s lease and other contractual commitments of $2,692 and $2,698, respectively.</div><div style="margin-top:12pt;text-align:justify">Senior secured revolving credit facility. On November 6, 2020, the Company entered into a three-year $150,000 senior secured revolving credit facility with a syndicate of relationship banks. For additional information, see Note 12(c) to the Consolidated Financial Statements in the 2021 10-K. As of March 31, 2022, the Company had no outstanding balance borrowed under the facility.</div>

2344000

2350000

2692000

2698000

P3Y

150000000

CONVERTIBLE NOTE<div style="margin-top:6pt;text-align:justify">On November 5, 2020, the Company issued $575,000 aggregate principal amount of 0% Convertible Senior Notes due 2025 (the “Notes”).</div><div style="margin-top:12pt;text-align:justify">The Notes mature on November 1, 2025, unless earlier repurchased, redeemed or converted as set forth in the Notes. As of March 31, 2022, the conditions allowing holders of the Notes to convert were not met. The Notes are therefore not convertible as of March 31, 2022 and are classified as long-term liability.</div><div style="margin-top:12pt;text-align:justify">For additional information, see Note 10(a) to the Consolidated Financial Statements in the 2021 10-K.</div><div style="margin-top:12pt;text-align:justify">The net carrying amount of the liability of the Notes as of March 31, 2022 and December 31, 2021 are as follows:</div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2022</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2021</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liability component, net:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Principal amount</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">575,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">575,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Unamortized issuance costs </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11,974)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,784)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net carrying amount of liability component (1)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">563,026 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">562,216 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify;text-indent:-18pt">(1) An effective interest rate determines the fair value of the Notes, therefore they are categorized as Level 3 in accordance with ASC 820, "Fair Value Measurements and Disclosures." The estimated fair value of the net carrying amount of liability component of the Notes as of March 31, 2022 and December 31, 2021 were $454,285 and $467,469, respectively.</div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify">Finance expense related to the Notes was as follows:</div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31,</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Year ended December 31, 2021</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Amortization of debt issuance costs</div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">810 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">709 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,339 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Total finance expense recognized</div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">810 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">709 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,339 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>

575000000

<div style="margin-top:12pt;text-align:justify">The net carrying amount of the liability of the Notes as of March 31, 2022 and December 31, 2021 are as follows:</div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2022</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2021</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liability component, net:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Principal amount</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">575,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">575,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Unamortized issuance costs </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11,974)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,784)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net carrying amount of liability component (1)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">563,026 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">562,216 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify;text-indent:-18pt">(1) An effective interest rate determines the fair value of the Notes, therefore they are categorized as Level 3 in accordance with ASC 820, "Fair Value Measurements and Disclosures." The estimated fair value of the net carrying amount of liability component of the Notes as of March 31, 2022 and December 31, 2021 were $454,285 and $467,469, respectively.</div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify">Finance expense related to the Notes was as follows:</div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31,</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Year ended December 31, 2021</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Amortization of debt issuance costs</div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">810 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">709 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,339 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Total finance expense recognized</div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">810 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">709 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,339 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>

575000000

11974000

12784000

563026000

562216000

454285000

467469000

810000

709000

3339000

810000

709000

3339000

SHARE OPTION PLANS AND ESPP<div style="margin-top:6pt;text-align:justify">In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). Under the 2015 Plan, the Company can issue various types of equity compensation awards such as share options, restricted shares, performance shares, restricted share units (“RSUs”), performance-based share units (“PSUs”), long-term cash awards and other share-based awards.</div><div style="margin-top:12pt;text-align:justify">Options granted under the 2015 Plan generally have a two-year or four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are canceled or forfeited before expiration become </div><div style="margin-top:12pt;text-align:justify">available for future grants. RSUs granted under the 2015 Plan generally vest over a three year period. PSUs granted under the 2015 Plan generally vest between a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUwNzhmNTJmYmY4YTRjYzA5NDBlODcxNzVhODgwM2I4L3NlYzo1MDc4ZjUyZmJmOGE0Y2MwOTQwZTg3MTc1YTg4MDNiOF81NS9mcmFnOmUxYjdiNjQ5ZmY4MjQ5YTBiN2ExMWRjY2VhMDQzOTE2L3RleHRyZWdpb246ZTFiN2I2NDlmZjgyNDlhMGI3YTExZGNjZWEwNDM5MTZfNzcw_dd7ecb08-50bc-4921-8222-721bdee0f2a4">three- and six-year period as performance targets are attained. RSUs and PSUs granted under the 2015 Plan that are canceled before expiration become available for future grants. As of March 31, 2022, 17,070,368 ordinary shares were available for grant under the 2015 Plan.</div><div style="margin-top:12pt;text-align:justify">A summary of the status of the Company’s option plans as of March 31, 2022 and changes during the period then ended is presented below:</div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31, 2022</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Number of options</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted average exercise price</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at beginning of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,549,322 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">33.09 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">575,246 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.59 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(175,650)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.14 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Forfeited and canceled</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,467)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77.31 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding as of March 31, 2022</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,935,451 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">36.38 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercisable options</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,787,733 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">24.15 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify">For the three months ended March 31, 2022, options to purchase 175,650 ordinary shares were exercised, resulting in the issuance of 175,650 ordinary shares.</div><div style="margin-top:12pt;text-align:justify">A summary of the status of the Company’s RSUs and PSUs as of March 31, 2022 and changes during the period then ended is presented below.</div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31, 2022</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Number of RSU/PSUs</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted average grant date fair value</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested at beginning of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,459,107 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">65.56 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">964,555 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.59 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(412,175)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.05 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Forfeited and cancelled</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,928)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99.97 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested as of March 31, 2022 (1)</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,995,559 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">66.83 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:-18pt"> </div><div style="text-align:justify;text-indent:-18pt">(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones which are not probable, as of March 31, 2022, in accordance with ASC 718 as follows:</div><div style="text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"> March 31, 2022</div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Number of PSUs</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value at grant date per PSU</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total fair value at grant date</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,703,852 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">48.16 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">130,218 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108,113 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69.37 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">124,701 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.59 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,050 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,712 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.68 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,532 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94.94 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189,626 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">114.26 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,667 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,154,536 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">171,935 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify">These PSUs will be expensed over the performance period when the vesting conditions become probable in accordance with ASC 718.</div><div style="margin-top:12pt;text-align:justify">In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP are construed in a manner consistent with the requirements of such section. As of March 31, 2022, 4,954,997 ordinary shares were available to be purchased by eligible employees under the ESPP.</div><div style="margin-top:12pt;text-align:justify">The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. We assessed fair value using the following underlying assumptions: </div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.824%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31,</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Year ended December 31, 2021</td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock Option Plans</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">5.33-5.83</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">5.86-6.00</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">5.50-6</div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">60%-62%</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">60%-60%</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">60%-63%</div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">1.58%-1.61%</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">0.85%-0.88%</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">0.78%-1.27%</div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dividend yield</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.00 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.00 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.00 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">ESPP</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (years)</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.50</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.50</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.50</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">54 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">54%-81%</div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.19 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.09 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">0.05%-0.09%</div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dividend yield</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.00 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.00 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.00 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div><div style="margin-top:12pt;text-align:justify">The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three months ended March 31, 2022 and 2021 and the year ended December 31, 2021 was:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31,</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Year ended December 31, 2021</td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of revenues</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">952 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">733 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,471 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research, development and clinical studies</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,801 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,124 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,597 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales and marketing</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,655 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,471 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,673 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,637 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,535 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41,159 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total share-based compensation expense</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">25,045 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18,863 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">94,900 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>

P2Y

P4Y

P10Y

P3Y

P6Y

17070368

8549322

33.09

575246

80.59

175650

18.14

13467

77.31

8935451

36.38

5787733

24.15

175650

<div style="margin-top:12pt;text-align:justify">A summary of the status of the Company’s RSUs and PSUs as of March 31, 2022 and changes during the period then ended is presented below.</div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31, 2022</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Number of RSU/PSUs</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted average grant date fair value</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested at beginning of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,459,107 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">65.56 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">964,555 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.59 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(412,175)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.05 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Forfeited and cancelled</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,928)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99.97 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested as of March 31, 2022 (1)</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,995,559 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">66.83 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:-18pt"> </div><div style="text-align:justify;text-indent:-18pt">(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones which are not probable, as of March 31, 2022, in accordance with ASC 718 as follows:</div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"> March 31, 2022</div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Number of PSUs</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair value at grant date per PSU</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total fair value at grant date</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,703,852 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">48.16 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">130,218 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108,113 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69.37 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">124,701 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80.59 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,050 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,712 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.68 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,532 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94.94 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189,626 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">114.26 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,667 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,154,536 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">171,935 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>

4459107

65.56

964555

80.59

412175

84.05

15928

99.97

4995559

66.83

2703852 48.16 130218000 108113 69.37 7500000 124701 80.59 10050000 17712 84.68 1500000 10532 94.94 1000000 189626 114.26 21667000 3154536 171935000

4954997

<div style="margin-top:12pt;text-align:justify">The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. We assessed fair value using the following underlying assumptions: </div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.824%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31,</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Year ended December 31, 2021</td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock Option Plans</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">5.33-5.83</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">5.86-6.00</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">5.50-6</div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">60%-62%</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">60%-60%</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">60%-63%</div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">1.58%-1.61%</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">0.85%-0.88%</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">0.78%-1.27%</div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dividend yield</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.00 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.00 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.00 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">ESPP</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (years)</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.50</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.50</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.50</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">54 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">54%-81%</div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.19 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.09 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right">0.05%-0.09%</div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dividend yield</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.00 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.00 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.00 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div>

P5Y3M29D

P5Y9M29D

P5Y10M9D

P6Y

P5Y6M

P6Y

0.60

0.62

0.60

0.63

0.0158

0.0161

0.0085

0.0088

0.0078

0.0127

0.0000

P0Y6M

0.51

0.54

0.81

0.0019

0.0009

0.0005

0.0009

0.0000

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three months ended March 31, 2022 and 2021 and the year ended December 31, 2021 was:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31,</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Year ended December 31, 2021</td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of revenues</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">952 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">733 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,471 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research, development and clinical studies</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,801 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,124 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,597 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales and marketing</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,655 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,471 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,673 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,637 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,535 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41,159 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total share-based compensation expense</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">25,045 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18,863 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">94,900 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>

952000

733000

3471000

6801000

5124000

27597000

6655000

4471000

22673000

10637000

8535000

41159000

25045000

18863000

94900000

Basic and diluted net income (loss) per ordinary share<div style="margin-top:6pt;text-align:justify">Basic net income (loss) per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted net income per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus potential dilutive shares (deriving from options, RSUs, PSUs, convertible notes and the ESPP) considered outstanding during the period, in accordance with ASC 260-10, as determined under the if-converted method. </div><div style="margin-top:12pt;text-align:justify">The following table sets forth the computation of the Company’s basic and diluted net income (loss) per ordinary share:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31,</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Year ended December 31, 2021</td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income (loss) attributable to ordinary shares as reported used in computing basic and diluted net income (loss) per share</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(4,647)</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(4,128)</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(58,351)</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average number of ordinary shares used in computing basic net income (loss) per share</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104,186,120 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102,633,545 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103,433,274 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share:</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Options</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Restricted share units</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">ESPP</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average number of ordinary shares used in computing diluted net income (loss) per share</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104,186,120 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102,633,545 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103,433,274 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted anti-dilutive shares outstanding which were not included in the diluted calculation</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,874,118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,734,269 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,524,922 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic net income (loss) per ordinary share</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.56)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Diluted net income (loss) per ordinary share</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.56)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>

The following table sets forth the computation of the Company’s basic and diluted net income (loss) per ordinary share:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31,</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Year ended December 31, 2021</td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income (loss) attributable to ordinary shares as reported used in computing basic and diluted net income (loss) per share</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(4,647)</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(4,128)</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(58,351)</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average number of ordinary shares used in computing basic net income (loss) per share</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104,186,120 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102,633,545 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103,433,274 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share:</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Options</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Restricted share units</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">ESPP</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average number of ordinary shares used in computing diluted net income (loss) per share</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104,186,120 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102,633,545 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103,433,274 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted anti-dilutive shares outstanding which were not included in the diluted calculation</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,874,118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,734,269 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,524,922 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic net income (loss) per ordinary share</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.56)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Diluted net income (loss) per ordinary share</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.56)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>

-4647000

-4128000

-58351000

104186120

102633545

103433274

104186120

102633545

103433274

7874118

9734269

8524922

-0.04

-0.56

-0.04

-0.56

SUPPLEMENTAL INFORMATION<div style="margin-top:6pt;text-align:justify">The Company operates in a single reportable segment.</div><div style="margin-top:6pt;text-align:justify">The following table presents long-lived assets by location:</div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2022</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">United States</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24,336 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">23,263 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Israel</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,933 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,297 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Switzerland</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,625 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,085 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Japan</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">955 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">799 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Germany</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">812 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,020 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Others</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,203 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,152 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">37,864 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">35,616 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify">The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:</div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31,</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Year ended December 31, 2021</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">United States</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">97,416 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">85,908 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">353,110 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">EMEA:</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Germany</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,238 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26,364 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">93,939 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Other EMEA</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,775 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,619 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,577 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Japan</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,278 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,640 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Greater China (1)</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,368 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,526 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,765 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total net revenues</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">137,547 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">134,695 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">535,031 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:-18pt">(1) For additional information, see Note 12 to the Consolidated Financial Statements in the 2021 10-K.</div>

<div style="margin-top:6pt;text-align:justify">The following table presents long-lived assets by location:</div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2022</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">United States</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24,336 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">23,263 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Israel</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,933 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,297 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Switzerland</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,625 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,085 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Japan</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">955 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">799 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Germany</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">812 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,020 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Others</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,203 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,152 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">37,864 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">35,616 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>

24336000

23263000

5933000

5297000

4625000

4085000

955000

799000

812000

1020000

1203000

1152000

37864000

35616000

<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify">The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:</div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended March 31,</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Year ended December 31, 2021</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unaudited</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Audited</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">United States</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">97,416 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">85,908 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">353,110 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">EMEA:</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Germany</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,238 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26,364 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">93,939 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Other EMEA</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,775 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,619 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,577 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Japan</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,278 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,640 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Greater China (1)</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,368 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,526 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,765 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total net revenues</td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">137,547 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">134,695 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">535,031 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:-18pt">(1) For additional information, see Note 12 to the Consolidated Financial Statements in the 2021 10-K.</div>

97416000

85908000

353110000

19238000

26364000

93939000

7775000

8619000

30577000

8750000

8278000

34640000

4368000

5526000

22765000

137547000

134695000

535031000

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

U&K;',PN5%VKHKEN-Z>#PGP&N_@]02P,$% M @ 73B<5/UCP2^H" JQ4 !@ !X;"]W;W)KP'JKNDYH1-]I!L MR\ZOWU?%[I;D(^/%SHC*J7FQ<%!+"JJ M=9SXAAS>+'VH=<+/L#J(32!=RJ':'DP/#[\_J+5QH],36;L,IR>^3=8XN@PJ MMG6MP^T96;]^.3H:]0N?S*I*O'!P>M+H%=D+0N"&7]T M,D>#2CZX_=Q+?R.^PY>%CG3N[;],F:J7HQ]'JJ2E;FWZY-<_4^?/=RRO\#;* M7[7N]AZ.5-'&Y.ON,"RHCS^<5Y;E3A^1>ZS>>Y>JJ%Z[DLK=\P>P<3!TVAMZ-OVF MP/5MJ9KYJQ,5;GWD5O3:DS5%RI+@-% MGXJ^0J[8# MHB;J@[_VYVT@]<[4)E&I]HPK;%L:MU(&KA=#Q/ NMHMH2J.#H3A6J2(U.O=U MH]WMZ)E:ZZAPUH?&!]EMG&PYT\::M2F^<'A_H1#I5B)OHFH"#IA&6WNKR*W M#L.IDJ[!) W'?XQ"<.T2X6<[^6CAZYH"9ZEW!**OVMH'=07*2FS\&T.VC&IO M='65'V$BA)J"3=_X^+%)K?)?,+:WA)XR<&.7S3DY A02*!BY7$.VGSK$B?EB?K8Q5XG=(C$UVU "X!X M6.'=KB!MHU<5\JL!DP)4G0,&BK1ZP=GF%,Q6@:1>U)X@XS=M-FN,#Y,JQ8OO M]$+MS2OM5I4VSR!E,E;O4CF!QWB-GZ.WG [$0S:/GDW4G @(3Z2.IBPUB4];@'ZPVKO(@(".U-'A_J\3 M]:H-C!5>O24=@%60G7I%!=4+J,MT=?2/<:<@!\W4C16)V%JPM\@I;,A%U14) M)"63;A4B'S)LP3.M 'T;I. >%Y<4Q(H^]0:2!:0MS&\X>0&2.@WSM8EQ4Z_ M#FH-0356MJ!P5NZN&;\>S M]M>()(R';^DK!]PZC31(&K>QL[PO*78Y([&)A;2\>,<1(3\D+Q3]0K]1O.%*)^HB ]0WQG7<]U#&-E'-X?]SXS$H,9Z #JMT^3NF$ED? MJW5EBDIIL*_C$$@51WS3=7LR!;", M+V/_DCWE7&QG)[L:G^*,87P['F>YP 37PG4K<@ P=QR$G1H^W\6?7>DZDA7^ M?3N;78*. OW1&MBTC5.AJ"_ =$PH*Z9K06/$T-ODU*5*(Y("^8R&.N<8WOBP M:8]/\D5D;T/2@=- ]K-<_+ -PRG32FM+51HH#8JM"D8<709?0Y>/6_9*;/\/ MY2I6HFU!BC\2NG#_WKH\A3_*(]HY-OEI:EE UL9MCIC;8+4TLL.5Q(@?MYPXV= " 8&DL=@YNS1G\F3*E>=YDAF=[:I". M8!7*:1&$!Z?/,Q%F1$>0KUD:S AI!WL(2"$2F\::C8\]^SPY='?Y)@(3L;#( M?WFON4E5]PI9M(DISPP#/C?\)ZQEZC\W8:SHAHN+=7,"&2?X+GRAYA7RL@\I M-81=4\=S*V9G-S]7Q]'"L1A>;LX*/ MZ4^O^+CD"Q4-5MAD<3+"/#%4=TEL(?>UG("&VRN*"9VRL"AR25Y/2$9,VYBI M<[VCSJ3%-6T -KJ)"=/0M;:M$$9LP:F]IKZC)D4:RPMMQ:/\PZ+/]F/'1-6R\PY>?YH_(V*]BR1/@RRP-MW;?IGN5 9:'17ACW*3<2CAQ: MS%"#K0/SX L 6U88B'(E N61)WQ'V3=],]ZA7,"EK5LKR.V'YQHMIN(+B&N2 M+Q@D;H_E/.,#L8(M[!+&^8YF% E\)J"91_1S\8M?G)AM; 3:H;!-[62]V6Z) M9^"@!,,S#X]8>?J,#14,/B73S :&-8'>2ZF8'E']D<+G+&\%%[7;]58TI9#$ M@W[;O0J+W2A 67QW8D _0E>;MA[:!%BZ>\.,.;/RYF%D5*YG)P=2SB #U3_0Y7&8M&2OC[>5W>O 79:39^ /([?0AA? M$N;!>2C0^V4IH;I3#O][<29??'FX.!^ZJ3G8ND"K*:SDFC#FS^=\ES:L#C>1 MLWP!M]F>KS'?Z[#BFK>TQ-'#R0_?C53(5X/Y1_*-7,H;T/I_M@DH%8=6+6=LJRO_[&3J"P6ZJMM/C)5O@!,W# M\D[1K+/5DO$"2\UE"0KGI]XX/#Z/K;P3>.2XTCMCL)[,I'RRD^OLU LL(!28 M&JN!T>\9+U (JXA@?&ET>EN3]N#N>*/]H_.=?)DQC1=2_,TSDY]ZB0<9SEDE MS+U<76'C3\_J2Z70[@NK6K8?>9!6VLBB.4P("E[6?_:UX6'G0!(<.! U!R*' MNS;D4'Y@AIV-E%R!LM*DS0Z.E#3N=P/CV TRN/M]/CZ:7]S=P??MX.9G>V*U1QY!9>[B3-B;.:Q/1 1-= MN)&ER35+.=I@/H_>5'C#5!NZH0]1$$5OZ.MN.>@Z?=U#'#"= M$P?TA5]SDE*&F4MRL M88F*RTR#G(/)%2(4=2Y(!0*UAE6.)2PKE>946ED;QDZ4(ISFVQ"[0'S %(L9 MJLTJ?4V.<"&+)2O7O_^61.'@I,;@Y-/O\:]0(:0D+LD0&3G>L;*G_*%D549> M9C!N_HZ+%B1^=]"G?]4?TZ5!O.=X3PH3UIPY2>+5VI-)SV_'_<@)LC!,&Z"?H";%@SBT._U(SN**.+#!*8OU#:R-MQ-_K*9 MP.\H.G<4_6%=BX*3Z9&CS,W"DS]]D.\BRM_WQM^LIH=H*'XL+I?;!PDV.2,, MML(%TYITHKN2O!Q%=F3DT2:-/7OS>.R9<>&I54U= MCZ8);B^[U^O-:GPU+O2BI.1!QLN%S72N?K@FG64@>4X[9&?.2(CT5EA?H#]= M'>RGBPY6)-O:Y(L5:=F4&09]GYHNO437-HGU^PJ9%;)R7,RAU1294UW76;*O MNKF:R>.%5/Q;S>\GI"T(ZU(@QQ7:%M-2-V."E2FZM\<)13:1:VK=AKNWQI,+ M2*+ AR:#/UHJ'QV5-R[%L6'*.L!U*J1=VV1X^[5GO;/39A6H%JZ9I$RPKM8= MUW9UVZ^.ZS;M1;QN=HG%!2^M W,Z&K0'/0]4W4#6$R.7KFF;24,MH!OFU'.C ML@*T/Y=40'V61XZW2+Z9$ MM/!:"6DF06EM/0I#DY=8,=-7-4KRK)2NF*6C7H>FUL@*#ZI$&$?1>5@Q+H/I MV-ON]72L&BNXQ'L-IJDJIG=S%&H["0;!P;#@Z](Z0S@=UVR-#VB?ZGM-I[!C M*7B%TG E0>-J$LP&HWGJXGW ,\>M.=J#JV2IU(L[W!23('*"4&!N'0.C98,7 M*(0C(AF_]IQ!E](!C_<']FM?.]6R9 8OE/C."UM.@BR E>L$7:AME]Q7\^9 MX\N5,/X+VS8VB0/(&V-5M0>3@HK+=F6O^WLX F31.X!X#XB][C:15WG)+)N. MM=J"=M'$YC:^5(\F<5RZG_)@-7DYX>STYN[YZN[QV^+FZF$<6B)TYC#?@^ M=7*#TBJ]@TMN,<-#/T0 CZ<8RBP4P"[9$H(9"#6H%N3(6E 9)34R=*?AOMA0(&R8: M[,,CA6[]ZW30#6IJ-JC0EJI00JUWP(F\K@4GMU7TI"UJ>FGH:?LP,RX%_9F\ M['X-,%G )>98+4G!WDI?I^I"5363NT\?LG@P_&* ']5 >AUM52M#R=1J=,3[ MANY)LJ;@3O!LOR[8EMX]2>-,&/@(@UZ6#/R:9F?PG5J?,D&MU9INTL @[46# M"+)>/$SAFDM.+5(X=]'DEMQ)+TX3%W5^GL&CLDP05_RY%V6IVZ2]-!["O]Y' M>-1K%>JUGRB&BFJD;=NNLW9#:];VZM_P=N)1[6LN#0A<$33J#\\"T.T4:0]6 MU;YSE\K2'/#;D@8O:A= _I52]G!P";I1/OT#4$L#!!0 ( %TXG%2+GETN M] , - ( 9 >&PO=V]R:W-H965T,6R :\NRDZ:=8\!)VLU8?J'.MH=A#[1TMHA0I$I2=OS?[R,E*TG7!'OH MBTWR[K[[[GB\TW1G[+TKF#T]E$J[TU[A??5A.'19P:5P U.QAF1M;"D\MG8S M=)5ED4>C4@W3)#D>ED+JWFP:SV[M;&IJKZ3F6TNN+DMA]V>LS.ZT-^H=#C[+ M3>'#P7 VK<2&E^S_J&XM=L,.)9-)LOKT]Y\].%L$O2CPI^2=^[)FD(D M*V/NPV:1G_:20(@59SX@"/QM^9R5"D"@\:7%['4N@^'3]0']4XP=L:R$XW.C M_I*Y+TY[)SW*>2UJY3^;W6_<$@;0W2R+MQ%%E>""]F4VMV9(,VT,(BAAJM04[J<"E+;R&5L/.S M\YNKJ\7=UP&&8M[EF# MF[Z .Z8KHWWAZ*/..7]N/P3'CFAZ('J6O@IX)>R QJ,^I4F:OH(W[@(?1[SQ M2X&;LI0>Y>4="9W3.>A*O6&=279T(5VFC*LMT]_SE?,6U?//*UXGG==)]#KY M[NG^'KAT4[$5(4RZ9)2R&]!=P;06F532A[C-FCQ.D)Q*Z#T)Q*^"9DXU[M'2 M5EAI:NAU0%%,8F.9FV2B41"DTN2N3U)GJLZ#GJG"*VS$_.";9PT-UE&L#2GA MX<$70N..)Y.&6\=$.=/X)\@P3D7!DGVVI9"7U/FUI8H3V'/,YC[E"DL#Y4 M:=2\X(S+%0BVIZ/^LPQ7+7H$[%P ZDW:'T\F$2(LCY(^>J"K.'8QM0>*HO!A5AX=G/\36;RO0'A=J[54*MSQ5U7RXP\G MZ>C=+^Y0"@$-8@MZ.CZ<6BBL'Y];$]WQ^_00W?'[D^?1T8"6K"5<.\[P"'-( MMT9M _$,6^D/_/<#NM%TC43$)!_''"?/#F_WE#=_8%,-P>99NA:D(PEE$_H9H+6<7\H1XP,DCD,,4YPI>ZF9_8]>&% MP1BVH_2G[.=PD0U;[8R2H2IS^B2U0">"Y=+CH,D;+C8HAB*B4?+V]V]7W?/8 M"Y&'MX5Q[+QHGMI**& SK8Q%]^J>MG_L!/O!MUK=\,F4*=ENXBQUN-E:^V;@ M=*?=N)XW4^I1O9GU8+R1.E3,&J;)X-U1CVPS/YN--U6<62OC,0'CLL G!]N@ M /G:('_M)CCH/F)F_P)02P,$% @ 73B<5.[6Z$6#! * H !D !X M;"]W;W)K&ULI5;9;N,V%/V5"]4M$D!CR_*:C!W MV=!!LR')I"B*/M#2M44,1:HD;2?]^EZ2LN*L#^V+35+W')Z[D9QLE/YA"D0+ MCZ609AH5UE:'G8[)"BR9::L*)7U9*%TR2U.][)A*(\L]J!2=-$F&G9)Q&1U- M_-J-/IJHE15&SQPW)B=,3A/YDK]<)-O^31*G" 4F%G'P.AO MC2L M_1DXODP)XW]A$VS34039REA5UF!24'(9_MEC'8<=P#CY )#6@-3K#AMYE:?, MLJ.)5AO0SIK8W,"[ZM$DCDN7E#NKZ2LGG#TZN;YZ.+N]_W9\<097U_=GDXXE M5O>MD]4,QX$A_8"A!Y=*VL+ FLU+O8\7^\#OE.<6SCE)A/*K#3"G[.YL9K*X:]/R/L->=^3]_]'_#YE<%UW M:"J6X32BMC*HUQB]H85K"5=JC>4<-0Q\:)(8;(%PHLJ*R2?@QJPPA]9@-(B3 M) &V7&I<,HM0:2XS7C$!K%0K:4$M(/F9@'*-VO*Y0+A#R96F'2P:R%?H^ >P MY_A_^6FBPL05PZ3WT^[1A9IQP*HZL:*HCA(#@.7<] M;H ).F6X7$*A1([:0QH.L&J[%6R01$MEH42[ZPZC90+0T:!J@VPG3NP=#E\'YT+=3S$)>Z]6N]Y;,%\I%VQSN@%[8?I=L1;Z2\%G]?]%LG5'9*DD. MQ$[J(=R\+M(6;"OY>42$)54&_X>H7+U3,%SV#45AK]N-#T;]?1JD\6A,@ZOW M(R#>2B#,OMMEV(N3=.A':9QVAWY])@$7"_27!\6:,HK&@G:-E:/++[6S\6%< M,*YAS02USVY@XYUZHM%3J!7"+Y7VGE D+W"- GHNERS+E,Z]9QM.33"[.X&Q M:_;HW/$_>/Y+9.XH"P7@<]0<;Z8=^0(@E;ST5?-6UP?%\5YH_FN)^/YJ]0?] M.!T/O$VK/QS%_>&!:WU3A8 *UQ.^J$GP(STT#-)7X677#1!VWC#SHN+N"TWM M4H:+!]W%LR/K#SIPZL77PM*@[FUESD)A^5YT3N;NTGA58^-N J/D 'IQKW< M]\I2M2[>J,_44OJ\MCR@Y2&M&O3>C=/9N;U+U$O_1C&T)Z4E7.3-:O,,FH7; M_]D\O*$H!DM.QZ# !4&3]F@0@0[ODC"QJO)O@;FR]++PPX*>&PO=V]R M:W-H965T>6;(LXW2=V8M MA&4/3=V:\\G:VN[-Z:DIUZ+AQE>=:&%FJ73#+;SJU:GIM. 5;6KJTR@(LM.& MRW9R<49CU_KB3/6VEJVXULST39\$D[&@1NY6EL<.+TXZ_A*S(6] M[:XUO)WNI%2R$:V1JF5:+,\GE^&;=PFNIP4_2[$Q>\\,+5DH=85O_GJZ7B[9;Q2,%G1&,ZR+TTK%[V!?27X"G*)7=>\9<>XX%__**(H>$OK<)3> MP[L'NN98*#K#;3ABFEDS\UDL+*V E1(6[--YP M71D@D7+-.-PQH@PTA3GC 4U =&2)>M,,#'5"$W>!UKNQY\M8WTIKV/%@QLW\ MUHP6/!$P0.?0GNLG>VK5KJ96Z ;,,^M1:025 MNUDS!(M@UMPR=4*);:EA%Y^NED+AE(>!9N#-=V!8"H@@* MWW-9\T4M<#%;]K:'9700. #=_IW6HX%,W<,*<,%:"T%&#?;Z[/I/2EH(NQ'@ MF5'8Y5BDT"VXTUAN>S.^#=#%<(?Y6S/ CW4@V2 H81DP%P!TI"Z*0+E&GC&L MZC7&!@4-\8''E@GD3,@$1MG;.C="S7S#OI).C:-6M^R9^-N6]Q5Y_G-/Z?P+ M52-X_]);T+VM\$2.AJYDV^(+Z$@N*[PTF7DQ"/DGBV,_F+$?!K^E>>I%2<:* MP$]GP(Q"EQ+Q>AS"1)8&)RPL_#!A'W=A)RM'0!R'L9=D^0G+M1>MG0>#H=<@!ZS60KGS5B6^45,8U"PZKX" M?Y%7B;H&]FSD \K!8BE+X4%CI>^@$7[DZ4;6<*!JQ9,R,M)KJ0#/#E*;M<2" MI-TDLDY'/>=:BGOJ+4CA?2$[T?N;6V4A:FJ!F/<.6NDA_GA9 M1(S$;:-;N< M7[$\+'##4M40:O/FN7.&<(*\CUQ"A> U5%SP!+&D*P&@';J(?570];#E2\LB M+P]BKTB1,1)@@ SN81QX$2@0!H47AC'+9GZ %D"DA M)'$88?0SV.76!5X:1VR6^+,$A@(<*F9>%M$!8>+#0Q1Z69:SV M30%5,,WF( MS '8!K"[$&]D70-&L?ZX;HXJQ9 FNP ,*;/!E,&Y U$=JM88D5=<[W]O.P7% M1S1=K;9B:$<>J:BC=FKH)[!%&_L))"S1EE#>X3O)5?.6]!&U7$EZ&$02M_$2 M^B;LBC90Y,Q:=B_6K6><-VJ"/*)5OUJCM7W3UQPU[_A6 [C@FZ?J2^=ATX1 UGL!,$JB!Z ?47:!)8P?YZ!NKRKNG MOAG<07X?2+@1?*2A^?"=ET3Q:.\G.$6W@.4;2,*V1P=4SG^$!:WNI7%V+!^U MHZX&!JWND46Q*0"\@"=I5$)R0R)0Z'&+%N3K78937VJ<*D#_!Q,8."I%GLH/ M%YW''LDYYS$JB^VAB#_V-Z@_DKS83UY4Z@_=)ML 52#>&PIM;\8Z\J[FY=UT M7JX5L!-4BDK4U*I!KS2VXV.[AH5W(,Q=R@SBGT&_-@#*KJOE\#F!7XEB>L5U MK9B1A"_<2Z?Y4'& QXPPJ.V>'8\Z.HK#-S*]WKJ> BJMJ^_?Z)A^Q7KE!M^+ MTN7KCB;A$NX5P-XFF+E@4LVS7Q@ M,2B'P31[W'"OT. :?9D%1],L.G+W8+C'1^Q&FKOI$HW 3,'/%::1>T,_+8ZF MH9^%1RSPB_1H"M<"GW,:C_(C]E[>RPKL8ULIZ@JF0(6C9S="^F$+@*6#OC:1&^K&_@AS-WZG CC8/9]VF)2+94C%K53NE+:A_*3[X+!ZZ' MA'1LA3P(F'V!^1R4GZ:$!K)?M?BU3XC_KIZ2R(0P,[+*]F5TA9AU?P,XKQ1^ M#"W! &(Y T5Q1M79M(H'_'T/W6!'/S^HVZIE*TMPLK$@$+9G M7@'E.O6@<+,(:C@0U9PC'>!JE_&8<1FTO"DV?B =:"W+8_:#^ZRBA;QJ0"[^ M+*%_!5#=,V@)X',#:G420@&?#8W&-T,*G7[J!4F*Q;[PB@R-F@&! D8._80Y MW?L;U@B]HG]^!D3WK74_QG:CN]^*E^YOVN-R]T\2X@*-KF&U6,)62+)TPK3[ MS^=>K.KHW]I"6:L:>EP+#J2$"V!^J90=7_" W<_6B_\!4$L#!!0 ( %TX MG%0HZ383^ , /(* 9 >&PO=V]R:W-H965T*&ZBM,D&<:UD*HSG?B]F9E.=.LJJ7!FP+9U+KU+[BQ9\!XN:ZL_\(ZW!T,.I"WUNEZ(TP, M:JG"*!XV?G@B,$[V"*0;@=3S#HH\RVOAQ'1B]!H,WR8TGGA3O321DXH?9>X, MG4J2<]-+864.0A50R*IU6("B2) JUS7"4:6M[4*#!K0II*)7 UL*@Y/8D6Y& MB/.-GLN@)]VCIP\?M7*EA1M58/%O^9@X[XBG6^*7Z4' C\*<0+\709JDZ0&\ M_LX1?8_7WX-W(XR2:F5A1M;.V4CX\V)AG:&X^>L ?K;#SSQ^]NZ.?@\]$,1> MOQIN2 MTT'A(SH,"**EB& M"XN-X'9^1]^9_^9:$0LG%Q7Q("3KWX*5W,QGLRZ?6TDX3/\P&_X[8.B/M!A'J4 "0 M"P!0^M*[<_[^@<)L-J\Q1_]RV[SF3P_NE&@+R>HN-N.G%VJ% MGKQEL-'>*2W'#GDW6,P.>:MA(1!_A*,L&F:C;ICUTK&?#<91?]#KPI>WA^,^ M)H>T]Q)2.1Z2VH3F:33L]Z-!-J!Y/\IHGHXRF&U#N'I\$<2N%(Y2AI#P(:]: M]KN/YE=BX#_)G,'GD /@8R3]\&*\12JA,F=W!/JMDF[_==BW MN/8;"7+P\7/G/DWI=2DIQ+VGJ1"PTN!M&:K6EE NJKRM@L]'T7A$%'IC.(U& M_2Q*AZ3P;#[6HW]'IS7?HGQDSZD1K/R MW197[5:YT)+L=G<-W47H8[Y=#]T@U8>5I+BJ<$FBR&PO=V]R:W-H965T^1%WO/&7=>TQFX$ M\]F:-WB/YG%]JV@5[%#J;D"A.RE X>K(6T2'QXF][R[\WN%6[\E@(UE*^<$N M+NHC+[0.88^5L0B; M]L@K/*AQQ3>]N9/;7W&*)[5XE>RU&V$[WDUR#ZJ--G*8E,F#H1/CS#]//.PI M%.$+"FQ28,[OT9#S\ATW?#Y3<@O*WB8T*[A0G38YUPF;E'NCZ+0C/3._?[R] MO3R].KU^6%S"Q?79S=W5XN'BYGH6&$*W=X)J0CH>D=@+2#%<26%:#:>BQOI[ M_8"\VKG&GET[9J\"7G%U ''D PL9>P4OWH4:.[SX!;QSE(WBZ[:K8$'UJWVX ME*)Y>TE54<-":S0:_EHLM5%4*G^_8C#9&4R

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

F1YJXC71M8._[TYO]C?GOH_> M8.M94J)=AL<7)T=4QQ=M]J][R;Q6;,Y'A^'],E?J.BY0.TOS#&MQ,.T+UZQW\#4$L#!!0 ( %TXG%2G MD73MH , 'H( 9 >&PO=V]R:W-H965T"BWIN("[Q3H;5TS]7R.E=R-O,C; M;\SXNC1V(Q@/-VR- U"LVE (6KD3>)SLY[UMX9/'#R^IL7IAQYF0<%KMBV,C.YN\(V'TS$I>J\B1P7]E+F1M$I)S\SOIC, MKWRP7YA^OK]^F/PUO5W,87)["?.K3[/%Z6(ZNX'KVX?I?''CCOY8L&6%^L]A M8 C?1@GR%NN\P8K?P>K"C12FU# 5!1;?^P?$^T ^WI,_CX\&O&&J ]W(ASB, MXR/QNH=B=%V\[GO%8+JD8M 7IE^V_(E5(SV@8D"YJ54YM2@JN%:/$VM3V# M?R9+;11IZ]\C^,D!/W'XR3OX\^9E@%PU)"SNCVS>OO1J/99G^D-RW'DT;O5 MJ)[0&T^T1:$"YN6A@@[O$G.LEZCVN_0U)<%K#=,//_^6Q9'Z0<-^9Z?F^ + M/]BA0LC)7&HL".3L%\%VQ;/N@.K&7PFR:M' M^HE:;46A81#[81I!/_'[_8RHJ8U4S""]QJ4!C?E6<<-10^SWLA (0T9VV3<]>X/($O]-(HA2D)_,.C!0AI6'4G\!)!Z=$ M^80E_E9&,,14?0.HNC]K"@F-6F0_VC-RJTP36LX[!X:ZZ3I)R_F35>FBUASH:'"%;F&G924HII.URR,W+CNLI2& M>I6;EO3G )4UH/.5I,S;A04X_-T8?P-02P,$% @ 73B<5#'EA/R5 @ M6P4 !D !X;"]W;W)K&UL?53;;MLP#/T5PAN& M#0CJ:QLO2P(D;8?UH5V1]/(P[$&QF5BH+'F27+=_/\I.W!1H\F+Q>G@HDQHW M2C^9 M'"2RFDF7B%M=7(]TU68,G,B:I0DF>M=,DLJ7KCFTHCR]ND4OA1$)SY M)>/2FXY;VZV>CE5M!9=XJ\'49Z.T,"[XIK#/XTW'%-KA$>U_= M:M+\'B7G)4K#E02-ZXDW"T?SQ,6W 0\<&[,G@^MDI=234Z[RB1[+._2?;>_4RXH9/%?BD>>VF'BI!SFN62WL0C6_ M<-O/J0!@<2HFU"U/+N"K4L M+YAET[%6#6@736A.:%MMLXD;B\N?N]N+I%:25L8N)0YYN_S?6+4TXIVM.;14!7);.#(5RW#BT9H9U,_H36?&X=M9$5_+8 M8;E"O;/2UQ8(YZJLF'S]\BF-PN$/ _R-$31(O6<4H SF!#O:PWT'=R]9G7-+ M0;/MN6 -#9]%S9DP\!G"01J'[9FDI_!(^T>5H-)J0\P-A,D@" -(!]$P@9]< MUJ=[L$D$VM8W.V@?;^^AL[D/;TH=]2<;.S.=OOHQG MQGNE?YH2T<)+):29!6UFU$4F:S$BIFVVJ"D+X72%;.TU.O(;#2RW =5(DKB MN!]5C,M@.O9[#WHZ5ELKN,0'#69;54R_SE&H_23H!,>-1[XNK=N(IN,-6^,3 MVN^;!TVKJ$')>872<"5!8S$)9IW1O.O\O<,SQ[TYL<%ELE+JIUM\S2=![ BA MP,PZ!$:O'2Y0" =$-/XY8 ;-D2[PU#ZBW_C<9<5,[A0XD^>VW(2# /(L6!; M81_5_@\\Y--S>)D2QC]A7_NF:0#9UEA5'8)0<5E_68O!QU. H;QF8#D$)!X MWO5!GN45LVPZUFH/VGD3FC-\JCZ:R''I?LJ3U?254YR=+K[=/U\_+K_.;Z_A M_MOR&KXLV4J@N1A'EN"=4Y0=H.8U5'(&H4[)6UIX%KFF+^-CXA6PRTY,=V&M!-"$B?))WAIDVOJ\=(S>%>XLG#%32:4V6J$OV8K8S75Q=^?@'<; M\X'[YX!?ZJK&E0!MD18+E#;3EI"??HOE(ST\1W74-\V1V>JVBB)TH:.Z@@>-)<9WS!Q M)-N"WJ 7QG%\8A%@I4BP?PF&[-E,D-",M; ETXGO!QT+\A(PL&0C/N/%1#O M5#,A3NEGX9QTO=6$B:=OM^?2<"B0-\8@$N+)+,%S2S2Q:85W3<2S\E8,YA MQ\06WP@;.I/:B"+1R'KUZF44OU;:9T)WN(.!:2$3RTH4SKWF>VY+6'VM(!A M$H<0W#C\9X]_A\Q5)S4^2MW_HZ9B33L 5P#$DE-#(OSWO,X4QT?2_&Z)["EE M:'5[W3 9]KQ/J]L?A-W^94A]VFQJ0<5K&VZX]-GB"PT1@_15>-I6G9R\9^9- MQ2U+C0A5W4O0]9(36C^0Z&07P) M:9BFE[!4EJJU>,<^4VOI_VO+![1\2.L0]%$3B4XZ>/H3/IM]1-NMEM M1MRL[NS_N]?SD3186+7Q?7ZE+$T-;Y8TIE$[!_I> M)+[L' '-(-_^A]02P,$% @ 73B<5+ 3M['J!@ '!$ !D !X;"]W M;W)K&ULM5CK;^,V$O]7!KZZEP"RK/$^,!)M"9%$EZ3L3?_ZFZ%DQ=ESO &N_6+Q-F[6YO#P7K:[AL\EJ+:NF7R^XI787HSJ%(T(/GR8C1SSZYB.F\.?"GY5NV-@21Y%.))A_SBY%#@'C% M,TT<&'XV_)I7%3%"&'_T/$?#E42X/]YQ_]G(CK(\,L6O1?5;F>OB8I2,(.=+ MUE;Z3FQ_Y;T$?'+17,+VS[L\X(LE9I4??$B* NF^[+OO9Z> ^!UQ-X!G=W MD4'Y@6EV>2[%%B2=1FXT,(::@17-F24A9:X6R=OES\.KN[@<_S^X^?;V'^ MK]GM F:W'^!F,9_#R3U[K+@Z/9]JO(G.3[.>ZU7'U7N#JP^?1,+!3=-SO/7 M]%-$.,#T=C"OO,,/S%I@^]:X#F>=X2?/XCM&W[^6V(73/()F3.'.7M&+],P MDY(UTYC"VZ^HMO3+FMRN&;K4K.J_)/G%LQJT>+I?\\>E9;H5/\Y B<8X 0& M3O 6'(RUOTXB"4LM,B>X//:..V\8HTZI/^C_"B2S]2:9?QBA&JN-SPT>5L M%WETBRXX,UTJW:S:U&O6?/\XS\2SXU_PN4.P9H0 #/'T I9,9C!J"8K2&<* M\E:6S2=6(_8FIQN91HZKLFEH@AB?.9.06&&06CXR^0%\WW92^ 5M M2Z1A'%I>$$'BV&&5N8R\G,)RYN1%S"FYBNP%@R"^YN=Q(R9H,$PD=\ZT@ MBD\ACFW??0WDD(H2_5#PA= A+9?K[DBK5[&"T(J3V(I]'T]Y@>V&<,2G MPL&GPG?[U-WB01E!YC@XY$Y'6?TE[O0PE_N3_;_Y4\/S88K8^M#SA2@_5++ M=6T3A3:830X4QH%5AB&O3-]Z7B=0A+83GC0DSI7"JW42TXA3>TT MWL-P2#4G[BGB2-,0[TLABNS$-VL?FZQJ<]27T:HN4("";3@PK!5?B0\9J\RX MA35#/F&-)PP"52GQ .9V+1JC8%/=$1D0"!(^$^C5G7=NBQA8+Z$'F&[-N6T M/G&9$L#>)_)P'J?N!$:K28>R?.M@U):4!+?3,C!;;HA>Y9N=V7\<2P;1$,VB-Z= M#8R6OACQ9PJ#N,]"#Y0'T88PJRJX^:,M]3-8>I8L,]K$')>'4HUQW'>8\#OF8<\>]4LP[(%IV!#V!:M1-ZX^SK]UQ_#7:F>)DL2HD158:+6("FZ7#M,QA/7CMPQ M.'82CB?XF] X-NM>/(8/Y:;,43YX+GF5XQ9"&'_S,8C=\=L[>BF61,%;#?N9/8I?: M.6#?L<(=KTQ8:+'SX7^J/IPG^^%\#:/XCG)TBX7OR@VV-6OS+C%M ]JBS%#)2B-# M)(^L!.M.:&$% @^+$780"T99CTYWB8T22X0];4@=#'+' AO%/OS"&RZ1$QUD M.3XI2WK'T-N8RE2$M0V[9RPZ@8N5.TKYG=-BHUK:#E!2%4KL9(A$JQ8\%0 M.!0)T[T7:\WERKS+%;+&IU7W>!U6AZ?_K'OQOASO_C= NV#'IJ#B2R3%7(] MK.S>XMU$B[5Y_SXC:]I,RPXP]Q+!W!_83>3>B"X0^1R_\"4$L#!!0 ( M %TXG%3G+%FC0, /$( 9 >&PO=V]R:W-H965TT'[13J1O.>>>^Y(:K)5^JLI$2W<5T::5!:6U]$D>;6^P5_ M<=R:)S:X3%9?74?;XMI$#M"#"W#H'1ZQM>H1 .B&C\TV$&^Y#.\:F]0__= MYTZYK)C!R4^\<6TV <0(%KU@A[J[9_8)?/P.'E2AC_A&V[=C@(&^,557G M3 PJ+MLWN^]T>.(PCH\X))U#XGFW@3S+:V;9;+5%K1;36C.\EZ;R+'I2O* MTFJ:Y>1G9W-F> Y,%E!PT5@L0%(G<)FK"N&U4,;TH$8-2A=<4M7 E$S3S!U; M"32]262)A(.\B[@O V8' F8PCLE;6G@1A98_-<_(O+[#))=!O/D). [IL\@ M[8>0Q$ER B_=Y)ZO/0(W@W3DLN-@06EO?39_GVY,E93 WTY@9_M\3./GQW! M7]^AJ!H-;PJ/YUI_Y[4O]MI_Z?7GU'X\-.?<_G.=%/Q[PK$=9T ZDS,"Z MVH%!:VA0VQ(L35/(NK',;Q5BYH:N:(C)AU]?C9/^Z(UQW?\#O7(!=Z5&AHM M.[JR Q4M+WW5/B/3W> UYEBM"&!73??HPT?)FH[<)?=^_UW89FUFJ^:-C.K M#B@88(9.D)J2)>_&T(/++F,GR$L3:WO_%WB=A<-LU&NM?C+VUF VHSHX-O%M"6SL$5"POM<-$[WM5;5Y] MB[1Q>.[D:.DWDMOCRV^6B\71R9\2]B6%?8FTCR1(X-\.Q:5;SUCJ(Q=Q6W)J M<:^T5#YHJS;1 M8X_+VY\!.A\VG/IX)IO^(# N" &0 'AL+W=O M:[3ZHDM$ ]^: M6NBI5QJS&0\&.B^QX?I(;E#0EY54#3>T5>N!WBCDA1-JZ@$+@M&@X97P9A-W M=JMF$[DU=27P5H'>-@U73\=8R]W4"[WG@[MJ71I[,)A--GR-]V@>-K>=H-> M2U$U'0E!2A<3;UY.#Z.[7UWX>\=WIO#?8E2RF_V,U%,?4"ZQ#6F!NK@=/T MB"=8UU81N?&UT^GU)JW@_OI9^YE[.[UER36>R/J?JC#EU$L]'#%M[6YD[L_ ML7N/;.UR_@=9AU1:8$]G0:Y]^_RUE8?'ILKV8F+]8D(Y$[XK.050_:(8= 4! M52_\C)L/7&%76:OO#MJ. 7H,BU(A0M,F)=JDW$/Y7^2J._P)<)MK=@A_ ?HL M\8>AA3XEM(/4H1'Y81@ 59;YN$>$$OI;B2="7:UN>BK"F0 MU](@$#>-=)B<2%E717]/^V8X;WO R_6VDQXZTH0.7!%HL%10J14;7=J-T9N7$=8 M2D-TX&^KR0]L=M8 _TOPNP'4$L#!!0 ( %TXG%0I>-B1&@, M ,H* 9 >&PO=V]R:W-H965T5GLP80"K24QM ^V_7]M)0_CL'A 78L?SGM^\ M$9.IK1A_$S, B3[B!%U:R;E_,ZV13B#F(A;-H=$G4P8CXE46SZUQ9P#&1M0 M'-FNX_AV3&AB-6KFW3-OU-A"1C2!9X[$(HX)_[R'BWJ%K:^7O3I=";U"[M1 MFY,I#$"^S)^YVMDYRYC&D C$L1A4K>:^Z%RQI@(EXIK$1AC70J(\;>]8[ MKEN.5@01A%)3$/580@NB2#,I'>\9J97?J8'%]1?[#Y.\2F9$!+18])N.Y:QN M!18:PX0L(MEGJP?($C("0Q8)\XM66:QCH7 A)(LSL%(0TR1]DH_,B ( EPX MW S@_B_ RP">23159M)J$TD:-^"MX_ VA#D<;\)M95ONG9M[YQH^[P!? M'X3D-)0P/N)#5T(LT)]'A4W7?X_<[.4W>^;FTJ&J?5T7Z@6LK]OG:4KE&RK] MKUXV<-6I>-6:O2QZMQOF.D'@N'G8AM)2KK3TK=(C"9=SFO9K?;SF_W369U2 ME0L>!E[%WS)Z-\C#A6ILJSDBM'5?98 I^J+_ WU?DGBYU_UP9ID),&9S:] MFM]N %XW-^R>K@895]%>MQPX6S78$^4<,"Z$^)O6B%P22#4[J1;&YFCQ&3:I(QRYD: M-H'K '4^8:IV4:/,_GXVO@'4$L#!!0 ( %TXG%2NP[$X8P, !H+ 9 M >&PO=V]R:W-H965T[/V8,SOGC#T[ M_3WC/T2**.%7GA5B852;C[;MHA3S(EHL0T6:F?%>$ZDFOU+38<26) >69[ MCM.QS:2T)S+ 1E!7!<#:R1^WGL!AI@+)XH[L71)6,_]&26#"Q' M1X09QE[(.JUPS%FF?:DXOA9.;7J,S7P>/SL_8LAK\@LB< QR_ZEB4P'5FA! M@BNRS>2<[6^Q(F0"C%DFS!/VE:UC0;P5DN456$60TZ)\DU^5$$< U[\ \"J M]W\![0K0-D3+R RM"9%DV.=L#UQ;V]Z8+0Q:,6&%CJ-D>1JERJ<'(Y'T>T5 MZ"=,_WF+.;%U#58.2 M_L$$QDQ(&!4)S#%F/%$K-T10H8T6UTN:90)H 5&J[&&!/(=9L4,AU1HF6DH0&&\YE;11>/>HU+OO++U[J'ZN]T;B5XY>?N@=K^N? MR'_.SO%#KWTA"8=RZ3;7RS&JVU%8YT&=7LEN&&"2G%5_@)&-:-)GT/Q M<_WWSLVA1+K!6^4F>%7Z5:7J^,%I;L[8>;[3\T]R8Q\U+KIK5'?VFA8",EPI MH-/JC^\;,3B60;T\LLF52=D1FFJGE%K@W4_HJI'%43W1[5[?#P+U!+ P04 M " !=.)Q4UY,('I8" !I!@ &0 'AL+W=OVX,I7\?&/O![G0U;XPS-X^9!T8JY3$'AJNOU:U>#T,:[ M@ 7'G=Y;@ZWD2_LM?!A#U!K' $!2#X6T"] -1=H;DR5]:0&=;K+D#9:.)S2Z<-PY- MU?#4=G%F%)URPIG>H#^[K8"]PNC[XWC1GXSNYS/HWP]A=OMM.C^?CZ9W,+Y? MC&;S.W=T#OTHXK8'3, XS5\DVY'3(1K&A3ZCD,?9$$Y/SN $> KS6&::I9'N M^(8DV\3^LI!WG.WW[;V]YEH]8, MR=7MOJ%?A 6M=C4LP][);Y3R&T?EWUC1"RNZ0N_,)C.Z A/N?(ZJM=OM5NM#5_R]06"','T^:YYJ$+@B8/7B MDGQ4^6#+-T9NW&QXDH8FC5O&]"] 90/H?"6E>=O8<5/^77I_ %!+ P04 M" !=.)Q4%;!QP\#D4/M+2VB%"D2E)6\OF5%1<% M5CH4:U>6 G!F005U \^+W0(3YB1C._^ M)N9DG2LSX2;C$J]A >JE?!(Z2J7SBC!R4P0I75,UY_1-:/P/#EW(J[1/536XT=%!:2<6+%JP5%(0U;_S1 M[L,6P(^. ((6$/PO(&P!H37:+.V9ECA9"QXC83)UFQF8/?&HK4;PLPI+I30 MJT3C5'+_^'K[^/QK?G^[0.8&^HY?%#)V?7: S1!AZSGDE,,PN MVP!37'RB&9$IY;(2@'Y?+Z42^H/ZOY MWIZZPZQ1,(SZU0TZ=8.3ZNX((_HSSHR\K$I5K[S!H;PPB,(]>3U941R/^O7% MG;[XI+YGKC#MTQ0?'%7PPQM%>YIZLJ(H&.YI&UL MM59=;]HP%/TK5K2'5MK(!X%"!4@4VBU2H:C0[6':@TD,6+7CS#;02OOQNW;2 M+"T059/ZDMBQS[GWG.N/]/9"/JH-(1H]<9:JOK/1.KMT715O",>J(32PLA* M2(XU=.7:59DD.+$@SMS \]HNQS1U!CW[;28'/;'5C9D)I':^!=@9WRG9 MJTH;&2E+(1Y-)TKZCF.W(B#!FF""/WP6I4\8TP&K[A?W&B@,OTO=A_(X6@EN&+!5/VB?;YW%;70?%6:<$+,&3 M:9J_\5-A1 7@AR< 00$(W@MH%H#F>P%A 0BM,[D4Z\,8:SSH2;%'TLP&-M.P M9EHTR>IJ?M<2QBE@-.#T=UD$BTFU]/%' VG8S2ZFRZBZ5?HH]MH>!7=1HOH M>H[.QD1CRM0Y^H(>YF-T]NF\YVJ(;UC>W// "[PA\ M5 ^?8-E 3=_"@R/P<3U\3.(2[K^&NV!:Z5Q0.A=8ON8)OEOH([%"(TD2JM$- MCBFC^AG]M .1)ES]J@G3+,,T;9CP1)@9(\F:)+"XTT=8T)E05MCYN4T;4MC M=OMN$#3#T// Z5W5I6/S6EYUWJL\PS+/L#;/NXQ(K&FZ1HS /D0X39#0&R)1 M+%(M87]O,8,VYU3#N7%<0QZB5ZW?N99=0YJZMME>;JW3-[O]5%?U!KZM2H]GW_AVHWD<6 MVJ^J?Z!KV_]="O7A[GLX:!=TU3!1EX!QFM< MPZ1^?V9=[3([(VR%!KN)]O!] MXY%G.;J-,(E+EL$\+E<:FN%'27E!4C#E20:MN/@IG\U&3I_[_#"H39[:^(J M62OUZHQY.@ZH$P0"-N@(S+YV, 4A',C^-,R@RZE"]Q?O]/O?.VVEC4S,%7B M)T\Q'P>7 4EARRJ!CZK^#FT](\?;&'\D]2M+PW(ICHBC;8BBX;-[LK>W# M7D#4/Q(0M0&1U]TD\BIG#%D2:U43[;PMS2U\J3[:BN/2?905:GO;1PFTX?% MR^WCTWQR?TL6#T^WY!NY25/N.L8$FBX-ZLJ.&))?]]:!S!$ M\_L#_*###SQ^> 1_DV4:,H9 2LWEAI>VF:Q0E<1#'6A8YY[E;M$N&5V,**5Q MN#N@8=AI&'ZH884V?VK;CZ#!(-'6/)3]8PKM4?KY4$?"O:%S]_<'TQF7A@C8 M6A#M78P"HIL[T1BH2C^':X5VJOTRM[\1T,[!GF^5G9O6</=_9B2?U!+ P04 M " !=.)Q4(4=4T,L" #3!@ &0 'AL+W=O%[L99<+I=\NYJ>IW96$X$S!51!=91M7K%7"Y M[CF^\S9QRY:IL1-NOYO3)=R!>2Z?))UE>LY)"FTD5D%1@49 M$YLW?:GJL 7PPSV H ($_PMH58!6:72CK+0UI(;VNTJNB;+9R&:#LC8E&MTP M87?QSBA<98@S_<'-Y'%T>S^^NAZ1R9J8R;88^8'56>DY7\A@1<$ M#?#!8?@0DAKNOX>[6-:ZMD%=VZ#D:^WE0]]CH8TJ\-P;\NL:$\C809_'Z!O MU?2MDC[<0S]53"0LIYS03!;"--5KPQ"7#/9"K_I1._(\K^NNMNORS[1W L-: M8'A0X(- 87@&_L"<,T+A(@B=2F<6LW7-&6AE/?/V^'.U;TH)V)VR6&M52 MHX-2)]@O$ZK4Q/+JISVG//ZB1OY[])>O1!4Q2WO"#>D=Z4AC<@;I8>U]+C M@])'VC!L9UCC!66K"@OH$ED_&&/PR@,.M&.R(:TN!W&YSLBW:V68]L]7KTE M$YIP6"#0.VNC3;5IH9N!D7G9A6;28$\KPQ3_.J!L JXO)/:$:F ;6_T?Z_\% M4$L#!!0 ( %TXG%2."E[/P@( !<' 9 >&PO=V]R:W-H965T64CWI',"0YX(+W?5R8^:GOJ_3' JJ M#^4+V.6[M5O8XL#6<";A7195%0 M]:\/7"Z[7NB]+HS9+#=VP>]UYG0&=V >YK<9WZCDK$"A&92$ 73KG<>GB9M MBW> 1P9+O3(FULE$RB<[&65=+[ ! 8?46 6KP4,@',KA&'\K36]YI.6N#I^ M5;]PWM'+A&H82/Z+92;O>B<>R6!2V[&$&MKK M+DDRJ)1S0Y<,AT;[3-A?_N=4;C+D&=Z@YOKQ^'X?M2_')+KF_LA^4XNF* B M!3)\QMK20,; J8&,&$E,#F0@Q0481,.Y%H:T&0_ 4,9UP=(MHBO7TZB#AS MFVXGM8E^92+:8B(F M5U87).AR"#;P$]V\\-HAX"/&6W2&KVFM1_M5+RBZI#$X3<2!5&T(:#!Y^GA M)C^[Z0FDV^COW,1-D<1.+]ZJA[]K)+11)9YX0WY?(H",#!3ZSP[Y5B/?&N$<@I'EO\'-.Z=&682FTVUD0E>N1$;7=;]$["H.,O5M.\CCD. M?KS').N8.([?0.\LM1M+[9V6[J6AG$SKDP3U250RIE@+QMKM-_^A)]US+J? M=F(_T-R%O?]02P,$ M% @ 73B<5"&?DCBE P "A !D !X;"]W;W)K&ULM9=;;^,V$(7_"J&G+;"-1,K7A6W N10;8),(<7?[4/2!D<8V$8E4 M2=K. OWQ)25%]&)MD6CEUBW.7/X43[.S Y"/JLM@$8O1<[5/-AJ77X0Y5N MH:#J0I3 S9VUD 75YE1N0E5H%E55.0AB:)16%#&@\6LNI;(Q4SL=,XX)!I M75%0^?T2N(;@X,Z.D9V4]"/-N3VVP>1-81Y)!JT'-QQZN(,^MDO'Q=R,: MM#UMX?'QJ_IOU>+-8IZH@BN1_\$RO9T'DP!EL:[7#^PV=H%C2T>JG(5?47 M'>IG1W& TIW2HFBC8."\?J3OC0@C@I(=: - 6D\ETWJEQ>4TT7,RD.2-JG MC9H]J)9:51MSC-M=66EI[C)3IQ>KS\O'&_20_'[[<(^2+\O[%5K>7Z.;59@ M7]$RRYB%1W-TR^M7P+\< V:LES],@NU\6"5PK3I=UGW(V?ZQ>A.<+U5Z(9G MD/U8'QKO[0+(ZP(NB5?PCLH+%../B$2$J"V5H#RJ<8LEKE3C41'[3B@TI\<$;\H;04%8(7D"E3D$/C/:^TFDM=RPDK-? ML_T"CX>C830+]R=L#%L;0Z\-N\>>U8Q:F='[HQJWXF,_IDQ;MBH8/HWKQW M]"D'9-Y&M)&4:]5%;_P3O<%T.)A.QZ?Q35IK$Z^U5>V(;4S.[@SK[-$94YY MEYW)?]K,:>MFZG5#(CQ$B6GO@8XC%PK1^^\I/LH/O(TE^@EB[>('3]^?-7&!1)>67?(#SI9$Q=N MQ!]NQZP?C4')4F.VCC+S,\&TMXT+4)Z .ZRBL3] O?+Q]W 7>X1?RH= T]6 M7]^6(L3E%!GV -J%%!GU"]HO_P;0+O!(1R= -T9(<2%%)GT -HE%/'_A_2_ M0?OE1^=!AT?C60%R4PVA"J5BQW4]J;57VT%W68]W[O%Z2C;3SH:9\,YA;4JC MB[%Y=V4]>-8G6I35L/&PO=V]R:W-H965T'P[";3UMK$SK'=[2+Q MXX_M=--RFF8;>$ELQS/SS=@>3\8[+A[D!D"AIZIDY[,-U 1Z?(: MF/ZRXJ(B2G?%VI.U %)8H:KT0M]/O(I0YDS'=FPNIF.^525E,!=(;JNB)]7 M4/+=Q FU,TLBX0,O?]!";29.YJ "5F1;JGN^^P1[AVC+^>EM$^TV\_U'91O MI>+57E@35)0U;_T#\21 #XG$.X%0LO=&+4UT21Z5CP'1)FMM9F&M95ZWA M#.KLE!"?Z5:3DT7GV;W-^AN_NWSW2V:?YG=+M#L]AK=+.9S] XM]"8HMB4@ MOD(+Q?,'=%?;8,Y+PM#K:U"$EO+-V%,:Q2CT\KW9J\9L>,8L1E\Y4QN);E@! MQ>_RGG:A]2-\]N,J[%7XE0@7X> M"OTP?(4\)#=$@&R>/?IQ&R=L]>,S^F^W MU1$B0.W$>C3&;4Z(ZLSNE3G6[2$-66,LC72)T@JP@K3?DW9WI\WZ!?J\JD) M46,NMN;,<7R<9G$TPF$X]AX[...6,Q[N1:$2@N)HM/R.(T#J.D&RQIP9A M8/ $(J=R %IR@O8N2.,D]KO9TI8M'4$Y;KY'0Y:-H!BJ,D M[>;,6LYL< R;7?6H8S=F:8IQ M-V7@'YIWYLE?MA+P"SP(PA]J;7;$=6"YM"3,XCA!WTQN(%&WTY9"L+5.LX MVLB8$!T296<;T#2HSAA[/JC,U$#QZ$?^?!<789RMR8SHYWH._&YY@/Z3_ M?\?\>^(92HU/J(/,#:(SU(<+)NB_85ZD[DE)0UV(3EQ(4Q>?.?C!X>X)^B^? MEP/?G:V&XL5/3LYJ&+E!_#]^[ZA2K$"L M;3TL4J[J8Z@:&K@IJ-X;>O. M)5>ZBK7-C?YO &$FZ.\KSM5SQQAH_T2F_P%02P,$% @ 73B<5/P@]Q\N M!0 =!L !D !X;"]W;W)K&ULO9G9;MLX%(9? MA3!ZT0"M)2[:"L= TC33 FUJQ$E[S5BT+502/11MI\ \_%"2(ZHCD:X[47)A M:^,Y/\_RB0XG>RY^%&O&)'C,TKPX'ZVEW+QSG&Q9ADMQGS#C23Z:3JIK,S&=\U,DYS-!"BV64;%STN6\OWY"(Z> M+MPFJ[4L+SC3R8:NV)S)^\U,J#.GL1(G&>#\1WGR3X?N:4BEK%+$U0];5C[UF:EI:4CK\/1D>-SW)@^_C) M^G4U>369!UJP]SS]GL1R?3X1R!F2[I-Y2W??V2'"7FEO05/B^H3[ _/NB.P MV!:29X?!2D&6Y/4W?3P$HC4 !X8!Z# 5;IK1Y7**RKI="+X'HCR:66M/BF M6HU6XI\S,I<"G4W4>/D=/[QXO8#^#J[^_3U!LP^7]S,P<7-%?@PG\W 6S!7 M11!O4P;X$MS.[PM \QC,RH/75TS2)"W.P"O@@&)-!2M DH/[/)'%&W51'=^M M^;90(XJ)(Y74TJ&S.,BZK&4A@RP,OO!A^_D5>/WJ3"NO/RUN8]2S"KS/=ZR0+ 94@@>V2O(\R5>ECY^,"O!:9:V.Q5E?SFK3 M7F6Z;/?=E! O@FXP<78]FOQ&DV_5])>@>2GIB'>_XSWRB>=Y_6AUKL"R9$F5#M58"YHO%)Z.JPF[:J 7H;!?3-2( MB7Z[-%@>GU 74;JX=.582[BLC8-;05U.B$Y(\;ZU2)I",QBL:1 M@7E0@QC^/HE[VNU4E5ZWVOQQB TJ-9JAGRABJT4U6_..NE MBAU>L$M3##WB85.G:IY".U#ON1I:W)EIENS5BGMU5,;]5MZ8 C;.@)I&& MW.I5$XO]E3$X&MNBS72V$1PV+0B#3YD!]]I:3T8:Z<5!2X./62(HZ8=LM/N MVI30LEV5M#]IWX/+=ON2< P-)8@T!Y&=@W]6@@>COY0@=A$T+#"09AZR,^^7 M$KS;.+!N'J,"P^P)QMCP MFD,:@F@("(N! //=?O%8(U ? ("[]:"VN_C,UCL8A'@'N&=-:,0AT3@D M)^#P.MG9"H1H&I!:4@T#7D8DBX,(S.B$%KZW^* M0\"0],+05'^:A>0$%LZ31UM-:!22@5%(- K)0%2-E2#77'@&PO M=V]R:W-H965T@>^@QD^^SY_-D9C+#K9 O M:D6IAK>(Q^JJL=)Z?>EY:KZB$5%-L::QN;,0,B+:#.724VM)26A!$?>P[W>] MB+"X,1K:N:D<#<5&V7.EDPAL-UV1)9U0_ MK:?2C+R,)601C143,4BZN&J,T66 6PG /O&3T:TZNH;$E&7Q_8OUGCC3'/1-%KP?]DH5Y=-?H- M".F";+A^%-OO-#6HD_#-!5?V%[;ILWX#YANE192"S0XB%N__R5LJQ!$ =RH M. 7@4P&M%-!Z!T"]"D [!;2M,GM3K X!T60TE&(+,GG:L"475DR+-N:S.#GW MF9;F+C,X/9I]'S_>P,/TC]N'>YC^&-_/8'P?P,UL.H4+F!DW"S><@EC -\(D M_"1\0V&LC)NLDW-3\1H" \QWX%Q0KCYM6%Z!Q.2S(ZW1(8;I1FYH#,Q)-B M\1(FG,Q?+@RUX%3!@^6!J63SY.:=""F'+P'5A''U^]#3QLADJ]X\-6BR-PA7 M&-0R%+%>F67CD(8E^,"-1]A!X!EU,XGQ0>()=C+>$=F$%OHV,>X9$/7I\-1 MF3UN>$#G5?""-:W,85J6KUW!EWB&@Z:=T;0M3:O[U9$THMGZR?7(C)A3!'K M"&,I2;RD)K1H>-[!\7-3LK/3UJ_@KQ^&$FXUC=3?C@UUL@UUW':]K4TH,JMH MB/XLJ-$EKN?FZ8+D?6>LG,^&QF<@RRHT,U4Z)ZFPJO@YCRX>9F_)F&'19NH M3 PW6PT^'.D"I3G0%23!#\8)FOHNM5G?B8P. -8U")/YC]?\; M20U=%U=J40.LUJ(&VK3(J\AD#L3GQ.@:RA1L],OE\.-\YO]][$V5:,.UWN_ M7E&,O)1 [FQ\1I2>U%"B9A>5B^'&&3%10QJU\,]IQAY08'<-< ):<%-4!TB MSL,%'\<53<^+%N3.^O]-"_ /W)6]$,4%\FH #3Y'@L!Y%8#=2?7DKXD:G@Y8 M+32$A_P $R_V\.)$^0>N2JK@1H3/CQP7CW@CU8/B9N4A8KB GD=@3]) M'8'S.@?6$?4NHF;YW @@U/L49R+TPWE&#J)R:1M]"N9B$^M] M(R6;S9J)8]M">S<_09?7^Y9@3K/O4-X1N63&9SA=&$J3Q4R:D_NFWWZ@Q=JV MP9Z%UBRERM0BJ3!\S]A1#Z,$@6R%JOHW\!4$L#!!0 ( %TXG%2UE?\' MOP, +\- 9 >&PO=V]R:W-H965T;7= ]$OME2EF$AFVQG M\CT#'&E0EIJ.905FAA-B3,>Z;\FF8YJ+-"&P9(CG68;9Z192>IP8MO'2L4IV ML5 =YG2\QSM8@_BQ7S+9,BN6,F \(02Q& [,6;VS<(.%$!'_$S@R&O/2$G9 M4/JD&O?1Q+!41I!"!0%EG\'F$.:B:9Q^^2UC&5,#Z\PO[WUJ\%+/!'.8T M_95$(IX80P-%L,5YE;T^ 50;[B"VG]2\ZEK&6@<<"YJ58)E!EI#B'S^7 MA:@!)$\WP"D!3A/@70"X)+HRA11=AP46>#IF](B8BI9LZD$7 M4Z.E_(0HW]>"R;>)Q(GI^LML=8>^+Q_OOS^@Y=?9PQK-'A;H;KU+D,8_1.L8,KFYEL2,TIYF<@1QK#^^>U3-PM((4"_E64!V R>DO MCNY^YXDXE;C9$;.(HX\+$#A)^2$E^"LU;C5C7,WG7IHQVOY-V_X98YCL0"X FU. MJ!ZWQ"?=K6U'_WZ5E.A>0,;_ZTG(JQ+R=$+>A80>J< IXK7APGI:4,SKHE4 M\ ::5RV0AZGC6YX_-@]U=]I1]G 8N^C%NVHD3>RK"KJE32_DN;W2IM3+M2W MQ^ ) ?>4ZV@H@S>AWV#J'!&]E7\/KUDOM.P[QVS,!M6M>.<;V!W>W3T?58/WX:EMG;<5ZXU< M+8GK=@1#RV[XVA'EVX[7<+8CRAGXHT&WMW9MT[1[U:UQK5WO;?2LCW;:1@=]<73NBO/K75QK9CG<8.!>,/\==C]>\<_ M0(!)?\\_)M^^_$S_/R;P=OY6?0W@BMP!TT#6V'#7W7 M;QK:CO)LVQ\U##5K)]L,V$[?$+A,.2>B.(!5O=4M9;/WHW^6_MF7MPESC3% MU48>KW8)X2B%K:2TK@?24E;<%HJ&H'M]?MY0(4_C^C&6-RQ@D"^WU(J7AIJ M@.K.-OT#4$L#!!0 ( %TXG%0HJO'VCP0 '(2 9 >&PO=V]R:W-H M965T#?#@8^ I72=#UC3R8:LZ3-5+YN%@#NK M\1G.64RY0P)NKH;?,6W(1YK@Q+Q9TJWQJKY&XP&J"8KDB1 MJ2>^_976"?G:7\0S6?ZB;8VU!R@JI.)Y;0P1Y"FK_I.WFH@= _#3;^#4!D[7 MP#MBX-8&;M<@.&+@U09>R4R52LE#2!293@3?(J'1X$U?E&26UI!^RK3NSTK MTQ3LU'1&9!HAPF(4IUFA:(P8%%O(IY3=)%Q2_1A@K$19PR PD$R+@24@5 M23-X>(U>GD-T\>42?4%6]52"/7IAJ9)7, C7WQ)>2'B'G%@8M9OMJ(ZOED5 MGW,D/A<]Y93.,>^]!LCQV# PO(:AAS/AB;.4:/CT3<(!=?(<=VG)Z MYN>;X[Y\S.8AC8Z9[V7C-OJ[I3_WB+][(ECUA(M0.1GK=X5"JMN$++=S3G M>0[3E TEW\;XO:N+PR+N]( M7+\?5"%12J3+0I%E1I'BG8J4B$A8AS98._YX$8E1$MA8SIFZYV M8&HE> [CM.:+E#L6T'J2M%O#3!@VL0Y_GJQG%/LI88=G"]N'[!>V#VD4=M20 M-3J3+)#WNBLM]#U2P1J@F=DF:914.C->DE-I#61HI3^(BT@6%5FE^ FB1@=) M#4=##^/.[)\?XL9#UW."<8>D0]S(=[RQWG3Z!HW%(V-%,T,1=O=Y2'A0L9M MK?3F7;UNN+N:V3>VU\GZ+%38B_(#>_?OR#)[;;EL8T,A/^ITSF+@_J-IT@X M#Q;VP\ZD8:?SPT8:_MCHJI:&)0H[K2_GTR^HN.UYL&O,O.QSKO7G NAWN$S M1B$B!&%KJJ_EJ9E>N]^=FMVU\#0D-$+V,VN[)FQNFYZHA"XITM5=E6^AVW 3 M:6UW@?W/+W&[P>/@YTHOR4$,":P53U5=F,]H. %XN2>DW._P)73V'+QI< M"KU%(9--:ZG4ZM:VY70)$94W? 5,7YES$5&EEV)ARY4 .C.B+2)X_AV1 -F MM1KFW$"T&GRMPH#!0""YCB(JWN\@Y-NFA:V/$\-@L53Q";O56-$%C$"-5P.A M5W;J,@LB8#+@# F8-ZTVONT0(S 5/P+8RMPQBEN9!X^ME]ZST_H&HWT3V:V#@'Q.>ISMKCN:^ SU)82E$23=WUR2LVS MN.R"HD$HK[1J/.JBRXLK=($"AEZ6?"TIF\F&K738^);V- EVMPM&C@1[I.(& MN?@+(@XA!?).N;P+TU2./\MMC2CE1%).Q/BY1_R&L &V!HGF@D?H_DV!8#1$ M'?.$0$BDNRR@]NO?5!/021_EZ1PTQ2N25$YDL+<0-\Z0M3X%V'=.?C&(?X3 M;UINM>97&O8F3Z^@RO.QGU9]BE=)XU5XXU9H'3O(T45R))VO=3/.R-T/TWA MGPQ]Y^#E<)**Z_I[T NJ7.[Q="K:;QJ:;R>%!3"DCYKJ5'MC+3K:8KZR;3K M!QR]NNONP2XH(O5J,6OL9./28TWV@;J+XA0LRAI%N?&+SXC=)R--TQ.QIY8 MY)%6?.+M<2^J$?#9Y,/EH^\[75%6UFHVI'#EG,BSX8:]TY%[!S#KW@'Q MPZ)JO7X$>#;UUFHVHG#UG,BS"8=KIR.O'="L8;/_+ (.\0Y MPCR;?;A\^#VKI:91MEW)!A5QSHB<9 ..X).1)Q;YW0@FSOY +ZK"'MEC;N?V MPO&+B-Y'+@(F40AS+7-NJOJ9B=W>?K=0?&6VQQ.N-!ESN-3O0R#B GU]SKGZ M6,0[[O0-J_4/4$L#!!0 ( %TXG%2? ""L@, #$. 9 >&PO=V]R M:W-H965TTZXMH=[+G[)F%(% MWK4R9$5[6]M&VYBFE&Y 7?4J;OK+G(B-)#L;'E5E 2Y: LM9'C^'9&$F:- MA_G<0HR'??2A-&% '7942\7]&4[T<6M#XF'I--K,R$/1YNR88NJ7K>+H0> MV15+E&24R80S(.AZ9$W@Y0R&!I!'_$SH7AY< U/"^>_S. V&EF.R8BF=4, M!=$_KW1T]0PZ3S^TFMZID&>'C]P?XC+UX7\T(DG?+T[R12\<@:6""B:[)+ MU2/?_TG+@CS#M^IS+_!OHQU++#:2<6S$JPSR!)6_)W4H@#@.;I!J 2@)H M]P@ EP#39YN'^[!=[#4[UBT2RG@:_!(7RG;40E> MWL$-Y1M!MG&RTM,;8][7&54D2>4WC7I>SL#7+]_ %Y P\!3SG20LDD-;Z63- M(^U5F=A5D1@ZDA@&=YRI6()K%M&H S_KQT/40V!KE2JIT(=45ZB7\8Z("X#A M'P Y"'4D-/U]..RJIQ\^HZMC\$_5X,IXG//A(WR5HVO!,W#]IJA@) 73_)6C M0@)M&YASMOD^UW_,"$RDI$J"?^::!]PJFLE_>[)PJRS=H0A'_MN MPY6.L!#K3[R+TSNEW4NA?YHK?EOOP'.: MKG1$H:#9QCJB]"KD'FECL.[$L+\5W^@-O=8/3..$D3Y5ZLX(!^=TI^ZK,#S- MG;"U8KO8;_6S=I3G(;_I3CLH<#W&N[8!WMI+<4F/Y-(L.([IHJ]8C5;G7LF M^6Z_,7\%+Z?%Z:6F0Y3>B>X29@$5UK2N&ULG53?;YLP$/Y7+-Y;4])T M505(;99IDUHI:M3NH:HF P=8]0]F'R/[[V<;0K,IZ<->L.]\WW?WG<^D@S9O MM@5 LI-"V2QJ$;L;2FW9@F3V7'>@W$FMC63H3--0VQE@50!)09,XOJ2<17E M:?!M3)[J'@57L#'$]E(R\_L.A!ZRZ"+:.QYYTZ)WT#SM6 -;P=N8YQ%9Y: M2U"6:T4,U%ET>W&S2GQ\"'CF,-B#/?%"JW?O/&MRJ+8%P0"2O0,S"V_8 5" M>")7QL^),YI3>N#A?L_^)6AW6@IF8:7%=UYAFT77$:F@9KW 1SU\A4G/TO.5 M6MCP)<,8NUQ$I.PM:CF!7062JW%ENZD/!X#+ZQ. 9 (D_P6)P"+"; (0L?* M@JS/#%F>&CT0XZ,=F]^$W@2T4\.5O\4M&G?'0[S>U: 2"DZN^@Y02[^QBV M%N"N$H\ 5R,P.0%\9J'OV'4E3S7G3TF\^,LO3UK&.M^O&>;DXVYWC/=Z1@]NWK^Z!V8:KBP14+M\\?DG-T5FG.310-V%6RTT MNM$V]8]?C ^P)W76N/>\/,U_T[R/U!+ P04 " !=.)Q4/!M5P00# M M$ #0 'AL+W-T>6QEJN&A2?ZEU_3$(FL625J0YES45!BFDJH@V4U4&3:THR1MPJG@P'HWBH"), M^+.I:NK2C?>0K9"I_YX,'GV]B5/_3!^[WLV7"9SFOKWIV]_M%)?OO'L_>3= MR!:D87UOS& P+R:7RMFA$1."I7FT<&AG4-X^3L6$5!VW9;#?\W[Y M ;"9@4#&^5ZMP3";UD1KJL25F72+.^,3R.O'=^O:"P568?C"W_KT-T,R5RJ MGJ!)O0WIMF4TP+D%8NX:YE'0"HM:S,(&>DE()T&C8>_<"$75#.;Z'WOA=[ ML5?%SJZ.8$_%,#2"^J$-8R<0?S>:C;T3-GE56]F#U)_;DTVHIM#K] ;10NV MZN:K8N#'HH=X=%+7?/V)LU)4U.;^8L+9E&S\O54[-&P0:E--ZT7//X']3\9^M<4D$5X;NB3>L? M"PP7$SE=T3SKIZJ<=T//# QK?X'#(7+576X$\[&8&P$,X\$48#[6"^/YG_9 MH/E8#-,V<2(3U&>"^E@O%Y)U'XS'[9.8RYUIDD11'&,5S3G@@RK6QS#GSL: MI@T\,!Y@^KU:X[N-=\CS?8#MZ7,=@F6=R65YK0-QU X\D<>\VQ@,>V"Y@ MO0/\;A[H;=/%,&N8MJP)QA'D@1#H!?=/1K'2'5B^+CW!WMHBA)W A@;@51 MA"'P-.((I@ T8$@4=>?@P7D4;,ZI8/L/@MDO4$L#!!0 ( %TXG%27BKL< MP !," + 7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$ M^0%6H@_8$@619V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8E MCVG.D4NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G[(S9WTPF7;UC+>W^4'LF[9&MTBTUMJF? M)]U>,]IT.\9,R9X.KV>M)3+X,/[TUB%GK@-95AMN)VL^_89!>#RP8=KP M^KONLH>LZ%,W]!CZM869!Y<3^V 6ZX[,YPQC$\MXPNS)Q];!Z/NN3!,+ZAA M#UH=]EP^]\/8JY@XES'$X;0]!O%&_Y\PJNV6UVRAZD/+I#G&43/1 \INQ_== M@"1MV3RX4R],]]=C)TB:X[49"^5$2M]P>T GS8#G$27/RCQ-%E$5+]!ME$;9 M78S91Q7I0.( 4!\-D!T45 'D@"0Y!="EI7=K.+, N;W"_BM0,Y R!G9X.\ MRU>% WD%0%Z=#W(990[D-0!Y?4;(O[ #^0: ?',^RA<.I!O I MW-.UXC!C5<' QKD+0S<5FKEJ$+X6)"5@D]:Z5\+(IT2(!1BI+L/E^OAISC M\D%""3T;!'U#JL&>5?-=.K]$4=/P_CPJ4.)B0M;!O]HZERCE]/A]SB91]RLY![B MV3T_P+SGDLJ:H?CSWLV6!'(/\>P>2)'V_KN8D'N(;_> F&Z12,!O9^>K1!'(/\5WI@)BN(@GD'N+9/?#KVRB:D(6(9PO]]/7-KA\[ MO(L)68AXMA"(.5Y"D(6(9PL]RMK._-S_\K$W/#&L[2RA?GU)9YB%W,&66@V M6&AR^D_3L"V7K,GL%)WMKZFH"XWZS?'#TNRJ+_BV!R'N;%\N4T6;TV^?TR^K M#W\#4$L#!!0 ( %TXG%0\8?4:C0$ $\8 : >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'/-V4V.@D 0AN&K$ Y@6U7X-U%7LW$[\0)$6S&"$+HG MH[",R_?%W&0WLU:$+V;FI3V&15S%V'\Z%3>6; M,@S:SI^N9W9MWY3QNNSWKBLWQW+OG0Z'8]<_S\B7\^>9V?K2^?],;'>[P\9_ MMIOOQI_B'X/=3]L?0^5]S+-UV>]]7.3N7#^V@[L=9'"=G&>K[2+O5UO)7>H@ MA2!-'V009.F#"@@JT@>-(&B4/F@,0>/T01,(FJ0/FD+0-'W0#()FZ8-DB#(. M"9)>L";06I!K(?!:$&PA$%N0;"$P6Q!M(5!;D&TA<%L0;B&06Y!N(;!;$&\A MT%M1;R706U%O)=!;7UZV"?16U%L)]%;46PGT5M1;"?16U%L)]%;46PGT5M1; M"?16U%L)]#;4VPCT-M3;"/0VU-L(]+:7CR4$>AOJ;01Z&^IM!'H;ZFT$>AOJ M;01Z&^IM!'H;ZFT$>A>H=_%.O4.\U#X\>NYKO/\[J8[7:_WC]K?E?1.?%\4- M9P?_#Y:_4$L#!!0 ( %TXG%28Q"$EH@$ 88 3 6T-O;G1E;G1? M5'EP97-=+GAM;,V9S6Z#,!"$7P5QC8)C.TU_E.32]MKFT!=P80DH@"W;29.W MKR$_4JL4-4JES@4+O#LS>7O -.WG2$7;>NJ<;.X\-X\,.;2@FKE$FVH"3NY MMK7RX=8NF5'I2BV)B=%HPE+=>&K\T+<:\7SZ1+E:5SYZWH;'KM3-++94N3AZ MW!>V7K-8&5.5J?)AGVV:[)O+\."0A,ZNQA6E<8-0$+.S#NW.SP:'OM<-65MF M%"V4]2^J#E5L6S'G=Q6YI%_B3$:=YV5F4[7=6A)G+&D,E<0^;I]J#?FH?C_=!VU^)^2=02P$"% ,4 " !=.)Q4!T%-8H$ M "Q $ @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 M Q0 ( %TXG%18M#&B[P "L" 1 " :\ !D;V-0 M&UL4$L! A0#% @ M73B<5+M/2==,!0 ]A4 !@ ("!#@@ 'AL+W=O&PO=V]R M:W-H965T&UL4$L! A0#% @ 73B<5'L7?28:!0 I1, M !@ ("![!8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 73B<5 9Z":YZ @ 6 4 !@ ("! MBR4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M73B<5,S38(.X! T0L !D ("! 3D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 73B<5.[6Z$6#! M H !D ("!(T4 'AL+W=O&PO=V]R:W-H965TQ2 !X;"]W;W)K&UL4$L! A0#% @ 73B<5+#H0<[! P KP< !D M ("!&U< 'AL+W=O&PO=V]R:W-H M965TM? !X;"]W;W)K&UL4$L! M A0#% @ 73B<5#'EA/R5 @ 6P4 !D ("!PF, 'AL M+W=O&PO=V]R:W-H965TQZ@8 !P1 9 " M@61J !X;"]W;W)K&UL4$L! A0#% @ 73B< M5,JO^(# N" &0 M @(%)=0 >&PO=V]R:W-H965T-B1&@, ,H* 9 " @6)Y !X;"]W;W)K M&UL4$L! A0#% @ 73B<5[#L3AC P &@L M !D ("!LWP 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 73B<5%%.2&3U @ T0@ !D M ("!NX4 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 73B<5(X7L_" @ %P< !D ("!8HX 'AL+W=O M&PO=V]R:W-H965T5 M !X;"]W;W)K&UL4$L! A0#% @ 73B<5/P@ M]Q\N!0 =!L !D ("!VY@ 'AL+W=O&PO=V]R:W-H965T&B !X;"]W;W)K&UL4$L! A0#% @ 73B<5"BJ\?:/! &PO M=V]R:W-H965T&UL4$L! A0#% @ 73B<5!"YX+CG 0 6@0 !D ("! M!K, 'AL+W=O&PO&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " !=.)Q4F,0A):(! "F& $P M @ 'LO@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 , P <- "_ %P ! end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / word-wrap: break-word; / } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 143 186 1 false 43 0 false 4 false false R1.htm 0001001 - Document - Cover Sheet http://www.novocure.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Sheet http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 1006007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) Sheet http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) Statements 7 false false R8.htm 1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 2101101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION Sheet http://www.novocure.com/role/ORGANIZATIONANDBASISOFPRESENTATION ORGANIZATION AND BASIS OF PRESENTATION Notes 9 false false R10.htm 2103102 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Sheet http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTS CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Notes 10 false false R11.htm 2108103 - Disclosure - INVENTORIES Sheet http://www.novocure.com/role/INVENTORIES INVENTORIES Notes 11 false false R12.htm 2111104 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES Sheet http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIES COMMITMENTS AND CONTINGENT LIABILITIES Notes 12 false false R13.htm 2113105 - Disclosure - CONVERTIBLE NOTE Sheet http://www.novocure.com/role/CONVERTIBLENOTE CONVERTIBLE NOTE Notes 13 false false R14.htm 2118106 - Disclosure - SHARE OPTION PLANS AND ESPP Sheet http://www.novocure.com/role/SHAREOPTIONPLANSANDESPP SHARE OPTION PLANS AND ESPP Notes 14 false false R15.htm 2125107 - Disclosure - Basic and diluted net income (loss) per ordinary share Sheet http://www.novocure.com/role/Basicanddilutednetincomelossperordinaryshare Basic and diluted net income (loss) per ordinary share Notes 15 false false R16.htm 2128108 - Disclosure - SUPPLEMENTAL INFORMATION Sheet http://www.novocure.com/role/SUPPLEMENTALINFORMATION SUPPLEMENTAL INFORMATION Notes 16 false false R17.htm 2202201 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Policies) Sheet http://www.novocure.com/role/ORGANIZATIONANDBASISOFPRESENTATIONPolicies ORGANIZATION AND BASIS OF PRESENTATION (Policies) Policies 17 false false R18.htm 2304301 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables) Sheet http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSTables CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables) Tables http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTS 18 false false R19.htm 2309302 - Disclosure - INVENTORIES (Tables) Sheet http://www.novocure.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://www.novocure.com/role/INVENTORIES 19 false false R20.htm 2314303 - Disclosure - CONVERTIBLE NOTE (Tables) Sheet http://www.novocure.com/role/CONVERTIBLENOTETables CONVERTIBLE NOTE (Tables) Tables http://www.novocure.com/role/CONVERTIBLENOTE 20 false false R21.htm 2319304 - Disclosure - SHARE OPTION PLANS AND ESPP (Tables) Sheet http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPTables SHARE OPTION PLANS AND ESPP (Tables) Tables http://www.novocure.com/role/SHAREOPTIONPLANSANDESPP 21 false false R22.htm 2326305 - Disclosure - Basic and diluted net income (loss) per ordinary share (Tables) Sheet http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareTables Basic and diluted net income (loss) per ordinary share (Tables) Tables http://www.novocure.com/role/Basicanddilutednetincomelossperordinaryshare 22 false false R23.htm 2329306 - Disclosure - SUPPLEMENTAL INFORMATION (Tables) Sheet http://www.novocure.com/role/SUPPLEMENTALINFORMATIONTables SUPPLEMENTAL INFORMATION (Tables) Tables http://www.novocure.com/role/SUPPLEMENTALINFORMATION 23 false false R24.htm 2405401 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Summary of Cash and Cash Equivalents (Details) Sheet http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofCashandCashEquivalentsDetails CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Summary of Cash and Cash Equivalents (Details) Details 24 false false R25.htm 2406402 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Summary of Amortized Cost And Recorded Basis of T-bills in Short Term Investments (Details) Sheet http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofAmortizedCostAndRecordedBasisofTbillsinShortTermInvestmentsDetails CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Summary of Amortized Cost And Recorded Basis of T-bills in Short Term Investments (Details) Details 25 false false R26.htm 2407403 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Additional Information (Details) Sheet http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSAdditionalInformationDetails CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Additional Information (Details) Details 26 false false R27.htm 2410404 - Disclosure - INVENTORIES (Details) Sheet http://www.novocure.com/role/INVENTORIESDetails INVENTORIES (Details) Details http://www.novocure.com/role/INVENTORIESTables 27 false false R28.htm 2412405 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details) Sheet http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails COMMITMENTS AND CONTINGENT LIABILITIES (Details) Details http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIES 28 false false R29.htm 2415406 - Disclosure - CONVERTIBLE NOTE - Additional Information (Details) Sheet http://www.novocure.com/role/CONVERTIBLENOTEAdditionalInformationDetails CONVERTIBLE NOTE - Additional Information (Details) Details 29 false false R30.htm 2416407 - Disclosure - CONVERTIBLE NOTE - Liability and Equity Components of the Convertible Notes (Details) Notes http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails CONVERTIBLE NOTE - Liability and Equity Components of the Convertible Notes (Details) Details 30 false false R31.htm 2417408 - Disclosure - CONVERTIBLE NOTE - Finance Expense Related to the Convertible Notes (Details) Notes http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails CONVERTIBLE NOTE - Finance Expense Related to the Convertible Notes (Details) Details 31 false false R32.htm 2420409 - Disclosure - SHARE OPTION PLANS AND ESPP - Additional Information (Details) Sheet http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails SHARE OPTION PLANS AND ESPP - Additional Information (Details) Details 32 false false R33.htm 2421410 - Disclosure - SHARE OPTION PLANS AND ESPP - Schedule of Stock Option Plan (Details) Sheet http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails SHARE OPTION PLANS AND ESPP - Schedule of Stock Option Plan (Details) Details 33 false false R34.htm 2422411 - Disclosure - SHARE OPTION PLANS AND ESPP - Schedule of RSUs and PSUs (Details) Sheet http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails SHARE OPTION PLANS AND ESPP - Schedule of RSUs and PSUs (Details) Details 34 false false R35.htm 2423412 - Disclosure - SHARE OPTION PLANS AND ESPP - Schedule of Fair Value Assumptions Used Only for Equity Based Awards Estimated Using Black-Scholes Option Pricing Model (Details) Sheet http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails SHARE OPTION PLANS AND ESPP - Schedule of Fair Value Assumptions Used Only for Equity Based Awards Estimated Using Black-Scholes Option Pricing Model (Details) Details 35 false false R36.htm 2424413 - Disclosure - SHARE OPTION PLANS AND ESPP - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) Sheet http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofNoncashShareBasedCompensationExpensesRelatedtoCompanysEquityBasedAwardsDetails SHARE OPTION PLANS AND ESPP - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) Details 36 false false R37.htm 2427414 - Disclosure - Basic and diluted net income (loss) per ordinary share (Details) Sheet http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails Basic and diluted net income (loss) per ordinary share (Details) Details http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareTables 37 false false R38.htm 2430415 - Disclosure - SUPPLEMENTAL INFORMATION - Schedule of Long-Lived Assets by Location (Details) Sheet http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails SUPPLEMENTAL INFORMATION - Schedule of Long-Lived Assets by Location (Details) Details 38 false false R39.htm 2431416 - Disclosure - SUPPLEMENTAL INFORMATION - Schedule of Revenues by Geographic Region (Details) Sheet http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofRevenuesbyGeographicRegionDetails SUPPLEMENTAL INFORMATION - Schedule of Revenues by Geographic Region (Details) Details 39 false false R9999.htm Uncategorized Items - nvcr-20220331.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - nvcr-20220331.htm Cover 40 false false All Reports Book All Reports nvcr-20220331.htm nvcr-20220331.xsd nvcr-20220331_cal.xml nvcr-20220331_def.xml nvcr-20220331_lab.xml nvcr-20220331_pre.xml nvcr-20220331exx311.htm nvcr-20220331xexx312.htm nvcr-20220331xexx321.htm nvcr-20220331xexx322.htm nvcr-20220331_g1.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nvcr-20220331.htm": { "axisCustom": 1, "axisStandard": 13, "contextCount": 143, "dts": { "calculationLink": { "local": [ "nvcr-20220331_cal.xml" ] }, "definitionLink": { "local": [ "nvcr-20220331_def.xml" ] }, "inline": { "local": [ "nvcr-20220331.htm" ] }, "labelLink": { "local": [ "nvcr-20220331_lab.xml" ] }, "presentationLink": { "local": [ "nvcr-20220331_pre.xml" ] }, "schema": { "local": [ "nvcr-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 308, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 2, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 7 }, "keyCustom": 9, "keyStandard": 177, "memberCustom": 15, "memberStandard": 27, "nsprefix": "nvcr", "nsuri": "http://www.novocure.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.novocure.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS", "role": "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTS", "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - INVENTORIES", "role": "http://www.novocure.com/role/INVENTORIES", "shortName": "INVENTORIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111104 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES", "role": "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIES", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113105 - Disclosure - CONVERTIBLE NOTE", "role": "http://www.novocure.com/role/CONVERTIBLENOTE", "shortName": "CONVERTIBLE NOTE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118106 - Disclosure - SHARE OPTION PLANS AND ESPP", "role": "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPP", "shortName": "SHARE OPTION PLANS AND ESPP", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125107 - Disclosure - Basic and diluted net income (loss) per ordinary share", "role": "http://www.novocure.com/role/Basicanddilutednetincomelossperordinaryshare", "shortName": "Basic and diluted net income (loss) per ordinary share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128108 - Disclosure - SUPPLEMENTAL INFORMATION", "role": "http://www.novocure.com/role/SUPPLEMENTALINFORMATION", "shortName": "SUPPLEMENTAL INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Policies)", "role": "http://www.novocure.com/role/ORGANIZATIONANDBASISOFPRESENTATIONPolicies", "shortName": "ORGANIZATION AND BASIS OF PRESENTATION (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)", "role": "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSTables", "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - INVENTORIES (Tables)", "role": "http://www.novocure.com/role/INVENTORIESTables", "shortName": "INVENTORIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - CONVERTIBLE NOTE (Tables)", "role": "http://www.novocure.com/role/CONVERTIBLENOTETables", "shortName": "CONVERTIBLE NOTE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319304 - Disclosure - SHARE OPTION PLANS AND ESPP (Tables)", "role": "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPTables", "shortName": "SHARE OPTION PLANS AND ESPP (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326305 - Disclosure - Basic and diluted net income (loss) per ordinary share (Tables)", "role": "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareTables", "shortName": "Basic and diluted net income (loss) per ordinary share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329306 - Disclosure - SUPPLEMENTAL INFORMATION (Tables)", "role": "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONTables", "shortName": "SUPPLEMENTAL INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405401 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Summary of Cash and Cash Equivalents (Details)", "role": "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofCashandCashEquivalentsDetails", "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Summary of Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i639db30d75f74e9fa64c8b0b7f595bf1_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecuritiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Summary of Amortized Cost And Recorded Basis of T-bills in Short Term Investments (Details)", "role": "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofAmortizedCostAndRecordedBasisofTbillsinShortTermInvestmentsDetails", "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Summary of Amortized Cost And Recorded Basis of T-bills in Short Term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i303b96d13d914571b33c733b6ba5879a_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:HeldToMaturitySecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecuritiesFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Additional Information (Details)", "role": "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSAdditionalInformationDetails", "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecuritiesFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - INVENTORIES (Details)", "role": "http://www.novocure.com/role/INVENTORIESDetails", "shortName": "INVENTORIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DepositsAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)", "role": "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DepositsAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i8da2ae8c63574bc685bd540d2e63099f_I20201105", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - CONVERTIBLE NOTE - Additional Information (Details)", "role": "http://www.novocure.com/role/CONVERTIBLENOTEAdditionalInformationDetails", "shortName": "CONVERTIBLE NOTE - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i8da2ae8c63574bc685bd540d2e63099f_I20201105", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i0e92483bce504c3fb3a97057111b4c28_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - CONVERTIBLE NOTE - Liability and Equity Components of the Convertible Notes (Details)", "role": "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails", "shortName": "CONVERTIBLE NOTE - Liability and Equity Components of the Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i0e92483bce504c3fb3a97057111b4c28_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i184c7f641f814b6086881ccf15a30f36_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - CONVERTIBLE NOTE - Finance Expense Related to the Convertible Notes (Details)", "role": "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails", "shortName": "CONVERTIBLE NOTE - Finance Expense Related to the Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i184c7f641f814b6086881ccf15a30f36_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420409 - Disclosure - SHARE OPTION PLANS AND ESPP - Additional Information (Details)", "role": "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "shortName": "SHARE OPTION PLANS AND ESPP - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i32bbe26345514b48bfa98c25448ed910_I20220331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if6b6c2afa60a4536933b758f5faa7ff4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421410 - Disclosure - SHARE OPTION PLANS AND ESPP - Schedule of Stock Option Plan (Details)", "role": "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails", "shortName": "SHARE OPTION PLANS AND ESPP - Schedule of Stock Option Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if6b6c2afa60a4536933b758f5faa7ff4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "ibbfaaefbf07448e7b3c60e619a539499_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - SHARE OPTION PLANS AND ESPP - Schedule of RSUs and PSUs (Details)", "role": "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails", "shortName": "SHARE OPTION PLANS AND ESPP - Schedule of RSUs and PSUs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "ibbfaaefbf07448e7b3c60e619a539499_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i5661a5f986b340919c4086bd3c9537b4_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - SHARE OPTION PLANS AND ESPP - Schedule of Fair Value Assumptions Used Only for Equity Based Awards Estimated Using Black-Scholes Option Pricing Model (Details)", "role": "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails", "shortName": "SHARE OPTION PLANS AND ESPP - Schedule of Fair Value Assumptions Used Only for Equity Based Awards Estimated Using Black-Scholes Option Pricing Model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i5661a5f986b340919c4086bd3c9537b4_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - SHARE OPTION PLANS AND ESPP - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details)", "role": "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofNoncashShareBasedCompensationExpensesRelatedtoCompanysEquityBasedAwardsDetails", "shortName": "SHARE OPTION PLANS AND ESPP - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427414 - Disclosure - Basic and diluted net income (loss) per ordinary share (Details)", "role": "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails", "shortName": "Basic and diluted net income (loss) per ordinary share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": "0", "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430415 - Disclosure - SUPPLEMENTAL INFORMATION - Schedule of Long-Lived Assets by Location (Details)", "role": "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails", "shortName": "SUPPLEMENTAL INFORMATION - Schedule of Long-Lived Assets by Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i84a52a1e5a684a78b9e54f32ab7591cd_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431416 - Disclosure - SUPPLEMENTAL INFORMATION - Schedule of Revenues by Geographic Region (Details)", "role": "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofRevenuesbyGeographicRegionDetails", "shortName": "SUPPLEMENTAL INFORMATION - Schedule of Revenues by Geographic Region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "ic43cd23e63ab43f98c6445aedb64614b_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "role": "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i3f8e855d05a34df29bfb7113501e486f_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "role": "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "ib9b8031e4f934acb8cc457cf987b9212_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i2b392605cc5549aa9eac68afa1a6fc88_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)", "role": "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "i2b392605cc5549aa9eac68afa1a6fc88_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION", "role": "http://www.novocure.com/role/ORGANIZATIONANDBASISOFPRESENTATION", "shortName": "ORGANIZATION AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20220331.htm", "contextRef": "if4dc75358a114450b6857d3f82fe429c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": null, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - nvcr-20220331.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - nvcr-20220331.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 43, "tag": { "country_CH": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SWITZERLAND", "terseLabel": "Switzerland" } } }, "localname": "CH", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "Greater China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofRevenuesbyGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "country_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GERMANY", "terseLabel": "Germany" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails", "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofRevenuesbyGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "country_IL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ISRAEL", "terseLabel": "Israel" } } }, "localname": "IL", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails" ], "xbrltype": "domainItemType" }, "country_JP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails", "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofRevenuesbyGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails", "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofRevenuesbyGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "verboseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "verboseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.novocure.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "nvcr_A0ConvertibleSeniorNotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0% Convertible Senior Notes Due 2025 (the \u201cNotes\u201d)", "label": "0% Convertible Senior Notes Due 2025 [Member]", "terseLabel": "the \u201cNotes\u201d" } } }, "localname": "A0ConvertibleSeniorNotesDue2025Member", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTEAdditionalInformationDetails", "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails", "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "nvcr_AwardFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award Five", "label": "Award Five [Member]", "terseLabel": "Award Five" } } }, "localname": "AwardFiveMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "domainItemType" }, "nvcr_AwardFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award Four", "label": "Award Four [Member]", "terseLabel": "Award Four" } } }, "localname": "AwardFourMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "domainItemType" }, "nvcr_AwardOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award One", "label": "Award One [Member]", "terseLabel": "Award One" } } }, "localname": "AwardOneMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "domainItemType" }, "nvcr_AwardSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award Six", "label": "Award Six [Member]", "terseLabel": "Award Six" } } }, "localname": "AwardSixMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "domainItemType" }, "nvcr_AwardThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award Three", "label": "Award Three [Member]", "terseLabel": "Award Three" } } }, "localname": "AwardThreeMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "domainItemType" }, "nvcr_AwardTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award Two", "label": "Award Two [Member]", "terseLabel": "Award Two" } } }, "localname": "AwardTwoMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "domainItemType" }, "nvcr_CashPaidDuringPeriodForAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash paid during the period for.", "label": "Cash Paid During Period For [Abstract]", "terseLabel": "Cash paid during the period for:" } } }, "localname": "CashPaidDuringPeriodForAbstract", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "nvcr_CostOfRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost of revenue.", "label": "Cost Of Revenue [Member]", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfRevenueMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofNoncashShareBasedCompensationExpensesRelatedtoCompanysEquityBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "nvcr_EMEAExculdingGermanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EMEA, Exculding Germany", "label": "EMEA, Exculding Germany [Member]", "terseLabel": "Other EMEA" } } }, "localname": "EMEAExculdingGermanyMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofRevenuesbyGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "nvcr_EmployeeRelatedLiabilitiesNonCurrent": { "auth_ref": [], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Employee related liabilities noncurrent.", "label": "Employee Related Liabilities Non Current", "terseLabel": "Employee benefit liabilities" } } }, "localname": "EmployeeRelatedLiabilitiesNonCurrent", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "nvcr_FieldEquipmentNetNoncurrent": { "auth_ref": [], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Field equipment, net, noncurrent.", "label": "Field Equipment Net Noncurrent", "terseLabel": "Field equipment, net" } } }, "localname": "FieldEquipmentNetNoncurrent", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "nvcr_GovernmentAgenciesDebtSecuritieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government Agencies Debt Securitie", "label": "Government Agencies Debt Securitie [Member]", "terseLabel": "Other government and governmental agency notes" } } }, "localname": "GovernmentAgenciesDebtSecuritieMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofAmortizedCostAndRecordedBasisofTbillsinShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "nvcr_GrantedAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Granted", "label": "Granted [Axis]", "terseLabel": "Granted [Axis]" } } }, "localname": "GrantedAxis", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "stringItemType" }, "nvcr_GrantedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Granted", "label": "Granted [Domain]", "terseLabel": "Granted [Domain]" } } }, "localname": "GrantedDomain", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "domainItemType" }, "nvcr_OtherAccountsPayableLeaseLiabilitiesAndAccruedExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other accounts payable lease liabilities and accrued expenses current.", "label": "Other Accounts Payable Lease Liabilities And Accrued Expenses Current", "terseLabel": "Other payables, lease liabilities and accrued expenses" } } }, "localname": "OtherAccountsPayableLeaseLiabilitiesAndAccruedExpensesCurrent", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "nvcr_OthersCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Others countries.", "label": "Others Countries [Member]", "terseLabel": "Others" } } }, "localname": "OthersCountriesMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails" ], "xbrltype": "domainItemType" }, "nvcr_PerformanceBasedShareUnitsPSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance-Based Share Units (PSUs)", "label": "Performance-Based Share Units (PSUs) [Member]", "terseLabel": "PSUs" } } }, "localname": "PerformanceBasedShareUnitsPSUsMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "domainItemType" }, "nvcr_ReceivablesAndPrepaidExpenses": { "auth_ref": [], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables and prepaid expenses.", "label": "Receivables And Prepaid Expenses", "terseLabel": "Receivables and prepaid expenses" } } }, "localname": "ReceivablesAndPrepaidExpenses", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "nvcr_RestrictedStockUnitsRSUsAndPerformanceBasedShareUnitsPSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units (RSUs) and Performance-Based Share Units (PSUs)", "label": "Restricted Stock Units (RSUs) and Performance-Based Share Units (PSUs) [Member]", "terseLabel": "RSUs/PSUs" } } }, "localname": "RestrictedStockUnitsRSUsAndPerformanceBasedShareUnitsPSUsMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "domainItemType" }, "nvcr_SalesAndMarketingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales and Marketing.", "label": "Sales And Marketing [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SalesAndMarketingMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofNoncashShareBasedCompensationExpensesRelatedtoCompanysEquityBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "nvcr_ScheduleOfShareCapitalTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share capital.", "label": "Schedule Of Share Capital [Table]", "terseLabel": "Schedule Of Share Capital [Table]" } } }, "localname": "ScheduleOfShareCapitalTable", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "nvcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAndNotExpectedToVestFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested and Not Expected to Vest, Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested and Not Expected to Vest, Fair Value", "terseLabel": "Total fair value at grant date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAndNotExpectedToVestFairValue", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "monetaryItemType" }, "nvcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotExpectedToVestNonvestedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Not Expected to Vest, Nonvested, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Not Expected to Vest, Nonvested, Number", "terseLabel": "Number of PSUs (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotExpectedToVestNonvestedNumber", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "sharesItemType" }, "nvcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotExpectedToVestNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Not Expected to Vest, Nonvested, Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Not Expected to Vest, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Fair value at grant date per PSU (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotExpectedToVestNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "perShareItemType" }, "nvcr_ShareCapitalLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share capital.", "label": "Share Capital [Line Items]", "terseLabel": "Share Capital [Line Items]" } } }, "localname": "ShareCapitalLineItems", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "nvcr_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwardForfeitures": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Stock Options Exercised and Restricted Stock Award, Forfeitures", "label": "Stock Issued During Period, Shares, Stock Options Exercised and Restricted Stock Award, Forfeitures", "terseLabel": "Exercise of options and vested RSUs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwardForfeitures", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "nvcr_StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Stock Options Exercised and Restricted Stock Award, Forfeitures", "label": "Stock Issued During Period, Value, Stock Options Exercised and Restricted Stock Award, Forfeitures", "terseLabel": "Exercise of options and vested RSUs" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "nvcr_TwoThousandFifteenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand fifteen plan.", "label": "Two Thousand Fifteen Plan [Member]", "terseLabel": "2015 Plan" } } }, "localname": "TwoThousandFifteenPlanMember", "nsuri": "http://www.novocure.com/20220331", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r111", "r118", "r124", "r190", "r311", "r312", "r313", "r322", "r323", "r337", "r340", "r342", "r343", "r463" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative effect adjustment resulting from ASU 2020-06 early adoption" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r111", "r118", "r124", "r190", "r311", "r312", "r313", "r322", "r323", "r337", "r340", "r342", "r343", "r463" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r111", "r118", "r124", "r190", "r311", "r312", "r313", "r322", "r323", "r337", "r340", "r342", "r343", "r463" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r223", "r256", "r278", "r279", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r425", "r427", "r452", "r453" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r223", "r256", "r278", "r279", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r425", "r427", "r452", "r453" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r223", "r256", "r269", "r278", "r279", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r425", "r427", "r452", "r453" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r223", "r256", "r269", "r278", "r279", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r425", "r427", "r452", "r453" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r164", "r165", "r266", "r268", "r426", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails", "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofRevenuesbyGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r164", "r165", "r266", "r268", "r426", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails", "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofRevenuesbyGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r112", "r113", "r114", "r115", "r174", "r175", "r187", "r188", "r189", "r190", "r191", "r192", "r207", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r322", "r323", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r377", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r461", "r462", "r463", "r464", "r465" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting standards update [extensible enumeration]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r12", "r47" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade payables" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r9", "r32", "r171", "r172" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade receivables, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r35", "r61", "r63", "r64", "r413", "r435", "r439" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r60", "r64", "r71", "r72", "r73", "r108", "r109", "r110", "r330", "r430", "r431", "r465" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r33", "r314", "r380" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r108", "r109", "r110", "r311", "r312", "r313", "r342" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r280", "r282", "r317", "r318" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation to employees" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r282", "r304", "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofNoncashShareBasedCompensationExpensesRelatedtoCompanysEquityBasedAwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r86", "r97", "r243", "r368" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of discount (premium)" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r82", "r97", "r243", "r370" ], "calculation": { "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Weighted anti-dilutive shares outstanding which were not included in the diluted calculation (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r97", "r196" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Asset write-downs and impairment of field equipment" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r104", "r149", "r153", "r159", "r186", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r328", "r331", "r346", "r378", "r380", "r394", "r411" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r57", "r104", "r186", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r328", "r331", "r346", "r378", "r380" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r18", "r19", "r20", "r21", "r22", "r23", "r24", "r25", "r104", "r186", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r328", "r331", "r346", "r378" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total long-term assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "LONG-TERM ASSETS:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r283", "r305" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r45", "r99" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofCashandCashEquivalentsDetails", "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofAmortizedCostAndRecordedBasisofTbillsinShortTermInvestmentsDetails", "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSAdditionalInformationDetails", "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofAmortizedCostAndRecordedBasisofTbillsinShortTermInvestmentsDetails", "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Short-term Investments [Abstract]" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.", "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]", "terseLabel": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r93", "r99", "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r359" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificate of deposits, notes and term deposits" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofAmortizedCostAndRecordedBasisofTbillsinShortTermInvestmentsDetails", "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r204", "r399", "r417" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r201", "r202", "r203", "r205", "r442" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r108", "r109", "r342" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Ordinary shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r31", "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r31", "r380" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 104,559,088 shares and 103,971,263 shares at March\u00a031, 2022 (unaudited) and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r67", "r69", "r70", "r79", "r403", "r420" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r264", "r265", "r267" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Operating lease and other contractual commitments" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r219", "r220", "r221", "r223", "r233", "r234", "r235", "r239", "r240", "r241", "r242", "r243", "r251", "r252", "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTEAdditionalInformationDetails", "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails", "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Summary of the Convertible Notes" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r270", "r277", "r440" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofAmortizedCostAndRecordedBasisofTbillsinShortTermInvestmentsDetails", "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r84", "r104", "r186", "r208", "r209", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r346" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r102", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r237", "r244", "r245", "r247", "r255" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "CONVERTIBLE NOTE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTE" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r26", "r27", "r28", "r103", "r107", "r220", "r221", "r222", "r223", "r224", "r225", "r227", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r251", "r252", "r253", "r254", "r371", "r395", "r396", "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTEAdditionalInformationDetails", "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails", "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r28", "r248", "r396", "r410" ], "calculation": { "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r220", "r251", "r252", "r369", "r371", "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTEAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51", "r221" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTEAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTEAdditionalInformationDetails", "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails", "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r52", "r103", "r107", "r220", "r221", "r222", "r223", "r224", "r225", "r227", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r251", "r252", "r253", "r254", "r371" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTEAdditionalInformationDetails", "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails", "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r52", "r103", "r107", "r220", "r221", "r222", "r223", "r224", "r225", "r227", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r246", "r251", "r252", "r253", "r254", "r258", "r259", "r260", "r261", "r368", "r369", "r371", "r372", "r409" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTEAdditionalInformationDetails", "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails", "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Contractual term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r46", "r233", "r370" ], "calculation": { "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssets": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.", "label": "Deposits Assets", "terseLabel": "Pledged bank deposits" } } }, "localname": "DepositsAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r97", "r197" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r80", "r116", "r117", "r118", "r119", "r120", "r125", "r127", "r133", "r134", "r135", "r139", "r140", "r343", "r344", "r404", "r421" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income (loss) per ordinary share (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails", "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r80", "r116", "r117", "r118", "r119", "r120", "r127", "r133", "r134", "r135", "r139", "r140", "r343", "r344", "r404", "r421" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income (loss) per ordinary share (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails", "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareDilutedLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r136", "r137", "r138", "r141" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Basic and diluted net income (loss) per ordinary share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/Basicanddilutednetincomelossperordinaryshare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r359" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Option Plans", "verboseLabel": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r71", "r72", "r73", "r108", "r109", "r110", "r113", "r121", "r123", "r142", "r190", "r257", "r262", "r311", "r312", "r313", "r322", "r323", "r342", "r360", "r361", "r362", "r363", "r364", "r366", "r430", "r431", "r432", "r465" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r235", "r251", "r252", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r345", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r235", "r270", "r271", "r276", "r277", "r345", "r381" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r235", "r251", "r252", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r355", "r356", "r357", "r358" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign currency remeasurement loss (gain)" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofNoncashShareBasedCompensationExpensesRelatedtoCompanysEquityBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicAreasLongLivedAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographic Areas, Long-Lived Assets [Abstract]" } } }, "localname": "GeographicAreasLongLivedAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r83", "r104", "r149", "r152", "r155", "r158", "r161", "r186", "r208", "r209", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r346" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesCurrent": { "auth_ref": [ "r177", "r178", "r193" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.", "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current", "terseLabel": "Short-term investments" } } }, "localname": "HeldToMaturitySecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofAmortizedCostAndRecordedBasisofTbillsinShortTermInvestmentsDetails", "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "auth_ref": [ "r179", "r181", "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity, Fair Value", "terseLabel": "Estimated fair value of short-term investments" } } }, "localname": "HeldToMaturitySecuritiesFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesTextBlock": { "auth_ref": [ "r180", "r182", "r183" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity [Table Text Block]", "terseLabel": "Summary of Amortized Cost and Recorded Basis of T-bills in Short-Term Investments" } } }, "localname": "HeldToMaturitySecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r76", "r149", "r152", "r155", "r158", "r161", "r393", "r400", "r405", "r423" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r199", "r200" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofNoncashShareBasedCompensationExpensesRelatedtoCompanysEquityBasedAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofNoncashShareBasedCompensationExpensesRelatedtoCompanysEquityBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r105", "r122", "r123", "r148", "r321", "r324", "r326", "r424" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid (refunded), net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Increase (decrease) in accounts payables and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Decrease (increase) in accounts receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued Interest" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r96" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Decrease (increase) in inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r96" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Decrease (increase) in other long-term assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Increase (decrease) in other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r128", "r129", "r130", "r135" ], "calculation": { "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Share-based payment arrangements (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestAndDebtExpense": { "auth_ref": [ "r367" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.", "label": "Interest and Debt Expense", "terseLabel": "Financial expenses (income), net" } } }, "localname": "InterestAndDebtExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r86", "r241", "r250", "r253", "r254" ], "calculation": { "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "totalLabel": "Total finance expense recognized" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r92", "r94", "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/INVENTORIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r39", "r194" ], "calculation": { "http://www.novocure.com/role/INVENTORIESDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished products" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r8", "r56", "r380" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.novocure.com/role/INVENTORIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.novocure.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r41", "r194" ], "calculation": { "http://www.novocure.com/role/INVENTORIESDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r40", "r194" ], "calculation": { "http://www.novocure.com/role/INVENTORIESDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in progress" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r185", "r422" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Short-term investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/ORGANIZATIONANDBASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r49", "r104", "r154", "r186", "r208", "r209", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r329", "r331", "r332", "r346", "r378", "r379" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r38", "r104", "r186", "r346", "r380", "r397", "r415" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50", "r104", "r186", "r208", "r209", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r329", "r331", "r332", "r346", "r378", "r379", "r380" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r14", "r15", "r16", "r28", "r29", "r104", "r186", "r208", "r209", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r329", "r331", "r332", "r346", "r378", "r379" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "LONG-TERM LIABILITIES:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r28", "r396", "r410" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Amount outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r48", "r103" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of Long-Lived Assets by Location" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r28", "r234", "r249", "r251", "r252", "r396", "r412" ], "calculation": { "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Net carrying amount of liability component" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Estimated fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails", "http://www.novocure.com/role/CONVERTIBLENOTEAdditionalInformationDetails", "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails", "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r52", "r206" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails", "http://www.novocure.com/role/CONVERTIBLENOTEAdditionalInformationDetails", "http://www.novocure.com/role/CONVERTIBLENOTEFinanceExpenseRelatedtotheConvertibleNotesDetails", "http://www.novocure.com/role/CONVERTIBLENOTELiabilityandEquityComponentsoftheConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r95", "r98" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r65", "r68", "r73", "r77", "r98", "r104", "r112", "r116", "r117", "r118", "r119", "r122", "r123", "r132", "r149", "r152", "r155", "r158", "r161", "r186", "r208", "r209", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r344", "r346", "r401", "r418" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net income (loss) attributable to ordinary shares as reported used in computing basic and diluted net income (loss) per share", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails", "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r165" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-term assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating costs and expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating costs and expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r149", "r152", "r155", "r158", "r161" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r374" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term leases" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r373" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r6", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/ORGANIZATIONANDBASISOFPRESENTATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r58" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Change in foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r66", "r69", "r71", "r72", "r74", "r78", "r257", "r360", "r365", "r366", "r402", "r419" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of tax benefit of $0" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r59", "r61" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Pension benefit plan" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r62", "r71", "r78", "r321", "r325", "r327", "r360", "r363", "r366", "r402", "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedTerseLabel": "Other comprehensive income (loss), tax benefit" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": { "auth_ref": [ "r88", "r176" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.", "label": "Payments to Acquire Held-to-maturity Securities", "negatedLabel": "Purchase of short-term investments" } } }, "localname": "PaymentsToAcquireHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r89" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property, equipment and field equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r283", "r305" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r90" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of shares, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities": { "auth_ref": [ "r87", "r176" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.", "label": "Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities", "terseLabel": "Proceeds from maturity of short-term investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r90", "r306" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r21", "r22", "r198", "r380", "r407", "r416" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r91" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayment of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r320", "r391", "r454" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research, development and clinical studies" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research, development and clinical studies" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofNoncashShareBasedCompensationExpensesRelatedtoCompanysEquityBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofAmortizedCostAndRecordedBasisofTbillsinShortTermInvestmentsDetails", "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r7", "r17", "r101" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted share units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r34", "r262", "r314", "r380", "r414", "r434", "r439" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r108", "r109", "r110", "r113", "r121", "r123", "r190", "r311", "r312", "r313", "r322", "r323", "r342", "r430", "r432" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of Revenues by Geographic Region" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r75", "r104", "r146", "r147", "r151", "r156", "r157", "r163", "r164", "r169", "r186", "r208", "r209", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r346", "r405" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Net revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofRevenuesbyGeographicRegionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails", "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofRevenuesbyGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/COMMITMENTSANDCONTINGENTLIABILITIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r375", "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]", "terseLabel": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSAdditionalInformationDetails", "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofAmortizedCostAndRecordedBasisofTbillsinShortTermInvestmentsDetails", "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Summary of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Basic and Diluted Net Income (Loss) Per Ordinary Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "auth_ref": [ "r127", "r131", "r133", "r135", "r140" ], "lang": { "en-us": { "role": { "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r282", "r303", "r316" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r13", "r42", "r43", "r44" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/INVENTORIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r75", "r168" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofLongLivedAssetsbyLocationDetails", "http://www.novocure.com/role/SUPPLEMENTALINFORMATIONScheduleofRevenuesbyGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r283", "r305" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofNoncashShareBasedCompensationExpensesRelatedtoCompanysEquityBasedAwardsDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of RSUs and PSUs" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r287", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Plans" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r143", "r144", "r145", "r149", "r150", "r155", "r159", "r160", "r161", "r162", "r163", "r168", "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SUPPLEMENTAL INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SUPPLEMENTALINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]" } } }, "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Stock awards granted, vesting period (years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited and cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited and cancelled (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested at ending of year (in shares)", "periodStartLabel": "Unvested at beginning of year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of RSU/PSUs" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested at ending of year (in usd per share)", "periodStartLabel": "Unvested at beginning of year (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofNoncashShareBasedCompensationExpensesRelatedtoCompanysEquityBasedAwardsDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Ordinary shares available for grants (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of options, exercisable options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, exercisable options (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of options, forfeited and canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of options, granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r289", "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of options, ending outstanding (in shares)", "periodStartLabel": "Number of options, beginning outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, ending outstanding (in usd per share)", "periodStartLabel": "Weighted average exercise price, beginning outstanding (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r281", "r286" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofRSUsandPSUsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, forfeited and canceled (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Stock awards granted, expiration period (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r300", "r315" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r263", "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-based Payments [Text Block]", "terseLabel": "SHARE OPTION PLANS AND ESPP" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPP" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r55", "r71", "r72", "r73", "r108", "r109", "r110", "r113", "r121", "r123", "r142", "r190", "r257", "r262", "r311", "r312", "r313", "r322", "r323", "r342", "r360", "r361", "r362", "r363", "r364", "r366", "r430", "r431", "r432", "r465" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r108", "r109", "r110", "r142", "r392" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r30", "r31", "r257", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "verboseLabel": "Shares issued under plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r30", "r31", "r257", "r262", "r291" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of options, exercised (in shares)", "terseLabel": "Options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofStockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r31", "r36", "r37", "r104", "r173", "r186", "r346", "r380" ], "calculation": { "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "TOTAL SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "SHAREHOLDERS' EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPAdditionalInformationDetails", "http://www.novocure.com/role/SHAREOPTIONPLANSANDESPPScheduleofFairValueAssumptionsUsedOnlyforEquityBasedAwardsEstimatedUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental cash flow activities:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r106", "r270", "r277", "r406" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury bills" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/CASHCASHEQUIVALENTSANDSHORTTERMINVESTMENTSSummaryofAmortizedCostAndRecordedBasisofTbillsinShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r126", "r135" ], "calculation": { "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)", "totalLabel": "Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails", "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r125", "r135" ], "calculation": { "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.novocure.com/role/BasicanddilutednetincomelossperordinaryshareDetails", "http://www.novocure.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269825-111563" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r455": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r456": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r457": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r458": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r459": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" } }, "version": "2.1" } ZIP 60 0001645113-22-000043-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001645113-22-000043-xbrl.zip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ô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
S<^7G87C_772I?!Q]Y@X[[-:><5:#39& MR5>?^[W!/1D_2E"[&]3J'R?L/&&(,-0GIQFB&?&'L<"04$8K8TV8.C98UZ^"PRXQ9)Y&A \W09/ @'2K-F=@@P;M9@%I.01;:W4-G34\@R MR\#<=0:[YS1'#R]SX^1_H_HP#6G%LN%X+^.-MET2C';NZK^U+&2SZ3WLAU M2F&M.%4PI'J_!;/D0O%+R^09]'_<,G$V$A>51:#OH/^. M"V2L<,@K9D@@BC(10?_U,IELO[WP;(1S;IE\NBRZ7)Q1KF1[R+$\OIFRA-C M+.URWT2-Z95N95VS%-P;+(7=8PF:>822H%0Q4D2#-FD<3$.84UE4P CK$J ME^H)9DP972G-F'N:,5,0H#1D9@< XX8,>"HF.NZ1E4;G$(M!FEL !<]$\X2 MKL&146J9D;<78IE#X^5:CM#O)./IR8QECM#=)2G<"FI)%%;"2Z6=B8(G1JU3 MPA ?GK\DIG98F\P1PC2ID)1 D6J!>$P:.6TQHE$2IL!)XT3F'"'#1)6+ M)T/;&\L1>K-I0&\QT^=Q"%=F^BP&L(W;:RP(3'@4R&7N(RYX1-KSA%3" &J) MQ^#MT@J3RVRR0N_5 T]C1":W=F-]O$=WCVM< >HI3)FSN,.S7>/MFKXCG!CR MA]Q1;G%_:_=F0M32XGU>B_?>I86[VPWALW)$TE'-%@V8+%JW(DCW/D$FP, MCE#L%;4J1;^T(JIJZIB;+86[_V4K+1Z2ZOWC5F]5S"NM'IG!VZ3B6".8^$4 M\B9)Q'T"7#-1(R&(PP8;0X5:6J%\F8AYLWIO)T2?7W:$3[TA175XTPQ M(XNM\K#6DFN'4A1BM31@H64OEW^H>N\<,]"0/3$)@ EVU#)-E2R#95L M0R7;T%/9A@#K_YUAOJ0;>CK=T)!SLF#T3[;5K_RR[>/WPCCTHYLIG7,F=$DW M].2#%>>2M3&YA!7G.BK'O,11$F,%,]R8YZ<;&K9ZV^B";W%F^TX._GP&6#U#HU\"S"0>W\!]O>_WI6_PQCW-H^K37^:M?/U\^VZ0]: MAV]/Q"1A?/ ;TVB(#., M? ^!M(\:2SXZH3 @71!MMH! 7OE5>Y,%6")[.GWW>44E#]"YHB!Z'F;,[ MIKD_8HX=WQ1%_FM@-'P"F^%G-AEO'P87HZ?X20NB)6,H\2(13SJ@!SF!C&2 ML,"889+/<18%D\F\R@YBDJ.HI>P"$/RT7,+_V'!C?3:21&4X)HH^%-T+U@_ M=R?0763#D5!!0T. M^^A$26OT.GK^LW &2DZCQ39VAJM8&CLS![/)O&.&>0#_C2,6N0--VSG58.V<&4/#1-:N="D)Z5'0VB'. M@T;:1HVH#M@DS4WP!NPM.ESA5:IM'MF M# OC=H_4D3!%9)6:8 %S9%C)B%O"?$L6LPCP((QR^;)60'S%]^90UOG=Q;4 M%$ERA]D HEG6F;^'E.EL-,:=C\A<4B<>6JH-QA>2T&$%E8]?PUZF2KU:H X MF2K%-,:,])ZY9I:!IKFPMAZ' MF4RT1M E'$3RX1$+7=@7<5,@\0)1<89CXC5UDL=2!!L:4793TKIHMG@B_ M4F,U65,UO'RK&T#8/B"B"U08#CMGMM]8K?6 [U,J1O86)6-KF\?AS@8UJ\= M[=FCRI[]%2NVTFF=9KL,KOVKY6.UTK']@WA4!9Z6S T:$UK#X_&2O!:8=Z&YE9/$='PT6+_7BK^&[+/Y1ERPM5O;G4KIH+E:WWL(T4USII'>U55K]_K"BB\[=2K]WNG0P^7%^G M<0J _/NHQK$ HFLK.9I%3I=5CB,>]@;%DW[HQS9\^%?\\Z:JX#4U\<[7KX M]U>L@PWN^.CFKTP4=;RHB! \-DU7?NY=,H<= IHBUX_V -D$0_Q@VR?V;+#T M[^O5BJTN&INYFQYZK+#QYD=.:<://%1)V=Z_6+=/P#FQ'[^% S"OO((GO] MO.7^HR6PTDG0Y)VW'ML.(Y:$554VSG=PC@;&/(V94J'_-V#5KV/_^V].6 M]84$)IZZ9(Z1B03;WLG97"KU"PJ@5[3,&J MI,O4/$_!GE<:>E=!:NT'"SA+U)=2\3$9Q\:B;E?G?.;/MR>WU M"9UI&?A3"E;?0,1D:@A66B8KZU]:S7W?\_YL%VH]EJ-O[. M?'LPMG4\'C[)S]#*(.T418J'**P34B6]M$K"K.J%O2YZ['F=A:%JZ6A:N/ MAD_ZZN#Y3B+/+P>=$X?[7BM* D4^YK,L3 DR41JD\[$$ML9RXI=6N%XF"U/& M6B)GB9R/0,XQQ 1H3$%8)833G#%J1'+18",3CI0G>D9XSIWG<152F;5 MQN2UR0#5,J;.U8DXT+ CD8>N4A$,Z]%D@ 5)GB!3>FJOANLF,P=TA;,;A( M'+S..=:8(J,31XE2[F2R3'73P]UE9 GG_67F=:O;E7DPBVA#3+;)Z2K4MTF(G/P7"P6@H);D?@ M8#=:<,"IM2)P"2#@2>ESO%N<&/"]@<(6A M"]?.O^;.$XPII[6,* D?$9(1\E[:EE2X%,$<"HHKRH\J^;0+QJI30DG M7Q84W.%4/ XC2J?BS>'#^1@^)U$$%0B;8E 7(-GH;F2B'J,J05[(>I9,725 MZ/#JZ#"&"H:!\COB=,2>,VD 'P.!!M+?+AKCYTI5/Q=G&"C.$$,2KHF#3" M(KI\&"R02P)>Q>!D8.!9,)6#DU4\I8'9W%++<&FU" MY#(E9JQ5.KC2JWA':#!^5!&IMLP2C#36%G$C!3+,:08EEAS+YG+1Q6JJLB3 M4^K6.2KFPTW.!6/@XC2J7AS\#!^4N$CE3%[$5)[@(?@(W+&@8^!27#95A"1 M%G1X\LDY#R4ZO#HZ3#2W=BX(%<&GD/ 2-@@5O+$N:$6]#7L2+,9%A$&P M697IS%%^?M"AUO:J#T(DJ?XLW!P[A/$43FM, 12>O2D('684(1.)N&I4"P MPV)IQ?!EPTMT6'AT&&>?#=KQ: V7,7'AB:$J:1:35XFX,KLI_>+$^,^A8N4 M!9-2 MBM:&Y(E7QNBRI.+]@,%D]3]/5A/+'&< !A0)9"S42#BI K2!RV)!3#0IBKI MDXM8YR\4^61(6+A2U&D/ME 8=[-G]#B@SVC-P=R$ZPVCQY;&PP%FO BDLQZ%T MC=XM4$RX1AKK2 T(@N( %)X(I).U2$D&4@$OM0:@H0JY3Q5D+T<9UK9VN): M%9+[US$4@.^8XLI1HL#1^QBL#X\+YE[.?EH7:)R;-3ZN\M(0F MX1GE/$KM(Z'AVA(;"()QR0X4#7#ABL$[1 MB'S KT@5G-DWLV%<[X0RT0%CHJ/)+;SDHPXG+]JLHK$7!W'8R.2DU6Y77S$ MTZR9,51Z\. 5T+-K;48.BV:LE9.]V"W>F][Q$7?Z\3+OB.W]!99OK'QRYQ- MTT:W\CT>'L6"D!S@3E2+A\\H9KMG%1MZA\,.Q)78.6SWSFL%#9WY?"X[_< MS2J';7CSC__]#PT@^>?Z]R]?BI?DSW]5CGJ5V/6]XQP]UK%Q&XQ;1&>ME6\ M&%URD#]J/4 A7+AWTHW]P5[K,'>KN#6?%FB_AQ48+Y;7=L_&PYD<#F2 )\& M5=K=RXMRW#ENVSSR0WO6[\'ZAQB._7 9<[\9^"\W)T%']K3B[* U6YL#-?] M1[?HN?S]"+X^&,Y&?JI:P#K?12[(=^HE^4)+C)Z[-]S<]3S!]?G9C0=A7BT MAK?H1-O-H@4/^#T.=RI.V<7S;F1R\YM5[[%7[%[G"<@#.>O$-E^[U=K,'R. M]'MT>4E 4O,V N/+@ED!L8:9+/[:&N2>'T,)S5_IQVN+]OM#([]7F4P',IR M9?7F;CH/<\08!3>,2L:%(-QQ[9(UVE/!N8[!$/S\/0:'#M5FMX=K/ZRK786 MP4^]?A'.?=.>5CO^Y]M98-M-]9/ MFY_K^\VM]9/Z6DW4&LU4V]_@=?"4C'7>1(9(H!AQD1(R@@;DP)M.SC'GDRU: M HK<%G R\#AJ"<1A-1>K,%(B7YKKSN;A@Q%PYM+.1_#U6M]FL:SN8-7@@EM M">%<8">U4($E35/DU$PO$1V3.K\'H-&.(_&9M-U&@_R>E?[+Z#F^@,IGDVPH MH8/!<6=HQQ4->!HPO+_:\.EW)U&[9]GWIK 0A >4-):(:XR1I4RCD#+;9'0T M4KU4B:!VA[ ,&;102$W@XJV9+H%+O1\2#C M?I;FO]I@^B$0L5X;I+P#$-_.8%2QL%?%PBD8MF* C0G0ZJ+AVJ4Q,KK\V&[= M'L ^>GC8;L7A9E'+&H$^VGZ[5QFTBBTQ?[>XVW)E"[1Q,(B#/-HKS_%[C,/N M:/FW8=NIL_S2_I;I#V.V[0VVSLB(+9;L7DOXXDV?A"2/:?HDU+)D:O:MB>@R ME8_K>'17'Z7[-3QZX& Y-HLR6+LZ8.:/EU\83X=!B%>F1 W]RG#]3<-(?9 MZX-!VX'/[0&"%6;O95ON>_38N4_PK]\[&3_I6(")V8ZV/YJ0M>B'GE.>D]S+ M"4P),JUOSI@8C?H8OOM&6-R-WBO MYGY/XL1_R@';XM_@=0;Y8-&>GE@RAX>%T=,%8"53N6/,S!W!O]ZE P_\9&G M-[XNCBY>XU1Q:IC)@ ,LF%5:RRXH:E5@9B4L)<:>W:?,%,.&KB[@YMN//YT M>?IW)3X(:T>NA3?AZ?V'<-S/Z[F8X:?1.>"G_=KY5[K=J.'M_1JNKWW% MS:T-OOEYXWR[<7!2[]3XYEKSH+:V?CIQ#KA5.Z^O-?=JY]]:< WX[K?V]OXN MW]ZO[VTV5NGV^2ZO=[Z>U!J?)LF#6@8W_^\>]IV?7;MECHLYHC].:FNK)\VU M[7-X!EIK_-QK=C;.ZXU57NNLGS?A^G7Z=^?_GG_=T8H)BQ&WN=DUT0LLKFK MBA>8D82-UKD,4"PS-MY^'MTF?U:HY+#B(2@!?C@V244C/8Y2,.S8])8^I?R] M-_GS.R;0P$E4R+HH$%>YEX\/#A&O4B0Z$>EEEC\](7]36CG/.@7ZG6\B 10U M.A6]$X1[S@W3@A+E-;.8:L+)2872DQ)5X@)3Z_58D[^?ZKO$[A>IW::3,K M\?[/UN;:-MULA+W:5OV@=@YSM_7U-&\BR@HNHP;5Q5;G Y1,.F$%BBR0@#45 M+O-3@1++!VTBW$?L0W")>\8U(T9@096+/'C "!M^2OE[S1O(EAIP;4GB @C M$2>&($.P0%A%+0&O0'AR)Y?EWR7Y2;R4IL(CSI)YG2@5G-&M/9,\Y@[GN;$ M=SR^B1!:O'"#&Y78DWX)F_=9K[Z[@&2KL-SUK;6N?UK0U6/__4VOS\[:"^ M]>V@N=]NY4TD^P6&@O]!E;"PB7")K%8B4"9IRH27S>1,2$$M^ZB:1:2#3"B3HJ3( ME%&8P"9RCQWD+827[XC!_>KEG(UVZ^CL5'D-[+O3:8==D<%4]=C(EHXZ6CN M]DUYV2?TE2P !,D_0[_T1O7T#M:2F@KRN@?L=8 MZTVR$6&9;!90CRP87(@G+3F+26%O0$ G62;_^03WZQF*^=['-D2DT80Y%;3' MG"CJ8F):$9_+ 027:6I4I=R&%E'+[PBR9+OXQVF=YKG9. $-WZ]MP7,TVFV8 MESP6F+<:;>Y_Q7D;,MYRAKD&KXPKQ%UP2 OX$4U4CAB:,.8SV88644#+;>BU M!=3O6.H%DSP@ZVGN]VXY,IA8Y#RS01@5:=#3!;3$,+**#E M-O3: NIWL)'6&261)3FC@6".=,ZM"9;JA%WB$B<04':O;>CMIO-]:PT.4,JU M'+E\N1\'1Y4^B'"9T/="T1K^K/B45_<3+.[&:&W+[?.QZ#1.PCN!3I[4SW^P M[?-/>W!/ ==LUSKK8GL+GNF\WMJFGPY@3SY^5,[;Y].)2H$90@G"=LGB0G9 MB!WRV-$81=#! CJ193'92>R%PXFO(#E]OG: NIWE -!3"(@(BA!F0()&:4C MLL[+D,GSL"X$5)9^G%E-L?KA!/+;6A1M/R.6 V,MU,C]?UU7MO:H-MY[.>U MG,&U7SSO_@9I[O_5J6]MLR8J+0)2B5D&'6(A\21E52BI +1BDJK'6@Y7M:3 MQ%4O'$XLMZ%W**!^AS"A,_<>N&T,(Q[!8C(!O#CK#;P!0@(_"P&=8B>5V]#" MA1/+;6A1M/R.G]MF WMD_@>J#9'HS-3YT:O+=]WFXWUS9.:OL' MQ3;DJ+5@3UH4?#"(TQ@02$W.(Y825!RGF!F\\;:@3>T< ):;D.O+:!^1Q)# M9, :!2/ 3CP%SF>>U%8QXE3QFHOLC=$)WG.'A%.O N@LO$VW>=1?YD.0GE M)+SU1-VUUJ]6B-U0.6O%]LV,(.^B_>5S!"=G209ZV_G>Q3KF#;GT>!PRP+)( XLU>X^V&#V;'M7?W(\\+:-Q&(B"D)%8DHZ5C'!MB/,?P M.C!O!%..EW1F"[NO;DQ$"8B1#)F4#0^(AX]039REIMK88&IB=$B@0+D#+?$YPT!T"4?LB<[Q@7MHV5MPH9[.:'-;?&G [^A^-C M[-^R6',!(:0V80Y[3;SZ%5(HC+G((BG42>^$9%\3(S- [F8[_P"#3=,A8 ME"#3K&,2[Q=K'N4%E%BSF%@SYA3(1'6,0:.@A0?7&RO &IL0T8DID; PT0+6 M\!)KRF3R9X2@1[E()00M) 2->4R_PN>?//SG[W:3MG^Y_=Y);7]7-/?#08W6 M#[;W-W"MD^?%D]K65Y@/&./YC[/-SS\/:C\UWK'8YWX:!DF#(]A02#'0T M:C;YD)7:2I^/32;?!$EM,PG?W4)93LTA00NFT(V<8NX VM>YVU6I(B)=!&$ M!JQY?;_BVK=[ /90=HKWFWKRQ-! 67BU(#CT=2(PD%1B7&F!9"0.<4T3T@RV MO4"U84(S 1YVZC)L4Y!BZQ9HZ.0\O0P!R4\980]#@(NMWM.LS/2?(UFUL_VS!/>+O1 M;A>LZ? :\T2&ATR$5M$2/"@" YSHY88"HE<[NJ!3CP2O!A+:$ M<"ZPDUJHP)F<)6X.]3C^GW8CANQ\VTWCEL]\YB_![[OUH^WJ"4[7;/%Z\V MT[?H>[M=FKP!8;6@\\-C@8-&-Q?\)F#Q52T=OS/M[/F5CATE,MFXQ-\;H/6 MU]J=YO[N&?S_7NWS!MMNK)\V/]?WFUOK)_6UFJ@UFJD&[]=.=ER204=-D#!: M(QX+SA.#D2: RAZ#OOU4B4"'!WF@'__.+Z4L-(LK(V]6#GJ'=EV!40>3O8 MJPSR.J.B1 F$Z_=5^)I?ATK_=BV10UTKV+;[4HO58[@EDH;/?L?_]#4Z+^ M'%3B_SMN'9V-KF,S. _@FQ<"DLN9BJ\=[>5DD@X,= ^^TPWP5LWV_=X0)!BI M5K@#G^SW9!_(Y7\(G\Y%T"-OK06?CT_PLC#BOH__@/<$ MN_>DOMG!2GR_RXZBDQFLQ,[,W'[7:UC_E8Y3EM WT/ M7I,MM/!K@)X=0_GY#X3W.^=C/LC"S QVY- 7LR)Z_][)>/XM++,=',]M)\ MB>;S?GT@16F(IC#@UZ[%2H7R[, 2YZW]?LXY,/''.V\DT]ZKVFX3QK'+.XS MW]--'@LQ=YQ4O3+N+_K_.C:X] "@WI&.\ ;F9;59/R=O/JLZNSY'=3ZWMK=I9G?[LY'MN?MXXJWW^MC<9S6T>U,[_;M<_UUO; M#;AOCNQN_;VW?;[!FEO;\'RK?'M_XZ3Y^5.JG8VUXMC=T3CBP+U$2@N.)<, M.6,"6ZHAO^XL0GSX(2XXW"]A+J7@3HV#G6,<.6\0!@6"G%F/=+).V2XI%ISSK1R M2RN3;8A?QM05Z)9B693T,P1 P\LC,0N0=V&):.FYV:4$#L_$%O_..$XPS+:9 A!P2<- MUJ0B2$=JD/".>FQ-WC75F15XSFA 2Q3'V>GT)@G3 )A7&'%,0-M]M%2G-/ M\?2N,U4O0<O2X>\APE (SB;S$%&PF2I$+22$NL-2.N,B+2H$CHG7'NE M0L_2"6)&>FM4)$K)ZQU47ECB):&&C(>TBF=H#E4Z'$GB&HI9+(,FF8_L'\0A&^Z8]FC?# M/#3% !)@_2;)#!.$6Q&=P$H3KY7$%G-W5Z_@$B]?'2^_3W@TGCKF+'%(L63! M[&$,.1($$IH0PS63T=GLT4@QRP.R='@TE&MRS$=PST%Z+5-0.<1H( L?5(RJB92D?XVBQM**K@CTY5%$J]+PI MM-2@PRJQ2)+A27BCHY0.8^8YCQ+CTK.9?X4>]VQ$($FDY% D#K9H;!S2>0$# M]18'QZB1H-"<5(EX,IUY>59S#WUL%,P@=Q&"+J7<\]LQE%), /I"+WC3"'R MX)K@MY@3/8MI6? ]Z%%L2^4>-$=[T&0I7&ZFH40PN2=XYC5S$1FB+-+<2ZL4 MB=2[I14JJIC/Z@!L=@JUD):"6@'I# I9Q&C,2>3,6^_RV850/AFMG&D M/']< $"=\-)3S0G%)"4SQ^Q,$A+!S:^53!#Q>M :.,ZJ6,ZZYP&U!-1W M#JC"> YN)1ZIW=N /4ZC>X8@>YO6MTL_WN<2&+-W52^TVD.YR$ MS#%WO5'/E>^-%(_39959/P][@U:^]H>" [7U_XF^\R>>6+H[G"O[]B'4S+ M\='-7YD@87HI5"F88 FY/@E7?^9!%JJ:$SR3H,DE;;GWV' M4IKQ/ W%%I"LUR^$[ ,H2^SG3\$@["N/H++7SZC_C[N7B0!"- HZW%ZJ?,P[ M1O=H\#__MBO39#X\1R".$'\50AB'7"VHCY4L],=+UN^UV I<&7V"\VLWDA MJM[\>+$M_3QH?OZ!:VNUDWKC6Z=V_I75UG[ UK0NMOJ>LX=SK<5IKL!9@&7.63&AE( R5;CRJM+J^UXF5/]J]P>!?ETNK: M_MDP\#R)]EG=%#I'1\-CF E0/XKX;B?_R]:OY?OTNJ% MY#RF$OPQ+,Z%!>8+>]^/8?@'BM7_E+J=_K5'K# M1@_5RK?O/^#GE^(GB$5A4620Z\5!I>LX>O?OWSY5WY_T(+KY.'?/IA6MV(] MP&VP70\/V3K:JZQ^_UBA$B."JQ4[ (L9=C78O^!:!1H77V\E-!H#_+D3C_;R MQ-YH:,P7\_\8-!9"N=H-([$H=HYW#)>G.X"2COO D?0D(\]_%HD-TRD-XLG4,-'H+F#0S^[E%XO7AT^\(L"T7? M+]T^69;$/ .#/=-\]@SVBS98>C_!NH%NW]R#T_S9.'P;K0[LFO5X4OG6Z]CN MD]A\I\<=GE5#RLX 96> X87$:VK1TZ?@%72G;%U0MBZ8I^DN6Q?,Y.@ 'O4F@C\V=X([[!6!D>,O.PIX>3?W<']0Y]Z'L_E_WC9U-$!/":\&H_B@3IN%+KR7]"4Q3B(?V0( M;W@0O]^&L>0^M3_;M;5= =\Y;:ZMY^_ O0)::#_,X2 M]5X8]<;S.:5G0J9 D!("(QX9S[UB(G(BQ AXJ(3Q&?4(U6\/]4I@X'MF?(L M2V![86 ;SZMDSDJIM41:2(:X% 8Y;0)B7BF:,+8>LZ45H:M,3#)ES1^RW1 + MY[?$PA]?A#[GWO9#GO7PDQ)='U(%&L&L_G^1OEVXV1;]\^.NBDH]@8#8??B ML7@S#'W#]9UM+ B/FPP7@K8ZE+-Z(6:;J_0]#8%V>NWU&\9'S'ECU>)C?Y,J^JC@D0K4\UU,]/3;5V-0, M'@:^'L0:]IP":\ESP&+:5[U&ATK8>OJ^K=>CI^_.T/>R+X1[L1GKAJ4&(99B M:;:F @IK:LC\,#!<%[[PD;Z-@6.: WMO'0-Z^NX2?=_2^._INS/TO>P2<"-7 M8X[%5 V)W.>J?HA9RH/#<>P;3_2;1OIVQQ80-^&>^N90'V_W2VH\V-=%S> MK52&E"-6I<\YPK_'HXK3!ND$I$U>_7FE3/#]ZFNBG!-&QVTF: M^B!J X>XQ^O%L(\.W "PW:TR+#BP/EK$KAO&LZ%O$W#G.,0 M6C9^F4TF62KTC]-6;M>7;-X%XB.;X<6G><[2<[IO5H1)]]YI/[@>=9K);MH M):MY)[[O>[$?FZH61C%H)9:G^IK'53.P8S Y BWT#8JT] MK2>ZXWNZ&;@X:=3272/@L>FY>N@9AFY;3KRK1Z&G]:[0^LH\4C^T(\WBM.K\<\=G0W-"PKMH(X\@QN6PV[>A9[6NT+KR]Z&T'$C)V1,AA3.-M2XYVBF8^V/UE>) MYH$]#1VVCC[Q J@CQ."M:(&!)'OV LXBW])[8^E0:7W96 K#P/5= MGZM:R,%8,@RN!I:OJS[HRI$&]E+D];1^U+1N1LPRW9C[OJU9@>8RS['UT'$T M/S;@_U9O+!TJK2\;2RSD4<28H?IQ&B6@V.-N#]3 \%V5&Z%F,?(W\8/V+?>9:]?YEF.0EA%(4I<;EN'ZOFD?Y]_/OKS]=Q@XIFL;D>IK:'MIM@,\VO95QG@0 MFK:O.T:PU\K G:CH@!S9CXXMW%,U8<\6[H4MS!;9@N9;S'(-1S7@+,%,LUR, M8&DX8<+48M]FH1WOM:"P9PM'PA;NJ0BQ9POWP18^+&D+EA:YGF:[JJXQ1[4< MW58]W[!4FX$48'', L/?:QWBO;"%O70HVM;Q%(E->F&7DC1(EM(N:_U9XV$U8C:G0 M]C%X)HY4H]BW_^$4LM&KL\\K/D3'CQ6I9IO\FSRD9;U>\$JX6V]@&]; QXEGG2'[WG.P;[/\,"SS U_E\;H0KII:OYCA<@.@5NK!1TY MJ>V'.S;6!?UG"OG--3ZQ'Y]&\;&<0W+>HSLT=AKCMHO]]AEK>GYSEW MRW.6/3NZ_'0M@-5BQCVFXZ8RF+?5W7'-BW#= +/]I#GV$XW>$[OA^F>'V9G M:#Z^51ZO'^;5E;4BC\,3(Q%"0/\JG#@Z%6:WG1^+CG-OOAQ)7+V6LY.6\_N M-\=P?$T+N6&+ 0M)V2QZCMAH 8>=^ 8N1:Z[KXLJYU(HN.F5\_8'A=CNS>' M4<_8;LC8EEU&(&]T%CBJR0F6H'.U""(8M4-3,]BG'LLCGO&UC.VQ\[8[LTK MU3.VFS&VE?JCR#!XY#AJK&LN:&P^-M&U736.--TT?=NQ=6M??JE[86SD 7A& M34I>U$L^JR9 B%\CI(+\2UB;9)6E/VXF_P=;WZ"C+]<\6/2^XTRQBZ-KQCFA4)+N1YSK&VXH+_?)E$Y:C. M]FO=&&GS6]A09$A6R\I;6!D .IYO?%1 Q9;&O=<)A+X-X$J:6CWPRG.-XSG 26 1_,K8!'L@5>@C'+D[7^Y M_IAT\^3%%Z0\;'_R$N5"BKWTV8MU.' 3FMLWSKIK-:;Y/UO;\9G7T#X@%#[X\M7^^RW]]]!0(WYWS_- M_O@MF@:&Y;S_]8_)'U_>S]Y_B9+W7_[\?O;KO[Z]_^WM]]]_^PIK>6W\@8+J M"PC&'V_B]S]^U]"'X,O'C^]>OW\- MBW^GO#U[\^'3^],O;S^^>A.F._>)Z.N9\Y<15S!7FZ4S M)9MRH'Q>8,4?<3$HO_;89:#G1U5.XQ-U0(D5)GI <7$9F":W# \3U]& M_F[C8YR-Q]DEEJ0O)OFO$ QHHP!&=0Q8H/""!V48 9?AD)<;52UMMFAQ/!: MQ2(M%78Z9M."/Z__^+D.6B0IK9QN^ED^7NIEJ%TL::?T0O'S7/$8:D+YD)$J M^6;Y\Y!^6EJQ6^N-71==^//VE#?^-M5C]5!O_?M&SWVZM]L<_-+;[58;ZO' M7A,-W"%&>45\4"C5=VFO>]=I+81,[UD>CA13'Y#I@2QUBS#@<8'@%0\Y==]K M04%?@,6&-'A/:XOS5GGR]O4X6.-I=W%C7Y-614E)8_VB\:'#I;3-4#9T^2! MZ]RN +-[=4!^37&GRN<2]=)=VY9N?<['X77>>===]#A?Y7!>98Z#%90:^93L:U__]=EU&@&HNFQAG61I6>8[]BTFIWXNU3Q,6T-Z MF]]_)X_QY%_??H=WG7W[YX\_OOW3_O#JK?;[CS]G9S]"[?M2KXM2P,K#CV//C 0FXP3;,MFUF]$O7@7&>VHD39FN<&.C-4 M(P+68P6!IWJ>C34E>F#[<11JV$C8'OCFK9E.]VK8'CO%QF'L>H'K63'SK<#D MS#1Q^J4>V;;GF"[O]80.4.RRGF YIN%8GJ5&+ 2SA\>V&NB>IH9P=&Y@NJ$? M!TBQAN]VB&/UGT^3(I?_!\S-+-CL5',4IJC3H0,XR3[-L)V:.;IL6 MXPYP&D>+[%X=>&CF>- /?^L:Q>J@L_O<,XQ(8Y:IR1.@;^A\&K>K_ 4GD2 MV!>>X<9.!-AH.(X'.&E:GFO&KL[CVR@"/>?8GG-\7I'UEA:;EFTRU3,]'!;B MVZKG>.A_U,(P=,TP\J.3%[Z]K]E!O>'?&9+4?-\+HL@QK!"4NLAE3.>:P2/- MMC3&=??FDKXGR5U(6&H0!4WD8^J;GZI;K@3!W_2ZU MUCY2R_Y7#BIK.NNM^J5,"=WUP$J(8L.P+$T/6>S'ML8#S?2MR/3]7IC?!^=8 M38:P/6Z;=NRI3JCC1 [NJH'!'-7WH@AX?>Q%6$[CZ;?NSMV;[5TC28?'/#1U M)W#CT/(LGWE&Z$2!HWM&',51[\7O KTN2WK?M )+CTTU<$U/M?S84 /F!JJC M&6ZHV2P, O?DA3[0;C_1MS?;KR.V#^6(YRLYH8_=2'"M6 ML/32]0+=LWV3P M7!Y;/LZ: "ATSOP'YROK,;SM3 R0S\(U,B+&%;@.RHS8DLUN.T[@>-K1N @ M7X%SZY -T9OU>\K[B[68,\>W+-,[3"P#&8XIJ8SQ_3LL-<$ND"QRYJ P2S? M=")##6U+5RT7_O%<)U"Y 31K<:X'H8D4J]L=GQS;%;_EZQDXE]6Z91;NY$ M\JC3K?FB]_6$V%\"// MC$(-6')DH87FNIO\%#E.C=T6V>:[G@G+TQWX#FW'J.^=XHYC/J3GF/V''-# M9BK8J'!8N9HS+)-QS=-X)5>;,>,N7%L]9IL!SCFLB9K>[;KZ:G:GI@J59L MX'A8SU:CG#MMC]WV];F$[_@:<5Q M4NKK[R7/4S9^616P0I[W/6Z6>]S\^+=M>,PR<4A/: &2&J&+^5:"J '0SGD MS-+=+7K<2(RC!F,/UG#LVCY,__47S]#=GPLE%TA"76[.&Y2 K\^!]@9P H> M<"22[@WE-C3W%RWQ1DH+.=44U@P[ >[)PC&^P4UW;,V1E>!]-%QS&&IKUU M8YHUVE67AR<<8[>? UJLHVWWV/7S=0S]BODZ#S)&QS^DWCA?1CGGR@2N&Q4* M3R-@>/.N2/OI(I,#ZUQR6!\ 8'[G+)< V;I'TA)JZG;74/..)SP=>)^@+1N M;;7-[=LJU4K#RJ.. )SZ35G(_MK0W05?/_23Z?N$]7W"KN@3UCG!LNOLL[X! MT&-PGX:6&4:&R1V3!989^U[H6);->!0XEJ-;P36CSE;]J-+)]!C\IQ.\+OS^ M_LMKZ_?)OYS'__4SW[\,OKPZ]O9V6^O?YS]^OOL_6]?82WGYK+_]'=T0/UX M#?>.DC]^>VN>O?IJOO\5GO/M+:SOO?;'M[??__@RFGQX%6%EO[[D/X53L%S= M](F5W/SWI^MH:?^5$4Z1HS=2W2+<=CS E, M!DH:,QS=A/]=,_6LYV?WPL_L97[&N>OXEJ_:KHNEFU:LLLC1U)@[H6OZH>>Y M!@:_S8&N[ZNDH^_?>#-B?/W^]>GS0S7M]YHHWS]C;WXL(C"W>\A^72%S5Y#X MNBL?:76GZ9NZ#J:_:UNZ%7JQ%[@V,Z,H\'G,3]WY3R\-G#V><65$T0!&#BA MI=J&QU7+L&/5M]Q(]0PXO<"P&;.QO-,?&.:^K)L.&3"/G68=G"(1AI&IL\"R M=2\PC2C08C/R#$OW9%9?[Y%X8)I=]D@8D>XPWS95C9L:TP'-!N:D1KH+(HC M-]0L=+\:SL#<6\)_3[.=H5G+!TKT6!RZD6U9C >FY=BVI1DF9P9\ZWN+M#L MLM4=!U&HA:&OZGYDJY;##=4+@T#5'-,"3'59&&#(Q!SXYJU[)G6OCT)730[J MIZ"@E7W45L<15YST."1:?J:'3D6'ANFQ8'7'@ M>\ .'14.)L!A#DSU(H>KKA.9<:ACP[_HY(4[<-V^I^/1D:S.G# (K=AWF&/Q M %LZ1A&(1B^PM#B^C!H)TAVQ>@(N!.X8&7H#@>29;:A,D,W5#<.#9_9MF%S M(%EOX.A=ZOG8D^Q>2!;]0(%E^)Q;IF7%+ "CCW3T>$KW;"7_02]S?$@)+ML M<]B.%9JF9:B!;C+5\ERF,MWV53OT-,,F:EY8'.8VL!V^PDL=TYN5[=:I6' 61SS451U&I M<'BZZH6.K1I^X("V&7,WTE!G<>TN]:[L_:3[\9-&NF7R#3<+ \2V=>K&O, M-QW3CK3 BWLSHPLDNVQF &,U3 _L"L?3/-4P-: ,P/MQ0%# W U]%T=2=9P M^W#DT9$L:6,:Z%M.;ICF6[D.98= ?WN15&(8MZ,Z,+)+ML9NB.9YD>"U0] M"CD0JJZKS&"1:G CYI%KVT8()&M: \?JDI@]TI3!7W/.2IXK+T=)RI0G^M.C M-CF.V.>BVYH9QJ"6<%^W7 /,=RVVF^[1NBXCLE[D^/!F>&'ERLFAP:&HF/K MELI#TU8M/_34P->8ZFDL"FS?CSJFVC5L7L_8DVS62!6[MV8YF<[C3LETMTTXTCS+,T.@6J;U)D<72';9 MY ACFSN!':H6:$FJY6F:ZH&=J-JQ%GL\,$$_,D]>&,; =;J40'"DD0WJ1:^D MO&RZ-QZJS;%E'5O?#OK.P'+@XN1&;7)[<7OXF2U" ;.QS8USU1]PP&CS3#@ M+SUVU-ADL>TX;F3[_LD+W70'MG7K2'EG&D+?;Q. GF?V/'-#6Q0?K&13YU;L MFQ8+ R\,01,/8]]S ]_0C=YJ[@+/7+::N1WH.O.9ZEH!CA[ACLJB(% Y]M;W M79^'>H@\TQHX_JUU\)YG]CRSYYDMGFG[H64:?AR'06QQ(PA\TS;N;)&5I".L0K5DGL(T"GD 7(C$JNJ;^ M8[@XAV)Y$@M^1H)/THK>>E.0O:!>YQMG7LB-6\;0Q>D3TZR@'3_/^1A>>\'G M0R>0/;5NE.BDS6]A 4"@C??LM(L^%Y/53>7 -[Z%Q=)[,S67"^VC3B(/6:% MH>9;&O=)X MD215E\"]"5)+8TXU6P"/; U!&.8F4,8793P4I"L]&Y^P<;(Y^%C M5N5W"PQ7%AB/E]BUBQQJ/S&%9Z&<"- @5X%+P9N!.L:P2KKE>,"X''?JE0H MEY=).:W574C>?QY+L7FBRCF4@Q7@6(L!?%7X%\YAY?!ENE;6%.21>T)) )I M37V @L^ )83C"G^$M7QD>2E^?CM0$-/%!QUW1PO_9P57 .G/X&BF65[BU"<0 MR_5UFOK/H?(%+XSFAXTBDR4I3GO+UD>J>,L^Q/!VMI#.6(E+. B&U]P)4^* M/\6V "Z@Q,#-9<(!J!_'G!7P.X_AQ24;Q\N'2)].P)0XRLDIKQD%2D-^4PH M"9_X.2P$+W@CU_1.KFFN'4BL4OBXX)<(5$N)#@."[<^A? .N"4$>IB,9>@ MMA7U2R_YH'Z&_ 9.=OFKJFB^J<^Q7O-\"!?^NOCR.0S.LHOL906K>Y=,$&$& M\D!Q,PE =@%_BBHHDBAA.8)SE;=L6_=DZZSZ:M$YLL$;58.0V!/E,B\(\ MH1!@0F?P&E8[66C?_^#,]TI6^Q88$6PECX U<,%"O@X_#Y5SG@(_&@.MPL]\ MBN?/YEN>YH GR73,Y_STU]/3CS4O132":_@4<&6% \X)=Z!<37H")# :O)5/!L(G 6QSPL".$!AF4%KZE%VH3- .XQ,IHXSR;+2U[#0!Z:%VP>:1C65-\F@9KJ<_Z?J'C M;#8W6#@,A/:WCIO":L6>$?L@LY3F61 " 5L,XGA78"<";#PD(0D$M#UHAQN M@J>"H(0C0@+$N^;6Z98&,$J%774(?L5?:5S1(?Y3LPTO$\TDYB',@U7@IWH:4X **L 7KE0WLKK#FWQ[H@7<'7 UX#MIG+.U0Y:SGVXX/E% MPB\/1(K])M@44\['60!'GJ7XOO.90(IT)@0;0Z4>1!;CEF))"4/!RE M\G)@LH %7ZH)$,L7S+LG-2_A8]#,GIQ\^2+^/ $)=SEPA&]E8]!+N%XW5A< M5U:IP,)BRD,D9F" P". \R9H?(!,/!/ M/D,IF^52(L%[X(E1G@"W@$U->$Y4R**,N(PP317,)SI^C5+D@K0%T M14"?"V(S2I%-&AE3(Z=GX.4' K> DP4D#D8J2 #BV-3M!0!",&,=DC: MTYL,K":$WZN\.E=.HPF M"@%F0$>O7EU>OT)4D_YASV]R>H"Z?T-(#;DY./ M[_&B2M'ER!:XNL12D8T"=)P)1BY"E?W_UNH45.J:;4^('%!S ,6\ C)4 M)KS Q0 &T-F__[AZ]N2U !NV?3BTZ-^D:D)' 4?)$USSPF&T@//ZJ]!!KX;D MRMD12-+-D(-%+-ZPR-SPW@D@)%HB\]N 69(A.M">2#-&F(_[!MRU!DY7( O M-MHY,$A$WEI35:J"MUAJC0% V@-%-K6FI=#A"XQ%\1.BAQVHK^W]F:+>@W&_ M1"@VH(:3^@UO1_Z9ITPJ9'&6E6A7 04<"A?\;:[&DK=H-"M()$X M'E?(S(1\?G)R]OGENY=([MF%($WQRP#6C8@[ 94" E-.TAY^U? O0)(E: M^)TTCK 6A@H8YZB)TCY1DQESY$"2^RH\S8'K$NE+M75Y\[1J8>TM++N!"A$& M:/8,+H(7)U-2\I-4./?P1OC#'!1![J,P&ZP]!HK0IX!,8J&$+/T/)L?A0&K M&6?EE@=!!D+!FZN9\)R= ZCR!C #XOE" 5L'C(!EA!< .9S! N!8X'SEV@# MR)5,,PPJ)2SP$'@HUA+D0EXRN.D7,":") ?%!X 657@8T9 &RII104R&9;G M;%8H<$4!5G;#:<77J("",Q6X;')-GF,,BB<+1Q(O&CCMMD',!\ILX3U!R@2 M)G\0KC.A?01%-(2JUG$A%]H#]II'[VMH[?6YNAM'XCM [%W[_:FIM1M8WXE%,&AI"18\DZ$TEV96R5&"C)2B-6YTM'P3JF+D.DS M#\6NF/]"3"A@$8+=;UO:_#DY/ B4[A]"WZ#WXYY) 5@%601\'(S%FHNC79AR MX7D@:8V ))!=:!@N$(%4:)QT8L-DRM$>"WPG)L7*\4HJ\:1C Y4)'C0VSF> M+P(4!@!^FO)(K'+EO%@8YA4\>6&C(ICP(2S!$I&>15P1@?DR&:.$GI^#4+W, M04O@ HAU#W$/1)3X5JVF=;#@ "P%W99>=,H70X,ANT0**:0[G-?#[F4JR;T M4JN1C7)0ZX12V6U\?(W20!9H2X\%_8$TC%@>)()\%6)7"N:MI/8VOM!D OI: M'O[W27H1YDVET+_/]>&WZ?D)T%JYZ:=%U< TM.GWG^4;I=1'@;=<,(AK$#]+ M6>AXUO0["L[NNG()4]#YV6B6;16['(%9?XY>W FG<)CT8-QDX$T)]S:EXEX M\E&X,(NY%X T]-HA(1V7#VPL("9, M;"HA L9MSE&WW0EU@8L [:"[@A@(TDV3ZT8P=H PD1Y25%4@MTWW#[%%$:, M$XHO:Q-=:,XH()'(+K-\' &F<0)+[16X1).D !NWJ$V9N2+/R#_AG %I4R"HZ MH"\LN63HHESH5]3XN9GR3CX?+WX)@HP%4A%53L]S3@:W\@2/#5 W\!74DH3PGR?T"8:-"8/T2X"N&&0XQ$!X?26Z2_BY"#"\ MJ=5JL'JXTRS3EN(HVD,M!X>N?=-,=V@IL;]Q$[?"J,3"\N>:^U2N _Q3 M3];0F3_ME+CQVN60PTVHWF%8 9X2D4\!L6'T/@GQ]?:SUI8F.9=%G.-PC<([L$62D\;)<4J<'X([ 0>'Q MGTOMJZI]3Q=U"+2HI@187'XOMJJDF'^A@'RCE'"3J%M0BO49,#BE96.Q2 M_LDZ?Z?(X#O<)0G]N5M,2H0Y 2MC!E;?J),);L&[=_A!$PS#_\Z^TK%?OV M'T3XOFV-:\(Z_0WU">7O'!3CD?(A/V=IK2_4"6>__?U#D[L+\!A3[D>]\9;O M%%"%3Y)PJ'Q.4%T25J+X#O04>/#<]9$&S8E_M'[&E_H=N]K?2^Q@XP-R14CKGI MI(,DI2C_$CIMPZX:CE0[NF3R0Y,:MY@,.$_#J],M:^MX[FW[C\B]0]BAWB!> MV+QG!%)=:!$1FMGP.NEK6GQ1Q&8 1Q7^UUYZN2G"TH%1UT H_P8XZW33NM< MTJ+"'FB)GRXDCDBNVRP;^"1G\$SQP@5;DZX# MQ@MF":I#(L.2@A858ATBP;<2:T'"=6D\2%&"AP4;),?A;FV=QPE4P[1#NT MF $+G@ I=-4)C>GS'R+Q.?1(BSSH$0.VM@C,', M)C8HSJ:N,9D@DBV8M?79M=5@>O4:%]K\Y5%4'A[([JB7",U6^Q)G!]@3!PO MO(Y\NU6>4KQ0YE-0TCIZ#,J6XQP(#W/=%A8Q$]]!W&21RJ:C;.Z]">'ZWE" M0<$H 9S$$\!L(8DZY"T9CPG(,KZX_J(+4-/1/3G!^&_]/AELG.,$+%UDPG$X MAFPF+)6Y08IWP4\<.=MY'9.DV&N=0TBQ9(>S$>&A[9SB3DH"'6B"8]C5+R; M=$)V";'K#9 M^;VR EQAK9'!6?)RF=IK&@ ] U-T1IB6)FR4I8[D(==Y,XT MR>=$%X-V&GH3#(D!"$PF/V"J!C'56M.KG]?@99-$BQF,Z$M$8PIQ6M0QM)F3 M3/P09X)QE'D M=/K[2PH24IHXG/:A%M>NKT$^6]/5\?Z8E?!&S:NB=W4P\NFWQ23B%E2KOB8X-OELH?_LYQ/?ZYFC[,=&-W7<%?1K4K9D'C2(J@H%$&DI[7 ;T6&XM =4 M@.=\ O-/0(AK2E+,VN?W?.-QW;3E+S%4#MR=-E!1\6>6\_-]3S^@3O>D&/4 M^?F^SWT1-+HUM''?V)DW\B/(U)??^Z!?7? YJ!U M6"PX!LP&"QD,Z^S8P=IH+'Z2'1Z$TZ=5H7C!6YO_V&"B0#Y19=OV+$LSE)" M /0BHG,6/2_G63YKM;5I[T-DD#9[N63GN$Q9IR!^#KT6O]^5"1ETQFE %V? MJ\+IC,N QPO?^N$BX%PWK<$U0$OD+G%P_4&=_+':'Q +2WX0 6E$]"7>&\ M1T=.6;/BF?! <\#K6O(AVR=H1&4E%\GRJP1GP?S.P"IL4Z:3-^0%2.P2L?4 M64.4,(VRO%31Z%Q(MB Z)KOPR9CR[)Z!P IPJ92&3H(L;P68,(D?Y8F>-UW MI+DH>:1[0@3M/YSW?>2 1 ,$+U -L!8?9Y(ASN\^CUXNK!L&H]$("08JDE M:S64$>8 \!]@2>.B=0M4>5SVNO<;-.@&XU,SE#NMQMO1R.==XN>XU_+BK MDZOC;JUKN[+,$S5:_<)D[98J4P@E%_3;4V2/:W$7D1JHEZ&&I1AN'2TV@:J MU8-ID:V&;KI)=0K0Q% 3 M="&G:WW?X.O]GF MYI=>=>>UB_6V>NPUD]6NG7YX%Z?FK[Q^S2@&(;;N5\%R%]MU?NTB"_BT>+^N46 _FVVN86Q[HX<&#U44< 3KWS%.$?#?9^K5M+ M[@+S0YVDN2[;HK-\\78S-!_GZ(#G4PD1Q_>:@)-9X9RW4C0]5A]C%A-P^DZ MBM4[B[CU@ZJ[)N6\XT.5D,>B:/_ ,K:.B>T]38A_C ML7H#4^_JL4H.N!3HU"D);^^BZU!8SA9[W9MG<0_ W.,BCU0@SK,:91)=:Q31 M\X.7D/M@QP_YC".U"C]MG:)Z\!AX3#:)90P,T^KMQ4Z>C3WP=:>W%_<,UL^K M"?)'S9+6G$JGT=YT!YZWTM:CWJ'8OL=SMGH ].^812I=ZEO=F%MK,TY:LYT M: +9U :VYO74B?/1A_H1N]I=[ MUX\57>[^KFI=[EWXLK>Y7X48G+NH?#0 MA^(]R)DISM!'[B:WWL3NG@TQL"Q'C[R?= =K=)_ZX ^X[^ >E.;#$%9OVZJR$G#L8E/KSR7[?N2NI4-CB4^,@:W; MVRMKO:2ZKV-Q3>M!CN5(;?FWCX4#'9JM: QTT^CS KIX-/K ]!\P9>-(%20L M)C\?^)>_,C'4WN[\ZZ[2/)/++"1W9T5C\[$$:]1%GN4/4J4U8T=_,WWA;] MN^?6GA030!]E%?:PZ["_9]M5'JD^\PLKDI#:R]H-31N)\/Y+CB B=J7'JNB M<[2"H?N\7QMJ#^,FN2>%I$>MQX=:]^2!>P"8_D8?L&D\K 7'>M3^"V)J".2\C8^G.NVW46><3-MJSM2 M8']^QQYI>Z3M#8B[,""BZ7C00O%_6B9AZ1BWIG]T!L/O?&P]\#.,<9O]A6F MV24:<\.@RS,::?3B($='1;QDR5@,==PT[695"F'JDK!M[E-7#],JL.4U0^3 M6O_8;@]TN4)Y[LK,EGZ8U#:2Y=ILD"X>[6[#I&XW!H?-M4/FWI$PZ8>P @Z MEF$<.]AJCR'=\BBF\_CV#:LU.I,CW,^;ZC&ZO5W7-#NT?<4IGX F/>-Q0^R M+M49>)K>-[?HXM'8 ]UXP);OQZN,]YW%NXWXSL"Q;Q@K.M!0W\$$5$#\ 8/O6X@>!_]B:U^SG=G;R;+R!;1Y_9_$' QH+GY=J/I0^=26/@$9 M^5B3I?"H/43[ $L7F8EA#[1;)BSM 30/K,+VI-&3QAH=R!MXSNTG MCVU,%WOQMR!_]FK="OO7M+.Z#G/$Y#,27AUP%7'S%_\!DF1<=9/F%IB'EE M$8"HS/)BFSTY#Y])]QM7 CY.^ 570CA?)A+!)SRG-LKSR2=%"?^'Y86% OH M)HW'U5@I,]CQ!2]PPYAQR_8N!(W9%7>?E)0%?#N NZF#+V9,N+C5T$@&/G MG-S:)6<3,M7F#Y5/Y,+E#?H1OAU3_%B434E/PI1V>,S'/(NJL"R4.,\F>"9) M%N'ZQ%]#!5,&YTGP+$0;4)G"6N'%A0+/@8?F;#I3DH>-\V3-$RFL'097%:B M'&[)A\IIJIPLWG^"-['ZDW(YRI2-QR^A;QE#%]/[IEF1X#:>YWQ,=ND\JP_S MN5HW2N+6YK>P .BXC??LIA<^HI;N+0&C_.VJR@J=P^&J0<_:GRF)8XG,V MOF2SXN39(M$ Q2Q!;M.FEU(T-V\YCO>\94'+$0^SG%3XY\"H>8Y7P2+8 Z] M&>4\_N^3OR2VYGJQ;<1![#$K##7?TKCGZJ[-/$\S ^_?N@FV":6P J&\A#\N2",H0!OTIB,000H-46:YKFO CS1'3G'XO<._( M9B:<%54NV%,$?&@@4X?QJ0WW0(?L!EP4F0D#/C89 HGD,,WB-B")^OL.5F50S742H-0,%0I0T! MPQO-B@0>D)+L2.$$\NEC;2@DY2C)1:=Y2UVF68EGL%%DE7%>(807+>(H?(! M%UD(@7\$G\&%., S!9H 2KXO'9^=SE\"X0Z)!I,;R16V6O>0XBS+02L]!04UJ$\T37]Z'6>_I:'1O5^]O]\LW2;ZU^]?GSZ_#-G#;5<(OB0J'"#S+]#:I"V0YCWP%+SMPH1,'PXSZ_(Y#B/M>E]_1 M%1QZ3+/V'EZ3"_Z[N=@+.\X1%]W^=$\#^6H6=A967H.T?2^W29^SD8\X8Q MK#Y=9B_I,L? C Y-#.O:KJW>>_WHG@[F\$LJ.LB!KD[K.08.]%AR3O2!Z1U@ MSDF??G07J&#M+,8Z@ J[S:V4;U21D6YJ2:^2M(I^5S%2^ZKW.@WA]/]?* M8B2HZ?P1L9)16P_LX/$UQ4%/RN>2E;+M^DN6LFA^09SD1:G\IV)Y9I>8>2< M+ER]/4O',]$P9#Q6,C)Y98>00^J9DG/E$O_1M;K!U_N/[]I\4N)!36T]G Q=^BXVP&VBPF4NGU(:87]B-EN M)#T>2 K?K3(>]Y+N>"" TGM ;0&HORHO1RP]YX\D,?2,EP<_(O8.=:Y^2.<- M=]U)-X[I#FSKAL'1(YN@T"/N02&N-7#\V\T&Z3SBWL#C?$,D[LJQ=G (]OUM M_J^K"M;6KNHN^0-92UJV#3EN3\';_O]Z!//.0W-,OZ7L>?0.X-;05>-L96 MY[4/G)R1IG9K::?&[R8U-4<'F0-W94'%6Q2-\U&YR]:&FF1+T0ZN(^1I?Z M-$_@+!-TJ%.;]'1^318KOKTR? >1],RJCR'SW"?O$",42T&\&C9IAN[^II_ M58!B+LO14#D%,D#O-!N/9X-FJ;7'?\FK0'L<.D&,Q:P$=?P^%AQS?W^KC'O$4^\%3!_+IE+,Q7CYFR:2HO>=? MAY^' X!)7,":X+$,%G=.0S#DV_!"F0_<:H<>PO)R_!6NSLJ$2?\\=IDO8&,X M[G$,M,3EK;"U&<\!8W_C=&N".P>,$1M':-/J:'3B\0+BN[$ L?$%5TM)# M!C^$8BH)XK!LJU[P!8A@-WK82584"?JK<1I)SJ,D+(>;YX/T_N_NVTV]_[OW M?W?.=O[OWO_]W%ZWO_=^__[OW?MS!#7V9%B1IJ[P/O?>"/P95HN /WIO5! MA^))[/'V"/'6&9A>[P$_,@]X!P^T]X#?R .^K$<]A!?\ \U57EQ'RR$;S!1; M.,0-=XT;>[N$9>D)-YRAM9TC_,WJX^4U _J^<8#3V,JEQ?>CDE_H7C\J^9&. M2NY"Z02%>IJH523B(Q3FD+1:C)+I-%!RO":J HQ<)3G@'P425%&\##XZ@)H M;$P:(]7;N;NT6!W8@0TG1*>.1%U&;'"_U.)3_B\/UBBO&/!2L0FSL**JCBR MZ33+RRH%VN:%&$(O^0L(SB2$UX6)K(DI0/IQ"@[)%M13:>PR7#$DA0C>$DQ MKZ]IC:_' <,3!D0&6R@&.2^BEE85CG/X2/%BO(LY$7!"S$>.O^9942AB413^\[2_[BHY$#([WP82Y/7W>JIV 0=6 M2#08K$J+:V.6/QD#2S=W7/= N4@ HS"0JE1I2,ZAJ!:#\#S[ODW$,''-FZW MD&P1)T6TDU",!.(<\(&@SQC.(0;&%:39(0;QZ/.:P#,&A9\5@'!4!DP/6P M MDH] ! M"2J7[0"Q^5H,0T&P=;S.O:Y$M9FYN+)TCCS^'VG_2A?U.EL%WD!<_9D&QQ/:UWB!UNK_\3@YR/5G[]?M/?#U&\X3 M/A2\?7P1_B?>RJB61QO=OWWWW0YR>$'1D5+U&3!:GL-:T>/[3>L:8[\';N MC=GW];V?L]$'IMV/4N_DV1@/,TG]8(3>P7@;?N4I%=-2!6\T2=D'-O.IE MW\VTW8.A85,;V-JNHV7Z 1OW)?MTXX8YQ?W9W+$A:.QL"#X6L7HCBN)T7"=?5E7.>)NSC&Q MCS9REMWM):Y[&MK!UJ%-WERP5/1"2VG1'-Y;Y3D/"R7]R"K2UYM_E$9)469 MX0P9K&MHNLAAQ[,\^TXY\?"]J?V5$O1)[\TE! EH;2 V$"-HPH'&8UA@A6GU M,AD?D%>5?R+\IYPFZ,BIPJ;8$8[U0;5VW>E>7G+$U^B#QY./J+)2C&0,\ MEZN6H_2[L6H"R(R MW4UE!@M$='T)JJGOJP15U/0H:TO=VBT:X8%BCXND0Y/?IZ$"MA#:=H4K(@2 MM 0K_R)1&L%3>%/(14O'>1E?7[Y[26N$J^&H4Z3.$"ME%MM#7G+1CS"]P'H8N'&^ M4Q9B)=O$DDUHBV)NCB^6'@'BT "!VJ![['"9EP_"'8UPLI44=925/1M7"$3 M.L>J)PGDZ#"TZ<16[OG&?G.9N.DEM753PDY6YVFC\H 6^QK)8HE"U53>VF M13XM\M5O2[[%%O3;K!T?"+<569KRL920?8E.7Z+3E^AT:[%]B4Y?HG.D5QYT M045?HM.7Z'2R1">.M3@\@.CAFR0%ZPO-N$:O?@V6C;A3ZGW?A]%W"8T+D[[ MD05C=MYU%UWZ^L#5_%V34W;<^)UGKBPRF^WKQ[7U6T73R@;WATN(Y5W>S@"/A]5K+V:'M\:L/3/_(V\MM%P\X MIC9=MOD0)]H1 CZJF$!;@WJ(0$#[_>WZAV"F_3-QVX-E"Q7;%/.XUJ3"KT: M'KB3O>P(W0< Z)J@R".%1'O!D,,JV--=[F4SNP^BS%^=O.2GZN"; N#Z'(> MCWF($U;JR@)9HS=)OF.(@$VG@"+2K\_JLSR&9T&1L5$ 8\8P?MRI,B2D(1 M(>O2K*?M<9V&FYQEJ?KKZ>E')6ZBG!, 596WC-0K-N4\_!BSW[C"QD56+YLJ ML !G ( Q:63[&)UJE4# M4E:6>1)4(E(&=U)U')LB=@)RY!6-5ALT%"9K#46E)QU8R(H1;()/X!R**9Q" M+,M:">IK@-ZE(K+KT+89W+5R^JQHG:N,UDOTC%>S$>2(O48WH4P)/(=M,'<= M#)4O<)QQ-AYGEW2X='PYSB@+$RP)Q>J8RCTK'VH=ONN_SZT&T?NNUSRA6X#8O;I0SY:5W3YXVT?!CCD]L0:.);;J=DF?>"V1]EK M4!;,Y-%V<<7M-7[H.T]]]R^;[7J-(J>_.(:J]4[4CN!]?U]08I8?WLGLZF M/?5'T\WDI<-OEGQ\'@02=7V+F#T+P$.;$G.C'BG] )_[T4UNT >D/YI[L>QW MZN:QY9DP'/NL+8G\VM MSL;L([^';_XO%3+VPFYGA5O669J R5%68=4F*=V/U^ZZ'4"ZR.D,9^!9-XR, M[P,HA^%BZ GA^ E!'^@[J\K'0PA'Z;TPW#O**^D(]>[28.SA.F[HQJHRINPZ MK@.G:_QD.$.O[E,T5%JU@?@K'.3Y:#Q3XC$KE79+IPW-C.JV&?.V1(LCR5.: M1W[!TXHKYS3+N:0Q'O2\>LQY%L<%7!?,9(\7[&M#C6(6)IE'\)AQ-L4?!["4 ME<'N8FAW!@]N=7ZAV=YKQYU/V/=D K"OQY8##E^6H\5)X/WNK64V(O:+ MOP7YLQ>K]R71?Y]P$FI#E)8U@-+2@JK227&W@#9GHL_"-GB<78I M6RBU6BH5"3:]P7Y(,7)_T><'L%S3@&RH!],:%@0$@N)D$^P4+Z1(W'#>A)J M^?.3XVM#FD0[(7C&4LLGX(G(S$1CIZ*HJ$5-)!23**Q[R M20 ,6JY+7^@@)GIK[;@:ZC2U%M<4; M65#%B%G90[Z\W!8,OH)EC6$K)2%! M"H>GZ$8M2@4+A;7C??Q[4E#3IP ;LO$"6/B8B61 _)D%R1CQ"38>PMUY-A:B M&:0,-CJ+%\A."@+?X$M<+1H^($6%5%L]:, ML36B<;'1EI##8Y'%&,'J8%NY(/?FNDLX,]I&DB[.X%(RT-CFH"I@5?BL&:RR M?ND,5EY.F60.(%<14GD6)R4Q!B;;M!%XM4I%^B2LP2>CUJCE-QUGS7X+:[2 M90+OIWIANX]^JE<_U>O!9,UBD[VBFL#Z9G7WQ;;J(#5B.?,/F$D$K OE_HAA MUTI0?@&&0)F1U#+@]BIE%7 "TF!3,O?IAGGS0&QORJ5 $EHUH]Z7X;A"%9^/ M"WX)MH#4I9-"^6?%P[:4+7+_;N%GL_+?/\H^QN=T-@/,BE^^O$=]"]P_IN=/OM1G<# MM.SPIM?TE7L,VWYDL]#0;TX:+EBV%TDD',)/C&D^JG2:A$]]S_?74>K(PR. M'FH?+W/@>'WKN1YE#P=E=7?@>KN6ZO5XV^/M0[-:0Q]8SO'RVEVR28ZC9^(3 M_0:5,G=YG >33'RS.IKNZUVGR4R?)/0 I;NK8]]O=%#/=R+K8UT%V] M+S#IXMD\T@,?ISN2=>9AKW?2@'(ZD/V\,EPZ^WE\^'E@5M#G1K5S'0 M-]B[EZ-Q![Y]PYJ#_FCN6!)8 T^W]M_\H#^6VQV+>U'4S3Z^IO,EY4>9)2.G/\/N#%)@?8:3S^"KN M,6[@[^(#/9YJ^YX(>B0"HQ_ZR:N/2'TA'#XA/#$QURNW>>-' $1'>C3C?, M1^6IV]AYY?XK'^DYS[$ .0FWJ(7\L";A>]XUX%Z :BR$[61.C9+E"Q&\=8GI M8&Y,L=(,>J9=<&5-<>1VTETA787,:>-Y>A?C.Z M.^_A0Z>UW7-W:A>D4PL'L]7 (5U!K5N_Q!@J7[ VM^DG@9UQZ@X!Z-MNH6+ M\4TWZ%"4E"-XYD]&&VCM)D5+"#601<2T+X"U,32:VYIU)M2_!+@OD,R4S9!K M" 3U!7_OBY@E (QSL_^8A '9[[1V8'Y>669[@@V'K)6#E>-;J MH 0+=EKK76TG1 A$IP@PV]!/J$LDM2,;?KLF@? AV/ '8/KDAFIFCTIRE8# M&\#RI;Y7P@,4\0.6+>[UUI!L6@9= MMU7;:QU@O=6%WDX35E8YMNJY8N/K>.L(RAM@4@.D1N.S+3-VNRO1Z"F3;= MOY +BJ-?GXHF>H-10Q&A#MR@T]>=;&]'P#^DW7!=NI]@N.::AH?;\EM6++)< MKT5&U[Y]5XZ[F0W=_O$&H=0ZU;EI0[.(:_AD_IWG82(X2"8%//40HE]?(F#2 MV?\IX-2S\$]Y!74:ZU0/NHT(O:['XLF+EUE_@9DTF=9>3"]$S^DL-P+T;/. MIK/5J&\9-A2$T_W)=NT6\K+S\QP[)U)[0D"M799FZ"CX>M_55I@^$S3Q- M-H&$E4<'VXK3Q )_NLOGF%H/]-/]+?^\U,A3\75U-A.W%Z!OAY62$E9 %"2 MK=%:UT:HY8/XX@R[R9U78Y93'U2,,+;D^YKUELTSJ!L\-U2)J4JQIE8R!> MH.%I5DN=,BEBY"GBHA!N9V@M4VM:>)YH<"#I4/Y!ZB MIG#:74.!8(#F8#8I6)Z& 8CC/!K?!#T_M0;K;Y'#%0["83'B4"PNCWX61# MD^59JUQ"CM:0SBIB42"?QFG".-FV&@1]I8#+F$+ M1>QF)<,+)V?9P3E!O9=4LJNL6>5_V%IA>@IO1EBDQ=9"!HO( 6V719R%+34 M$I%TW"8 ,AX%^$1_X6P2 +8WN%EG"%)OQ262%,RAACJ)3WDPUQ"K>!\UUUQ8 MC%RBL$_A)?!CP.6#ALII&-(SL>S@1"7Y$\AY,051)!D!#%;<,3!X+L6J] M4@=LD+RB1K1F4<3^LZ1+UJ->?K.D7WGR/MF:\+AR:5S5O)L9&<@6R_EK5( MF8'A!^)+Y#.KKZJFPN5!SZ@5G("-J0&TY!\MA@$:1 4+28AO#,BMO887'HJ\ M> -,=Y)1UTOL!L\$DRRX4 X476/#VEG^LMU7\TW35_-STU>S=AN31:-KZC^Z M)#5W-$"^U :^ AHL $**&C4K_D #1&G98B0Y" W(JK 8.A>"M-5Q8[,0 2V MUK)/I,U06PRH18PO2#%:A$D=,BEFLE$KDHV0@8 SHV0Y)3^60ACY037HKP4 M3W@CGW#RE-I9@WX'R%<%WR1UUVKNDA(\3D!;%0\?S,,=^/"5);8:9F.;Z:)D MHO7\W()>MQQ4+G]/0&(WH"/P-[2C>.G9B;;3BT@)!%?4>+GJZ=]ZK^"63= M'-=,M6O;>';ANDU<$2+Z!RT409H)P.SM74C8Q154"1@ V"$2G1ME\A&VF>< MY&!BC!.>UDW5J3IE\R/0^M7=G\&F =41[-H/K2,7IT:&;6W0DF+TK2:D%6@ M%,#>J#5QB)[ IIL[&7'5G!#&U,5<%- DF= ]49'YQZW.33@#Q8 ]=&-8$@" MRR$13]%4E""+,]%%V00Y+ 4%#5DG-3^)!J]D(8SBC>2 8O?$D.B\&>:35 M MYQ'.'FQ"A7AC4>!W=D!:A@NC?G\155884K">Q9>AF$'V\^ MF 5MIHRZ^U\WY>)2]IY&5^&X#B2Z)UOG2EP[TB/-%CARK7$) MTH##N)JUK '$=C-F/./D>NC=$:AV'2B#"GO.PK("8O@P]]>)\3)S CT0G>0+ MM5>?AUQ2GH$')%(7>;K-&[OECZJ1$E!3J6HUK;G&N8:P;DE&MB'@P8?XEC] M19+'YQ$')G6:YPBO0SI]4.^B)"EB%! >C(W9(DAA@.?D-YH(0W+\8QN'9#' M)@.@U#RC("P%E"07>.0H+1A)%^'GX?9V3T(G#;WA=5\(2,15DWSV1WO3/ MKU_6OG0EK\9KLURV1#5O"U1[VE6)R_>@A$'NHO@U>+??U8@<4C1OA"3D."+ M"DG?!D&Z)+Y^$AB+2#)2Z'="'KZ MB-'+"'&B+?G.T-!Z3U$!B[](BCJKEQ1; MXOR8-H-&I MX0&.2J3XDWAV-#_BL'W$T^:(-P\($\8+>0 D'Y_VD""IRV/@&?@B13UD?"G M=)-N1_+3''!M0 ^4"4<+=N%-(DC86CW91$, 5(T!FWPB.,T,1'WX2DMF'YK M,[4&8^":@+=X7!T(HD='U].(W$^902K"_<4$;6^"19< PL8%9"R:M8( )" MGI8-ECIFA=,P($#Q2&8SXN.YP!3Y2@K8U:J"L.:2^7!0:[!^"^$N;GX.Z M89NP-YVZM-R$AQG%V=S)--AX4Y? VAZ/2%X24&FJ5,Y-DBY<^;8&4&UJG2T'8?/W]W$S/! T6@EU@W!RNHK@M^AAQW!.='4XNA4,344;TF5'P M;@Z?.3$-@?KJA1&ZG> &1(J"U-Q"8E.$8 1_!6LMN;,R)RF8J1LA@':)' ME"R%M:$3,4O)3\,6$7C80B!Y5Q(537)E8R\DP"/>GY=L]4(S;+-$/T^LC0 M^[)S.:\- &U[UGBY62?Z3AZ75P?^VIH0NGBW4>&W=YJ4J;]%! MB.YAJ7Z(Z8ES$(M!9( \!Z'U IVT>C7\P#K))^V%1DX,SW.^;W?MK7X M'S&7[8HL.^(3^-9:FT>"),Q!RD???C%'G!EP^C^1.979ZO6#W9;9SY@\>=&: M=;22;"#.62=].D%QY=><)]\]>/IIR_V[>D[!@_?_CR]]>?E+=G;SY\>G_Z MY>V'LQL;ZFZW'(?2M<7K/)WH%Z-A=U276'8KB^(6\+OJHL<+_5H@!G5B M@$KH^Q>@8V55 7(>=SF=[Q+4NC%+)A05IIJ1ML-\G-2?:[LH9I2MR9_(P2& M+Y.M@?/7Z8I#Y=W\[@1E-4HV\DA6J8Q'+F6D76(.7(K>RRE&+D!))ZM77ES. M9%2QI%I%D692<F]POM.8^-JK]PUBE%K=**XOEP,::+9GG1UMJ?!)4(.9/A M0CK_4WK'1<(O2?L2X,(2PH/1:0PQ3S+)DH%C^$@T5#3SEI1QSJA%/9=Q^:E M9#E5 .8)QC '+1U83FCNY@G!%;CDK)I4=>K9=E\WV)M(@FVE4"\(I!)H=XP MX77^U%Q6A JS_ZH1T-O1/$B.;A+]Z0+5H^L5 V2(&@="\-NX8,M,S#;'W4G$ M7_3 ?@2%4'D[4"1,:N],&QRU&V8E1>G& 21=,P_%8VLL8,G7%(SOI!!Y0)]I M^CM0R6M1\[04(/DJ6$4)(>"5&=9RF]!ZTXG:7TQ-O-I!T4RE?,9Y:U(?/# M>QP'Y7?RH!;C(^_A(J"RF -QM6)F!W- 92N!Z>9'I7E;UP5!_(E_YV M[KL]F$-:2T6/S_-@[L/SH.OV?;@>8).A"N#"])[G(OHQ^[GK_HB%1?/OHR1( MRI^/SDEQU1'=/X]R%GC4:P'T[LF/#?'U__W[VU_>?E'>GKUZ_;_UFD7OA8;+ M4+,X6,:830O^O/X#8ZO3,9L]3U)Z+-U4$XAD34A?2VW):+_BYSGI#35!?K)A ML'RS_'E(/RTU2ZMO'=J^O?%G;:C?\#?;W/S2J^Z\:K&V.=1-_U 6.[1<[T#6 MZ@QMS3B0M=I#7W4->WPU?9[7M)HY$2^!Y Y;Q%O#8:I-'#ZQ7P'9Z8&T)K-N)O6O&@5RQ>^&F6+$BLNF]=C8&0T._ M&Y&_Y8&+#5\5H-^O::]UT^-P];DQV%4EM/GSYY=7EX.87'#\^SB6?+]_T59 M^-_/3O-PA)F!SWATSO)G$2O9,]VQ;%TWG\%BY9^&@2LWG6?I19BKF+&D69H^ M')5 <:\GTW$VHQ#JZ7G.96ZFB'2'+K3:9Z,E29[+A!]Z@)>7F+\["R[R%YB M2/?KYU/EW;N7]..7+(J4=UEZ7EQF>3GZRQK?QUTC73?HS%/_<6]DUHT="VQQ M!;8\LKW?'5<]N%CZKWP.1CA,Q<9IJGS[]]-70J.EPC3&-/]95[-QR93?S5] M^U.=<_^5R@GF]4'6$]8J1J%/L@/.#J5"=RU>^DL[RTO^=YTSX6!W YSQ_F1F MSQGWR!F_$VLTKF6-J]4K/6L\[$L[RTR.C#4:0_W_]KSQ8'FCL6>U,;@)-Q1M M/G2/>G.\'"J8XN#^K)NVUO/)GD\>"Y\T>CYYP'QRSSIDSR\OSV_I9MB(\20Z^RL,@3W7?W^T]/R%?<_2;#(#V5[RE!I??0Y'?,)Z N\)_%@(_.7INY[ YP3^DHW# M2K1P4MXEZ9_8([LG]Y[@(_>.GUX^6T.?T_5','NBU]Y[,CY',K4=%XB^I0>M'G.)$ M+769Z!F,%5D%D J3T2/%UE5T>8(HG4VC:(2S<7JDD!@E4][-M"S@6?4B>+% M7?Q18B$NHJ4^MQYZT_Z7Y M@^U8/$ZGUDX$I11#:&-H4X$C5D8LNEG.)^-D!0XT09[28]GLK4V]E+' M(E=QOZZI_Z3FH]B$J>F4[O),6\-L-ABH!!-I98/$3, DJ6Z]/D,0#&6$U8' MKX$C$A-L9477.]G7<^WXCGGF@+F8.9#M/.ECH%R..+7"FK (VS+B0/3YW/?% MT=H PT5X#59FJN-VSGD7'C,!\GN!NY=92XD\-^Q>-A\VUC=.O^\5/.A<]CO%V?7MO3Z__?7L],O73Z\_;Z3J MCHTE_5CE!8ZUJR?BR.DSDWJ9-&JY9[M#6]M_#S!C:WLWNO&ZQ^G9ML;;T']R;<777/3^N9Q^BZ<>2 M:GL3G\OQP,S8"F9"S=N3=^K>\6"]E8U^F>>RL87AW7.O@H[ X%GQ3#DM1F,^ M W4@C[(+]O#4T-660MOVOE@$)QH?&V:6T6]/ULVV(^,IQ)D9I;#'Y]?C3TMB MNO[]Z=9NHPTV4><,I@>VC>S-MM&S((MF\+]1.1F_^/]02P,$% @ 73B< M5(=X.%=X# G6\ !$ !N=F-R+3(P,C(P,S,Q+GAS9.U=;7/:N!;^WE^A MRY?MSJR##>1UFNZ0A3,$.!BI]U[O^P(6X"FQF(E.PG[Z^^1C,$$$#:0EKO0 M:0NV=5Z?HZ,CV1:??G\=^NB9<$%9<%VP3LP"(H'+/!KTKPM/SKUQ4?C]\X$=]1C[,A^L;X=_J,#>.S(KIE MHS&G_4&(2F:I]/8JOW)/>Q>GY0O/N"A?8-R?N$:70\3X\P\N^R6<>F\=.G] MUK_JF3W+.BU=&!>7Q#(JI%0Q+B]+)>.BY'D]L^Q>FN53Q?157 EW0(88@6&! MN'H5UX5!&(ZNBL67EY>3E_()X_UBR32MXA^/#5LU+4S:^C3X/M?ZMMI+7D137<:2!"'+A3[E[(C7 \ M(F(Y#5PNRLM2CFF8EE&:D^2%4[TF--B?+& :Y"Z'&+>)V$3#XD889=D\,3G#PA)@.APQ'B(@@72'A9= MI:K@H22SI&'2A3&D#>;B4,6I;"\2VQ:HBL0/A3PR9CQ.7H57&;7(!)&'^/1 M!EJD6--)F?R:Y.6.OR\K+XD-PN1Y+8TJU-^17PRKE$[LJ.+/+AB,CH=N% M#K/NET^'A&Y+'99VN%41L8Y2'8N,:BSOP!F=D!!(ZT_S"!3$/>FSYZ++HB#D M8Q7.:[K ,I+D0 7_)O(]0A6CORH9I<\(Y%69R;C2B08_% M)^"4#)NK)'8ZI)N" M'&:,)(?^Z>/N"6B2-%D0,-\!Y.4BD!"_,;,DH94Q>%T0 (-/8M_LL^$C&$UR M&@XD @8P!?3_O?TN]O/:#R1NY/\SS/=(+Z_Y0$(#NH'UDMJ!ZXAZUX5;!M5Q M ,)?9,P:0,IJD_%MVW?<(D$\5K!9_7] M;61/B"=--(1O0B(SW;POEY)-3B;.T[FTU;1;C?I=U:G=W50;U>9MS?Y2JSEV M9C>O9!QO:5<7P)_V^ XDO@^Q0I->&8V1$1QVYC#E8-2$A!SZWAF>>FQTKV MX^Q8H8]SO'\]4.QL!_Y_K#4=NW7?:MLK^T.HY3ZSS6FU]KMJ.R4^9\F9VCOBN6+;4B, >E M9/Q;G"13_!6H2H(A1:"4C".42QSOXZ?O6_FYJN#M6Q6RHL]-#>LZ&,LZ]A5 ME^%@1\,AYF/6N\5B@ -/?M3^BN@S]L%\<4="3/UWP#^C7%U\5,S3RB[B PJN M6!G$>DCJ@4"?^$M(_1QHM,QCK1X5H>,A_1OXMTR$58#KT-LY M7>K[@@;V )HYA _KP3,1X?#'!-L.E--'Y%EE!P/1?$1.=492:01:HT1MI/26 MC1Q#J8YH@)3R2&J/4NH?PU<;(57/4TQ7P]ZC ^5XN\6CUII^@ [KZCU]T# M;8"2NEPD%$B'=-T6IUZ+7/AFB;15Z87UB)>>K#='.^HG14%\U7I87'^N3U-^\NVTUG7KS 8X:]>I- MO5%W+RT&0G^+ 4XJJ&C1E?E&)\1"SMYKS507:.^@XFYSV;X7>@?0^2 M3\>IWT!1U')J.9;RY\CT?:IL+<-DR@%)%H?K\YQK2$N)M4.^52DOJ8K?^/\0 MQ_TWOMS)+"<'2WTB.ZVHN]=ZT(XSE=5P-BB&63\-QSCPY$I5.+YEPQ$+Y'R? M]<(!N67!LWPX$\^R42>X%E1^+T87!647>QUX7!5+I:G8OEHYD"!O+UC=KKB 3R\5E?OO(5LIU'2'XY^M XKZC[X>M"8R(63>2B MB6 4LF-(3$-"/?/1:JO[HXUJ4Q:A-;O=SHKTG)]771A+:9XQ0G%K)#BI4I6 MR>T(1[Y22<]$7S)=EA>G@1IH#K%Z6N'>7511F[#6YLJ263$O\^!Y+S6(RW? M_8BG[">'3+W>VLDQ;5]O".TU[+7(VY5+#,?XHE 62PID2B6B:30(_#+D.G8 M3P(SC9\[!KT):SU@$-%M'"[.SO@4IRJG:7 (]C+$+G'E'_%?D2J0D1#U37$ MDQ+FCR%!QI..&PQGJB^8>Z(F0CJ4I>:3H$'_QL?N=V &(L6D+W/JPH5'YA%_ MU]'S(W35AV.Y8BW<9\D>CE)_I Q 0N0- %)&Q 8D4SSE!DHM@--#4'$J1, M,2:V3!-:; U2YAR#?5D -5G@8C&P!Y@3Y6 YF8;YD])[,I42TSF0HVZLW[5NKY"E9$.)1K%LU!VC1/HQA2X#JT.> M21 10.F!L#['HP%U.Z3_#F&Q7I(^+JRE3T!O%F+FHB6X3 3CF+I__2X^%2< MWZQ)6:!20BD$3# M2!X]C.>-6GCL3RE#(G7 NH!6KVDQM<$"X,\!!O(EFDR] MS %)// .;FRX,1P[["V>EB8-I9/>R+J;=^OF)YX(FO=;$O[^O#!=E84;0 MXC-#!D4\%.L9(),O>K4Q]>XB3H-^6^ESSWAUXL=5X;>6;.?A&)\!]B O@UV0 MA:NU5\ALY2.8A\Z5X>XA#ZK0A)BKR^3[@)M];:R7EAMZ.I4WWP89XM&$1SS(H MI9KMC>XV?JK5/F@.:54]F #]30U,:HAZ@J)+R)N8>GNRT>Z#E>\Y-K\9 MCZ>#=3-ZZ[L?5BZL4RE'1LXS;DIU108TE,)55VUX+, TJ4J#@)W)$ZA495IH M =I-!Y+;B,O=DU8Z=$NNFX]2+B?>^PU3#Q 0 -V="O55/?%-HWWH"B#,B#IO#!GP"+Y#- ][86$J&>_](.:GF8O>I;G-RTB\#W:J'4&G&19IIAKMP_:WU/BJSXVDN>;1/8>=\T0 MIJ79TVF4\GXKR()1JM4^(-0AU<%3!=8M'-,3R1RW4 M>+FR%%O1^&>OLD>5!<""O;TJ"J,5)/=(O:^$N%6J%]$W_FZP7\!X!W;AF M%>M=9&VQ)/O.T3&Y5]3JI:%7]Y!7QHB.9#?E^P!:&%9BH99 MJWU(5BLB4'E;_!PWU+8>R6,A:4%=4LO_IFCSQ_^!U!+ P04 " !=.)Q4 M1@LCF+P5 ?P@ %0 &YV8W(M,C R,C S,S%?8V%L+GAM;-U=6W,;-[)^ MSZ_0\;X>Q+A?4IMLR;:3!E4M3,A^YO&MV-1N.?__I\.-OZ"%T_70?S][]VKKQ2(>'\)\V'K>@1\@;7V:#@=;?R;H_]KW>)P MZ\]%]]?THR?DE_&/GB^.3KKIAX-ABU/.+_^V^RFJ;)6PB5AA/9'&1A2!ZI M=D%X;KA+__OAITPS8XI;8ATP(H%+XASGQ/4,A714:'&B\ZF\[]^B_!]["% M@YOWX]N?GQP,P]%/3Y]^^O3IQ\^AF_VXZ#X\Y92IV???K+\^N =YJ_S\_=WNA5O.%Q]1 MHQW\&!>'3\L7GC[?>_-^[]7NB^W]G1?/ME]MOWF^\_ZWG9W]]PA_O-QP<@0_ M/^FGAT7+&#J M0(7/ \P3G(KD[:S1;SPI5E1R([^\N9#S ;/YT<]^2#]T>3[;Z'H7]^W'7( M_XD6+CCI,I$")$6>RA2%\#M3PZ$9.Y)TRE![',NHP^SZ,BEQ>'17V5.8 M#?W9)T60C%"VU.<_KH5QL;5Q_3<]P?;\U1^[/SG&)_,&5ZTWQZ>^ZX[01OP MAY\=PT1P'B!8B\-,0&0D5C(F1@.4J20E4NNR5CO!>^B#,Z1:;N+6XLN08>& M[%X33(=X/#L[XO!J\618=%:,Z>< MP!&M2YK?8);V%Z_]<-Q-AY/W$,O/7P9MH'(DC.,643VG1\L1;ML^8Z6QNY M\Z;-HW$'L/L0A7]W1FIC6H4>0?]T$TC.@B%P&=0)$V14ZN($-81J9(BWN-+ MYD)[G%VCSJ$),:Z%@<1T("%&;R!X0R1(D"- D,8RVBWAG6\S?]Z"ZCZ4D-\=):KI86UF% =Q\A5&CQ/< MVPZ._#3M?#Z">0_]Q"K+@J:) TXHRGCB9-:$\HTR(H:.XR^N\^S;W4;3Z M;A1=6:S5#,#N_",.:=&=(-\F46OIM>=$RBSQA5%B&9/$"YUIQ \C;_/ GT=Q M'[WK[T;O:\NYFJ;?#XOXU\%BA@+LB[LZG$RX5YESJ8F)1#I!",!G0TBI'$L M@8\NRB;ZOHIE[2AI<7BXF(_7/76['3X_S&@@DLTFLX$$ISU)%EN,SI;UH;8 M)B"ZA&238I\U.7 E %I'Z/5\F)2F9>Q^]A;-Z>[\N3^:#GXV40+OEKS"<$OS M$GU1$I+-)!F<-1WDQ+)MX[Y<#VB38IO1BA@IH^[?%A$2VDO>$ .F3I40<' M.,E./\+N/"X.X=6B[]$0[^5]_WFBLLZ2!XWSKA5$:AN)TRX2HY1TX"P-M$W( M\XU -RD8JLV?ABJK&# /?CJ'M..[^73^H3\'^@7D:9P.$^MP'M?18"!/D>\8 MNJ'WYAD!D85Q"JS4JE'T?!>V38J;K.GLFJ$>;5U(?I;,STH+M_S:"CLR X M!G:61AQT5IY8:R6!@+^)3@>A:1.ZW(6LXL@G-D70$#,&,RFB9O%_ 3@0K;EG M+J7,&SEBYT!LD@]6E167'X55!5^-\\4EG Z'8R)\GIXOY@,^D3"/!9"6(G#E M/8EESP&0T Y:Y+!R1@MNBAF4M^ ZA-/> <3%% MVKH4.0X29P&3T5"'-I[871;P<9VMIKQ84PTM)LNS? N #TQZ2TQ&=T R-&!6 M.X7$X$:H:."-G2XBJ56GOVM/RGIO_W.)S@;9DB2:QH9R2FCG=;4$V<\)TES MPSDU$1JGV:\!M:$3YBK,N"G5OJXJZF3:QW#G$J17X'NX^-#C-[IC^)(K_B(' M[;GP!HCEH% .V1#/:"9>>"89"]2E2]2Y(1._%HP-G4/7([F-,6$\8 M),ZXLX3E6,=".@$2DJHTX:'P#5/HHU)&>]?9Q1?TNXAQ\BD(,86/]:2#P8 MA8,)2OE(O52-\G@WE_%L0@G+-VGYBA5<6<25N?IF,8]+%-1J6/4Q.GLT?J& M0+R30)G@4DM(VX?!E))MDTKI>D5!MU.W"^AH6AX)1_\428?_"YD9 EFS MK(0AK<)!V]7][>/[&VW.()N.'D[\_,!)X3B1A^52NL]9G(O TT$C3YI;:' M:A(LJC":'&WVD-ND_ZX#=7F&;,5>7&9ZM544<>[>SF%V04,YX:9K4@27"+> M4@S:T!\@(8$GH&P2/LBHLKN7[W;+33;/DVIYZI2K6;:]I!SON131N_P71'F M7OZ]AW'($V&MHY:B>4VRY.&2)]YK072"0%-V@NLVI;FWPMJD!$=5$U!/&?7X M,082EP=IA)$LF$@ DL I/4@2/ XW^M >=CHY+M:^%LTOI073ZL+?P6.:X) M>"HTA8"SCP>T-C!B6U7SMZSOK"+Q%DP^]U!I)2D+P(DQ!H.4")%8)RR) M(6DKC=&9-T_8;J;STT#_\J],052UHD9(8B+C!I!">!JTRDYS93Q9QD;8Z M>U!@A3$NYA_VH3M\ >&\D\D3I2X )?C@^67YB>2!T$Q]IL9:81LM:5^+9T,- MW8JLN$+Y]750)YC;.3R:+4X WL%86G)QI&?6.,MDK,"A66KPX7;$.?+8RZL M\08=_>,ZNYSMPVU<&LJOHVP&P5[9\!.S@W:,BD8SXXX6@:MK24N^$ RDE1( MH=&7U0\0\%T#;9."OOJ6HJYFZD9_UX]62LZ\29'@/(UQC4QED1WY@^)(8G3 M($6;I=^;,6U2'-B (G5T4;%<:CYT/@Y_3H>#Y\?]L#C\"N\\<8,41J''AZ# MA!Y>J?"(7I/HH\U")J"V36'I/0%NTF:M^JQIH:5+%/KGT\N2>X7O:S2(>+^/ MKZ]WWNR_WWNY]W;GW?;^+O[V(HQO[Q1QPU5KMXRX#_AO2-^[19]_[9;Y.DP M$<[Q(!R0J 22!1T)XCB^Y138ED -(IBSH%8OUS](\R/2[R94YM)A'/&;(2 M-4J\LNK3T)B0(7).)U&122G MBE@63&6I^AI=%FU29'?"FN3K-EZW+BF+T4E;=0K$H<9_NH#(GKMN[_@W% G MB3F?2R.=8(3$X!\U&:1VQ&M% X()PK:Q>C=CVJ1\3%UJ5-)#-5[\"G,?.KWM()SPGRTT&$H 6.V9PDQL=E$I1J8XL[)-'T-F+4?@W-N3@!O M32GJ RT!!9S0+\&H%E%$8$PQ(65ZV)AE0^;&%75_A> KRKJA(YB\3TY)17(H M2OE#0D6HQ!&C;39:N54FW6H.QS!1W;^:VM^/<%7T_\;&,X-R&7O# VE29A$ M"^U8V=7 !%"<)-H8Q1L?0%&.NW'SJ[TDM4X^FNQ&.4]%+DBWG_#/B6_8 MV/>?H=_YC#,+4FHZ]]W)+A)AS/5#-UB]%%VYP-TT(]==A1H?"J-%Y%(Z0/Q M$<-SH\'8A-%?EKF)A!H.:I,,[.I\O-H<:3-84+&KUA+HTF(\0^=H3$7HB"$3 M"X1)0"%ED4H"01%32NZ33S9-@_M#8 VRFS7YM-ZXJ_,A3;D%LAAI:0ECI;6 MW7:V6F()%HN=0"(5+=IX/5@)JZ.SY]U"DP$1EAIVB8MI2@G- +2>ID-LK1 MQH[235/FXYKP3>'FC1[7BCJL^/">CF9,B84ON3":!+.&&2C0?\/'/I_(08, M!QPUS-.D&F7S469\4SE5096/LF;[?._UVW<[O^V\>;_[Q\[N&WR[\VKO M?=4%W)MNT7(U]U[#JK2T>TT[L2^MQ,!'@R&A) P#>@SEHB'.44^TY8EG&P.T M:IQ_,ZBZD:(.209O%3XEP1&)D2OQ);5G?6#9Q](LK4UBZ)9(\7&GO5I\N&QB M5I=[W6S&]KGO42K._VPK)Z,)_N=G_<^CCJ8I_'=4B/I_X[[8;FW[E0J5G&E MLTJ$L]AGF6%)A@",9DF<%ZQ$!LE39N,9Y,6:EJ1<0.8\""L?EL^&(&/WWJ[ MZ(<.AFD'!?8R\BO;@?MK!A-+59B%3+00I><^2MHQ7_K5HB/!0N(BMMFPTFA MW[B\U-81? QB/Q09'L<3W'[_V\M7>W_6]?V^7+2IMW<]]$K^73DKP?<';[O% MQRE>[=G)[SVDW7GIN=Z7'(;3=O'T\U75$4JV>C?"U/0%')P!SA&@)5/.AH MVF0"[H]Q[784_F1L\[>_V([_.4;NW]@486(E#=XAT0%X!WMR\D2 =!/D9%: M@RG;5+D]\?XC7YC\Q1E"Z)=Z6+11H/5IF.$$P'2&. O3S7"(8_G69Q\Z3#I M9[-^+]]T]-%$I0A6)TH26G\,OGTF!=RQ96T5_- M1?GKI/ E@7U."IGJR$4)FLKV?.F2)@'P+75>6FX"Q-!FL>;^&"NL=75E[]T+ M./V)-REN^-2IF[/T)#N.$9U1C#B)9D$'3Z4R-3P2 R[KD_F MXR^_;P2[5M!=-6]@,.XM0O,V';AXMNF/YW?#MQTK#H$B)PI7.4SI%XCG.: MTQY2!K"V43?J6T!M4CGQ _&GEHKJ]K7?CT%3R;MW[@9A203$-9ZQ+?:6_]I$^/[MRZ4 ) M$9;1/=>2^PY$=25PE471,6J:OAW:1=X(\VG557;$,2GIU62"EY+RE,A A M5.DP3(%8BW&Z$BFHD&5I9OY 7#L'ZQM/ _V;NDBKZJG>)'=NFMW+I7[FQ;0? M>?ZV@\/I\>$$#--9<#HVY4S2'#N#0)1IJQ"S"ST6U2R7="NP^%S-_+M55 M5]M9\))I/%NZ^]K,YT+K/8B/>%4<)F,1,:BJU_]=%YPG19&C[4HB"[I5$YL#&-:%>-3;FR)6:6DP61EVDQTWP#R7C1Z M[7YVCQJI<1Z'3,.? ?/T :F4B(%B&Y,C5%G58Z4$V:<(E(Q(($I201.HBPH M'WAL4P1\/9Y[<>>1E]!K4Z>"9EHO6[ZI36KD)D3?P[IC;=)4T4Z3"KJ1LGM'X]:XG<_0 MQ2D8&+!&DCS@.&8O2K4B"(DI.<@F9:)=:JQ_R=T+Z#1<>6%F=]==5K XE# M+_].>A'/X,QWNV';AH'=#+P%]OS=/&#<]]\"]UTD:Y&SG%VG,9>)_' SS_ M.S_ 3LX0APES6M&4(@%=G!]O&+%"HVD=N[^)[QMXT,^[#@?L"1,2.1-U)88 M5PYB9"QC'%I\2B.!FQRN#>J).R1]^UM+M^OR3>T($'K ."ZZDV,4I7&4= MPUF2VT""XXA/ J'9=&J\&75+1./O)_ONR?INB1XC"B5RE3Q+!9FY+N]V= M]R]@\--9?_&V]]O2>LU5:NQAO0MZYW_]!KIVDW]K!^W5Y?.XMW'4KP$VD5/%6&\ M=-LQ2A,+A88"L1 0ETNAI)8\42\$IVUR[O< MTD!1WVR5%)?;:\+(W% M#R#]NEBDR\ \)+ N(Z;2DEEI1YS%D.5X!"TI%JW2:7< ]PF>?[UV5)):U; M:ORQ\VY_]]FKG3=[^SM?#N_RIWOIAY.R)+N8%R]ID8<#>+[ T77#-,S@S6 M?@TOI=:M[7GJ"^&2O[0A469F'VR )ZDXB]+YH#XK,8&!XE#\LZV.D;XQF6R M57:3A6%WCL[X\;C_Q'?=28E7#TMAV@0XBY;A/$NI+WT'#<='+U$2J;,ZBN0 MMUD4O W5)OE _/AZHZQ2FJHN,TP0]=!.LUA0#EDJA_-<71,46T( ,-1&AI( MX):1D%G$X,P$L&T./+H!T$:M$U?DP_K2?\C):HESV;!T>2#RL&@Z2WW[/1M, M3VL.O%J4B)%CL12=&ZRDL8:'K17K8X6N F[M:> M+VG5\;&8&.&T8,QC<.@%.HA,D* Q3 3FF)=1@31MO.K;4&W2++4N.V[?N;.& M-II:J&>^GT9T&M-T=HS/Y+P<"%:JV>+OC^"[JR5^XNOY;;+ M%D+;75<2Z6,-V(0IRYTT@H@8$Y'.E#R&D"2PX+U.+";:L#7(6M@WR?RU9.BU MFWP>3NO5O/T;9'1%./5F62A+.-1D"S1J95"4V(5OF3/ P7NM+-M%K_">8F MY3\?DH/M='G/^7KY>7D)R/)??OA_4$L#!!0 ( %TXG%3<0&UL[7U9=ULYDN9[_0J/^W6BC'VI M4UE]E+:_] M$/$!B 41^.>_?SH]>?01)]/A>/3+8_YW]O@1CM(X#T?O?GG\]O@YN,?__J^_ M_>V?_PO@OWY]\^+1LW$Z.\71[-'3"889YD=_#6?O'_UGQNF?C\ID?/KH/\>3 M/X_]D_MSP-,!Q-9V&4OKZ 7I]G7_[AMVCTD_,_ MTD>GPW],Y__^Q3B%V5P]=P[AT8V?J#_!Q<>@_@JX ,GFF:'K;X\>G4LN M3-)D?()OL#Q:?/OVS<%5I,/1[$D>GCY9?.9).#DAQ/,GS#Y_P%\>3X>G'T[P MXG?O)UAN1'\QY I5SC_5I_V9&U,[PG())U%!/HMCBK!>\1XW=/7Q_SE69"Q MA+.368^(KSZ[5[SCTS#L4\!7'MT#VOF#X!1/(T[ZA/K=<[_!>0'R,L+ZR-'X M(RVE$_Q[&I\^F<-[>OCJZ/#%P;.]X_UG1\?T]>7^J^.CP^=/?]][]=O^T<&K MH]_WWNS_?OCBV?Z;H_W_\_;@^/_>/8C1QS2!NO0R>3[9_VV5UWPS)B+/<#2L MZ]$+^G'QKHJ_]>CPTPQ'&?/C1\/\R^.A" 6C19TD8TJ9X&.@;VP4)3(GA!NL M\L(ZS(N!GHS3=^\_J!?"A\'1C';$NCF29/" OIT. MBN464Y9@G+:@DLD0C#5@T?B4D@@ALNLFUZPN(1IG/-N\0KBG^!/\&0VO?A- MU2T'QA=+^;_=C.58Y('75D9M-0A.V[N27M#.KA.@9EP;D4)2UTRX'H;>$>CW"TRUBGKER6R\.<6$/^^4Q6Y='1^_#!>'9[-J M%%4["TV5-^Y3\E>IP->F MPI6A#K3WL3H0-!#DI@-?D]0D$1LTVJV%P:+9B7L3QP,JPG^ZML$.NR82__ M]]ET5M?%Z?%X+^>YL,/)ZS#,!Z.GX<-P%D[F%XN3'XZ/OU !N+<,WJ#-(#I M<(9'./DX3/@:)\-Q?H-I_.Y<97^$DS,<<)8,\UE#YEZ2$ZD4.!4T<%M"T-$K MGTP3;K4>V<-FZD[QXBKOY:J\KZ;Y^30\F$[/,#\[F]":?([Q?F>__'P0T4Z MW?]$_N:0!K@WHA%,9Y-AFF&>?VOBI@D77 X(YM[.HB:)9N%!8S61/)EEW0YE7V:E:L',^;58=3\Z>!^L5/+8:)>A1<4 M"V 99LW1<>G7(NIJ=_ZN"Y.]ECJW<3>^@_&P6;&ZQ^JW_4?V;)DI'G#!109R+/PQD TR $YDD^A M>+27#?'-1+9Z"=7H2.(V+@(R[DC:.H!S40&).H9@0E0L;B54LT;D_CC0=C20 MC!M2DZ!!)?JB:06)#BV@<"ASMN0AMIFYW^/H<>I^DZ!M'H]>0YC7Q1@?G:?; M_I%.QF25_O)X-CG#K[\X-@]25,S^:;X5@!I>2^;URXEI8?6[Z-QU)N(4)ZZMOW$KV&R,&=\XDBS8 M:H8H^A8\(\O41^Y"\L)[>\[(;X[\[%]/G01>0,>$)S3\;FM^W)N(@^R\K$H M5F-UF8$'L'GG$$'U,(+,G(M;\!*U V[P7TH)QG_)MD,F^(1=Q CP/@1(]2+K'-/!T,AL\ M/:DA%$I+Q5O MH1=^PP+ZZ3(#ED5TCSW.)D+O<5%8!M]B)BR#L(L'V@L]MN&&MM%I!\LH9 > M#9$N2+FK!_\D1"-HQW-! 3W'@53:<\>Y"%D\",K:N#%,^%([3QNCC.7T6W..FFEW2[[TSJJN=$=_N>3 M2[)[03^N7-R=_1[_7\MK_AC[T4MP-A[]>SH]\,WQ\?[;UX>O/IC_^AX7I=Q M='9Z&B:?Q^5IF+X/HUS_4RV_C^&D1HR>59/M9+I2O4O?&/HHAFDJETN5,HGG MHK(T642GE+?119M,K#83,TK0>]HUHRCT4/WKCS[:V[**1Y4YF3PEY)!,53@ M4RE0>"G%<66\:).=NP/8VO'#:Q^_-WL:)I//Y><'U:-AFGT2+XI,IKDBNQ> MFNX]=(BWJ:]![SV0D>ENOAGCM)26AI MA,H@G+6@A"T0E$3@PL00:'M0H5&R?AEXF\ITMR1+_WK8E6SX#=.@&L8A!TR< M25)\=/5PLB?;Q@PS ?H%E>R1$.[? T?TD0 M)T4!&G(TD;IE6U"A^OQ_$#4Z$$A34X33Z,)V&&SS#.CC"=34C^> &.)XX, MI0-MF"$.>R0347LHQG(6>1:RD:MVZP?B#3]J:?!,8&G.)D-RY ^AM/#\@P_ MC?#BP!PK:#RJAZ%FF>PJ_OJG!. "HV3)A=CVI@OMX#ZD7C3DVIN/%RP[=C\ MWNF81O@_MD\?.\;)Z<'H(RXJ]S<; MP.\!Z':B_'U+^%(JH%;F1$P2KLRXJ.ZD:K8IM\P6_XTD^'K\,L[H_??ZZ3ST]FTSH18-D M+"M2%6#6U\,QRH(SQ0,C&]F&I+1H5']X![#=RQ%T8.N49%K5[(I M$:R@34 %XDI$IT%'[B0J+S6V>G;/0JNGAW8&@.[:\!\]X>'==N&&>3SUC:J#MO<-1(E#?12,7"!53M6>2!^GF#6^"A%B\ X'%V6ATC/I2== -S=26 M>MT/P(I&LM]X$B&P$HK(CJP%U#1V4<\"IP19V:$B6@;I9P>4A)AG66E/_5L M.(D@C-1,TXY<2,.@LN7@,LF &RX<2X%$$7XF$=KQIB?5[%H2X6O1]L&HC">G M\P:]&\DW/KFC8;YEY?!I;A]+C8(9"K'J%3)T6-&H] &5"D7T^4(_ZT8V@;B ME11A.SH^(TU"KDX/ -490NI86 M^4@!2<,I\&S1L=D[X2V>\'X+BQ9-AB_FB:V%HY7R3CA;0"KZRFF% UXR1UH M'J73,0CK?Q[67XLH_>MA5\+Q7ZC^Z^__Y!7[$DWD8QIB0 M,! M:>R(%\"X&4-'5YDY@[3&2:$U MRM(FK+$##+LCYKYS!.NBJY;$.AA].".[H4J 7SC2JE9$%PU)D204K>7@4VT6 M+DP6SB5E;!M/Y!90F[?$&ZKS)NLJ8L-=2TX?/GR8.$MOWKV]/#5\<&KW^BG M%P=[OQZ\.#@^V#]:)W"Q_--[N79SM;%<[B&@@N4I!FT+5R7/^^DS7T3PO!B9 M\Z##>]:;UM7^)^ML@GDX>Q[2\(0U(;SUGAP" MZ45NDZ]%=:Z2]DB"CC=FTYQ1HY/4C:7U_>#>R7FC)17C7A@%7L3PD]:\IZ0;YN>O&^C)\&IZ>G?XZGDS&?PU' M[YZ&#_27V>$!S!& @KR82QTD!,]6X])R4SG&') MFU@*MAA;WP0#NDBY267$Q_')QVJY?F_7+LXK&M3%B !1L0**YP1Y0!DVEA5 M6/%@C164;HYF=IG,KS=@81VUB3UZ!Y6;!VO)N$8JXA&G!^650-34/KL>U'0-A M?;W=080UA-Y@J[@!G:\]+)VAQ8HYPH2VME%U#%1Q#D52G+,V1XHV284[#(5- M,:&+K%LPX)OE[^+V',%0>]!E%(;W"@%T2A/NLK,9,4PAC97'5_%LH4(4P]: MNB7 L((-Y4I?_7'_IOC@U]?[+\Z/-[O_8Q_A\?WDBM?<327DN5!BV)+L))< M T7S/D:A?+T_I%Y.Z 4?='E1GTFDKZ$OKGDQB3/(02=0,=:+R5D F7S(4B<9 M2IL#,#< ZC=91A89[IV.ST:S@2HJ:4>S3V1#%K1A9)8SC9"LE_6H4Y!Z$P/] MBFCSBU,?'+@]9;:BO!MX+-_C.AC1HHS3V9LPP_FE8?DUF?CTA_ .!SY+FHY< M@,1ZW9^H-T8BJ13=3IH)@C\!IAQ&\:'R)7>=-(^Y3[WYWB21@O/P::Z# M@4I)3@:^1S+['GQ,9&T-+Q,-Z2+I3;J^=Z/ZL:,AG?2VK _<7>B;HX0MKH@ M%7!.'ILR2D+(3D/FY!$F1NLFVTR8=->B(0V8T$7633IQC#[6JGU:\"JP+RT> MI+'.%D@F"E R1]HLQ)"ULHZS9=7!V)B;225=7SVFN>CF+L><@YV60T:MP>L'P97 U M-09N0K8=^V:C.L+1<#QY-9[A]-D9DHKTQ8T R@143H#Q MK.:">( HM(7L6&:,%:[#)?O@AM9M2[UNVZ&D554S;BK7K61)7@Q#G!\8"-< M6PO,/C\=GWX8CVKUY;C,WN,WHSP?7V\9E)5?W7]VI1\I7,J\H$&C2^"84U1D M:@0KN8E%,5DTBJ N9UY6!M$FZ-#$"D35\D?JB6V(8#CQ.008\1B@BZ^31AI M(UF9BUMS%YD";ZP@?07(J;9/C)E!<$ ")&1VJ(JLLV1LMM0;7N97(T+M^^* M:\B]B;M4<#+!_'PX"J.$]=0Z2N&>_"R1 B2ARRXK$4S MC>AP+:"'PH3UI=TH9G:\B T,0K99%$W;=/:USI)SB,48$-PX$\A&H,VL6:3L M L7#4/?3 EE2<47ZQ%6C OWKX#P\ MK:\FZ0:%A]<%@#0F&E@JM>T[,1)3-?H-?4D610Q18FA3?[B#N=3^]O?NLMWQ M7&H,&&T&$^JA.9M()EXH,#%7^AW6;8Q!'8]E]I)P\OE4I>7]"9SJ7>C^M%S MJ1WTMFPNM;O0-T<)-%)7JP6TVA0-4I&3H@J2XZL .U5L9P95D0; NQV+K63KI;I781]&9RJ=D4 M%TT68&T=8S61?"@,/ MDPT:&-OT0M[M7.HZQL":4MYD+G497#]V+K63YI;- MGJTB]DWF4DU"XQVM2RYJYM\J?0Z,.4SH# UBT%$K?X0Y!R2GVAVO92N!H7+N]\O0,X%2![6!!6\G$BCKJ'M=V>Y* N4:#X!L M?$U@%9EL]31\+H5,-L6 %]KO2U$RZDVX1KL6+^FDW;OC)5VDO$G'>!E@C&A%HRQ6GO5-6P53ZH0&X]NV1'/)!X22?5=(^7=)'KIOKU>2&3 MDRY"B2:#\LI"B$73]I?0$->SQ7;'ZW;Y/,4Z)L':DMYE1 M9:YM 1M][5B+"EQVKK9TX<:ZC+2'_8CG;KH:KG:] Z"WDP"Y>CWO3?[AZ^/ M#PY?O7ZQ]ZK>UK9_]/IUWZW[5GE-#VF2M4=WN:#,8Y36I6)$HZ)$$J15G"3 MBN=X&"5%ZYAWA^]#Q-\&CX,9^'D:RC,$;&,O<:)\-QY@-KLXG6.PBVU&)AA32AL@.1C"23#4MIU'VZSU%L;L'K MB317KD_?EDH;.$USH/'NL<3+8]G_]&$XF7_X?"0#5K3B1P2%SDM]MF30Q&" M!RX->10B)>%".V[V,82'0Y]I!VG>KO/QY/? MZ-_.!K$$,CX2 Z4E63:)IISH+-VDAR?2WZ-KUI6HWH87!VVZIN$(\XFHW3 MGP?3Z1GF9V>3+PO^.=KY'P\_U)%.]S_A) UI< .7I?!>UNZQ=2L("2':9$#J M%)24QF?3ID"L.];[3[NVZFE04G@KXGWR2L:?$>GTV2>]INKP^":/I( N3 MC9 !#!>U09@VX'36\WXS-BK+HF]S_]V@!\VM7I2U%5^K7R#XKD4TGO,9R>X M6$X7\CB/%/M@SK^Z^26MCU/TK.I>9;8K MQRDJ"VNR:!X+=-GZK ,-8%Z@ZWB!$)PGT6CI5>WC7]HT?OX6Q:;S)?VJ==R3 M>!O8UQ=8%I&_9= T39)\CV<[R9'5]7.#HM<0;GN5!YLCRR6 UL&0=R-\FDK0)5=^1_&BEZ2XR[?ODP_%?X^/WX[-I&.7GPS)#'%5PBSA\ M;:K@?"0OB!,\OF\QCKB'_<0G8-XG-S5_=+ MADZA",QP"TZ)1&3U]%VL%R$QXTODC#?9E?^#L:#VI97%W"+H,%=P9#IK:'E M^3!&^=\6&9,37?W%J/:CHVP!EFZAKTVI>EM1&]7&1M:GB2.RR#K/4(Y"+[ MVM5)>R(=K^\P>W::VX+6$/^Y#5;3[GFIVM#E5/CMJ^^A"E>67(L@TUF< M#O,P3#X?A?FN7\WV\R6&^YP%HSW>R5PO5O00O.&02E0Q&&5T:'.UQHV0'H1! MU_@>SS \@785SC5RC\LQ^0>3$.:%Q^N!#>2/+@'UWA ]\= Q\24H;+#ZF1N?HML29.\+)6Z-,%T6T#A1? M^!4Z1\V\A22XJ\%T!D%'0HBZ&N,TY>/R+4($6\M.M.SSFX+]:X@\U6%E[L MPN/RYNAM/6%00T3]5Q;>^IIVE87+C^Y296'R/BE$S:JV/%=><4;V"&/"1OI1 MW519>.L+MU1S\N++45TC(?-#"OB)5HZUW,9%L1RU$ZI5DV#4N@UL^M8J= M\XL'OW:GF![.WN/D^'T8+0[@OZJEQ=,9YC?CDY/GXTG]1P.FF$\R,&"UI$-% M7\!+SD&D6&.X7IA2=DO2XUS!R/M_5TD-DBJ,7#X$ M%A6C@:(DDTP7D-(G-!:CEXUBS8UQ'LT53; U1>AKAS_FTE?FT!LVV<1YUY7'^ M,=?'EW$2U[W3C$$=%B@1ZXVL7H(.WGKCDC9BQQI;=!SAS^FTE>FT!LU:E/ V M&R=IH>#PVZ&BUT9KIXGX;I[DL>#JY6C>UL;>+35;6X'V. @?TZJK4RJ]X=QD>A9F^.7VYV^G$++,K+<1B(0):#YQ"((5,"ZJJ)(-ONJ\:Z".(> MK97W)I34C(CWRC->7AP#'EB,+)(":\6MDDI#,"Q!]LA02Q%MWK'V2SV._A[- MP%V8 CLXG3OQ]U[-X>_##G<+(EEAG!4()9'U0XX4@RB9!Q$\2\PREVR;0N2= M$<'/V;R;L[DED^]QA.UN012E"]E6Y+D%0X)@Y-_X7,C7S#%H@]::>Q:.Q@I>%))!JC>P>A3U+M:BA2O1N8<;P%JOJ67# M R-:&O<229V66B%P'6IE?LVR>!X!DR6]QZ297)/ M)U:_#.O116@ND84 ]D;YBG2^#MX+]-(745OBS%L:%@A&!4!MK->:U,H[7)BS MQ9'\G$D[RYL6UOCW!:TKM8,Y+W\-T@:9BP<]WS5DH.3C%2@;!;LN)EHS14 M7T/8U/7SV\[A;D7EN]0_?N&?<((D>LM)M%DVK(B^?3.TW#L[=0L=N?(VT7!?3=DO%5Y+2B78S8"S1B=IR MI<:O0;%$!A%7$E0RTGJ>)KE>C6N"60'O:?F5!AO28\]%H\NWX(247&%@=7& MSF3I($?P/F=P"F6Q)GEKU5)$^\FFN]G4NT;Z7K;F43!R\>?KN>1:\Q! "J3U MW$9:V8N34"PR9F,JUL>EF/'-0W],SV MT?8=S5_@N##PED!RO2E_N[W85.O M)^9K=+6&C!I-S(M;;((PV=&D[)VH%2)X(NB]<@4+G-@P>NP]JZP89LI:PN MHNE;2?-EXG!TT4(1-884'(<48@0ER2 .Q4HPP>H8A(AF21ON^^=N^.[+-<0[ M[DN%)D-B. 8V=+2@\^68#&N$^DB&R\[.KKD^^SJE:43]]6 MQ1S,\_'99($E.,-L+ADL:L+B(WE CK#4B](2%UR5RT4\M^GJZX/OL:I6E$[? MF>5S+,./%ZPI!ADZJX$57A-VRD.L"3OILY$^%BYRA^7OZX/OLZ96DT[?]RW/ ML1P-/RV@.TE8[]+;FD9O O8EFE!N7_Z7NEHYGCR[Q#)7)CCB M?9+:^IRMH''N[M;;F($6V^7&95+VAL',D::V;:D6DWI 9TKJA3O5.+U=;' MWDO6]Z-(%Y&'?E@9=(DBZQ86O, M)F/:P=ARO^R^-F>V?7KL4LO+VT;VQ_B$'G-"2^(;6@,7-XT,9!0H-9D=Q08% MJ@@+C@P^P!"PEH")Y-LTY=[<&'_,B;%[]-FE6O\.(SV_SV7 G2W9U+B""^0( M16DA2G!1!>9$SZQV.C"E(V-\>=$V0WZ[%(%_74C?3.<_OE\@GA CNP$I[-O M%P1;NVV6H@&K#ZJLX> M"\!Y##Y:[Y+?L>8U'4?X,R&C$NMDJWK088HO !;I/(\%!9WK8UKQQ'^G"[0)U=O6^;;]\-OPXS#C M=9R#7 ON=5&04A:@6+;@C8F0>+%!3)K?& MUM-4=>Z1Z,5U]')U.8>IP=6:M6)";>66G71R'TI4EEF3#]+K58HM>I$EDU4 MJZRBZ?O"8FE0168TQ("U];O6$++M0I"^ZA40+6E.^]VAKV=2JUVCKQ=%-SZ MNM7S9/;B8(BU?IY6!YZ%!I7)VO%%FGK<GHLS+I&S:1OA+2#CE!SC=]V6>O MZNHQ\5@OKG]3I3&?789&)+5&L)@D)\\S:XL@6&.B4P2%G&I9FKTU&_X0C]= MYLIWK_TQ+;G5)=]CEN +B 4+EX'1Q>A:G@C]+Q%WVT=KJ."R$M>07X^[PF4X MJ/7]2"#F//2($)D'%D+I1TCEF_U&&7W5#C#89"_UKL(K:>M;=(B5R<:\<@ M1'(:, D:C H!8C(%F';)LD0[ANU/?]^]>G-[]5K"'_@8RLWCII:8FQ+$+AF)0)MOJ6XIF7)5<\0-U%=U5JEPJI8K(NFQ0STU81 MQ2++,3#-M/>"["EY=R%5SV"W7C/%K,HLH07M99V%44,@)P\9,B=1!_"CMW2 M]**OFJF]D_EG%JV5;E+FP,@2, 8-F3F2D!UBGRU EB42]EEEFCY/U2^'8P M1] OZZXD\OM76XNZI-XJ8T>!,$!43N"(#&.EBXH9I=;F[^L\33ULA MYG94OBLGG@Y&M..3@4Q=Y MJ7=)-:'P+:#N?P2H$TO&;;35P#F[ =K""UD&7-/PSZWPMA/YZ4V9RY%D#4UL MG"[>>6M1,6 8,ZA(@UTON;>;1.!9XFYK=+=#DCF#/=EC210%]=P5[.I[. M#LL;_(BCLXM,2XI:9B,2#8U%45VD3'6 W->VZ C;?_+];"]YN&;-\5[E/VX M1\$UL??X!3I@>_W1OD9X3H9?Z@#7AC["X@ZA.RY-"!5;0L9@X5H=3VSSED( M?@@V]QLN 2XA\"-5KKH>][78&;MNOTR3/[$66U3L\BR^J#)A#? 0\FUE9H@ M3#E!8K'8;#AWE].0-]U3=?T+'H.>Q-@@\KLWW"$DW!"P/;RXWSDS\U M3&&4\_#D;(9Y5"E>943>\I0\.7KS1GYV_^&L;!Z7U M#L$)6<\99P81B7W2AAC(@ DRM:D2O O9NDO@YR=S^<7)-Q!0)%"$!%"LJJ> M ;'@E:M%GCH&9@,3IK_\JJVNH@;F+V7;AX]O^%W$3J:'I[- MIC.:>+5#7YV# ^&X3!9MK=+4H(PO$#A3$+32CFODCK4)%7>"^<#XTDY%#:(E MUX)=B.,XKW\WV?3V3SJ&.O>GF8#%DR**"7($E--VHO:A-70['!!6,9D]&YS M#%L>^(_ N49J;&#(T_HZF1NCX>3I^/1T/#K'O#>;38;Q;%:CV\?CJZ'O;R+C M ZUX0>XC:%E/CTCO:[=Y#JXP5:+"P*5J0L3UL6^>BQNER]7PX"9UO:DU\[#< M)+^!0VN-,@Q"**["M>""U.!S%IIQR8)O8WQV!/HCK(D]J:G!4>>]T6PX]YC( M83Y"DZRJUE!FB!5)8?ELNCV3L=GH]F 2Y]2;3ODA6@ M=&T$YK($G53,Q?&4=:-+?/N _\ 8N'F5-FA<=1G5N=DJI2X^2PN,0O2P<. M'0>+CJ&0,C,M-^)0/T0/8GV1-VC9=,.(!R+4DFU9+V)2],6C F>SANR<+B&H M/-FF+ ],"YL(K8K[+!]'><[0: OWX^M^Z>GH3I]/Q\BI(&I4(.,57PFSJBUI0[K96TT?-OF]PHHK5R3N2DST3DH25G0H MP"JCN3'(&6O3(W3'FFLUTOFM;;2ZR/Z^-"!:9DP_VVBMT$:K$UDVT8EH%4W? M%Q9++I4IT8&4=9R?@TAU=NR$DO1L:B2W-)=.#O#WDYMM':.O%T4O-$V6K2[ M>)4S@DQ1':Z,@2^H!MCEP^^#9:732^=!NM+NIJ FH69= 85:/"@5MA_>13CVK;4'FW MHA%Y;0Q8+1"4(]?96Q^@8":T7H>H&H4M=J\>]?XLZZ;DQ]EL0_O;UZQ?[ M+_=?'>^].'CU_/#-R[U:&?RU&OC%>/3NQ? CYKWI%&?3^/G+Z;HU2KS7?FD? M1=O]COS2D;+B<[09'WZC M^"> MU#5N)>N-$<%Q3"XY2TNL4!$X>"]JF4P&(427K+E+GW910+ M]9[J.9W)Y\';HT%V15CIR6>UBL:D5;U7BVL@E]4+]!H>]M9ORFFO[\;?WRR M>.YGA<_S-4\5_#7]VVV0VU/@A^O);4>3=0+! JVG;R;W@Y>/ 2]=91:@_GV]/>!< 6UE!QJ\\!:5JPAN'FTJ-C MBU"YW+:H=M/;T]\?@MXZ2JW'X_X7"/[C]8!)BTY!!EE+0(ETGA5,M3[:I%9 M)2SV-]_^X_5#T%M'J?5X1/D"P;/]@6,FFI@D)%F/BCCKP>MHH79/I-5 ">Q1 M;\_V'X+>.DJMQR.\\]K]P]E[SL$,<7K1W;_DG%@(X%#4C(RF[[)D$)@O M:)1$%^X,3-_\^/NLMIZ$=N,)W,TF)"X\\_CYJWC>X+O&&8F[W[J)E$3'L5_. M2=C,>0DN<>M(U2Z&Q!,W0OEH0RKR[IS$W>_?4E(B:^:-))^+9>5 9?000L[@ ME$]9&;+I6Q#@JS"09<>RI'W1#%W5L M+.:\#@?,_G025U+!9]7D?7&B%#(L+6>61 RU.[G%9Q6$;0EM([Y(,52YU!V MD0 K)1_ZUW\7$;=)/E@7E"E& @W)UP-X'(+S"8+03FMI%(K^@C.[DWSH)/BK MR8(::JV-R]7%X3'6FGUBDO4,'A$8PA6O-01 MZ8;(VLWON,\[%-\;5(3621:$)0$ZP6YK-Q&\ X+>,:SUDIZ=VLGH?N:FEAG M-G:46H/4Q--7@V"T,Z(@%!\2.]%/=OF(7>9G-1OEMK<@ZI@)?/02]=93: MC:F)%6/:5^(CL.,9CZPNEE$[8" MZ!:@[F$@7Z+/ZP6\:F7&8=G+XV_+W5I$JY]T;IU_&E.3-H3CFI3IGHOVML/ MF2QXPL"8:3B:Y=Z\\=CM;=J\4HC?17A=[T]<_+I^B6&__K;_P=02P,$% M @ 73B<5"%/Z5I^R0 .AX! !0 !N=F-R+3(P,C(P,S,Q7V<8 MX[_FF-0)ZBQP]J^D3Y 1T<'W;] =1)0!>@/W3HUXMV,-!>C"R,C P,C(>9 MF9E8V ^SL[,=9F/C.,)]E.,(UQ$VMJ/\1[EX>/GX^-@Y!8[Q\Q[CYN7C_=4( M'3WM&@9&5D9&5EX.-@[>?_J@M@!<+'1-]+7T=">!0UQT]%QTU Y ' #H&.E^ M.X _'W2':&-D8F9A/ 0'3W](0;Z7Z.FU0;3Z@$&+D;N$V9F:]RWV?]R&_H+"HHKJNJ;V4UU]6WM'9U?WYY[>H>&1T;'QB>\H#';N MQ_S"XL^E9?SFUO8.89>XM_]++CJ GN[?CK\J%Q=-KD,,#/0,S+_DHCL4\.L' M7 R,)\XP<5\R9[[SD.?DV:3WY:WLDJ49&3LZ02>8H??9\AJ,75^$M#RK WWS< :6+@1]=9A4G2V6%W0WR$B(L,/=^X>Q3 M.5.C(?KI>-BE61"F)$2="@S>(SZE A%ZNU1 ] WGTO58BN=?J6L7,F"O-2 ME4/'E&BLRK@IX^5ZK4;YZ6D.4G9F!D?RUJ(@$-6.]9D4FFO_2 Q3M)M[4<\^ MUAV6V?!7WYBW)?1@YX5VUSA(>A!KDI8GF$=' MYN>B>662>04IIF@E5!LC?IQV%:?;V/P55&Q?XF=76==6-F22(1]I5Q\CA%]DTPD] [I-F2XG;"_ M&U6-3$"M1ST0:2]4/3NKLW7HW<-_+VO'CSC!TFI2JS^=5TVB AQ. M>"0E3J:#DRRGC"2N ;"K?M9;-K_[7APW!AF C\KH!>I0-L[$A5(IDPGZ9" M,9F#MT@W!,-AJU,=+,TU/2;:O:-=W/71U77]%%8T5[!@Y-)OMB>?;$2\Q- M?B ^G5.4(1!3M8FP"5Z]@!,=^2?&HSV$V4:8KRW9@7B&XV4.Q'1G7N%.EOVR1/. TQ=/.M#SV+C-#<-QU<10/%IX( MNK\1E243HR-%;.\04APG),'S/;)V1OL;)_U6\AWPC1%V[$7M$F%O=GCI2# ] M7C.Z?[6 >YM@EGS$%9+@RHPB;G=51K7[F8X",6!V;1AJGJRT@^8VC&.O07]_ M/(])<#S%]^.S-] MU-OW0>U-=E?'JB:UA1TH4Z/K;[-F@D:J4TS,INU8O+Y)%JO]9 L>HKNM\X#S MRQ/Y;6&"$]&Z%,J)J^UVT,5TUW58<7 M,K.-7O1PR0L)6+RC.E[GA]Z<#DTQ&L0_ %YF,(#$>] 5VRTN8?(0NZ2[(<; M969!8L0P$XFU6OY'>?TYM1YJ"64-PIY7(PR[["3O'=+@# /3440]Q,6DAK3. MO1^8Y62#ZA_ QV\U5X;?S%E_SUI< M;9@]\)V;A[?WTQ-L\4RI'Y::982"(DW\%)D-=O.++NI'@DC"?DB[UO0D=.O M7K\UNO$8?@T7L+HTNQ&&K.Y>;2\E6K=;.?(WX57$Y$QT38?\[=:N?LGVTKG$ MTZF(E:QS?KDHRV0@/<\_.^G.><(+:)O;KYHR=74.@TG2QGL# M&8Y>8OX@)P3(OHO]K>R O^=3KBHAJ,!=USC0CMB(9V_Q,P%OB=;CSR(R5&@ M B-!YHAOR._(;EMT!5PAG_WIBC'AP@0P;.?UZM[R ;YGE\C@[U'55VEA2$H MZ9G'>]$=&GQ;+QZ#X6"9'XBQA/$C8CI,ONL,K%"'\J0&^"%17O%MI(DL'M M_'CR;/_)$K]GX?14)->5OJ8)A<-\1#/.;WOYXWEZ(6WNR(^< MKI_97SAW!3C-8DP,9V'H?K,5S<'8F"5 MB'#H.=7%>']P:+,4<1QKD2^C&>W7G$J=/B>P,\[DF?(U4GTB?VW3)/V/#^ M^F&K4)!R 6(%OJG$AR(FK@,@AFM42W.NMM;$NT=Q,:?S_=#; MNEOY+Z_8N^,5?L:73#;.S:\LEZ( 'C-]7XK3Q"MR#T9L"AR]5H-#4M1^HAO M>Y3S$ E"4/:L0 +4$J_;0=A:0K)4^3WBRKU/JX8G5Z=3Y#I[? MT9]NX=O#X'PH1N/=/B0>1>3.B<'BW@+Z'=>.\1P1?$:[MGKQL!3K7-%)A\H M7\PA'R8[K.N?F!1=\N7X:,@O..$BJ=N$:[+9VMD&B8?TZ0@,4GAX2B#"F)GJ M@J7Z_ C;SD80YK/E28;56'#LCF2[]2%NL1[R1D!;S-.K[Q(6<&+XI_"A"O MA+5O<'FBKN>7036)L-GSZRD[6MH81<^V=/[][.5WTIM7D"Z-FZIL=\2S.;W M^DYR]QJ(<\%:K^IP_H1SPC W2N&150A.8J5YE%G-J+=?OQ#Z8D7CK?G02=#$ M$/9FQ(MKRT/\PA]9SP/[2IFS$L;:Z(8I(@M%6C5]O?BP5Z'ET$TK7&O#YZE MUVY!RA1M.87Z5)93>KNE3'!D\K!/) M#=4N'_N7ME8%>?\;G]-Z_+)T7+Q'BZ[$MJ:[TOM((\^ZO>$<-U'J M;A6OAK4BF""VI/9ZR\A"_&5TM^U 9+7F"B1A/3M8K'[\==(J+=@ AJB3YV)EZ0D2G><4#;F=IISI+#CX&T^'![-JO!VQV.C9!., M-IM=D.<]Y)8W.ZZ]0N]6^JB3#>6:S[D[NX<8'U$!FBE$8S880FCLX:B_/,TQ M0SC\F_C'=3.,1QM/80RW:V9VK7!3]=.L/X+>/SSUXQVCC/B9I3V0'A!,FV>6 MT/UQ"8JP'C3E'VF+5P/[S"36< :/RNY;__87#C3\GFCK%GJ,:CIJ=,S:8' M^3KRRET;23,7\"52'(GYA:")Q_I.XD[Q+%Y/+3[K7'NXF']AU@]Q^EWH8=EW MH=K6[?!-3]!1K#JBQN@/%\9G;=<=:0;]($:D2Y !HR&O5 ;YD@\.J+4J_1; MZ% OX18,]M>4(343QWN2S$+)=G --#-DGS:Y%9A>W.N5YU&QZ MZ(5]5K516@MEXCL) UWHJ\C1\ '(J>^05ZF V\;W+0($EYZ-W[HVV"R\_(0= MS;;>>$YAOS.]R5>U?T0C8@3L%BN[&)#PN.V'Q'FG3S]P%W;BQ+]3@196DB_4 M&:XY63'J>S/];=D782 MNV/I?^9TE_Y5>%H#%> ^8KD0) M9U=6J$!HUD!''Q40)Y(Z4-YU6$U%UQNQ MVB?/-U[2;@S@5I!/2D]O?7BAN+$JY0O .A4 6(4+@9KU:&(0M0QS!W/ZG&J M$35O,6C69=18)C:ZT;S ?EG=Z[ZSITU>#9=BUOMR_9)>\0=W+]H_DJX^2 IA MAUKA:]MH-P5-MS(V)HXK\H+J,5ASZ9GEEV5,.<5L$#99=IN9SY+U;KTLN@4 MRY.CG+V'Y7?"N\#ES&W3%#ET6;)=ES5A?-WV\3,:F8VLB=UP[;I!@QO!/) M7IV[+2/QAO34\MFXJC!08C,-GF$1P$A+$0$COG6-Q4[)!UX"71$1;B/0VP) MY;X=>+N'O+626[=);JH[)Y]"O+T5ST :J,7\C1D$%P]WCFY,0&?]?]!4:E+ M6>Q.IYP:)AN=JZE C$1C0'F+='HAKV+L0;V'X:W7!&J&W"Q9DZR4#VQ'0OC M@I!:!'14QW:H0)R&P5.O/]'FZ.WP^;TA^_-4.S# ])M741[;K.BF #0<3?$ ML+;%;'=K$UN7(_U8LRCQY%9;?48$#4K:ZBT" L,K NIG/;@N7TGIM7Q5T+XD:=U1@:>P"M.VUP;V1#Z,J-VL8^V<%Z@KAZL6 M+UV.%R,F\N(P.$"/Y-CXC MFLQ3"+V.Q'E%Q-?[A&WW??=R/"B32K[WHDKRZA7C8Y+2$=6&D[3W!#CZ'!Q M=HH@ETZ ]N2I8FF9O-:$VV!IB,GZEHUYDUUI,S2?RR<);5]620S8SQ"G;^K/ZO)%. MTBQF[WFZ-,V8NUY8+^O!GY]2"90&:("6J21YT@E7L ,?S#VVI6_G IPRQ^8 M7DHRR0E$N<;0%W4KV(N&/H\^L[7N'7?E($7G" 1$>'X 3]_ '"340[K:.PIU MGMXIF%K>OY:A]EQ>5^U/E_:>&^*16A;H86Z[''**%DJG0P[]BBVZ^L,8\V1E.+"K:N'WMXZ=!U% M+GUS%;V'Y?F(AJ$[6$]!.A9O )3LE:7YFWW2^FL#ZD C+?<7T4+&S?L^$- M)WI9]I?90V0UTK@1H]C!ZT9.;EK^Q-T!ZC2+XC09YA ^R#217G_%'SOXBAH3RB)^$1]M9,Z)VC K)" M^51 PHQY]9U+QW[?,]CA+K2C%3-:7HYU+$$DAG8(/7J$ O4R$5^#Q"MV/) MMXD@:PL3[E!=YE4X 4'+5),+J "4;DA7\#;%J#-IT6P354@V%(/6DP%./4/ M7B)_?H#-T]^D C\\0)B?Z$J! ]X!\AL/.#GAHC@M5O^?P?WW#LZ27$TCQI:E MM#L.9!/7"$N26(KYD23OO;Y)I MR-74ZH M9=O,Z?%&CA#8HB/W0@451_.(^0$2!5M)G!8K=C6I2P//V@/O%&9?BWQR- YQ\7?=P#"C(M7;1SP@,B( M)1@Y]:(8ATR73S2/39^[3&+C54+Y(RM$;W'+J.8YM62(Q'I!Q;Q#F]'CY01)-S>N@EH/SQU]">*T($B,%@6D@WP/LO;9**(/ M2=>IP"#M/O52,JA CPJLO0SDCMZ7ANV!:31@3SI4ZP:)$$[,U)[,0[G;@0_ M]LN\LA\(=ZR'E7\^^@;B[,^(7%V_L&##C_5(WGX.:QC99F[[=>W>,[. %17 MJF3%TG[$UUI?J<[LST45F?/I<=_LF2_&1\AN.0X]X]E%E=:MDV;2]P .G M38#_>5-'_K[GDBQ>7_7YO7$JTIN(\E-HZ='6NRQASA-0W-KE0@[4"9"J2X MT=!L'S,W;A?A.91WLS :#%>L&6?Z!/N4&PY5]J(>EWD/C&G!;2#]HT]X>1 M>+1HMK" D.L87 IMAO=UI;1:QY3WO +/GY595H'N_2CMF(+#&V^=F\M0C: M7\71G9HO@U5.0AKUH2X_D6&K ;]+![2]9/U$HQ/[U!U:O2:%CATKB0US-- MI]$AZ!V:^Y$_/P_YRN#I+(#XM3\P69BN/V.XX;!H%I04]/A4> MOIT'F8LIKB2U,3'3ET;H2N$WRPD9[=IC!I% ,RA1YL YL2'7CF?W99[>/. M>/\TQVP&K$[T7DWK8I%TXEO_B\F6^WNDT&%MQ]?H\ 8=-6ICML@.N(!'C=50 MMQ;_;OW:R&"GY'TA=4MW%BLK(.P"PR&YC(20LQ J@+5,:,J(:_3%FO+93/8L MM/N4>NP)'<1)1Z5)+:(<)_5Y''<^0-30=V)9 2U'_:3#^8>P&8D>/EY!CE7 M1ET/[U!W]Q$YW, O%6]4==R,5_88X'2L3-T4;U7[_N>3FABG$O#WGZBZ9\L: M_DW#W3Y!\V?<&G^V3DIW264\T#22O-N<_GO8B/^ET7FE!9I#<$.N=Q'ZKN"/ M%.?:H(U]M$>;X4$7%-&]'O/M6+CZ55\MDY6QS:G#AS 3Y M.C[M]4+^\2P%@UN2#2N.R3'G/8L\_%$4=W]5[B .OH/9WW<.]=$X1ATV' MJOO/CG?N[]1DES48%]NT%W[]N'P$'5AV5$UINZ!KWW3?RG4>ZNL1\'_&!#S M8"9:-Z^ACZE ^=E)G!#5 AI6B4>QX&KO404+H!T8ZE Q+;R,RLJP.I7Z.\3 ME?%49E0U)JMST/;\-;V:,YNX/AE%5H=/DN.?Q3A^FQX@W$;BMBL!7U[%.J; M:X#9X+2C IX31H1)XHZPHA%FC4MB3_+?[7AO5Q^#^H(0>_^ZR :S?)'E), MTEIQ/(P<._+:5>RU,X$\+IO':2/:>T],&A>74TX^_@=1O\Z(Q#,B1=H!;.' MR)+/XL:BL)R,_<%S7LP$[QJ\Q MGS+.=Q9/K]3/)ZSG!0AQB49,O_XB[6:VOG7M(Y// M%+GH4BMQDK!/I)L="".(-2BF")DG=CD)=">N+-0D@F MPD@?]>7LI_.2 24^(B&MXC6PCN]KKOC(IV7$,D^S/A_INCEA^:YG:NH,9V?4 MOCTN>SA./Q2J\ZJ>J#E[($!A)>$U,;"GS<>A&J.:R5^KPVL\-=")&L>ZKP? M7U)HF^W^I"LV(1$Y=49:G^&VF.F/U\'!M+"B]3P-#0D2NJ-5=N,X.]N^Y^B M/6R#D;$JQ+4-:#Y:X/6Q!MKLWJ/-;E,)I@I:I/#?B__-4K[_6E\DYCX;;+5[ M^2!;RZ?0O39#"37=0[.-F7G:-L[:,)0Z%I689CXGL_Y-LOM1RP,UHSYM/C& M.Q7AL3^?%.M?K.ASRRAWI%H^^++;NH^5R_39_N->0ZS"Z>S7YWKZ@YT_4%K! MHE7PB) 3Q(G-^]+Z YVF7 MKZZ.ZJ$ TJJABAD@%.@5B47Y9%^P27.9;RY\7IHS3VKO1R>,' M\UNS3V0,0OPA74(>E^/16'"TM8&#-58\=D=U<-VI:5AOH=97MOQ3TH']QW7? M^7HJP;$LNHYJ+HQ:8Q5W6V#'2>T\>+1T-5?3&$4;#YF-_TDX4+U=W-#>H* MNR>NILM]F5/H?[TZ2FK_2,QTEGQ1#BW%UFI62@.RQF;B\-.:C\?'+:MX[\[ M_2VW_)'[Y=LRQO#1(E9; Z,Y'YIENJ@"),+L2\4 MO=_BN5"=CU[.)L\TS?V1?EU,49K8+ZAMH2DXKY;+_F@CI]>1=S/'&]2Y.N:- MNRH"L\/KTA=:I6M^RF?@0]()!OCZ;T7QKL=N3ZS'!)> 9-]2EETLH_\[A'A_G MA8_NT)<]DV($NFPWX6B&A=IJTP30T>J&"+@Y'AV#6'2XKNWN7#^F)'D')N(I M$G"[,G6QQ"VZXF"VX(T(G2/^#S@O$QM#%^#1>->KI 2VDN11"$2ETD65!@ ME%TR+0@:]D%21FW M%YS1U53: !6.<1O\RR,A52:XD]:\E\G8MG?L3N@EIF M9M;E]P(QJZJ&^+_>(Y7XM0)E(\'<(KX3Y1U))F^U BK#UTK[:Q 3_S9E_3 MP;",HV_I. OG6?X)%D'@AWH_6)X(ZM:1) ;1N)0'T:Y##^RVE2AD[ F1C V M(G"S.N _WN=F%ER5_TD%_I#2<2;&<^))U0EV-T9]R ^QQFNF-X;11LU-=:-E MDEG+/5\=4=9-IB[9YWNWMRWY&0@7\9;MSM8.9BVZ4B-:\ GKP3]@XF;W\[O@T;:+,554@-O#41.O]A:K" (Y MC:Y7Q\5XKU6), MU\J4B^\,(O4?#58R7+SZ_/I@3EC3P!^!^V,TX241Z;GP4D>.B.)165@P5>ZP MCFNV&-.-N>!#J!_/'O]?8J;_M_ M$FG^964LW2D4[\M=_>[KCG1B+X)/I72K4T;BO$'Q-)U)!PM$#+P9&!-D.0< M\LU6/ZG,34?$@=,&SX2$%1!3%HR##$OOC%PU[)Q+O,RR95D'W+FUF'A1Q^9= MTQP6O K&,[?(8PJWK89#9)>:3U37-7X<"1%KW_B%&TL;[]PMUQ>J4_B01X8^E_PXJ#MMNZ@:TIB1'L@XN4)0,A MF:,0Q; 6M;$3;O2?W1"71I&N2;'U1^"%Z&48.]DI_]92S )ZVN&GP$,]MY?3 M]59N+9<2'TU@"R"IL\@.929(B&)0AQ@#7BWB[9>;!H7+MMJ=397II#=7?_(N MUG"JT'4-.E!J23KD&[BO24'%^(<4'">N]7Q[(:5-:;E8XJXBSI.57>L&9[V MB.I=>D?FQS_.P\NWB3&-J 0AV3US3M57U@QG@NS!@6]\[AT+_1ZG^$'!5M6 MT'4]C 4P/Q'O=,Y0VIO5B+IO;#T&/2G\^%5?8BJ%B[\:Y[ ZOGMZN=,F(K?C M6VY@_AWABS2[(_D0\,)KL16O]7GY%/XQJ_EK)E.N/DY+D$%^E<&NX]S@W+ M!M8/G]:PO7\,%[W'+K=-+ M)"_+TF>_:\X5QYG"!98(]=<<)8@1N.'6$(E11:?&:APRNE'?JUK-"#0:+O[B MYCDQ0+EGKA3B"Q4@1HB'TT)$19]#D$RH_#PKLO9(T@,%:.4@^2!;C;3(^TO' MC?!#%,EN3 9>@JR#OP%YK'FS.=BARB[9K6;]Z9"36G^8VN5C:@\N,8A8>FZ$ M4[2&R,("<0@H#U;3E+4W1O+)]KY)VZWZ.KICURWNL!L"BZ_BS9@E] (TNEM@ M,2'B28:I-XD!V"95U;B"5;^QQD&ENP+CW+#B2.[/6CW"1,M'IG>N#X6P$'NW ML#[/&IF+W#)HB";!GFZYG=CY8U1@[>P4Y>,+PW/1^8_=39BI00:M@)/'AA M/0PZ"KL-%H;(M(><&U"\!-EL'S=43OR7C6@XV"A:;!!2@'TP>;V-F3TMX MNR>E\]Y+9P >>/:LP5QAL>.H2GVC)/7CKOX&5UEV;VO M!(K?$SJF#]3J-9^[+H["F,&WJIU .EDX';[;1-1[R_3QG\6#GH[9S3!Y'2 M^CG9O#ID/[LN<138R"Z9FD/VX6\7!NR)MYYK/Q#%6MP?NL[!^W.XFL1L]Q= M/(\$C_([M'@#R6P % M['X"3O2$.=6JLQ%=+V%>USKG^NY;TF(D:=-DX W:@)"HJ^%7H1,L5D$<8I M\98O^R(CK_E%1I@E'[EX?,?\3V=_HXA9DHQA/1I#H%5?')SR7L/_26F@]9HB MS9RN&-)X\$ ;;/_YTNAR%6"NQ_NW"HTY"X)^O".STB[XND@%S-=^E_C"G09(HU[,QBP4ND67Q&8%#! M>;RT:NUD]RPA C,0B5J(FRW5-%87V.2P7<:..;N\S.5>)V!J/P.,1BY]5MUM MH$G=-LTK MZN=JOWN7?F^O'O/"/A3Z[,MBUAJH\$!^2S\6.#"G07<2CLHE[.)KHZJR#V#= M\$-:%F^-,(4Z_7Q?U&SM>6PD$Q[.:\C&]'=P(UYB;JW?907H-VL[0"AQ0WPM MF5?3F)A6 [.:,T"Q5<-^SR(W^6ZE/?=OJ-8TB/T]8?S\0U'Q1S4QZ%0'"( M#A]^"/>X10UN/%85SFGGD1SM@QFJ9BV]L<8TRVTN3'L H)5,WI2-<[^AV>[HNB.11RFFVQ!9!>\X?S4? %,^2I>+=#) M3$24D-U&&MF"2NU01J60ZZ:'IQWMNU7,#'CRFCJ<>ML5/.CN/GATW:!7VZ = M5-6]NH^B6N&STU[;'34PCE\H!KU(8B#\E-"SVK6H>5'%BMBM(8.G8V4 M8Q%N"P=GOJ AZ1Z\)N"9)&[$\9B/J ,5:%,56-V'TNN/V5+!>4WX3W]\K2[S1TB]?DMRBK>:[18^D=U6KGQ#E7LB: MYG.:'BHV6M4W-8V4O9N?.0;]E'I9OKB[;>6#XYRQC1>(EUNG3.=1!L2T[#* MO-,>S5S#6OY> :Z%]N]+%/W<5+D4+I]_O''EUJ,V59/O,O-3UT,\WH7J[#4> M-#32Y9.=ZX:APK->YUJ;V<=U)-UG3N!!\8S]\VMCI>[N1:5# _.@&1/:\ M[/FI7EYNSW>?#BJTSN&#VL4%H#)E9#^\0+OGRH9H?\E/,:6:X0TEB;K!BVCK<]\>/#,37JS3I5CKA8HV:) OH:3$6(@POCE6/]($J!WT( MSL=>C\$H7M\TY=:P:;Q>P794J'O,D%Q7HI] D"3AF%5YG4ML+BQ&OT,_(@ M%2OMS5IX(>)ECL/&?"],92,'&=>_)U]MZ^-]SVUC^N7RJUCR%LZT2UF,K%I5 M5XV+2B ;8.P\,[9DHJZ,EBD,676IG^U:/C9+EVK_-:_0844H8O3@8&1\?/Q& MU:Z ]5E!J2Q]JY;H5/IJ!J$JB3H=P2Z0TGWH#1%#,W2'AOVSDU Q9)I& M;W8U>6(F08?VCCJT,;C=]' T=.O^/NG9GQ$:EDWW[IH/"UD"+UYO2J))$6H0%1UX[ M%O\#ETF+UJ\JM\!)(NNP';$QSU'/WN:SL!X](@\5<'H]0,E%]3\I_?=4LK]6 M JVC:41GJ5D,-I&)]3E0^O:KC4:#7TP MT7I&."!+3T._P?#^=+H'67Z9XL M\A!LU;?N5WZD#<(2(4?LH0)2 K.F!XD!H/TD3Q6ZY2K:^/CVK(.I .-!$6^ MP"CKN^N<.T@/D^^;M<&#"1.+@J"B MM'EPI2E-Q6":BOEAR[H%WYA;Q'%SXONE\#T/V[7?_P<4F2M@N:!BN6<%N/Q MX?OIB?U@JN+F:OX,S$O936X(T<9?%,_ZF]?"3;#]1]!K.=Z5^9T$S0F5R=>[ MAEIQA8T(Z>G-$)M[I"O"9N3^18/0@#+_ OI-!$6$YG8MZF HBEE+?<_G2%& MLK5MNV]\0M96-=;6?_KXTLY1C[UHS>M4@A379[K>,XFWT.ZMDR=SXCFXEL?. M>=0W0M(WRBTT^7[0O"4RWP7JY_LE)QZP?)QI%F)/FM""RD?$$]'_TV1+>XE M.^D'W([.E7HY2[?L1G-_?V]HHS2;\?<'_W_A+^BQW60N!(4/UH84A/11^D M 4Z6J%==0!"4B?I01%5P#G-&'YK0-=G@HNYU_NN#)]8K![2PEM:0="5M\G;T MTZBVH0MBH2(45!0KOV?][I__GP="V5&,QI)I4Q[^C KLG!@N'O7\QUR,0T<9+_+K?T4 MNSES:C9-)LR24R3YH[._Q/&P\\<3=Z3^@RGYQ[/Z'\3-=/..M#F=^H$8^"N= M.@:YW7#I5R-X<5K@VCY XM$RH0)Y X_C:2N@2A:9,;Y#$$.PL0I\\G+B1Z9 MNU6;2#QWW%_L4O">;&N42!BG[D71/%X+6STKLR]T3A$,.^=EZ'',FV^8S?5N M-HZ6^$W&L04U] 79Q>TE5+^RN%HP?C9ZQD+D]JL&%FPR(?YU>?G/]]\8ZV5+ M#H(ZA, 1?K2 QG:D9#M8;I"]5F!\Z_W1R^'%FG6'WSQ)O2C$:Z43] "%4 < MH,:>94NU.B)N.D/U'>K)36^C!+<86FN\NC4K8U5 0A!8QXRH"ZM$7L[R(EOS MY[J?0#Z)MXX7V>J2 [,0)]N11U7NC95$4LADD,.F=PDP\;$92;G\[)&7THL+%RQ5::%LLZ0E7J%(FJP0TEE3ZSB^<<)(]\^V J M\LE\H/2ACN18HP3.@!!"05?BIM%QT!-O)SAL;PXG5'=V/.^=&URK<]D&()^ MT'^T)E'^>:JKZ4EC'_@@NUD<\F[<1JC#'SXQC)+P)J%,': MUP]:DK).W;.?DV^0NP0D3EYOP(,[#L1W+<@75MMI]TUI&S$7XDM7@YX]3Y(BK1]0 'C#R4D4#L2"8K.B.CGYW1VEFG$G9SPU7$KJ MKZ4__MIFTW@F]_/=)A[]5:Z X_(\5UIRR0>15* ='DW(RN\P%2"2;*QPG0G= M;1N'5S**"Y3:\[N&/5.-%L_=;%.+U6-YWK Z:!<)9ZV-<4/\^SS9A!^&4]> MUHRLS\8>I TG8VC<]-NN#T[W=5L49@4]GC=1>;)"@8=Y5--2G#Q.JN.K!]* MC/'=^A2+[0M\R%Y./_^9MRK;^)2LU(M3APS8Z; :G!V@Z'00ERJ8:;(=RV%L M-JJE7+2"DD(G\AC7A$[;];BG+F23O_5^-%X> #S+#A_%GGFCGRW=$R?RKP MW71N(2I@CI,;%."/HQV0-MZ6O&K[=8\;'H_%!V5YGTB'64N\C'&[$+;%W[P M&3:9&G<0O99@K@<50)6[CUMK9$QX;Y<'%'AD!3$&6>>3+E%;R+/)?;SI%QN M-.%YMNYIC1!AHA,&?7ABV:KF<:VZ<:%,6J!2,>QA@8D63.>DN[=D\A?/!:,: M[4GKH-OL60#6)#]6E9/'"+?,4:,[351-@BW_(2WFW#O+P!7=XZVO7^8ZDFP MY%(LMSZ$UG1Y]N.,PE0$,DG+%XM(L((?P> 5NY]7%T1K;!26_R?IR>CG7K(GH^ZB8ID7N?\[)THP?3Y(@GI@#QZ00F]>E<><@$7<' MU[P4.H2&WT%3O,W!M2Z6K] :<)R7X8%AD=VNE&&0 J \!2LQP>%&L95B M'%:2![\YI I2AMV2O.^&R\Y(T'G5$QJ1EM[+2YN0J-T&E7;T.SVT-XP+C[ M62X;'"MH% BE!G9[03/P/NGN/CK!D^-?@F2>MN]R4K? ,'F"T2!640,LZ78 MB:%UY=NCI9(5(XH2(]YO:AH3YKA2%B+!3;<_KP+YZ^5 M302JFV+B.B=S$),U0'G>#^YWAEV%52>1LP:Z3$D\JO"#$UG(K%Y@OQ@#BVG4 MQ:"_N[;1+!A8&(:Y'CAS;IR\L3U]%TTRX-=00N\Q3_8W]/7!2B:3U.>_VO'I MT!,'.OIP8.Q8G0_^R1RFK &&17/V!6#&@Y,I)M=:\9F#&?L9%TROZ-WGWU" M7;N7/ETE+H>#=\5Y,;>HA7"-A8@3P5U97NGY 44HX]^0CT5[JE.+]Y>CKP? M0'=>8TX&@?7SO]I:Q7Q=N5)=6(9P4H:TUF5_GRZ4^C MEHG$ZDG"WT$"Y(=L)I[6N!<2(9Y[>L;BXYXY=@U/\(( M\Y?D/N%EWTL159GR)HO[K/S'+<>1I9W=R2)7L)P"D$\V]''?"2);_E>98F' M0UD+/0,4\]+FOF9]?^II)#-9ISBG)/!00"0Q]3OBC-21NNCVDG:_%X\F,70 M^V2+=Q/5Z7#LQ':FM7EHVF$E%IMGW/9=-P];Q6"A\DW>9F/:%N$Z)WO$^.A%/CQ'4%(8 M%?"8UL4"V:H[-7C?ML\4?__)M>"EJL1 @P;:Q* D#,O8B7(EL] M U%_8'T;$77+0 6?IM M-@JK.>D^!&&]T[&&8,K1[1,WSAZ.XBMSZAE!4L Y=94(/_^D?P#,E1>644 MND@2H'12CATD0]D(GC[RUOB<7'73HZG(E_L;-X=.'4X)[R8JZZN!9S[[VZ6 M_J^PM;\21?W=C&/.WT5'EW ?NB8M\./=?<9]D+(U%WQ$XZ-6#68#"\RTL%PO MY/B^$/PO'F:^+8#2X;P+L6MV':EZI=)OBZ]E"$4T(:-W9!6\?]R2J.50S+)G M"]"Y>>;$M.!GO:^&;S@O?".;EQCADO0&[_M[A0R#/S6,3NK7XK6=H42%I+= M89)60[G+PFMMP@'ETY)1)X!/%^4UZIOABZK7QZ3_ZQDM: 9O=:1<\-XH<#%_^) ;YVSI!C< M!E>30?..EY'(:I+>3-035"1'"U=9$U"D4>2-%+ MDG]ZCDY'/\A+_=GO;U08KD7H=735QAU^7G@L'9/;]?)ZQ\NWWJ:F"GYG.[D MQ ;](S/K E]:_E2-E3]#15PA;G:!+^S^!$<=LNYO+I M<60W%>"H L5DA<#=RSB,+$P;!,8JW36:9C(?\K9=.#DE79U^X4R%#6_9JNA4 M(B,0J+T1[J^H?@-7N;P/U>_NS $Y.%D.KM\SP@QS:\M9>,0D93QHJA(JUD7 M\ZLXF]J>&&%M/$@Y!373(V(=^3RDM$?14BZZ;+N<.S&G#,,EYK2]2DW,A^7591G=E\;F% M"1F>!<[MOF:U+4@F9-@.)YNP//[#LKH9VM&^K/R)EM>W!E M&WUF@%>"M::^++VPT6"IWFX\.1 [3WDYV4[UN\ZHF3O!DYN)"L)!5SZ5"@ MT(/#'/TUQWC)+07CQ W:'M(>\>,:E-UW6"&?6UE5;C!ZRZGV(FO5M@KCMSN M(=]TV5.XCUUJO<%H>9!#/@G5+/J9.D4L(YF.Y!LFM%SVG>7;\VP/J/93/' M0Q?;]R^7(NH"?U.S]4T7FCSBY3<=:$U__Z<]7]ZEO-K;]HMM!30KY' MHR?G;C D& QWNY7TOZO)???LO8S_I2U;TT^WTTI=J78P@\F#?[#YS]GW[NC M?\N^_[6@_EOZ_:^5_3^EWX/_E'X/_AO/4_Z' M_9;C#VN/ARW7P.8+J#77@(J M<.0,%2CZE7J>3P4>#_[%^?AO&Q=0 ;]M7%!!_GGCPO]1.@BB AU(H@28+(\\ M\GT9B:NE E4Z@Z7N&@:I5(!E(UVK3ZA2,37B.R2M(_^+17X]6[$$;6-0Q MC!ZGPKT65"!!L\YL #:S5 NL&/N7^V+6RB3J MGF[6S)(K=86=WDZ&L4B^OQOIXK_!CB 72G=R'?9Z![XJSV-DLW:'$Z)->, M"CS/B%%2[+@Q)7OA5KZ>MK1V57V1X&2^3/O]>^>\D!PXH[Y [#_+;_![ M">EW]V/)=+^34_P_R_!K]Y0\COGWDL#^ KNA((^0WUDPF/:3 3)O$"$&SY3W M%HPFZ_Z[FR5(OVJ^LN:C6@YE>R"\JWY.25AB\>M9.B'TO]P]K #1(OZOZ@?\ MG@K@3)%$61TXR<0-1P1UG9M<0OLONT!6+!C$N9?OA5@[@'.1O_6O)OQ.^_WSYSPL!?V\1 MXZ\O;/R5AZS(/-#O."$0E-_NP#E+!6+(G-@# TLT9Y:JJ/5WFPQZN>.0=MV%3F(3SL58/,F\\S!13S$A/%0E%IVJ=N^ M?G;N)"1G3#Z:,NI58R0:E_SJD])J,/+,E+]8BQDTP:T1W[6KF=PD8LOP/S M)P0U^;:?=M^'AMC5PC56-)Q[KH5>IBR@7/IN0U]^-60N(2KCOT!%B0[8E]O$ M;;L-KFD(_-(8M5:T)4HB]HL%(K#XNM]$^&2^V)!SC,14AT)Y:$S%YG@'0.A M(8XC/AFY0EWCWZ65,VO!TV/[QZ0Q0:-%Z%Y)GQ(#1KX:9+LNXNFU\?-W/0TJ4W^D-/WPXR/#/D\"&B,0&QC,,9'! +'AJ3O\V=CT$>Z@S!VBL+F M\)L-6>W&%;4Y?;OI>!3B)6'S3>J ,U#X@QM@/O&!+(.K;9]FQ@8/= 0KVXWM MF#(3B[K;D'=Q"]5'7N7X%1=FOG>7KORDQ%>U<_A0/EIRWPJQBL=9M("J##I, M1=P]8440'KW;_P;>L$6-\+PN_Y885B"1FE4IQ3Q%!8I2&SK[C!Z4OQ_J[=?8_2A][2PVL_?&N,^YRB+TF M&]MG\X!%$\;6H .!.=1NQZB#V^"'?Y MLK-V&A^W9W<"SH95\X+:TW7)G?LG7CYYO:9X>X06^,9XYC,(S<_W/H.?W32]PTQY,&ECY][IZ:4R81N>4'2:].!4/@'E7^P %'&TR&F@'^= M4XU'=%I15$?[\\-4W=94D,RZ[OD'L0?Z"?G3>^QK7H1PA4H'PZ(KY%N7:%R[W>5!GE3Y:^0 MW2[H9%#DX7C][W1?;4!F2':7?;VG@MNS>Z^IEBGW=/:- M3[6?8NUN?],RK.F8SJL[+/T.46O)$NOVRXNE$+"P,)4@P7T\ 9)B!T$YW=/ MKLE6CGB-\,D^[M,YB]"/MMT2WI+OSC.&1X]$S('-B(-W")ZJWU1$?;J$2D>X MISAD#&)YLZ1B[S"\LU%RCF3)O#?5(&;VQ2GUME="TA$':FEB:4&8ER@'^>N3?".[1U6XV]G?28$0>R#7^V5RKWJ MKF4XY. [9Q"M$(.X6RSW_[>6E? MU5OS[XT34,0Y;L9R#"S!# P]A]/)SUW2D<8OY)=!0@9L(H>.W7\[(E6;+OLY MYT?51U3'&E)MT#R?/S13T+U^>&->OYS/DR03A[CNC&_!OG^D_O]9??"IFQG M[&WZ5)+5TUK(3(#S<YA(M MK"M'5(7CC#5S[R;,]_"UM5?27CPN6'AI2?65TC]"CVIAS+[J\CF1_O^3+23FVP%!>Q3$B9W=ZL];' MYA1-X7YQ\V'OYO:")8VGSZ8FI@+-^^8-[Z08]ISIYPE+;"DN9,Z:A4KA3"V^ M4TYWR >J;[B19)+^<+/<>!1UZD M:S_7\I>S&G4$\)(S(H/^',:F8]4;DU#J0IEE88)#NBL35^0@HXU[#>33ED^2,HYIW5><$S'8[7^#1/ MMVM=?XLSM:L_R Z1@>HDKI@Z>':X]RC<,E#EZ#JC:4\VNWA%TPU4JYG!'W M^;P:0AFV!7)X\>#P1@OE 7(@PS3=^6E=.$2>)VL]Y_L9_VJ3JF]'WD M>A?'U\HIO9,EA["F%[1J4L]>D;"6ET-\Z,>2V&!"MD3'NWB/@,?QJD#%B,^(V.EN[H->08W_H@ M5//6)QCFR\]]0]3E:=;YF,.Z+Y0:3T<1HF%KG[=-.8@!CG$FQ"C?!\C;D8+/ M';J=SJB-UUX^>^3&,><4,YNK@>67.:4N 5-4(&:@Q+E'OR&:-RA(UO?8.,: M;C)$Z9).&95V2UGYDK5P_LJ-B"V)Z>./=7]]XYJ MJFO3AX,@57H'(0@(2)6NMA($Q$4D0XB'0P!I00(A"]"2@H2 =!JM30 P0I M(M)!Z0FB=!(4/$(('\S\OM^:>7S6O,_,>F?6^\WWLA;_)"?WV6?O?:[[NLZY M"\]PJ^B;]>RS4W70&SO;1BBEY/K"O:G)>T.M!H]Y(U#R[T5N\UZ6TUJ.H>WC MB.K>_IR)V?\6+8G0M,.O=[1?:JD=@?[@JD-R=W#,\[H()V-W1 [4>Y/K#"XZ MFAF^/'A[8X,=_9HHF-G%,Q6RBZ1;"3X[,G6M%CTJ,EPW['VH0:>_7J:W)1QJ M'U$KSJMUO^BV@S/BV5S3%54T-SSC9]>^Q9PKB7N":.[]D=G[D+LBS7YMIM(I M\B)HUVM%#EZ>0T.T&D;8E5FZ3D:Z2%=;DDO)2[VT"A-B4SN2%)?D!E/M#K M&7:XPO5J26)"K.IW\NZRLB050 OT N[O+F-D,%=SI#2^#[HXCMTSDQDGB!X M@T/)(.%;PXVGY>W^V"/09TQW.RN@F@?8:XW7!7%:C/D,.MT6>0[^7#ZE/RY3 M.8>-47N]\\%S]IV@=JY8VK3"0JWD%77Y?XDY2(JH S,!@5T: @2G]'+1:<%T M725D2X/HET9[J0]VR>GNI3W6[]]V.0MX!JL!.-29='ZFJX$YET_WYH#S2!WZ982)5T6I_4+Y! MF6LP&Y[_Y2G%[@&G].4>>H;?4/+'KI.,F?=!;3MTNS![]E#U&M[%]C2L5\J MU(] D?5E.8PSEFWS13@)>Y<&"P=Q.H54_]3"HBL4J6R/H"TCDI1+6"B[!-P M@M,]\MS;Q<9^\'(?!5ZMMF@OF%0KK\.JO$E?4$8IN24AFWH.?\,1NYB'=:$ MGI;?@TUIR+MJJ(]&OL1"F) PU^\B":5 L7;(7LMQP9J@1 MNMDM&6JB8^V\B(XFL1JNH,TC[D^/L%JE20]B1V76AZ7+DZ$AK?JF5>S') MP5J=,IXCBK!W,?[J&%M"V1!%8-'?CK>1K4TUB36D_@37U)S6-5"-DJ^"/>+8433-][RAC#4O= 99> M^0%>"NT'M;VL=K?(.GN9BTF##1G>&5.14_V96%(U?@O3D7K-.1DFD#BTF?QZ MGMHGA?<7V8.UON%\E]/"H+92$/3SB%$6_<29-<;P![^J-O;P:>B;%XI%DR M6WN]7X@ZHC0H737ZG'.F^(=+@Z# K+]GW-8?@Z^F2J>^3QU<#Q[.82,R'EPG M6HRH1-D>OC!(U"$MN-+M;H!"'GMV3]J M6=?_OB[N^_MAW-8OO?;):A MZ$".:#<"'5TR @R7XNC\,G@=T[YATI/+]"7CV&Z'C828?_'6LBG_D.OP5'SA M=RL'A[]EA8!.-DS_PLF:)Q!/UMSF>,T3;A^!SF0=;XSHA>.-<7X;#4P<[QL?8+1(O1&T#$C:%\ MN-.>&B_YA(>TT1%HP&.=^PAD.DX$:/:=_S\8YTQ<(\(!XR58++A>IY<=#PNO M/P)QU?'U]M[TA)!XY1'JPG9!+H"T-#?+QFY=6;4=,@FG,@+%N?LXC4-A+ M][0 I98WKAP!Q>]ZPDCS/3NZ]BU)!XZ1_2:Z#(V^7 _C97<5R!8#OFT<$/0Q M_':3&CP 6H_Y\U )>J:.M\1WNK-VZ-56_(-+Q$\_T7.VLG+:6O3P<\04D!1 M>=5FT,'].7@L;JDG0"<2(;MT6?'E.^:?MPY6CZ!W@NF(#80?:A MUE]S\$.=[>-,%; %JN#&;3$]53@DS#!@L-$3A^[T^W/'_L\?@Q7I%FJ%=;^ M$)T&] ]=;?00"8&(K%1-3@P10CU0B_.D)RQIY(G)6/C/%,.-4;6KM-U@DBQE88L@FEOA;33[Y\#@= M]/];=E[YO]4G5^46S8W R?H)$.;-B@=C7 MZ=8=;)QX[027%YSS+Y.LJ>6TE0QO?)PF:K=ONO<*N"E**)HLPJ"6G?L_$WVB?^30 MKV0D12OJD3E4CVX-V6%K%T3D-01JKK)[A"ME=4;EW.3 M/U;+YTVX^F^+O[DOIQ(0NS^PQVD=> 4TR$-H[Z.-2/U,<- MBEX#(H1M1+.H#P1;.AWWGG;7FA=]2Q^GWK.C_(^X^![B=VD7EO:8'ZB\F$A MT18)P>10NS.YHLDJU'AXPRCPUWX?7'_;%P.)? M)5)B&S- Q,Q\M!6)FC34#(NM"!88+$>H ,Y8='S#_F"8FPUW/?ZPKK"^U!M M%:]29Q%HTY.V3DD_55;^&0^[&]X7ISL #"^SB.SA7:!'B.);YM>03+:8 M>\;N/ ACPP(MGUSSV0^3&^4SM#><7)YI?(I_29Y01X8'AP53$[6 YT7Z;P"= M#GXQPKW,,SW3^H.LVDVM$>=IR^UE>"Z>81_>_.C9\9-]8-V"OPC;=N^;_L2/ M@PJ)._5(Z4#53Q;<^;"MYHNG#:O9?R9MC)6XJ#AOD.TE,2-,ITA,J_T$ZP$W M$F]]8_;:.L]=BAG&\^.OE\]TSCPYUDV9%_3$ ;(MZ MC'KU7:Y2.RQN9UEP.0+55FTE0"IBTF8H5.K&5DE^#0^FT&5PXO&^M/[:7) M+RUTYV:D&%/3SM%\M[(O+:%:+F(_N."'7\#P7SPL:I<&9+K0=.UL+CRVF -K M-6V4!E74O=;VC%]"+XN8_(?/)2IJWW2@8&Q1P[56X2 1)'XB-<%Y,QE'+X]- M"D=H@B/ G3LK%A[515I>CH[G?PC?'.FY.AWQ6MK^#MOF[6%:$!&=C[Z-? AA M(!Y+QR><>T7X^0A\66<[)S)J!'[G^';^D24B!LN 7H,7-FJXE8AG"C-']X). M(>/(=];^?8P!J?0D(G[M;T8AI)V$,Q0B/WW#0@YUO==.WF[]'GSO\A^%5O_W MQ'R=V/C-P?V'X_CO#0E'9PQ-]Y)N92Z)'B8&#)'2#8Z98[ B,$.B01(,]V* M+ (8QQFY>[PC/[LT]\83KWZY6FICK>/9?J_,AQQVM\&'V^5%O.QB8E0(V:\I MK6,<@1BN LL'($T#8^E.)%K ;G#!\8O&Y[0% 4BY C4F?#S"'1NFJ#S?3X MJ-^_&?D3 R $V?]^TYT6)OC177W5,2@L0.JK7D+]&>D=3E#KY'VW24!T^# MP)QNV S8EK" "7+NF#8-52/';U^;$D7EF-F>7G'J,=#I>RQ\05XA:4'57!X^A_@LOYQ3-M.: 7S(JX=D[#K1#O ?1', K08$T1#OXTA(^MUE"W M+6SG%8;8F!4J2WA&KCXH\:0AO]3/Y_Y3Y)]8\S^;?C+ADM_..;+KGD-U4J:X M$G&Y=-:_V;<>'V"YR;)V[\&\W0C=K'GMV83W^OI<0[+I1KG7]$ '^;%X-#< MT1]I/[\V+T58B)1"Z.?Y/QTJ!-N)YH3+^93)+KL/6>D.(_[?I,@+RO?^%10 MN]S["(2E'R7)(JX2-HL3O>$^FW37F^O'%#:I[B6J9FF8#19R&L+O.TR/M36 MF:<&+]2=7N_KPR_E6<.V]UK"00;L!K M?\V+AUCPQ4I:[U_XCC1H1'=F-2Y?[I\NV>QKDIXUOC51O.3 ,PMX8ISC/D MBT_/!\(W^^]4GNX4?]_!1+;RS)036Q5&HL3?>ZMHR "WO(G?/-#=&=1(]FB( M7/VLZY0ST)M]Z_%+9;X.92-ZWV=_)>"#;-GVMWAZTK,CD#OXEV).?,Z>B#MD M7U,1J7ALS.9YU:K21=)@^^GQI1J4P8UO[]K/-603'MQ6J-9QSJ_SJEV2+!F[ M8:+7(7<9#/\"5!=^6FTG!V2]7!UA[EY(K$1<9K]=S.U*1YZM"J:4:Y363[RT M,Q-O?1KW-CJI1U%5CJ J G0PZ/KT**?)5M'7[C9);GZLN1T\H7UUAO2D,=)=)GW/EZ,O0Y!$[UTG+=V]X@+K;&HT&GS:$ M8 P9W=#4E3_HUH=X@%0S?%MZ,HMT5:F66HW;J.5+^S0)^.9G9B?C@\:>4RDN MY(O3_X5PR?_[?ZAX#$LP9>NX9/,F\!M@JWQQR>^,R[!PBU(@+#1,'4&N9QT M)07N6$L5!B-X3,56'(U#:?;OVFVR']_\+N)&$E^G<)HNHN^,_&BL5#1B^6S6UH6K:&E%ZHQ]':L/! M'O)]ZSFLK>X$6T. LP 6-;B"YNCXNL3^/>E;#5;?;(M]?EL)/L?>D"_F', MW\]?;_3<))>]%Y'P3BJV<\A;@^!AT\K"S#'@S:8Y!(8;XGCRU MM.^S] T4K>R[((.W^#\-RE^ M/DU/&^1+E;.).O[?&X'4=,+:4DSZ1U\2K9RU_1C,!4P06"]#1CCQW#.T<:8 MIRXV(E%7(M,VUU0-46>T5;8, M?F]9S9ZOE70V.D9Z<_L6M-BG7D K&<21[;\]ESB2)BG&'EQ?KL'"E_>')R, MK:(;K0R@[.^FU?8V513J\[4&O5^X?W&0Z@AF77KG=1@Y!(=E!>FEL;UGK\ MH\&)_QG1:D^@ZVB8=G/1.(4:5:AP[V]X6?$0.N_<&HOC>JZKT1C1]=\SD3C ML:R1]Q!' DB1Q_F(6.=QY3 !#G\?E[DQ,/O2T#O5Y;2ES[WN\74)J) M:"QFN5;(E!?1HD&=FJ\B'SR4('>MMMOGGTT#]^+&>B#"H[\D+ \71-BP&NE M.+AQ6XR7!:G$3NYV\A3CX,-31HM_+/_B_D$QZ?-2U_[/C0,H/F 'JD54A.9I MY6K!:P47A&5GHCFN"ABT.W7V?Z[[$M:B9_%C7XP\E)#>Q86 !OJBVD6F"H85 MV5SJ;>DEW^H7K\G6/9 _&V9F8[8D?EE7.,'RL0=]XU<8%^)"/4&I&7'UM7L MKSUUF3<_?W))\/^-3/EV0]Z)4V9]<_DF;6/$FI%,Z6[6F;4W[&1?>,7!$1= M<;:GY@'?I6Z2L'YFQ:U>,^CC32\#?[ZYPKWO&&%724,83U1]G&RYH/SWK";? M\W: _&$QMLWY&B$IOE5SZ1!R>\>DE'186-EY"'M)#&(\)I?TQ M!^WS)MO9JCBXIE^.<"8P)CG@-[.>6:3%(',M5IH1D5R24DZCYTL!C'.\Y. (]73D"18F?/+?/\8> M@4AG8.A?#"%J'I"9)1QE!<&P>_];;+T4K)M$3F +2,CZ&>(T=3[)D,/OMAY/ M)^?[>T),WA"VKRR>[/NL7CPII#7(I()H=QF?4IWP#_,=P'6V&JU]2LH=UB M_S@PR,N++42FCULF%J09 4^YR<\6)/^7V??4$.S\,L;\G21'@A#7@^RKPM$O M?YF\$H\4L!<6_U9)=2.R_61Z?[N2I#^Y8/)%6HGM(]!?G H-4/Y_I^D%0B^1 M172),43!$FIH="P0OJ)RC,?JBBS=#WKLI)8WE+QDZ5TH1\YW<5SN,^H^YJRVUW9U.E+'4W9Z[>@](?8LV6+24RNT997:AM MI4>O/J69?2\;IKL"^1-X"1&K0O\)[A20SKXAH$F1.5''NT/V>$-]40$!IV/ MM\;O7_RI68G CO;34R01>(L^'AWQHR7!V6;\Y/%9TMI\T\_?]""AL[C&B$ M009!F#^YZ.!0$@;YMNKX% Y(VOJY)4MW-+.B6-B:Q;C;32_IJP?J#8NTW=3< M#\@O@YZ"3(PH25U'H+?MH0?"@,XF"NT\&2RXYAGZ9IVVR8QM\3!C04CPXI4! M3ZOX5Z!2]-V_]4;%S56#:@"<0-3#T:OBJ&)_N!LRV_0BW[CX0NYSI'Q(\[3P M,.<9J;3_<._M-P?,4]T> TT5%_I@\@<7 M$V#SILQ,([/,=CW#HT8XTGV=MZ6ILBA-=]HLB_?4'D[VJ] R+WUCBN'KDZHY MY<$?]Y6J/:O;6RHM7:K7&TCGHS3KT^:D!,<%QRESQ\B"HTK6VY\[V%>< M^2VFGJ <]A!A4@$W-&Y)PZDFT;O!2C^72^8Y/"^O?/B^CS;%=#EZ23G_BK M1:8 6C'RH#]@?<&X\KHO9BX'4BC9D+WR 9M[Z6A^O MP?Z(#CJMZ2),\7T G'%JT::.A]%TK%(S-SR5Q,6KYL1E2@')IOKI?"=O>2G,QM_KV0>08="X^\UY1OBMEGT2MU-.:9,VT52]$W1?J'Y8GD\ MLS.2\"<78NXS/]UA:2ETTL@\7ER?;YW6IF;X[-K<=3"[FF.Y2.[>$-_FN_:D MLY/:W&FV<]%U/QZ(ZXU?TBY8!5"J:(__.B\2\N9NDOW.>Y8F'HM"_Y)+ H)L3QP)>_N)(VD^1HM4B:_H MB"-0;=;0NSER[?A+XT&]MW9(A,_RGY]$8<^E'RX6?=Y>C7J_16MMJQ7Z9W4 MH5<@@5JM8+S;F#Z0CFNQA'##<[IX9+KEBO)4HYS1@T9TMD!EW3:HG-,$/=',9SQZ[/'('.NDW^9'JQ(;,XYB%C MP^MI=_ T.MFJ^D$O_+1L!FA7YO?9$/N326MW(7!NK/L?TRT+X%T^O&"3VHXGQ9(JWHBJ[IC:K9%. MJ%W%OU"[TU,+Q)/1J(>]?C@&>VW&-.0J%?]ED"WNXOWS1C,@LH"I;(#S))YM-7XA[@>494AK2C'H!ET2Z_2[I06"^[R.M: M>,K+H'W+WY<)\MM:5L6V^KR!"QD=,!+/M?,3,-KD=-'()3/BB)$6=77/]CD M.2H]7N,QVG>Y9Y9O?AT?OFB+0?N02A;+Y2N9LOE=.9ZF;BIB:]YQ&I!1& MFR/SW"JAPG62!.TT07/&:;9-.7:PV!VR#?#OM\!)HE/9B8>ZACKQ4)RVR!U' M>'K'0F0.#<(5_[.[79Q0'(7P5CAYQC#K-D(CA%U7.R:T8\XYD?G)^IP,\OV MPQ\ZVD4]\"]-4-AN^/WI^M712:P"1O7P.8S;PHYAZ:WN MW=-2&X!LE>X4B.J&=EXZ-;$':$O3CH:S=^7KR:$MXMP+>T FH'+W>L;8O< M.7^^LF_: 74%PRUN=HJ!>N5/3A0BELN(_FNWVS%E )UPAK\R_K^'V4.FPQ@D M=($A>,KFC$"T@BW_:C5YFB;H[BP\2 5,]_#><+;15?5N;5QQX8EZW8 >I4TP+] ]=Z^8MHIN=,,E=+_PVV_C%=S;,YK$>HZCZR52O M!OT\9<7ZB>G@3(1A;0.BWFH9!6(,RF^"0G!^D;NV'&XDGCITRI+YJ/3IACP MWU3VNJ2FEPO2,]"7$BH[1GZ>A:!=EV&3@_1V>A'J_MCK M]9SEYP668W0?\7!(L&OZ9?+BES0 2KW"5\_^=1K9L\UH1KR,3X^NY[L#]5S/ M,&@OHL@^.PRKY-]3CE529C:_GFJEP_R=#=LIQD7Y\+M%NP" P4+H5_WV[$L9JIEF0CJR'>]C#;HC=7QO4_81!_,= M1$B9A%K,9 X#XCR.3_->D-?NH,C"'12,8<6O=@#)V\O+&RTI9%YY1V8^#T,I M&V6TF>U"/BI627X7("Q"!5SSH8\',^_4M[;4--369G\-CA/$=NZ+9BHY/N< M'_ZLB^J%WB7C^NI1N&:/A6EB7>@;5Y:/>"I9/;ZYPLETIC[0^?-A#GI"GM2J MUE<[SSZ^PNMMFHG$7(?35'Y@=IOR$U1=KU#Y^G5MRUC^CUNV@_U4MI9]Z9O MASZOF.M+]I#9HF?AEL&2P!OLT.DUH]7]^)]C"WK5&3,W1K?JN05T)#G,T^8O MG)%E23CH5RI^'^PA1EZ9WUIL?IA79R"#&PI#\)Y^75!F 11K-TY ZQ-D;K:V M-?!Z2)U[XO^TBQ ]LRD])%2?DY(#LJJ;5B A)D=@6#(!R\);PXS-\-.Q2MK MH>WN?^K$W&=BT%[NXXV\HB!6R7H7F,%B>K$W0G,NK%UX75CI$20\O7VMI;4 MOA<8B:ZBZT5/(V]&4QYI\UD[U%@U\%U2C%%1 N\;?BYF@E%,36#0FLWH[4, MW^>!/F>@?(/ES 5J1G+BJ5[GDN?&K]9 Y%U>TH!V R3(>VR4QM2HBBI(;_B+ M%&[B%/T1BOK):+L#S])%:1 _#!I/["R"&\)H[".^DI&8_@8RK2:2W[\I(L77 M4%:>R=DH3T6-76+Q=RL0P]=J[";?!05LLO?#"W Y4:V\%1:K&>49\?)6TMMU MFH760ZZ@E3,_9;N'.QAABE/J90EC1R 7 SE,SP+3#PBSZDPO=M.73V7: 'S MI8G94N.Y/=RI->6\=P1BX.6XGFA:ICUY:!8;%T2_^P:F MAC/7C- 9 M):H6K#-952)Z4K:6[B0:#+:X7FFXS=Y!P8%(38[C9P=0V!SN=6/7 .N)I5E! M&L&4=?WF>E3+-?GF:?\'9EMW&?0B7H&TO9O\"7\-P=-_TMWM%OUR(.S1/.3 MFJ %_R=[]C_Y3_4\>!RXP[AAFSPQB,:S>V3R=$Z M]@ UWCKCZZ[O>IZ>=VY&@H9-XL7 4^)91XQ\IEV;J!Y"FN[:;<(X7#,.<2 M%(M0,9+U4.=W%K9[X9PQE2959W)VS4O!9/ V63E3P./,>FK#[^L\9CN%25\KG\^SL2SL%'#)E/W M\%%N:J=M+#.1]S ?X10L"(YI0)_Q@09?]<%!&-8RV'='4WBB%\5PO4QHR9I M5ULE$[@'JD7K$2U:H" 9+T)9A_[!'03;N/?YIM%@'H1JRT@=4$_WB7%:6@I: M-3@QN%%]G89>.-5K_KJ):&$7O9OZ%IP?(4:.2& WN9[-QH?A>S.MQIFKV M(H7Z>!7.S5" [.#$??4FBY]R=@76I39)"L"9+0 Z9\Y/%-7\$F1 M=9D#MJQ$=;BB:T_)T!LW>36D_=GFH_7BPP/-OB>@2Z!7 M)D @0;7+1@RPQ=O>' ^^N$"4F CF6U..A >_\_>4/I>QIE_47'N@]DATFNH5 M@3W310BL1$:_X\A&]@GA0$A(ZC:,F[]$L'D)/9^66;F.FBZJJ'N?AXMUCTIF M#DLAH^TXRWI4N-/W?_AN6/ZXWG2T\H6=ST#]@X2&^ N^N1914]"KK4(0XF. MA-I[Y/)"\YLCD/DX,0=![DRBL3^@!2)A+"YH7JY^K'0\&ZQ&LQ='=8=-BS9 MNJ.VZA4FU2=Z+#&E'J?N'!/]R;6'7H6RY5ZE^6TI04@LF&R6__FK==?T:AM M]_[&N_\_)(\F8Y$A#>DY'.WGX57=:0M=A_Y1/ MO9#/B9 RA=E(0I7MAWSKW)&8WT8)X?KR^!.W" MIT+X-EQ Z,DW-IR BMBJ63:$VSE_R[MS0\Z O8,LY/+-)0J6C&:@K-M\ZT#(V"8K?T?6 <2O\JSE7.ZEGMSA?7&ZK7JB%9;)#FE)O.>7LWAJ9: M58O@9?I!RA9CDKL)CJ).G5HE![66%2]U-!&(VIUGTOC)C04S'R+T-1:"H? M2D ?G]3]4T4Y87#3!<;"C,6(H^]A?N^R=>4!E,>6B!41I%7;W+_Z[=!/5BQR;,/ ML->N+[?DU)-KH<7-XN7N['?%2_I,+H(C:B2E]7T6B#=-/P9<.''VKJ_= M5/BVTMV]R/7=4"@+1-ARUA[\%I)3_!",Y+Y:VO-(N1=[:> MPQ=WWT/7G8YK->72DMOL/CQO<.CX+E"4R5#%'T=]:7+<._5Y4+\'8UE20D8J&/LD,71#B[%=H.O9C(=Q[NRU0A7= MU0]FZ;Q3?SKI+"B@6W9WQ<7(,<<#PYRTC("$M%[9F^+Y,?G6O<$BH>@5 5S= M4/5FVB9=YWD!//.'KQ1:CYY]\D"[NUO<&#(=WC]5;4)8:]/34GMK MG>O"&M:_S(3[^NS//GP[UUPFK95N(S'E+@VC@UG/F[3SG[5 _E4]]/+= MJ_VK_LJ67RLPC8DPNO5E3$!:O-<1\VJ<-,FN0[[@C;UG'2"#RRD&N:-FE- M[X)0J?DO(B-LP%"A&XD+/9,J"]&;X$UEM,=+A4'#N\W/'0_NUEFVBDIWW1P M2IZDO-/N[K5[GHT,IZ$$^)69-SS')H!U)J41=.Z%TZO-UNF1BCW#1Z#:2D&Y M\//CP[.:LN$#E@XFX?YW:ARY+LXL:_ "K$N;C-CY&(IV/E%(H67)D.JE4?3C%:I4Z;U_K%HG?I\?F MN.5L22YCMG=.2,9DIFATJ]C4=/C=&_7H4SG"% J47APE_,>$A;S!?&4Y%Z9 MFR)4FOS"<=9H@]$9B^R">R_PN"I;)(6WNMN7N%Q.D3V)!QN514I#,&$;TV^ MU4=0 :$7CN'"9G7&;?KOO;1.AW(?E[P7100,6_TK8_%B+Y%RC_8T7QTA$M M_P5,3E+V&:!B3PB[GF">CT99MO F&&/V(S/I?]QLF=C\TARF$H-$[R!>G]U M]=C^>383B4V+!8/FL8JOK"]EOBD-^]_;N9'7?>>&7\T;YLI/.5\?E5JZ?7M< M(L#IDO^VU7$I@1&[E<11AN/='?/^)2-5SN&GX_.]4D3WG''=6OX^'T%E9XB^B?3[W9<,Q"/4C,ST^[YQ(#6;O1\6WG=4 + M?Z-5_LFPW-I5=O[?E8YL[6A4PVYI-'[4W MF'RHIEJPX#9=](7']Z4=1;JI:?H=:EP8VYTAH6JLR5T6O44RT[\AQ]'_/A[( MW_2WKMEE$\C?8H;(#@[_5M=LV["?-LQ3#Q'CCC>+,[;J&&9UX&!UOVBQN\P[X/0%-^W6%N M,$C8:1CUA%_99P?^JWE]NW?1D&\,0%Q0L;S$7.N=G2(F#%,PHCEC&5K9?] M6;@=DQ_$D+ETS.ZH"";^:U;33/![,.]S?>7.(7 $N7 .W<)]Y!=QT&'I'QN% M@_]]Q_&J+G4J;&\8/;^;?E7X MT3G'OC/QF'BZ#@B(PX2-=TY>BQR#HTQ%KE7+U1/2A;6Y=CUT==HT8>'?U3E M 1U^^5OG[3CFY#\/?NMWCOSWKFGBJ[R_Q.@;XO7I"08<,BY['D(S!X0;HB;YM[[,7&LP>,SS MT<;HO;VM9+NMY[3<(]F,0^\C4"K^"%3J<\ -ER%AD?CTH"02<"4295.^JCD MFXP< 6F@ 1AAO2.'0^.L%?P(A G8SEP<0KU5ZPI/5Z=Q)[CSC":DNU]D7J& MY^K.J41E1RYR++JWZA3"#/#R6CH"T:^WP\EB-]%4"6?AXHMGSQQ^ZXWB:A<^:O]#.K[AXSY F>-+ \6YI=%](_/ M^L=<["P$"X@M^=X.T> E!N!%WR5%TKD#(579B\]0$^"UZ<L M=R&![."#4QIQ[>'#P/(KQR3RC>V;I/[T,DLV,57_'O42DF#((IQFW/ M=1-\NX] \L_OS)BJ9ET%M6BQ)^&J.%:SZ4;!=R:NP MR4KH23QE8&9_L11ZA9?-5 #-@1"?I],0#SHJ/-)%K _UO#=K-^5J/BJ ME7:9=H"7PN',]>@KJI%75-8D(NJ ,6SFL9"<7]];K3* .JSS#<8"L#NDT>A: MJ-6GH)S-2^J/E^U=I+)R,YKP![C7H83+/IIY1R!WH=54J;99E?:8P(!MOC0 MKE]^1MV]RXZ70?',ZU?X?/XG(,=F M30P.A1,9L6A:J]D2O:_#/^("E9]?[;LGY@&2NW11C3"HU6]R JPDTH95# OSW<_'\HF?OVU/0Y4=>B?&TVDZDOSU,I=_][6-H?3JTL^ M1TER3G6)SR3UE7WEN+H<.L#0!E7?-DK4JGB=HY@U/YI.U4IZC =_&N&[JSO M3 O@WIS4%7 V@#XR.D,I.T,Z9P]6O3K@%C8_L[&1!%ON37BSK.!56DM/1&Q5:EI(BRTJ-!EA;+&_;P^.04N7C[M.NS%WW[, 7,5\ * MP-(-@E/3:Y> K5JH;T9QV&X%XXU85]/W^E^A3GVV"Y(>OG)MA2[VGOHRF2JG M>#W+LC4@S&J/"?;O FRR7IM+1479C%I?'" P''N:'36H1PIO ZJNYID!^-68 M5LS^Q#V=,WL:NS-Q0T0._+9G^'#1A?S; N, ;!=,HP/ M%H+W?+^;?G>L_:R+2@4Q@Z&Z1+_8:HAK8O+[QF3GI.H3$[//0K)V%K<%3%< MG,UQEMM6^ FN_=CRWF>A7CC:SUV=^7^_:] M7C->UA3J.;BTLT=_M'UM6PE< MPZ\VN4"_EG#!F?S5!TI$!%XAS48LJCO-AJUQ_'Q#>C=G1L:$XTMV=G:DB$#(BM4B9._Q8/Y"@+5O3$!,Y$, M:(I><(Y+QD8X6^_ 4SV>DOB+M'T2TVHRBT@&N)!!^BW\=M2/-G+##.T,?6OI M]ZHN69^67^6+G4YZI&UPVS;"AE:W[D5ZY_ZIWD(K/?]B@3&!=\]V5-52NI1( MFY^S/M4LIFSHG30$YT$FU&<]QMIBCD"Q[>+H\7J^,W 9G2E%=0B&IW!/V2+H M0SW!\R">OFV/[EP^$^9QJK/26DIK9G:.4E)W89GB68$F_1BUS1].^Q47?I- M.:(F&D],XK4LC-RLV)0L8M7YIC#RP,]!9#9)\DS:WN=V#D!N<872EGI%+HP]V)G+R%W3-M6JBH,Q JF]%ED]S3+2"A5JCG4Z\8)D)O- MC6'4V1JG=]T:X M!":F>X3\V!Q MYUFVDQ!G@R7_N!6_[.M/0Y/X\&1#TFRP3T0FG8:9$$G#L*& MJ0#B,'Z/.6F;LYX3X[XTC(Q:&OLV"8?T\[-5LW>2IFU$1EN]\#K8[F#&N"$\ MY'@YF-9(E&_'6U<6-F/HL]-6'^\L:03&O20CI[A/;**S%5O/5IPDZN4!?MKC M]332WE6,EOJN1=-/2]-&^M7264 @;BG)C^\R)8-O9Y7FWEQ@4OP&!(%#IP$P M76^I4DV:QG5_3BA+UZA_IM]W'K&9%AAWCW\NH\UAG<("A24Q""CRRH='=?-$ MQ0@3LLOV-B%&P_?K:L.5C5^JE3UK>[X\#9C,G0E\EJ:J.^UOR_PO%=!/.,?0 M,>?0S!VW43@L;'4ETK;'P0PTMA8K6T+IS<_":8=N=^6H<=5V[_W8I/CMI"L M</G9^&OC?HY;&OIV>QCKD-T1#T M^P\\I^\4EHAOR-NH'UP!1&"GW8.YS!">"TP(^9(5HWEXH-E3?5XZ,H7AZ#-R M\EQG'FMZ1@ITGRJFRBA:/ )-\_:2R&-'Z7FM=,LW?_@KD-G[V$%]W6>I,O- MJ;%JD#/OG=J?/E=L)JWC\H%] "A#>3A;.-XWKTNQ@4"VQX/-W!C%?:HNK!1 M.G>7[\L8MHOY.CS22Q$F((=AHD_OB!U_[L_%( (DJA7V_DGVQ7@5(:$QS.] M6%4TD^O>/F9N-M/E7G^EO?G >^Z;[LOI UN\VK>TY6TKU E1IG#5P\W!8]9-?AOFCGW=['RS\'\]T MU),[2]B?&VV+C(QKK"NKK@^E1 A!RPEU"2#=V%".'(ID$5:7_BNR7\]8!&M- MK1?W;.IWVS:@.I%@-WYF_:2HA9J?(6J0$L."HJW=9GO?J8IC2J0"8I36"!8 MKK\P#@/ZGTAZ_J+\]]H&M,:T@"D9BCN".2V'3T,P#">A^F&X0^;U%RK+#B M#L-YV/;E3AJNRP\8KW"'4(TMX'61T0L@#ANN-HQ7-.4M$@OTR<.(7QMV<+ M3V/9'G> O-G(EO:M_*86Z(CJ6')8T.-2=TZ>^:J"&8MU5/;94(62[;E-H;2= M"8H1**JY]C;/FP?L.]RW![T"@EX=@?A:S^$930CJD\5?IX&#;IZ[/VWX"2)Y M%ZP,SS+=3)[)3943U.A#\.PS_E:>XV8;A&.G8LHWC=TR9UKHU4K;[5Y]]6C M\E58J87.8YZ^0G;/2NHSU!3\N;&1WSN"N7G6%+U3Y,>(Y[TT MRG #YI;$WG538GT9[4G1WU>Q5@7(,@$I%M,VF"XGHJ@U\#WQ7=M14E6"D?>TFJ)=+.KR+X,N^;!H\6Y>YBTPGKA:F;V.K7H"J_^\VY)#NX+B M^?"57+I .HO.2O?^0N@@_L+26.:OHLN.9B]KN3G]9)UT **6<-0\S@^D0 M^DT$V^C=)$ZWBX#&Z!94TZ(Y91(NLRT)_68NA>BDZU^>N_S]Y9FBD ??BH)D MEV38M+"6=[!??N)!7Z>#1E!3VZ6_E0^4WXMTH.-PIPOLT8HVRO<"4SXK6B MQ"/H,AW@THS\W-Y;+%5%PBKK5%'I_,K%3\;Z>D/46[TRA@8LN+4,=7=5>( M2\F_F^<>(9J\QEQL2ARR?!N[P_9,0NRI<&S'15.O%FX,\^PPU;-U&]8F/'\Q MEC[P;GMU?:HY8=JM7?2Y69Q3BK4X5&-4;"!15FZU^LTONAIG4/M8-3BVH@X2 MN\"JV%2):QU^J##'>LM=W[KFIB),:7/Z+'+(-''=@+8('7/)ZIZ3I0&QS< M2>)##RLP4@)(S>&JS]G;^F/>C5;'N;/)+@%K]-^2VY3"5 -IUF&%!D]HI MM=B+]PTA,=[/!8+J^ABRKS7Z'(%T9I;Q:^4:-M14);EG;.F!8B0Q13"$<>] MH6#+ L32&,= 3&8BXF.;-<UP&#I-?7L8#EMTQB"I MS-9\+:@PV[0KO@'YDGY[^QYQ4!C?=5O>6DT>6C36]Y+LT'N^?C>)S\@%"OX M50V^D;I#\AM1AR:)Z6YIPZ(')2%BQ-,@]_^11A2V619@(CLYUGECLQ0^AMV. M46#DLEFW@,03];\-%7V>[O>8]Z@/5-EP;M^9'[W;,D7_H+4?0G;0>>3_ Y1 M T(JJ5?=^0BD_SJ7<<(0"++M9-QG;Q= +C;W_M_$!::3Q 4<%8FN'/E+#LU> MDLLXG?//(___>.248<("WA06OL#23@<<=DX1Q](NJ 31:(5CR]M:LSOF MFX4QW._GJFFY>W0IEBY1%?FB\ ?"B>E$SL3DHY YZ9P]4@3-C(\%?&R M\6+4(3V$"8WMS_)+T9BGFM0(X?'3DIS4BI!B%&VR)$K8-!O'^O\\9<^/P__ M5QG,0+- %E,6#4X5U5$VF"E ,;R"!2;>67LZ]BNP;6%C9],UFM[::E"+Z!+ M3YTN+)SFT[UT&=?^'OA$ .8+E6%(U07VVR-)A4@IUQ9KPIG<^"_C)A]6I.] M9MS?T$C'['6HJN7M8?RZD$_[WGTG]3E(>\E04/D-B!]<4%!D#&=%PQ@;$C MX_JPGFA$ZV6%>THJ\4;/=J"5I[JMKH1>K.XFA#X-WM'N0SP\3"=$8ZV_GP M-E4E[CS@4(68W!1#.O@CE_'/EQY%[[,6)V.;@P]96K)(8BC MH(E(%(T_$_XS10.-M4ULI\=OA^T&:9H-$VD#2A2X):85"U[ M^Y)W-(8BTXN26MW4K'1G#;FXJ;:%'T;U#'U&=J'Y$+S8A=-K^Y'5>0"K;@:- M,!X5)1+;TWL[EB7;H+[#+"Z:283C4O9%.<9YW<_J8;$@PA$H(:?F"!01K (H M8]KI)G;I[37Q(LD+'I8&(,!>T)B =MYM4SWD&I.)H&;DEYJ]QW K'JB%@T$7813N^;/9DCP\FF+W?!7FB)[("UPY849#M[1 M!_$7:3:J+!I;=](4V+B1.]T!= M1U2X7EL+ZB:7U>E8?:Z&'HA?F-Z= 5:=+^#?D6[BS$G-?XU3_\$7HN/X?7, M0^2_IND?0S!/\#$$]QQ#\-/U[7TQ\D7&/WZ\\OM/VX\%VI_:;&\!&/&LG0NU M29@9"!5-_V(BTJ[%?ZE_ MSM^E:V,'&KA]X4 +V:E%$H9?VUD+4KUZ!'HR8(.>]&#MCO6QRL_;OU85$/. M=(KR7(CS'9.0SL,?59UM@7L%XQ GF6GCO;QF_'R4N]>2#!.0='?,>YO)FNVI MJRS2]>;W9/> =FG%"!96MH+YWH'KO!R0-XB(Q1ATZPXV[#-5GT?=RRO3%0- M?E+0VA^N?7 L6''J>7%==.-SM_@FV)=+"! M\Q$K2-0V-YHU4-S=+C.U^XQ'DG5VT(M)Z7LOPQ)% MCK,4Q^T84,ILJ-7'G",0Q3R06@:O'-)[2^ ,JZIKV6:T M)ZN_?V6]I3_5QA M:A>':NPX-+4]!)UF2Y52OSL\:#;0)]%R8@^=+-MH#Q;?/1_"2"Q0NV8?"X], M]^_^F0H'<3$5HHG?W\_'YW\)HZT^K^FQ:9Y1O/G+#ARU1;R K8J8;.?"7P\^ M/8G@+7+!KS.J-:2XW>F4_)ERB^!DWSP'\:M_I,]''#X-8S^^[12#!0#3SN;B M&,.$8+#;Y+UL_IQW]X97,[I'A]ZXONVIT?=Z^'H6=H6/TJSD?"2C8%T]&! M M.B;-!G06>%2L@B'CR@C BB&)3VT3GX M=;GH$.7["TG0.APK\#GDZU/6XAB8#73C)3C3=)-4E\P3-H? :"<:=[PC4 MQ;D'00&:7?/LI%'2Q$+M 8]_T7KU#('SW1SNU6VKSH58"-ZN_PE"PL!QLL9S5!4BN9='H_A8QIDPA4#ZW)F5A,L+!W MC)]H[JN_S4VW_(8 B9BKR"P=,VM[&8CH9"R<) M7%B5.U3^"9?.]Z9.O7]YJLX @! HYRN"R'S3/.Q0,'5;"EB7 @"K^\P7_TN M;K;]\X(HT]B7OH:Y:-2Y97/TS';O]/'S;EQ+%:SI 4@=#YGK(.;X;4RH# MWC-F9;LS-W@]/H$G4H6ER3C@]];5[TOJ477= .-B1:24;&3&1^CNW=N5&K,/5-__#)/YTK608P%,ECGFDGH;TCC5CR2 V:Q (!!8&U(X5?9?X MHPL=3F8FVB?BXZE7WBKK9@X=4=WK[YL:4Z:U$XR3;I$>6)>9;.#I8XJ\0-7 M AD;!F.@[2-L6=6Y;X0_9NIM5&WC M[KXR#6@?N!TK2%GR7B :N'$$JCX"X0R/0&[$PYO1R G-%PV]@BD9-&S1>K? M^V$#>.H[S=7TARBY$C =YM)Q@0SPV0O$G#"4PA&(KBL9[UE^W[R;[YW&X!2W MJPULMEKU'3A=9D+8S?%$723F 9H?,.E0%FBI)W&N%T<3-LR! S@F[Y6YC% M\%JM<'-2QV)$%S;1,BCA!4M,ZET_V3GGCY1>JVH#&X.C2IXF(-C4>H^O?X M: XWQ&IBY5V3O) #7>\0U^@A"JF'E_H'_@>N95,'"NLPIRU4"?+5$03Y7L=-SA.V(2G/HNRG;&P2;;9WLY6^#8 MU%F1= CE-:]-5ULO [XV-"F.XY-=>,0C?J5/@O797Q@YV?^=KS MXH%#UF$A>OX5C WM&&N(3;W[G7.6@W#JK1 ,N#E?'V<;R2%[E:QD_=#^>IG MU86E+CKVIC>!*$I<_BVQES%57TA5Q#>2 M62#LU-QJMT0SJ3E(/YE,7T?DF)VIR\HZL>**!;P?+JBM]3;>;, MCW-+G (4BPL)EY.HC6N.F^!-4AU1OJ Z;R'-!HCN;RVT,RP@O9T##.R';8?- MOUJ$F9'BM,4^?99W6?9!5G@#T ,3I/^"0\BN7DC?/"P\FP$X:Y./C<2A.9 ; MKJ)^&^ISV:+Q!IWT%$ M0IF4S+TD9;;-ZX=(T(J6OJ^I'$,R.IX\?H+F%^\FZ%#&N"='K9".)T:J'B!Y M00\,^!N^(_H&N6[(S8&G@.S^6\UCHE$[UOY+O:.I)@+W4NO/5]0)C"8Z!0> M6_?;Z"JT@P)@Q-F!/F]+L&UE]O\>@.QVF5HW!]<&/+.8_Z@]/>'9E)CRV?G) ML0[.'/YX?CPV83!.> >0!X]]BD0>^'[.=T]QX'7,XI%=#7MVA&HC/QY5FS0 MR]7AV=4R?@^KPT9)]HX^4;2]\3B0GG:J-::NYJT5RHZ]H$ M+",)B^A="4&QTSPR<%!@?WMXUG6\/R!YK1E9O-8N>9A7."Q S02?N?7MIS# LS7+#AD[RJ@]XN96O'O MYE_]1G8P_B?K27\'(N0?V0#V=Q[DG_[\(\GS_XIY(OZS]%?VY\JQL_AE^5?V MI]?HX?GQ/A@5Q@$3FGV%@(GPQK"B9 GH"+F2"FZ@I'_$6Y=F; GOVGBX+_63 M7Z8OU$@_^?U=Q9,@LO^YBA4],O>UXZB\WR\'D9W_7[W__>O%%$<=1XL9A\\#P8[0D1G M@-YM0&\^X)K!.T)JF:>S'QS7>Z4P^%Y52M)-[QAVNP=T#SSHJ$P2T!VK9#KT M0-FO-1_J,2CIN0H$/0@#_7;Z%TS+\7.N M<-=D7?)7,I/6KZTA[>C]A)71U9J?:41_\LEU@G_W+-O;8=DC$!. YXU04GVU M6CHNS^%4'[=>&S+B-JM9]JF[E$>E\0]5AJM=31N%TT%_68,//D%,@(AWWX) MQGRK"(+^[>E?V",$-7(H(@("2%7^0A@!'9"C ,K?3O]VY7^VP@/P?$[7)AUY M WV.@)Q(Z4->,2?>2;W4[T.Y^C1%T6O=/#2PLPJQ]88JR/?97R&:_?TM MG7^',?M/^&-_5?([%.X_S6?]'WW8_RS%N/EO9[$_DM5^O1KYVZVGO^:(WZBX M08]#1T?DY:ON3]]Z:]$>YD]>CU2]LD?Q"UWW(X60#HQ6[#)\O2GKR;QO_ MD3F[E=+\^1U%6\Q%<4MI; YM? 3L%,D09]R4J6?I M>:MQF&FF 9O@-U#M/[)G-Y.X(=[5>AEE1/3"T))TBP ++6)=>.MY^3LC[': M?>GPP G:75>UU@I^]JD(<>)=O(Z;[\=[IX"&\7:Y#@600\@L#QN(25 GL;0 M;I\>U'I8VIO.NJ&I&W9!]$%__)[JFPJ4-ZY% 3MF=::)>"K%&<_[Y5-MX^WQ MRK/3WQ3?W;3PIUBE1BT?F&HO'/N<&+9J71%DU9T1=.7&J2?..#YVJ30S]7=, MF=%O).V8Z[.UV1_&XM,C4G(?]H=N-N=/0%MDIB2$)C/&7K2RTEIM/?%0-? MY=_7=(YTG.;S XIG(5C$[P LO)_F(+>GX-"R/&"!')ZON6W 9,=6/.9 MW=:.I8X!_W'5.BS6/:#($FG27ID)JQ(,-PF;,AJU;QW6+Q!G@;MF]@BF M4W-J68!"5/@'<7H15AS$!5A%6+-.'A!9_3.V9GX(@6^4'XJK[%FL_-)Q4$13 MJ:2_L.[J_;T?#"ATO$6&6[P+%H]^(V>Q(KNN2"%X3=@Y--@>?JND%AM;&U3P MD9ZYII\&&-8FAKWR\%H'F[U-ZF.JKE.L#747/"KK3;>VXCG M:?RJB^F=+%0Y-3;7E?.%S-DRAG)E3PL1?"NV;L9\4S7_C4;1,[!-:?I:TSC MJX\Y:5RB_M"(0/81V0!IXQJB?+QGP6JIH5YK&%DLF/A4[SS+%==W+&<,6MER M4A7Z<9FP9!N)\GGQD3!@5U95&E2TT_R M?>7[B;3 G71QU]J#$2(4 M"WJ[&5G4SFBLU+KS!!)K,9LZ7RE7$73 00>$6=9GE"2-ORZ&S3"H$FP=DLYM M#+JXJM#5Z7$M9B20"XC%07FES_+0YK)<2#>5ZP+%FXE/0$0B;XQ:'R@96EDBD1.W")W>;,F3M)X MTT49[+NNLEHMF9\B<72TN8Y'( X4&"^IN'EWJ-D.=WBG_?/>=?FEU?Y[P:8O M&Y/4XZ[YVGEP&/NQG("D5[VF%#%1+7#:4UQ_:C+INM[ZRDXU91I9FPZ1Q42 M9J#:1A6@6I&$LB1LP,[ '^O^^)AL87A9@.RO260TX#]G&Z=CC>1YKGL1@E' MEM-VQ$8QO:]'E;-Y3,QR3!8\;\! ;RD_<^BVE-L0.C0=HO 3 E<43J,? Z0 M;%9[;7'X:;+UG2L/+^IES:N-M<1^B-)JJ?R MBF KYC0USJ]ZKY?&M2_I/&U&%H2?4[AIW&68.AF()!LFUZUGR(Q 8F$G+T' M80@:@+(S4(2(Z72];MLR(AL/[O<_E89;DC"8$8ODOEF'%HEKBF2Y('XAM6=K M,^S7NP_G!>F)'_BT<"\PG?/D0F%90'$T^]GPD+?)A$1TN4&JRL&<,'M MDQT(H4[N5&Y]PT5,SI:N8_P2:EPPIS5Z(Y>U"PU,?C[7;]KLM\#]&7%HW4_ MWO\Y.&TZ?1EA$IGV]/WR$N.EO>[W\F-ZH2<>;ZBL%9F.)2#)&A3ZL2ZJL 3 MVI^%QC7%KXME7#''7PP>.QMU18H[W_!,EPDU2( 9G$IB.!"; Y;Q(G/@\/AF ML5SD%I_!=RTTV.G2:IE,G]O&NV0)>9D;S'YN4S$OSHG@JYK%#R[/ /:BKOA(GN5P$@6"6(0;QS+YWQN0;C;;J[%X+L&S87T/\^^55>+8D:&CJ5 MXU$PD$^CTJ3YHOMNY%O@V$K70AC+ M_NVYSDS.>V42F;,P(8G4IY_OJ&0&]P9K1VD[19X;W!G#HRD-1^314>23Q)= M,EJ:NGF^FT.?DN>J7WSKX6S1OV4/4&S6FNJS/U#R@K >>#\]\Q+$J7<5E. M" ZD7OMY?-8-2X6.L4"AENSSN_ \0=A'%C6A7(2RU4]S.>FM91$C/3KRI\?D MIGP@Q)@(CE"Z1MB\->A=0%CL7(XJMX^%&?3,N$137;YD2^E9>3,IR5^A?22SLXX#REES:&QY6HO?)>G+ZHT)5VF?$U"O M,N<+FVTGSXJD<'^@333_)WMYZ0@$#N1VPK ^)-YK=-GS(2(1-^O'-_.;$Q," MLL5B3Q:R+4XLQMX[<\+40_S[H+<34B,=ETL8RRE''K<:Q>/].T&%Q; M;JJI'Y4D<Q,YRM?^=K3&I]Y3/ M@8)<2):E)!4")GAG:N;.YJWJ:(MH@U3X8FW4I%DZ@\[5]W?K$K8ZM47FW3/V MRM3>!TH1T]9^$)XH727P+. 5=7#BW^V(NH69I3.ZUN?'Y5PTPH9PKC\T&VP9 M).YX"LPT:)E_E21IV\Q#)N+;C:T$@(!1C6- M==/741S%TM%KAT2ISA[A&FD\;UO"U"#VS8DFH]8?I MXB]0<@F\$CD/U-HG3'' > N0GDS6<9=+2/T:/?3!4[C6T5I=_J/%&]QX(= MUIK/?8U^WK0@6@^C7\T!K^V(OV[6P^6PKN[W:G7-;FL3V5M"FQV-;I1TG'VZ M]E4>KY7H0<=%Y08U0Z)Q>C&RZ(GP+F4H(@P.=5.9AC8ZB: MHFBT+28"7O[MSO@^WX3I;BR-V:O(E1W^\34GJ& \^H1:!TSFY=GK1ZP)J ;>"NY_[P".U#+YDP!=G[KUXH M&[F+,B!^KEG8Y($K@H-E+355";5%'&GN_N[XJY;&RNRF,[Z66M78,/&+"J MK3@/H\BI3IV_?:FZU"R\D-Y,273&DS-? ^A.SYGO_)UF&&K[@Z%'QQI=X] MUBN/-BPZGTY);SYX?NJG"37=%7S0=:D%_/A3+PS5)%!G,;YS!&+\ID"A.;G[ M/7W-0$RRNELP)S:_ZY? M%SQC< WN )_XZLUOLK$0[[&\7!^CC$Y.2D=$<@#0#OV=?@L-M&N1B+0Q' M25<+8V%WAQ&;%1E+UY /.;:ETQJWOG)GB!HQBVZ<>;ND1(F;8_T&953F>_7/!F;'9.>99663)=@>7KI15>33Q1HGZ]5 M&F+>J D@M+/ [-S-1-?9=V U'$=@3!?W>;JYKA'L_6>V7I=.R]N4\,/A9 M1M? <)5H7J)MW=;@_O.,[0KD M;QV3XY4=<:D^<#6FEY(JN^^FO1!SU2$V7'"$7?A5&93#R;PK+3]MP NYVVL ML86KJV\Z$ '-9PWU5DXPVU 57_.X6-B)* [9C0[8)45;0%"'1T_)@,Q#@K! M;M)KN=5>3<'J([(+J&7O.,N:,=M!7 Y<9[FI;H!85XZ>/N+CF_5KJKO3@B MG=19OE/&NFGB3V7K"Y^:%_07>F^0U%J58A1S6 M&WM%6/\<"@]HI0@089XFU>GQN(6Z+IMEZ$G[=#X0EI+G0X!1N.[#'P^PX:$ MW$EDE9:CVHH/3]3TU/W28D:/CDK_G9B89Z+8=Z1,WA$^$#TUB(8?+C]+$; MM9]O4-2D4U82YK"''OL+6)Y3%;AH9S3OM[':M$5'HW7",F"X%6SA;I$;NP M4PP6NO6R#\H[.DX45"@0,@;9(CE&.HRWEH5XUHG^SJ'.#M4.@$1CNYEEOA M!!+%D((2VC7I[)?>&+2T41',H=AUA8Y6"N=IEV/E36.QI8=]HRC.\6I=N)SO6^5S36,BR.61&NG3 M2.>[0SRX"$&J&ZNS9\^]TF+I3@BA;GCXB6E^O^JU9.R_Q])Q?Q&!Z9_I'#9 M_C&Q]4/<9?\+U8T=NK/ (EF_U:BGIH7W4$RK]L\A%#Z(,2]#[#+_H#3KB M%8Y 8G=I\37L!X;'5FOX"$2U?01ZB?D%NWQE&[WE#?GO5QS62J1Y4PQO=,OR M>V-EN;+_4,E'/OGS)GMQTW.^AS<>/5L4N'NV]R) M90G@)]OE19\-O@K293W2Z7YR\+&G>00B+/0="WV$ BA3#QPYON&Q+K4=SX;? MI/\ &S^E-$?TOP_=@'L-AF+KH1$'$>_.3QNB&L:!([,"[&P^_0]WP+[:31X M[+EVZ4XMK1;/Y?Z)E$P&?KG2\N2^G)-D$+ I!UV.I#WVV.:+$B:JYTKWE^R M^'2]F4.>Y$DL\CC?]JR%OH4X%G $^<=/ .AA[0NQ6N,>#UY:GQWMM3M!Z? M]"0^>9C%:8LD>3@75%PX H55 H)'(/7D7X#P[!Q0DD\\X P)ANR84..0#A] MFR-0]Z^77?\%14&_HSQN'8$ZXR<1\WL%"_TAG!PY["3P_YSWB'R99=6:-T9S M6;5NIJO+Z/"X7>'-UQ\-JM#YD]O](C#8JOC]GO\E19V'9%V=]8C\R0[%PI[ MDX7/_5C[7?T=9/H8B6\_-BHFE>8SJ]+2!$D-_O==YB[S: SOC>"6UVL)61M MQJ"@#OB2!!ZF4POWGD@74+&>? _S9Q3W@K0'7$!$FC2.916.TT">9^XH=01 M!98ZA>]G1!I-[[<7A;0]RGOUW726@0!Y@L$93'Q3M,^R?@/(D+'5D5ZY^.LW MKCZK3OK<7_]I\W!U^/3VIIIDO;+4WM1/]/:8.S-VC@8W7<.3DZ?C<_&E'C M_-06O>^M]N1:DSY.<-=RVMHEWTKX@.J2?+R0^UJ&/ !A1VD2YCI:!8C@<&^] MTT 2^L1A52538%J7G<1[]-J3MKUK?NAZ6ZQN0&UX8\CGSU%A;X$Y]:XFG>K M#E7(7;^S-7=GV.65?V9);X/QN0>1;%4?-K#41G>U'SX"B8PV_LS#MM%X@0D.EE71+I8-+"W+N#1%T_;J:L,YK=".F@1YB(E2W=&AB4D\E-2J@.4%W$I16$J M@]QNEN2[[^PB6E/TK2F$2FQLTJ'SUR5W%].M''&>%=0B]98PWNQ=<.FD;GQ M,:RM-N?6W%7X8L<[]:B_ #5XN[X0YHY[-8YKT&[D7F+,8-'7#<0#JTI4$8O+Y6'GY8.V-L7MZC,HI(N(:[F?]Y+C+[,(:$M M)K<(K8[O[/-\KXB(.@XO=?I/.S/,EYQW&)6-Y9<\Z_5ET<+:@W7?HEGOD^YI MUQK$)6.C:Q!!+=K!9R;AQ!"%DH#>$(TU OI3LOF'E)2P.LX7Y>3[64X?];. M%:+7@+2#XQ)D-2S2T,\DGC^D>G+CB>9[-'.S/G%;G9!D[FR23:&KUL:C&860 MKL[4\2M\C] M<"&YOM9UR%-],XL,:>>8/.-Y:ZM?UC&'/O^242B6_>RS;9K"AG#]C1#DIOEH12A8]UF6T70[#<6"&?@UZ>G+! M>#9$Q]+J3E64Q))->Z3=-_BNT&L)NKYC(AG5](E,1':U3MTM!]V3&:4Z8$3 M9,KQ5F[DZ6YS,$GDKB/Y$K&VL-%C?.^UVF;#=)OW,\$0N'#& MUED 1US>>SH8&"6P]Y6^LW ]/I>$:Y%8[_]G&!-793VEY4]$XF3Z7E/I@\3 M%5ZKZ(FP4FQGL>_&=^K%6LD/TKCL$!9 M"!"_1RRL/Z62KXZ4K8S(VTQSN?U79XS68T%IJS2!?5Z9M4''5'Z_X8HB-^ MXG,G2KU+?X\,@50[M_?%H\ZD9]LPLD.-2/5P4[NL%'FB_"I6CT"V6;O M]1@075]IQIF6EBVG.R-NL?8\JM1EY@OL:^%+2ECZ Y-SK M>.R;#LP=H55)R+SUM$"14>]UBX['X9%29^06-]<7!P.;B?5'RXG\HU.;KA^ M_2F9I/<1IR>VYI.I,5&M$HA\_9>$UVKW3NL7P,^PC9GW-/;S<4BO$S7Q^%? M65@UP/5RQ#>YO.%@0,PINK8RVIOMP)%47($Z;#RT++Z&_L;L5+1-K+YI[@+ M:I(T71B7KIZ2T0#1=NR8?&/COT!(#5G 3 YK$&]23VXT/ M4BT#%EKB'W5]LXL2@ZZ%?1_XBN3="TQKXQ<"8/.0,XX00F)G ;WJS'FL9/K M5DUU[8NCEIU->D/),K0CNV>_I>M&%U>+@JAUUW8-,]]CF =KE4?9]M8.K0)XY M\0=6.AI:[1W_M":>>?[LN!;0FQJ; '\\ES/J621@9;EYXPGUPJO]/E,OZ MK42TG55']K='@L$?CH"U4D](83?(:(C91%@"Y3ZV^J&H?4:;>NZ$#>6M$^IUPM8>B)UR&L/6$'EE/C^""4S(F6G.4UD"HHU:9.S$JM:J:Q]DHY YR' <@/X] P2%.T"J.&G (R5JNJXC0N._R+L@V32,E_G[8GK/561X MT\N9!EN@/ I$+O22]+U#U(BV5GA'-O/3@DX>7]RUEQ+) J9?J(\YHI ,)U0 MQ3B^F\2:N5=.7 X)/ >'T2T,(YIA\RUN/N)PVC[1".SB1D)R:(B8C" 9T.@ MA['>Y.._M]%-[37)!?#+ ]X#MXY=S%:N=T2#=Z\&-N2BD9LA,K3Z7SGGDFX MW#\([,CU_^V&N)> H8WK&^#[PF+!8K.)3Q6R??;J@RSO#>$C=@4.R7F ";0 MXT6Y?",[QO<<5^[J&08_@H+0%WY.J1$UL7:KW.J5X[6'.@&XC=-7'GFVIV+ MIIT4,M0+2(D6M^)?(^KH7&>[O9+XJUY_3.5:V&5RQJ+/R&(FCD FF5CS'\%R MZL2-EGS=/:Z="3?R2_?4_$.0-A2<[]F_6S-PT$:,>]#;:-X?= M)"0W-B77W:27Y,?<=2_DW?\H['?;/=AC33A^-KOWA/.#J\DJFKPA'ZRY4VT773/?/:_A8<% MY=UDM4^DT:D/F]C7!3!J4@&@6@M(5V(\"WD!3VNHCB4+)DEEE0W/FY2)W^R MLYU:@9?TUC>A?F9DH(:8M,,>&LWZ^,Q/'T.\LE2#?#CO]R9CZ![M0J,::M_Q?A$=GY8\F@-L44]]./FT,V!()_31IV5KI?RKMJD?G MIUKZB[7/GTDK(2TKUX5,'FEK\E./ZD&LKLQ$.]NQN4NJQ:KZ#H1+/T[XD M'Y]BP#[N_CT9'#Q>SFO\X=H1C/+'Y MH8Q=V%4.A00!"CL[J71>;G?+=3:CTYH!M2E4D>R_%"%;+]B1U>VP]X.U#$E M<&+)K-.6%$:C--7&&KA6,3/S(U),X9^N/CD/::%#(!>4SWTQ/\S>O-]BJ78W M^9//]K(%TC5D/HGSA_Q .2?EU\\RVF)/29(% 2]42%L1P=6Z=AX_9EB0&Q= M^I;?176>;AXW#[.WQ32F2>X]HC6O7XO-AYFDZC]_;PE&I5^96ELMX[F%A;Y M9BWI4PLP;V(YVH2L[)Z+]_4X;@J6HIXE;IH,MFO?#ZV(.#8.5)Y5I['/ZMR"J'5&/"J^?IA:,7$QF[O MZ(@1>2Q0]P:@[E'3M97>A)7PLD']X M6'O(3;;%8./C_N=!8SGFLU]E"M[?$(Q^MV,EO1UZ_3=N4O+74X2)& B9#,E ME?UU>M7?:<1-;NJ,2I5/S1^\+G$&W'A-N6[-]:8)>&E/KBC,L7 L8AF5B== MXR=V>4MX717]/@U=3:(3J4\]Y@>$]Y4_W#.+R;<_0K7-\>_(HK_:]+XWQEI M3':?E\5G0<#[O&'QOVD&NA!;1#T.DJ,F#NE2F#>>J=$T[F)!9FVKV96:U- M^NZQJJ]+57?)0ETF!.X'NF#\F9_K$M49?G?3R2+L&\1Q%8'AN]SI+QR?#Q; M9E/2DA)9[^YZ-E_!72-1:5CK@XEO7;/1T24"Z1Z'P$"NTPY7[(Y687G6PHA5.A%&T9U?<>5IH%?.HU5LC?I2R?)W](^+R0TU155 MX'>[Q.T,TT^,"P-00/2>32%TXS:>E 5NDU#NY:&NL/EV"%U3X0(:WK1L8U M'Z$;V/8([J!I+CN]R3G" F2_+.>G$_J'^0OOH-0@CC,)-IHF$2;CU3#DL&$ M'PK1-W#QE?HA->/SQ0[\EH.-7/FUOG2,YD99T4X\#6@CEF!A/+LE##.N M+BXNU;U&E4,[ED)?+$SAM:L>0L$"=P:3M$521;;NT$#5CT"X+NBN!71KY BT M,0G]RP,0J1<(77#>C+12)DI'UUPIFQ^I.;RS;-08-6AFK>V04N"M\@E[SN$ M57,;79-)0&]0%-',.GDY/D<39,3F)9J",$>UXRQ1!][4!;95L@0RGX;HIA M&^V%JQ6#_7\AY/B_%+@R!VR"9MQ/Y"QFI#]!'<$.N%(9A]+P\IG6#WA&XA; M^JF%'6?M=Y<8RFJ(I[E-9:__9"B[XD#7N54(&"Q':8PI>!YO3$^C10](U)KEI1I[>(OHKW!QN MFY4G(VB?[#Y["A<#J?Z/.Y_0'UO1+)X+5-VNCIK50;.N1!98R7[LS(M$N%90 M:JB!>#]5Q]@&RUN[5,?(]M>]Q ME2;:&MLT?0IC%N$&I:&HJ2CV(7^W Y9-8@/EOFG1Z#UO484E)"!S)!F M7X78QZEOE><=N+&>:9CB)-T6_>#:M]6]_; ,KJB9? 2BZT^I6V^,;4E[GE-[9NU X[#^9ZWKQV7ADM]&YL+QH:NDPQTB M]7+D#BSLN!6DZPO1SX3)K&46B^LU,[/-"+S_,/JXFQ:(KV>GLZQO@_K@$U> MZ\QA.#8LO"K#'%W[$'[S@.1[32-Y?N6&7[-XM'04$G/WTS"['5FFVH&)#^ M]U05>@6E3?0U)RJTS]$")QS+)+W C'U^GFZ21F,Z;\KO7^YU3[NP\ZK(ANKL&J'2#E$U"PE$.EI4Z"-1]!U%XB8T'!KC>3HG?^JB[R=69"8>F7P MB\RBOGM(7V#0$:@C!KU:BUX\C@YFJM%_>4#QLX30C6?O;C\"<6I66P\#JPC MAP84]16M9OM.; @T56<,V7HR)GZXS+89')=_Y@S1$)CK-I>.6EN?'R+S K(NDVO%R6LW=>^OZ\!T&YP_+1_YXA"G0GR0OP!WUWB7^%=1( MDZ[4QZ7BC&^1&1^US?F:W@[H,E;J,/!UBRIPO^]7U>SY4LL"-W=+S+7@];_&8-HKT\F::M_F)^)A^3Q::WJ'3?,;F"&14=022 MU".OY_W5T4OPQT;Q7C]%S8_E#2IN MAD] IGV6O_^2S7IX8&!WE9O)H?T:J?XZC'2EFUSB0#;/.9Q2@:1XF:P6_<49 MS7_F5^\O)&% $Y\3IZP\K,0WORZC:VB!08DXM]\,V=01]M(:\3 EYS_Y:RD% ME!T(DKMFF0\32)Q2F7G0O?&(S;?>>BS3D(9F[2+ZO?KTECW5+JSM<4R0-%[ M5P[CE"0/A)%4\'UD_#VBW;ZXL^!9GB]>W\:OY_6O M_QK5_R>O$#R510'/E\AWXWK!>V/X:?BQ(/(S+-?V46\+32Z5IF[$"5]CEO6; M;%,1B+L0BFG#T)DAQU1/69,;=$728AX67--GNO4 M_N69EN:ZNJ>D3[XN'6Y4P4<@"$E^@"PWP\HK)<[JZN\!C/ORU_]\=@.:TCW M-?I1QICIUZX>6X.FM[X>5]A']%7.7,]IRV&8!.YL=W@6EI7"34SH?;Z7?Q_? M?T'\%!/+VWG]TY .BV8LWVV7)DLU=Z,T%9J0([$^1II.@&+5=!O#-O?6O2. M'GQ]__Z-05G#ZX3,=4FAPVSF,[U-+DX-DY0!KEXZEJ'C.W$6_ M3GN5\?I(+V;T3AU@//2Y-$ M[R+1]PAC-2_/[G9,PA\7YKM2EQ?)J(OTGQ&Z.FMD?4:F]6R<4JF+ADJ?QRSX ML- +S>V8?9K(A DE:5OCI%G5'HYE"XT(U82-7=V88&5PTOF;NX0B>1?C,V5 M>$]_RI'RBV,YSJJ78]5IQ >R$8\U6+G[#.FL#_ZE%FRX$6;?E2.O&WJ X50 M2<295Z8RE=1<)UMY 5P>,O/V^.X5V3ZKN5N#B,V=INB>>=T;V>_LWD=K.)5 M'SX3%^7?4,D$JRV":','[TN%$+5KM"O6I4EGP!_XV!NJ;+J%BUSI?W01C;C M5+ 0_IZP5T2!9>)(XX81U6DLZ=;AV$$XD=R,0S0=L5"],68/3?6+]#"''. M3+;;-V.2_3AE_!1T3ZNFB]I/2&V]U2IF"'I.7VNXORP\F7SCE)D+IK9%!G? M(0/GHOBCZRD;$_Z#K MCG,.S"$U+0E-%I5;F28'XI(C?N^3Y.NR[U0US(AH^H@KQV3--BJ^1$(.\>% M+.G8YXPL5Q+,!]Q,):1V)2_0B8Z(8)+HRF.F!#TO R>2=^: MD=$M1XJUCWM8U;Y:Z/T".^01YW5&2DNQA5+P>G;2'$ZUHK#IP@(/DBA&!ZU, MO ]N.IJ[UD9)[P2X]1N->,\!&E\'F],=FBHQ!U1IW]GPW);CC8&//+N!]\^ M^R2U[Z40,;?3;A&INUIRORNSC,CRFE8@JBWO7)%"&-/'1%/FFO4J]BQ5RQ1? MN'Q9AGVJ0JTXR0>,4P64_@BY]_GV1XH0"CEH+V4=><:7'@0H@2RGYO W ;B& \;0CM:1_?EU'9>CL@5?R,-SWK!U7ATN MZWH19AN9Z?5KMU[,A[UOZQA .UC:& [M'@IM?=S4!9[8++B"VPAPW]MO6'L# M^/.:M;>2$\^^$#2[(U_U0OY>$%CK#^:+8<"="X?()Q23'IQEC^VY12.6DNN=9AVW:A38^7"621UO0>[GN>E3 M+EIOD\-\C%VFWI-6FL$:7>B]3,NFNK'RG>N/B9;4KQ-SH[9UDZ@F^8S]SX]^ M.$L8K)^^PD:!^:WIT+^6E1YL0J]M7V^= 3ZOB[@WEC= NH2CP(,C%,:J;MJ] MS9)DW.YV36^XNV5Q@\,U[,6/4' Q,$8W0(923"B;W"Y+V9//D^R^;+6QRYG MU$;P_0J(DB[OWL$,[2W0#\@_((CMG(DSK MWZ2'E$'!9S'(X!S/]9/+S#)\S+!$#)=<&6ZA%6Z)KNU4O7:["^%Y6-IR&I MCC8N7M<>J5%E/W6XI_&4:#]DM\>XP\N+OC<'UQ<0T>@GSRM1KE!RL5_3X4J M4AS_H?&W:'Z.L K9Y:MPI.5:N4:>:):(];&#RBDF4',#"^G&FQ(2B7F MQB7^KYQ2,U(S?95S7IM]2N,8]WG'M1BF+I@R^"RXE(ZY8-0$/3-JC@N!Q"+ M)[$I]N[%#:TW,RR4I,L>@2+W'I%77>CPX\+ZR2(/'DC,G["ZU 9J9&IA3;\ M'7#=/P.HPA(.V)(OD0U?$P"2FNL6@=\RID ?^P3B; NTK%>S(+<:12UW"O$ M]:1N&/A\;G:E!-VEK=>W0KPBF;6,MO)-.8\%LH\TZQ67+8ZE^19\8SKQ;L9\ MNM?9LV9C\93,;\]?XK"-@ 1])6!8Y\>I/]I?[CQ+F(L2'Z!,CD; M/Y8=Y]C3QL-U7P[W?=K*O]L6#^V?WM**X.WY8O9^)CFJ84&/30UW!&)%GNRR M:#KP'9=[(POD545Q1OE8NXMVRYV?8V1K+KB^);\\";XPV;\6F***&KLRZ)LZ_]F;PQ/ Z#>)BCY!F@XUC],43 M:AD[\1QP\_Z_,SKPA;)'54?IVQ')-?Q&X"J76D6#\!K>6,X !HT1VU%V4IJ1F"!0]G<"I$AI;H1GLOOT5[9(9K MOTC=S[>CS-]X4$EU0?T!9&].TH6 IXR_ZQD6,R@5;@] MM\[DZ7JN-NI<>"/1>M\=.=[VK/:LLJGF#GF,"Y0XA?6 MA_X?6!\9Z]93D>@O:M U2^P#XWC: YO0TWA@33BTAC?=VBA)\YE&_#D9V@>?97Q9543&2P=5(/+?(%6!#;Z^T-0=>Z8][:?7G].$!A M/KO.[D".) ,\'C='[_6'H7%L"LFE\7MP:)6TA$/#UI3]0H.K+7W_53+0^M MO<9SE+U>4'I@"DJ3+:X]_M$%9 # VNG"VO A_W=!/4G8TW'6K4&^R+&J MJPW5R?O23!@J;CU^]HY>M;X1-D15O5^:?/Y5L.6)D/=6ET:6L=WTIP4;4? MD31>XLX/]DL=H@D[/R8:NP"[^/K1QZ^OB_GY#E,7D>2+4S/?6MD)RL^)I]M3 M&]D:T2'#T$&T(?^C?>)Y\))(P;JH/\NB-0 MT@O@4\BF>T2Q8&CE[LU1ZQ@8X'^_WI_+MB'>Z>R(K[O:Y3P_ >&\F[BG=]AAH>F]G?M[F8?M MC66TI9E;?7:7MN\(= IM;ZGS?E9X>&/=!27Y\MO>$8C9ENCA2(8\G9JR,,>$ M9=[>>AC[T&B;NG=3["2WQ_I64L?Y2O >?2"-"^RWY1SS"?1R1P:GCN4GRB2 M/K6J:)P7$,!6=?,D(D+G^IM)$>IVK2+'-F7,<:.D8Y3Y@>0%DR>[FPS('QJ$ MENSGL@D]SM1E(Y/Y"CJ[NQ8UOO=(ACM$ MYB)= OQ>=Y9]^R&TW4Z(E]_Z/&SRKO69MM!$N\UL:EF$NU#:UK8 I=Q.UG\B M[340= 3J$$,ACN="A5^0$_3^FV0Y%3YP,-IQQA GW:9'O](;CV>BTP<\+$. MAMDZ,R>&]OVO%%0/+=2ETI<_2.ZQ=Y12W3S^/&@CL"SZH6>U%0!T >CHW4 M+;%%\20[O#3K-)"'W2RW=$K=M'.G9YG .YNMSSJX]"@OB((] WV)_X42V6QT<@6)_[=#.(F+($7-8,.GL)@88!3UVZ-+GJ4@HJ-;+P$E M:IBP(71$^/P ;4@]#M]3DW[]G&<;^ MPC51.'89>']A53QM^?&OL"@+Z$,63 0$T)E#$XM!FR15PL&>/]$W+I\HFD-$ MDUF@MNL+3MDSGK"^EI&;4Y#"_6;7U>!TJI$L$4%0J/LK['T';,9!6N/Z+U M,O((1#YMFD^H:"_3/(#H#^Z,UB4M:=D/FD]("$QQV>DICG$+)BQ0(G\&607Z M'8'"[@!S1Z";"#PMF?7'',DI'K#=C#T"[6B0!= XZ8 C4-=KRJ%FW@/M;U:\ M@ G1UW),0G:3@Z0)I.'9=/74,)QC>Y4K4[,;\>U0S>!)-RH4N65_%+U$B7 M^'@(GRR4SQG-U"H">,RI5Q&+'=6TB;3A&]7);R;;Y,J_.XIY!E:=[<]TLNY. MM_.ZN/BB=JS\\M]VQY]TV5:S+N'8%-XB2ELIQ M=K=[YN"RO+99O=IRY_B[7[;(E6N5Z M7RD3[_QCO?+Q=871?T')6R,8>UB,HF3C?2<( M/7=-."Q)0>W2WP8=='\(H-27$3)Z/-GC$G4%K]7&Z14'+4+^[WN M_U?R;TONE/1/I"V9VO%!(6\7?=7-=6ORBR19? M;;L>&Z\N6O9GMHS?2/UQ!4G&M^L(M"^,9H82TEJ/0 OWT/_K2QK]8@ZA^GH< M'SCUOM0K(AD F+QFQ7P7L4$E\= W$%&-7?XG B2)ITV M)-/WH1OR)C(&PN_$P&\CK]8.1CWV:D89RVEIN");S.$L=ZL+]>&-OYMJ M.]+J<4]/5;ZWY'-!FBC@;3Y@"' MV/2#0N%G\H.F!U!'("T-C8/6)9B4]M^9'593<^23PX3]W<6_^9GMI\K, M;GNY-U"U$_4;%F8G M[$S.IOE,)RG.Q4Q"H[TWF&=49X=+Z2A]^->L-WL/55=(MY%A&NRW:B M>B(L58S9#[_:-ZT>QV BA)R89E7<=1Z='#!2K[U5A##VAGTCTJYH];(3![]Y M^T C-U-!DXH5?;D@M?"#S-&W"YDF\J#?U3^MKE5 M8_WCZB-]B9NOHJY>FUN[X.6MU"U6R[M,?;T"38SO>UI.S$N;&&EV)_IGI>Z& MSE,M]X[Y)]/I$+NC-M8?UC^:W_CH:HX-,+L=_)BQ/>K:RM4'^58^N+UZ=D?= M[5K;QVZ?EJT6VG=M1RJ/=:"<\,/=#E0!.8,/(Y,%5D!Z&4!&,;"6 M$K$''5GF>+_^T[.]8:-1Y5V,7Q8WQ'/^<_@C]<'_LX:Y95_/#[82.5WF)R> MJ_4JVI_IGLY)D8\F?B>B(Q(DM.<(<9PSXO=Z8?]0!E0YN?#=F )E-__LW-] M&A?Q#_!\Z!Z+. ?: L6.[ B.SUK5"D.I=K'Y8&A_@,HL>VR7^G''O;/5Y_ MOZNA:_=P5ZQ)W;RW[9.JZM8FLYFZ%PR.>4UC:&ZRXL>,TNRKP/I""S->^T>5 MXE#]='\4'V/G=:U/>HK[X+2>KF M6+#(GEINP2+7C"5.OT:!#F/%B-C%HTIQ#VTOD[X3^^C]]Z'[VT4ZF0R8H MFUF[U%'HA]CGDQGKGFZ9YI;X=^.D@VL6W7)D8MIGN#N^)^!XSFH0:E1#]JR MVPQL43X]6[46U(__T =N@+:#]_=R6+__%W-Q5/&HXE'%U%9\U>.?^!_7ZWL M'\Q-/WK/_,.^Q^B9F39>_M\$ %!+ P04 " !=.)Q4/O#VJ"6+ "PU@4 %0 &YV8W(M M,C R,C S,S%?;&%B+GAM;.R]?7/C-INE6)6[9(XIP?B!\. M@//RK__MZ],X>)7%+)]._NV[Z,?PNT!.^%3DD\=_^^[SPT> O_MOY/2O M_P\ __/GNT_!ARE_>93>7!12#J7(O@KGW\)_B[D[,] %=.GX._3XL_\E0+P M[^5-%]/GMR)__#(/8 CA]K?%WWBB75$2'DI_+; MY:6S?-^%^K'13__SMT_W_(M\HB"?S.9TPDT#L_QOL_/GZ:X+5F3A:Y>J$N M)ZO=W?9U,FB=R^QK]=B.J?C'EZ+53-K(H_-'S[I3W4SYD$-9%JV4U/WFJCR MZUQ.AS87HV=\WN\MF?'PLIKR9S6GD82A'B- %4) E 4$]X^E,.(NS"%6,05'\^58&-\'JN=7,QOBG"7V2LV=:WZ"U-V9+ M!2UL4&AISXG2MY__6F%V("Z?_S-=NJXV_XL]0'&U!'!NM+! MFM8!>PO6KZLU#TK5SPC?%!J'ZRI?Q88 #0+" (+@K7Y7?CKPJ4[ZA[MA8 M==-BN]^F_-WZ;<6^,PUYV6FSEB)>BV3[D$8_23'\]GB+\#\!811;4K^<^_" M_[0S'L^+!=TX$=>QOJG_A4&]W/<[#Q7II%ROMVR7SZOD.Y>E4U2-\%TT+( M0B_[]@"^),#)R_:RWCY'R_Y_.UKX"35_V/ME]?GI@L1DJF:$X 0(A/1VJ3"\"XU"".,4XY))DBH4V MT^$[ZS&TV;&2IBJX/;^\RSX/I\$,Z/Y[ >[>?&]7XOF:?(;ZNSASYH5',$: M'D$)2& 0"6X6DZ@&)5B@$LRG@<'%_+5&1G\LL?DV7B]1[W.5+?YG>,TV%/K_ M7S<'TVT@G5Q9".>3 MQT]2B_8IIRP?:X%T(_RE+1 (VUO01AA!2(F8H!XE@ 2:<.+I23<0H1Y-)E M"^)HBT.SCCY-)X] -_04C(W$,[>]@N, VRWRO<+6L9VQE#4HA3T+EN6I%P+ M[&\A;8V-UQ7P\59[7;I:@["]YK2_L1W%?)!LOBXC_J5.7^:ON@7/U.QE"P3 M0"14:6:)8H SF (5IAF)&<,Q3UV8Y5!#0R.4\\?'HMS.#IZ+?,+S9SH.:"FI M&[4.!F>CDE@&YG@CTK$_\\? S1"X'7X[V^IU['?J.SV MP&^^N-VH/Y_-Y'RVLB_.F286RN>C2&&%S5#2Z$- A6&@$G$@%(1@[',$&1. MIYV'&AK:V/]T<_T+>+B\^RTXO[^_?+C_F]O@/XBGW?CW@5+'%%")N+YX"/Y8 MB.F1!HXAX94)#C;6QD<4WF;#XY>WXX2NML_^;W<[F:5)XYHUB1A&8\ Q!3 MIBDF#?6:@Q,@,D4%I2)-,1NMN\9T=_KN+K5<#SJ/>1S5%;RN1\7]=[I';M1 M=-&1W_Z!T'QCA[Y^5_2K4H$P "^EMTV#"\5^&_#2^EEWBS8NB;?OM)KVE MS\9ODLY>BERV?/O^:RT(_\\O9A^D3SR2A+!..8,!CP?6JF"> ,)@ 'I(, M13SBG9:%3NU/C2+>BA-^RFE,XP[GA>. U> M9PIO!9-7'G:3H%T@[6KN6\ZL)GS[)3]/9;)2F$1(P3K3!#3% M,8H!Q0J:/7\H4B0C"=5HOG3K/CJD-I[N1$L'/-2].E+)N39QC'3!]V,MGZ-! MO(D<2E$8"2* 9$CHI4K, (/Z4XHH@YBPA"?$A?#;(]>'"YI/Y"#,TBP5 B1* MOVDHUHL\PD0(IAP3%&"6!B-%A$\'>#6&'W46H!G<^+G+W,J=DMG4_-P,TG MM'BK5V@!G06%?)X6QAA_F546N;[_^:4\KM46?LY+HA?Y^,5<,]EIX5G;]N7# M3NDAN^FS]1O;\?1H8+^J0?E4@G^!?LM]7O"O1<)KS/@9@N]SG![E=N>P?9? MU/-NTSXOZX5WSN_3L7Z,.3DO_:SIUS"(\N8I$J&(.1=\8'JNN&\;^D[OXW\8.5.MNZ322QTX"'QZ@=R8_PXWZ/)/E2<]( M12S!DH8 "T4!D@D!F9Z/')&!4DA89F3CU9C:T.;!Y1O]O(\=%,[ M"JD,\_NYYB1#8XM\)N=?\]F(A1A$G, F4H PAD#3$H,PBS#'/$(0^QD #>T M-33ZJ)>(2UF#A;!N)-$KAV%>,L8P(Y"%?PAY'4XWZS!1Y>N:.IO5Z9PT+Q M;=ZPN:5%$/$OV@[2!DWY$A,J<)@JI(U\HFT,I$) 8)H"3HPC"*HA1;1_6N M/7AH?%"+=NQU;@:K><2? D''P]N+]@ZAF"U1Z"DVLI;.4T3B'ET;0P37K^\O M9F^/E!M!=/N^=Z.663$?W9D%5NT G40J)%PP0'F( (** $J0 BG7JQI&J8J( M%;-L/7=HQ&+8.9_-L MV0OZMVU;8?N9O0S+ XHL1N6AK]O&@3U/9_E\5KF0CA C(6,9!Y%B,4")GOJQ M2C@@7+8,2KBD+M%?ZT_?FA#]'8LQ:.>_1B=_!F(6E37<\-_.Q,__:H=#Q* M%X)5.P.'H6@1S;5/8\\Q7!M-]!RYM4^]W7BMO5>U&[AW/L MG&L3Z65L/(P_2)7S?#XB40Q#05( !=6K?&W( Z9G7L 2)#%$\(CI\B-XTT. M;8 O) YD+7+P/5T)K8=\;6C6X,%\G8TX!?/CJEA">7E$LHU>8,/QZ!TI@Q[ M=+S2B$6SO5+/0S;=.-PYPDG]NSX:0K;\>C]^IP7Y<5U+(!" F&,.5 D80"% M$09,B1C$!(8X)CQ4,G(^D/ C>6/5F)V$9/A'W?^[M1;K^C[5]@KKWU-IK M VU-SMF\R,V1=TE#GR?:EKV[_USO3(@PBA0A#-!(FE"() 44ZY6DDFF&HC#) M0IRX69L-K0V-EU?"5FZ8P2G9#^M2>D)M,ZMR25>U9162AI\KV6=_=!! M+@$K7#S;D4TM]FQ"6BB_:SW:W-32<%P<7-VH\N%?IF-]\ZP]'(,E+=ZUH#> M_-5)ZE0%ZQ+_RR)JLXL@>B>4_$[J5BWW.V&[@+$S&3O=W'9\Z =?S68O>J7V M4NBU6UU]I8P6N'QZ'D_?I"PONM6OY1<][=_J=VPVBHE>2$& <]2LWMKBO @ MEH$LPAE.4!K3A(Y>9<&FU@NI=IXC+=U>3JVRV=!7JJB9V?=&<&SON$0/F6 MG61+:YT#WSG1F7F]4B&H=C7,V?5ZL?X!->U$; 0I6@U,4G^YT$IF<^;"=+ MSPQY$F"[G'G:X]Q85,A\=#F9:SK^F(]E<:'Y^G%:O(TBC(0B/ 8R"QE 4:( MXP!"$N%(BDYQYG- N7 \X>V)E$#$H9@X60=A1W",%FZO* 2\>4Y :)-B9O=# $846P_O89>[#]EYRS0_S MM\NOF@4FC_):=^8HB2 -8<(!4PD!B+($4$KUCY3'"D&LC1YJ.V[W-3"T@;N0 M,5@(&1@I[4?N7A"/#]U3H>G:G'!#Q6GP-JG>>O3N?6AOP[=)I?7QVWA=VWG7 MN<6S]-JZ[%<,%V8O3%V\54R!'F4(4L-'D'L-DH9FI%T- QABL> 4(>0V M#S>V-[3A74]"&S?50[6&N:@ECPPHKO.ULVXV\[>WM#L9S8_"<@6<[P5/"?. M^1XKS5UG01UDZPG[0:BQC M 4<1BD.4LAC "$&]HE 0D!@QD%"18IFA..JI$17M89&F+7L4I0Y,+@IU#P> MURD.7V9BE?MB,)D.G5XBA[/R=Q=V0.S?7Y;$-8#.@@5$08U14((4&)36(M\' M$,K>2;\/(\S=KVK?1@A\)]W97XK&5MULPT^WS\498#!6[VVR>5LZ:(@PTQE M A".&4 X1H". 8X4216D:+Z+R[S]>&FAC:'?O[Q_L=@(6S \O'8T3FA 56[ M"
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�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end